








Angiogenesis, the formation of new blood vessels from pre-existing vascular beds, is
a requirement of embryonic development but only occurs in a limited number of
discrete processes in the healthy adult. In contrast, abnormal angiogenesis is central
to many pathological processes including: tumour growth, diabetic retinopathy and
arthritis. Consequently, pharmacological manipulation of angiogenesis has great
clinical potential.
Angiogenesis is inhibited by glucocorticoids and this is exploited clinically for the
treatment of proliferating capillary haemangiomas in children. Despite this, the exact
mechanism(s) through which glucocorticoids inhibit angiogenesis is (are) unknown.
Whilst glucocorticoids can act directly on the vessel wall their effects on individual
cell types and on molecular signalling remain unclear. The work in this thesis
explores the hypothesis that glucocorticoid-mediated inhibition of angiogenesis is the
result of direct modulation of growth factor signalling within the vascular endothelial
cells.
A well-characterised 2-dimensional in vitro model of human endothelial tube
formation was introduced. Glucocorticoids were shown to inhibit tube formation in
this model via stimulation of glucocorticoid receptors and this process was not
influenced by intra-cellular glucocorticoid metabolism by ll(3-hydroxysteroid
dehydrogenases. This demonstration that glucocorticoids inhibit angiogenesis by
acting directly on the endothelium is consistent with, and extends, observations of
glucocorticoid-mediated angiostasis in rodent aortic rings and during cutaneous
wound healing. Molecular and biochemical assays suggested that glucocorticoids
inhibit tube formation by altering the balance of pro- and anti-angiogenic factor
activity. Time-lapse imaging of tube formation, combined with assays of endothelial
cell migration and proliferation, indicated that glucocorticoids reduce tube formation,
rather than accelerating degradation of existing tubes, by preventing morphological
changes in the cells but do not inhibit cell division or migration.
ii
In conclusion, these studies demonstrate that glucocorticoids can inhibit angiogenesis
by directly inhibiting morphological changes required for tube formation by
endothelial cells but without altering migration or proliferation.
iii
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Angiogenesis, the formation of new blood vessels from the existing vasculature, is
crucial to normal development. Since oxygen, which is an absolute requirement for
living cells, can only diffuse a short distance (100-200pm) through tissues, it is
necessary that almost every cell in the body is situated close to a capillary.
Consequently, tissue growth must be accompanied by the concomitant development
of a supporting vascular network. Dysregulation of angiogenesis contributes to a
large number of clinically-significant conditions characterised by excessive (tumour
growth, diabetic retinopathy) or impaired (Alzheimer's disease, diabetes) vessel
growth. The mechanisms that regulate angiogenesis have been the subject of much
scientific investigation over the past 30 years; greater understanding of these
processes opens the possibility that new treatments for conditions such as cancer and
ischaemic heart disease can be developed.
Glucocorticoids (such as Cortisol) are hormones that have many effects in the body
but are best renowned for their anti-inflammatory effects; a discovery that led to the
award of a Nobel prize to Philip Hench in 1950 (Hench, 1950). As well as limiting
inflammation, glucocorticoids are well recognised inhibitors of angiogenesis and this
property is exploited in the clinic where they are routinely administered for the
treatment of vascular tumours; for example in the treatment of proliferating capillary
haemangiomas of infancy (Hasan et al., 2000; Hasan et al., 2003). Despite this
practical exploitation of their anti-angiogenic properties the precise mechanism(s)
through which glucocorticoids inhibit new blood vessel formation has not been
established.
The work described in this thesis explores the mechanisms of glucocorticoid-induced
inhibition of angiogenesis. In order to understand these investigations fully, it is
necessary to consider the mechanisms that regulate physiological angiogenesis (and
their dysregulation in pathophysiological situations), the processes that regulate
glucocorticoid activity and the existing literature addressing the influence of
glucocorticoids on vascular structure and function.
2
1.1 Angiogenesis
Angiogenesis, the formation of new blood vessels (neovascularisation) from
pre-existing vasculature continues to be a topic of major scientific interest.
Angiogenesis is normally tightly regulated in adult physiology, but when
uncontrolled, is central to many disease pathologies (Carmeliet, 2003).
Consequently, modulation of angiogenesis is regarded as an attractive therapeutic
goal in a variety of conditions. Indeed the therapeutic potential of targeting the
angiogenic response has been realised with the recent milestone of the first
anti-angiogenic treatment (bevacizumab/Avastin) to reach the clinic (Willett et al.,
2004) and several more agents are now in late phase clinical trials. In this section the
process of angiogenesis, and its cellular and molecular basis, will be considered as a
model for regulation by endogenous glucocorticoids.
1.1.1 Types of new blood vessel formation
Normal tissue function depends on an adequate supply of oxygen and nutrients
delivered by blood vessels. Nearly every cell in the body is located within
100-200 pm of a capillary since this is the maximum distance over which oxygen can
diffuse into cells (Carmeliet & Jain, 2000). Blood vessels are constructed by two
distinct processes; vasculogenesis, whereby a primitive vascular network is
established during embryogenesis from pluripotent mesenchymal progenitor cells
(Carmeliet, 2000; Conway et al., 2001) and angiogenesis, the subsequent growth,
expansion and remodelling of this network (Hanahan, 1997; Folkman & D'Amore,
1996; Risau, 1997). Both processes contribute to the development of the embryonic
vasculature. It was originally thought that neovascularisation in the adult occurs
exclusively by a 'sprouting' angiogenesis but more recent evidence suggests that
incorporation of bone marrow-derived endothelial precursor cells (EPCs) may
contribute to growing blood vessels, thus complementing sprouting of resident
endothelial cells (Asahara et al., 1997; Tepper et al., 2004).
3
1.1.2 The cellular and molecular basis of angiogenesis
Angiogenesis is a complex process tightly regulated by a balance between
counteracting endogenous activators and inhibitors (Carmeliet, 2004). The activators
(Table 1.1) comprise a set of pleiotropic growth factors, matrix and adhesion
molecules, differentiation/specification signals, chemoattractants, and enzymes that
participate in controlling the various steps that go into forming a new capillary
(Tomanek & Schatteman, 2000). The inhibitors (Table 1.1) are equally diverse and
function by blocking or markedly attenuating vessel formation, stabilisation,
branching, vessel remodelling or specialisation (Talks & Harris, 2000). Together
these counteracting factors provide the necessary balance required to maintain a
normally quiescent yet highly responsive population of vascular cells. In particular,
endothelial cells play a central role in angiogenesis. For example, they normally
divide approximately every 3 years but can be rapidly induced to proliferate in
response to a variety of physiological or pathological stimuli (Polverini, 2002). The
onset of angiogenesis, or the 'angiogenic switch', occurs when angiogenic growth
factors are produced in excess of angiogenesis inhibitors. The molecular basis of
angiogenesis is most easily characterised by viewing the process as a step-wise
progression (Figure 1.1) involving: existing vessel dilatation and increase in vascular
permeability; degradation of the extra-cellular matrix (ECM); endothelial tube
formation (by collective endothelial cell migration, proliferation and
morphogenesis); stabilisation (including formation of a new basement membrane);
and specialisation (vein or artery) (Conway et al., 2001).
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Endogenous activators Abbreviation Endogenous inhibitors Abbreviation
of angiogenesis of angiogenesis
Vascular endothelial VEGF family Thrombospondin TSP-1
growth factor Interleukin IL-4, -12, -18
Fibroblast growth factor FGF family Platelet factor PF-4
Angiopoietins Ang1, Ang2 Tissue inhibitor of TIMP-1 to -4
Hypoxia inducible factor HIF-10 metalloprotease
Platelet-derived growth PDGF-B Interferon IFN-a
factor 2-methoxyoestradiol 2-ME
Matrix metalloprotease MMP-2, -9 Retinoic acid RA
Cyclo-oxygenase COX-2 Plasminogen activator PAI-1
Transforming growth factor TGF-a, -p inhibitor
Tumour necrosis factor TNF-a Pigment epithelial-derived PEDF
Nitric oxide synthase NOS factor
Integrins avp3, a5p1 Secreted protein, acidic SPARC
Epidermal growth factor EGF and rich in cysteine
Insulin-like growth factor IGF-1 Tetrahydrocortisol-S
Hepatocyte growth factor HGF Canstatin
Granulocyte Maspin
colony-stimulating factor GC-CSF Vasostatin
Interleukin IL-ip, -6, -8 Plasminogen kringle
Monocyte chemotactic MCP-1 Glucocorticoids
protein Angiostatin
Platelet-endothelial cell PECAM-1 or Endostatin












Table 1.1 Endogenous activators and inhibitors of angiogenesis
In normal adult physiology, angiogenesis is tightly regulated by two counteracting groups of
endogenous factors; pro-angiogenic factors which drive this process and anti-angiogenic
factors which act as the "brakes" to prevent the process. When angiogenic factors are
produced in excess of inhibitors, the balance is tipped in favour of blood vessel growth, when
the inhibitors are in excess, angiogenesis is stopped. The normal healthy body carefully
regulates a perfect spatial and temporal balance of these modulators when and where a new
blood supply is required. The key players identified to date are listed above but there are
likely to be many more, as yet unidentified, factors which control angiogenesis. Table
compiled from (Conway et al., 2001; Folkman, 2001; Polverini, 2002).
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1.1.2.1 Vasodilatation
Hypoxia inducible factor Low tissue oxygen tension generates hypoxia inducible
factors (HIFs), specific transcription factors for over 70 genes, whose products
stimulate angiogenesis including: endothelial nitric oxide synthase (eNOS), vascular
endothelial growth factor (VEGF) and angiopoietin-2 (Pugh & Ratcliffe, 2003).
HIF-1 is a key mediator of the physiological tissue response to hypoxia during
embryogenesis (Semenza, 2001) and, in pathology, has been shown to promote
neovascularisation in response to myocardial (Martin et al., 1998) and retinal
ischaemia (Pierce et al., 1995) by activating transcription of the gene encoding
VEGF.
Vascular endothelial growth factor Vascular endothelial cell growth factor (VEGF)
is the most critical stimulus of angiogenesis since it is crucial for vascular
development both in the embryo and in adult tissues and it is endothelial cell
specific. VEGF-A, often referred to simply as VEGF, is the founding member of a
family of closely related peptides including VEGF-A, VEGF-B, VEGF-C, VEGF-D
and placental growth factor (P1GF) (Ferrara et al., 2003). Several different isoforms
exist of which VEGF12i and VEGF165 are the most common freely diffusible forms
while VEGF189 and VEGF206 are usually sequestered in the ECM (Ferrara et al.,
2003). VEGF family members have a number of discrete as well as overlapping
functions mediated by a set of cell surface receptors that initiate signals through
activation of signal transduction cascades (Eriksson & Alitalo, 1999). These
receptors comprise a family of three closely related receptor tyrosine kinases
(RTKs): VEGF-R1 (formerly Flt-1), VEGF-R2 (formerly Flk-1), and VEGF-R3.
VEGF-R2 seems to mediate the major growth and permeability actions of VEGF,
whereas VEGF-R1 may have a negative role either by acting as a decoy receptor or
by suppressing signalling through VEGF-R2 (Hiratsuka et al., 1998). VEGF-R3 is
expressed on lymphatic vessels and is thought to be critical in their development.
Disruption of even a single VEGF allele in mice leads to embryonic lethality due to
severe vascular abnormalities (Carmeliet et al., 1996; Ferrara et al., 1996) and mice
lacking VEGF-R1 have excess formation of endothelial cells which coalesce into
disorganised tubules (Fong et al., 1995). It is now clear that VEGF signalling must
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be delicately regulated in a spatial, temporal and quantitative manner to avoid
vascular catastrophe (Yancopoulos et al., 2000).
Regulation of VEGF expression Oxygen tension plays a major role in the
regulation of VEGF gene expression and VEGF is transcriptionally upregulated by
HIF-1 (Pugh & Ratcliffe, 2003) which is regulated by nitric oxide (NO) (Kimura et
al., 2001). Several growth factors including; epidermal growth factor (EGF),
transforming growth factor-a (TGF-a), TGF-p, keratinocyte growth factor (KGF),
insulin-like growth factor (IGF), fibroblast growth factor (FGF), and platelet-derived
growth factor (PDGF) up-regulate VEGF mRNA expression, suggesting that
paracrine or autocrine release of these factors co-operate with local hypoxia in
regulating VEGF release in the tissue microenvironment (Ferrara et al., 2003).
Inflammatory cytokines such as interleukin-ip (IL-lp) and IL-6 induce expression of
VEGF whereas IL-10 and IL-13 inhibit the release of VEGF, which is in agreement
with the hypothesis that VEGF is a mediator of angiogenesis and permeability in
inflammatory disorders (Neufeld et al., 1999). Furthermore, VEGF is produced in
response to endurance exercise (Waters et al., 2004), and by the oncogene K-ras
(Okada et al., 1998), demonstrating that it is a key regulator of physiological and
pathological tissue expansion.
Actions ofVEGF VEGF is among the most potent permeability-enhancing
factors known and was originally called vascular permeability factor (VPF) (Dvorak
et al., 1991). An increase in vascular permeability is accomplished by redistribution
of intercellular adhesion molecules including platelet-endothelial cell adhesion
molecule (PECAM)-l and vascular endothelial (VE)-cadherin, and alterations in cell
membrane structure (Gale & Yancopoulos, 1999; Eliceiri et al., 1999). This leads to
the formation of vesiculo-vacuolar organelles (VVOs) which allow extravasation of
plasma proteins and, eventually, activated endothelial cells. Consistent with a role in
the regulation of vascular permeability, VEGF induces endothelial fenestrations
(Roberts & Palade, 1995) in vascular beds including the abnormal vasculature in
tumours (McDonald & Choyke, 2003). In addition, VEGF acts as a survival factor,
mitogen, and it induces endothelial cell migration (Ferrara et al., 2003).
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Angiopoietins Although permeability is a prerequisite for angiogenesis,
excessive vascular leakage, perhaps not surprisingly, results in pathological
outcomes such as intra-cranial hypertension, circulatory collapse, metastasis and
blindness (Carmeliet, 2000; Conway et al., 2001). Consequently, permeability
changes must be tightly regulated. Angiopoietin 1 (Angl), a ligand of the
endothelial Tie2 receptor, is a natural inhibitor of vascular permeability, tightening
pre-existing vessels and preventing excessive plasma leakage (Thurston et al., 2000).
Angl is though to play a more permissive role by optimising the way in which
endothelial cells integrate with supporting cells allowing them to receive critical
signals from the local microenvironment (Yancopoulos et al., 2000). Endothelial
cell sprouting is further enhanced by Ang2, an inhibitor of Tie2 signalling and a
natural antagonist of Angl. Ang2 is involved in detaching smooth muscle cells
(SMCs) and loosening the underlying matrix, and ultimately provides a destabilising
signal involved in initiating angiogenic sprouting (Maisonpierre et al., 1997).
Whereas Angl is expressed widely in adult human tissue, Ang2 is detectable only in
the ovary, placenta and uterus which are the three predominant sites of vascular
remodelling in the adult. Ang2 together with VEGF act synergistically to promote
angiogenesis, a feature of many of the pro-angiogenic factors.
1.1.2.2 Degradation of the extracellular matrix
Degradation of the extracellular matrix involves an array of proteinases which
provide space for the migration of endothelial cells, but also results in liberation of
growth factors (including VEGF, bFGF and matrikines) which otherwise remain
sequestered within the matrix. The most extensively studied proteinases in
angiogenesis belong to the group of matrix metalloproteinases (MMPs) (Bellon et
al., 2004) of which 28 members have been identified to date. The MMPs can be
broadly divided into 2 groups: those that are secreted and those that are
membrane-bound (and require initial activation by other members of the family).
MMP activity induces changes in the ECM architecture thereby influencing
endothelial cell behaviour which is important during all steps of the angiogenic
process (Mott & Werb, 2004). Natural inhibitors of MMPs include circulating
protease inhibitors such as tissue-localised inhibitors of metalloproteinases (TIMP-1
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to TIMP-4) (Brew et al., 2000) as well as thrombospondin-1 (TSP-1) (Conway et al.,
2001). The role of these factors is exemplified by the demonstration that
Angl-induced sprouting is, at least partially, mediated through the secretion of
MMP-2, MMP-3 and MMP-9, and suppression of TIMP-2 (Kim et al., 2000).
Furthermore, MMP-1 and MMP-3 are thought to inhibit tumour angiogenesis by
interfering with binding of MMP-2 to integrins (Brooks et al., 1998). MMP-7 and
MMP-9 generate angiostatin, a cleavage product of plasminogen and natural
angiogenic inhibitor currently in clinical trials, which is thought to act, at least in
part, by inhibiting endothelial cell proliferation (Pozzi et al., 2000). Another
proteinase implicated in matrix degradation and subsequent endothelial cell
migration is urokinase-type plasminogen activator (u-PA) which is essential for
revascularisation following myocardial infarction (Heymans et al., 1999).
1.1.2.3 Endothelial cell proliferation and migration
Once destabilised, the ECM is conducive to proliferation and migration of
endothelial cells from the vascular bed to distant sites. Interaction between VEGF,
FGFs, angiopoietins, and their receptors is intimately involved in endothelial cell
proliferation and migration illustrating the high degree of functional interplay
between these molecules. VEGF and the angiopoietins appear to be specific
mitogens for endothelial cells, whereas FGFs, epidermal growth factor (EGF) and
CXC chemokines induce proliferation in a wide variety of cell types (Distler et al.,
2003). Since bFGF is a powerful mitogen for SMCs (Lindner & Reidy, 1991), it
plays a role in the growth of vessels larger than capillaries. Furthermore, VEGF and
bFGF act synergistically in vitro to stimulate capillary tube formation which
comprises endothelial cell migration and proliferation (Ribatti et al., 2001; Yan et
al., 2001). The proliferating endothelial cells migrate along a gradient of
chemotactic agents through the disintegrated basement membrane.
Integrins Integrins are cell surface receptors that act as junctional molecules
between endothelial cells, and between endothelial cells and the ECM, and play a
key role in angiogenic sprouting. They are composed of different a and [i sub-units
(Humphries, 2000) that bind selectively to their ligands (e.g. collagen, laminin,
10
fibronectin or vitronectin) in the ECM. As well as having a role in cell attachment,
they act as important signal transduction mediators that give the cell critical signals
about the nature of their surroundings. Consequently, this
matrix-integrin-cytoskeletal signalling axis (Davis & Senger, 2005), together with
signals arising from receptors for soluble growth factors (e.g. VEGF-R, EGF-R), act
as important cues for different biological actions including cell migration,
proliferation and survival. This is one of the key mechanisms which contributes to
vascular morphogenesis, the carefully orchestrated process by which proliferating
endothelial cells organise into multi-cellular tubes with functional lumens (Davis &
Senger, 2005). It is thought that av(33 and a5(31 integrins are important in lumen
formation in vivo since both are involved in endothelial cell morphogenesis in
3-dimensional (3D) fibrin gels (Bayless et al., 2000).
Thrombospondins TSPs are a family ofmultifunctional proteins and have roles in
angiogenesis, apoptosis, activation of TGF-fi and immune regulation. TSPs
participate in cell-cell and cell-matrix interactions and 5 members have been
identified to date (Lawler, 2000). TSP-1 has multiple receptors, among which CD36,
CD47 and integrins are of particular note. TSP-1 acts to inhibit angiogenesis;
inhibiting the migration, proliferation (Bagavandoss et al., 1993) and tube formation
of endothelial cells by interaction with CD36, expressed on the surface of these cells.
Receptor binding also leads to expression of FAS ligand (FasL), activation of Fas
and caspases, and ultimately to endothelial cell apoptosis (Jimenez et al., 2000).
Moreover, TSP-1 renders endothelial cells refractory to stimulation with VEGF and
bFGF (Iruela-Arispe et al., 1999), further augmenting its angiostatic effects. The
angiostatic and apoptotic effects of TSP-1 require the sequential activation of CD36,
the Src family kinase p59, caspases 3-like proteases and stress-activated p38
mitogen-activated protein kinases (MAPK) (Jimenez et al., 2000).
1.1.2.4 Endothelial cell survival
Once resident in the vessel wall endothelial cells become quiescent and can survive
for several years (Folkman, 2001). Together with the aforementioned functions,
VEGF acts as a survival factor for endothelial cells and this has been shown both in
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vitro (Gerber et al., 1998a; Gerber et al., 1998b) and in vivo (Yuan et al., 1996;
Benjamin et al., 1999). The pro-survival effects of VEGF are developmentally
regulated; VEGF inhibition results in extensive apoptotic changes in the vasculature
of neonatal, but not adult, mice (Gerber et al., 1999). VEGF dependence has also
been demonstrated in endothelial cells of newly formed vessels, but not of more
established, mature vessels within tumours (Yuan et al., 1996; Benjamin et al.,
1999). One of the key events resulting in loss of VEGF dependence appears to be
recruitment of pericytes to the vessel wall (Benjamin et al., 1999). Gerber and
colleagues have shown that this activity leads to up-regulation of the anti-apoptotic
bcl-2 gene (Gerber et al., 1998a) mediated by the phosphatidylinositol (PI)-3
kinase-Akt pathway (Gerber et al., 1998b). Endothelial cell survival is also induced
by the anti-apoptotic gene survivin which interacts with caspases and has been shown
to be induced by Angl-Tie2 signalling (Papapetropoulos et al., 2000). At present,
the molecular mechanisms governing its expression in vivo remain unclear but it is
known to be up-regulated in response to hypoxia independent of VEGF, HIFla or
P1GF (Conway et al., 2003). Furthermore, many of the endogenous angiogenesis
inhibitors provide survival advantages to the endothelium (although their exact
mechanisms of action are unknown). These include pro-thrombin kringles-1 and -2,
antagonists of PECAM-1, IL-4 and IL-12, and cyclo-oxygenase (COX)-2 inhibitors
(Conway et al., 2001).
1.1.2.5 Endothelial cell morphogenesis, differentiation and lumen formation
When endothelial cells reach areas of reduced vessel density, they form tube-like
structures (TLSs) that contain a functional lumen (Lawley & Kubota, 1989;
Taraboletti & Giavazzi, 2004). Compared with the abundance of studies of signals
that stimulate endothelial cell migration or proliferation, relatively little is known
about the molecular cues that guide endothelial cells into 3D networks. In recent
years, however, some novel insights have emerged. As discussed (Section 1.1.2.3),
the matrix-integrin-cytoskeletal signalling axis (Davis & Senger, 2005) is likely to
play an important role in endothelial cell morphogenesis. Furthermore, in addition to
their mitogenic effects, bFGF and VEGF also play key morphogenetic roles in
stimulation of endothelial tube formation (Kumar et al., 1998; Saito et al., 2003).
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Notch The Notch pathway has recently been implicated as a key player in regulation
of endothelial cell differentiation (Gridley, 2007). This pathway regulates sprouting
and branching behaviours by influencing formation of vascular 'tip' cells-
specialised endothelial cells at the leading edge of vascular sprouts (Hellstrom et al.,
2007). These tip cells extend protrusions, called filopodia, that sense the local
environment and guide growth of endothelial sprouts along gradients of
chemoattractants such as VEGF. Notch signalling is a negative-feedback regulator
of VEGF action and occurs downstream of the VEGF signal (Hellstrom et al., 2007;
Leslie et al., 2007).
1.1.2.6 Vessel stabilisation, remodelling and specialisation
Although the endothelium has received the most attention in angiogenesis research,
the surrounding peri-endothelial cell layers and ECM are critical for ongoing
structural and functional support of the vascular network (Kurz, 2000; Conway et al.,
2001). This is achieved by interactions between endothelial cells, between
endothelial and mural cells, and between endothelials cells and the ECM.
Mesenchymal cells in the surrounding tissue migrate to, and proliferate at, the
abluminal surface of nascent vessels. These cells then differentiate to become either
pericytes, which are located within the basement membrane, or into vascular SMCs
(VSMCs), which are situated on the abluminal side of the basement membrane. At
least 4 molecular pathways are involved in regulating this process (Jain, 2003).
Platelet-derived growth factor (PDGF)-B which is secreted by endothelial cells, and
possibly in response to VEGF, is thought to attract pericytes and other mural cells to
proliferate and migrate to the vessel wall signalling through PDGFR-p. Furthermore,
PDGF-B has autocrine actions on the endothelium, inducing proliferation and tube
formation in endothelial cells (Battegay et al., 1994). TGF-(31, a multifunctional
cytokine, is responsible for the transformation of fibroblasts into a-smooth muscle
actin (SMA)-expressing myofibroblasts (Chambers et al., 2003) via Smad signalling
(van den et al., 2003). Finally, sphingosine-1-phosphate-1 (SlPl)-endothelial
differentiation sphingolipid G-protein-coupled receptor-1 (EDG1) and Angl-Tie2 are
also involved in vessel stabilisation (Jain, 2003).
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Ephrins The ephrin (Eph) system is involved in the demarcation of arteries and
veins. EphB2 is a marker for arterial endothelial cells and SMCs and EphB4 is a
marker for veinous endothelial cells (Wang et al., 1998). These membrane bound
ligands have long been known for their role in axonal guidance in the nervous system
(Neufeld et al., 2002), however more recent studies have shown that the ephrins play
a similar role in compartmentalising the vascular system (Carmeliet &
Tessier-Lavigne, 2005). Analogous to the angiopoietins, interference with ephrin
interactions destabilises the developing capillary network (Polverini, 2002).
Organ-specific angiogenesis factors A key unresolved issue in vascular biology at
present is/are the mechanism(s) which enable(s) the endothelium of distinct vascular
territories to accommodate local physiological requirements with respect to specific
tissue compartments. For example, in the blood-brain-barrier, tight cell-cell
junctions, comprising occludins, claudins and zona occludens, exist which constitute
a barrier that protects nerve cells from potentially toxic molecules in the blood (Jain,
2003). In contrast, fenestrations are present in endothelial cells in endocrine glands
to enable secretion of hormones into the bloodstream. This plasticity suggests that
endocrine glands produce signals that are essential to maintain the specificity of their
endothelial cells and endocrine-gland-derived VEGF (EG-VEGF) has indeed been
identified recently (LeCouter et al., 2002). EG-VEGF displays little sequence
homology to VEGF-A yet is indistinguishable in its biological activities in select
tissues (LeCouter et al., 2002). Another example of a tissue-specific angiogenic
factor is fibulin-2, an ECM protein that is a marker for transformed mesenchymal
cells in developing cardiac valves, aortic arch vessels, and coronary artery vessels
(Tsuda et al., 2001). This tissue-specificity is of therapeutic importance; if
tissue-specific blood vessel regulators contribute to the excessive angiogenesis that
occurs in cancers and inflammatory disorders then blocking these would be expected
to have fewer side effects.
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1.1.3 Signal transduction pathways
Intra-cellular signal transduction pathways are an important component of the
angiogenic cascade since they convey the necessary signals which lead to gene
transcription and a cross-talk of signals that ultimately determine the final cellular
behaviour including; proliferation, migration and differentiation (Munoz-Chapuli et
al., 2004). Research in this field has also focussed on the endothelial cell due to its
central role in the angiogenesis cascade. Extra-cellular signals that stimulate
bio-signalling involved in activation of the endothelium are relatively well known.
These signals include the previously mentioned secreted paracrine factors (e.g.
VEGF and bFGF) which are ligands of surface trans-membrane receptors, and ECM
components that usually bind to integrins and to specialised receptors. In contrast,
the signal transduction pathways that link the cell surface receptor and the final
effectors of the modified cell behaviour are only fragmentarily known. These
pathways are important, however, since specific and essential components might
provide novel therapeutic targets for pro- and anti-angiogenic therapies (Munoz-
Chapuli et al., 2004).
1.1.3.1 Focal adhesion kinases
The focal adhesion kinases (FAKs) act as a 'switch' for multiple signalling inputs
and contribute to integrating the signals from the 2 main sources of angiogenic
signals; i.e. soluble growth factors and the ECM. FAK activation is best understood
in the context of the engagement of integrins and the cell surface (Parsons, 2003) and
has an important role in endothelial cell activities associated with angiogenesis
including proliferation, migration and differentiation (Ilic et al., 2003; Shen et al.,
2005). Members of the FAK family link transmembrane glycoproteins to the actin
cytoskeleton and, therefore, have a crucial role in mediating cell shape and motility
induced by cell-matrix interactions. Other studies have implicated FAK in the
transduction of soluble signals including VEGF (Qi & Claesson-Welsh, 2001).
Signals through FAK to Rac and Pak play a role in modulating cell adhesion and
migration, actin polymerisation and mitogen-activated protein kinase signalling.
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1.1.3.2 Mitogen-activated protein kinases
Of particular importance are the mitogen-activated protein kinase (MAPK) pathways
(Figure 1.2), since they carry angiogenic signals necessary for ECM degradation,
increases in vascular permeability as well as endothelial cell proliferation, migration,
differentiation and morphogenesis (Bates et al., 2001) (Munoz-Chapuli et al., 2004).
The main VEGF-R2 induced signalling proliferative pathway is mediated via the
extra-cellular signal-regulated kinase-mitogen activated protein kinase
(ERK-MAPK) cascade which can be activated in two ways. Firstly, VEGF-R2 can
directly activate phospholipase C-y (PLCy) which releases Ca2+ from endoplasmic
reticulum (Munaron, 2002) and activates protein kinase C (PKC) (Munoz-Chapuli et
al., 2004). Calcium-dependent synthesis of NO (Bauer et al., 2000) and/or
arachidonic acid metabolites (via the lipoxygenase cascade) (Antoniotti et al., 2003)
are thought to be the links between calcium signalling and endothelial proliferation.
Alternatively, phosphorylated (activated) VEGF-R2 can also recruit adaptor proteins
{e.g. She or Skc) which activate the small GTPase, Ras, a main activator of Raf.
This serine-threonine kinase, when activated, triggers a phosphorylation cascade and,
consequently, activation of MAPK/ERK kinase (MEK)-l/2 and the ERK-MAPKs
which translocate to the nucleus and activate transcription factors involved in cell
proliferation (Munoz-Chapuli et al., 2004). Since a significant part of this thesis
concerns endothelial tube formation, it is noteworthy that this Ras-ERK-MAPK
pathway is also of particular importance in the transduction of morphogenesis signals

















Figure 1.2 Main intra-cellular signalling pathways involved in angiogenesis in
endothelial cells
The main signalling pathways involved in the transduction of differentiation and
morphogenesis signals in endothelial cells are shown. Other key transmembrane relays
including; Tie2, CD44 and VE-cadherin have been omitted from the diagram for the sake of
clarity. Signalling factors and their abbreviations are referred to in the main text. Figure
taken from (Munoz-Chapuli et al., 2004).
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1.1.4 Physiological and pathological angiogenesis
Physiological angiogenesis is tightly regulated and of limited duration. It is an
essential component of reproduction and embryonic development. In postnatal and
adult life, angiogenesis is a discrete process (e.g. in the reproductive tract, wound
healing and exercised muscle) of relatively short duration (days or weeks) (Folkman,
2001). In contrast, pathological angiogenesis is usually persistent and unabated and
often continues for months or years (Folkman, 2001). Numerous disorders are
characterised by excessive (e.g. neoplasia, rheumatoid arthritis and diabetic
retinopathy) or insufficient (e.g. atherosclerosis and pre-eclampsia) angiogenesis. A
wide range of other inflammatory, allergic, infectious, traumatic, metabolic and
hormonal disorders which are characterised by aberrant blood vessel growth, and are
said to be angiogenesis-dependent, have been described (Carmeliet, 2004).
1.1.4.1 Tumour angiogenesis
In 1971, Judah Folkman proposed that tumours are angiogenesis-dependent and,
extending this hypothesis, that targeting the tumour vasculature offered a novel
therapeutic target for the prevention of cancerous growth and metastatic spread
(Folkman, 1971). Eventual acceptance of the hypothesis came following the
emergence of novel cell culture based assays using endothelial cells, the discovery of
the first angiogenesis inhibitor (Brem & Folkman, 1975) and, later purification of the
first angiogenic protein (basic fibroblast growth factor, bFGF) (Shing et al., 1984).
Tumour angiogenesis differs significantly from physiological angiogenesis.
Differences include aberrant vascular structure (dilated and tortuous), altered
endothelial cell-pericyte interactions, abnormal blood flow (slow and sometimes
oscillating), increased permeability (leaky) and delayed maturation (Bergers &
Benjamin, 2003). The importance of angiogenesis in the progression and metastasis
of cancerous growths has led to the development of novel therapies based on
targeting the tumour's vascular supply. Anti-angiogenic therapies to date have
essentially been designed to suppress the neovasculature in established tumours.
However, identification of the mechanisms that cause a tumour to acquire an
angiogenic phenotype is starting to lead to the discovery of new medicines that could
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be used to block this 'angiogenic switch' (Harper & Moses, 2006). According to
The Angiogenesis Foundation's website (www.angio.org), there are currently seven
FDA approved anti-cancer therapies with anti-angiogenic properties. These agents
fit into two broad categories; monoclonal antibodies directed against specific
pro-angiogenic growth factors e.g. bevacizumab (Avastin) (Willett et al., 2004) or
their receptors e.g. trastuzumab (Herceptin) (Izumi et al., 2002) for patients with
colon and breast cancers, respectively, and small molecule inhibitors of tyrosine
kinases for receptors of multiple growth factors e.g. imatinib (Glivec) (Druker et al.,
1996) for patients with chronic myelogenous leukaemia. In addition, other
anti-cancer agents may block angiogenesis through mechanisms which are not
completely understood e.g. thalidomide in combination with dexamethasone for
patients with multiple myeloma (Kumar & Rajkumar, 2005).
1.1.4.2 Angiogenesis in cardiovascular diseases
Angiogenesis may be important in both the aetiology and treatment of cardiovascular
disease. It has been suggested that neovascularisation plays a key role in
atherosclerotic plaque progression (Moulton et al., 2003) and that anti-angiogenic
agents may 'normalise' the structure and function of intra-plaque vessels and thus
stabilise vulnerable, rupture-prone lesions (Jain et al., 2007). Conversely,
stimulation of collateral vessels to areas of ischaemic myocardium may result in
improvement of cardiac function by increasing perfusion to the ischaemic region.
This notion has given rise to the rapidly growing field of therapeutic angiogenesis
and extends to ischaemic limbs and peripheral arterial disease in diabetics (Li et al.,
2007). Proof-of-concept of therapeutic angiogenesis for ischaemic heart disease was
established by Isner and colleagues (Schumacher et al., 1998) following success with
similar strategies (administration of FGF, protein) in patients with critical limb
ischaemia (Isner et al., 1996). Thus far, however, the promising preclinical trials in
dogs (Banai et al., 1994; Unger et al., 1994; Lazarous et al., 1999) and pigs (Lopez
et al., 1998; Crottogini et al., 2003; Ninomiya et al., 2003) have not translated into
clinically-proven benefit (Kinnaird et al., 2003) and there are currently no approved
pro-angiogenic drugs for the treatment of ischaemic cardiovascular disease. The
underlying reasons for these negative findings are likely multi-factorial and may be
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related to insufficient dosing, problems with drug delivery, patient selection and
duration of follow-up (de Muinck & Simons, 2004). Despite these set-backs,
therapeutic angiogenesis has enormous potential for the treatment of cardiovascular
disease and remains a promising area of research.
1.1.4.3 Other angiogenesis-dependent diseases
A long and growing list of diseases is caused by or characterised by excessive
angiogenesis (Folkman, 2001; Carmeliet, 2003). Historically, the best known are
cancer, rheumatoid arthritis and diabetic retinopathy but the link with angiogenesis is
emerging in more diseases. A large number of diseases are associated with ocular
neovascularisation, including, retinopathy of prematurity (ROP) in neonates,
cytomegalovirus (CMV) retinitis and age-related macular degeneration (AMD)
(Henry et al., 2004). Indeed, topical injection of anti-angiogenic treatments (e.g.
ranibizumab/Lucentis) for the exudative (or "wet") form of AMD is now in regular
use in the NHS. Many dermatologic diseases are either angiogenesis-associated or
angiogenesis-dependent e.g. infantile capillary haemangiomas, psoriasis, purpura,
telangiectasia and neurofibromatosis (Chang et al., 2002). The reproductive tract has
been shown to be a site of pathological angiogenesis and manifests as various
gynaecologic diseases such as endometriosis, ovarian cysts and pre-eclampsia
(Ahmad & Ahmed, 2004). Adipose tissue is rich in blood vessels and adipose tissue
mass may be regulated by angiogenesis (Rupnick et al., 2002). In the lungs, reduced
angiogenic signalling is evident in pulmonary fibrosis, pulmonary hypertension and
emphysema (Koyama et al., 2002; Tuder et al., 2001; Kasahara et al., 2000). In the
brain, amyotrophic lateral sclerosis (ALS; progressive motor neuron degeneration)
(Azzouz et al., 2004), Alzheimer's disease (de la Torre, 2004) and stroke (Krupinski
et al., 1994) have been linked to insufficient angiogenesis. Consequently,
modulation of angiogenesis is regarded as an attractive therapeutic goal in a number
of conditions.
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Glucocorticoids are well recognised inhibitors of angiogenesis and this is exploited
in the clinic where they are routinely administered for the treatment of vascular
tumours; for example in the treatment of proliferating capillary haemangiomas of
infancy (Hasan et al., 2000; Hasan et al., 2003). Further, this property is exploited as
a positive control in basic science experiments. The precise mechanism(s) of
glucocorticoid-induced angiostasis, however, is (are) unclear. Preliminary data from
the Endocrinology Unit, University of Edinburgh, along with suggestions from the
literature indicate several possible mechanisms of action but consideration of these
requires a comprehensive understanding of glucocorticoid synthesis and action.
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1.2 Glucocorticoids
1.2.1 Steroid structure and secretion
Glucocorticoids get their name from their effect of raising the level of blood sugar
(glucose). They are a class of steroid hormones alongside mineralocorticoids (e.g.
aldosterone), androgens (e.g. testosterone), oestrogens and progestagens all of which
are synthesized from the common four carbon ring precursor molecule, cholesterol.
Individually, each steroid gains its unique properties as a result of substitution of
chemical groups at various positions on this precursor molecule (Figure 1.3) and by
definition, glucocorticoids are steroids which activate the glucocorticoid receptor
(GR).
Biosynthesis involves a complex cascade of enzymatic cleavages and side-chain
additions, which is subtly different between humans and rodents, ultimately resulting
in production of Cortisol (in humans) and corticosterone (in rodents). Glucocorticoid
synthesis and release from the adrenal gland is controlled by hormonal interactions
between the hypothalamus, pituitary gland and adrenal gland (known as the HPA
axis), and can be influenced by both neural and chemical stimuli. Briefly,
stimulation of the hypothalamus in response to circadian variation entrained to sleep,
and in response to psychological and physical stress results in the release of
corticotrophin releasing hormone (CRH) which travels via the portal circulation to
stimulate CRH receptors present in the anterior pituitary. This results in rapid
release of adrenocorticotrophic hormone (ACTH) into the systemic circulation which
acts via cell surface receptors (melanocortin-2-receptors) on adrenocortical cells to
ultimately stimulate steroidogenesis. Akin to many other biological systems,
glucocorticoids themselves provide a negative feedback loop to regulate their own
secretion. This occurs at the level of the hypothalamus and pituitary and acts to
maintain physiological plasma glucocorticoid levels.
A series of synthetic steroids are potent glucocorticoids, including commonly
prescribed drugs such as prednisolone, dexamethasone and beclomethasone. These






Figure 1.3 Chemical structures of Cortisol and cortisone
Glucocorticoids, in common with other steroids, have a molecular backbone comprising
three cyclohexane rings and a single cyclopentane ring. The unique properties of each
individual steroid are determined by the presence of different chemical groups on the
molecule. Functional groups essential for glucocorticoid activity are the C21 hydroxyl and
the C11 hydroxyl groups as indicated.
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1.2.2 Actions of glucocorticoids
In the blood, glucocorticoids partly circulate freely, but to a greater extent, are bound
to albumin and cortisol-binding globulin (CBG, transcortin) (Hammond et al., 1990).
As steroids, glucocorticoids are lipophilic molecules that are able to pass through the
cell membrane by diffusion and subsequently bind to either mineralocorticoid or
glucocorticoid receptors (MR, GR). Pre-receptor metabolism of glucocorticoids by
the enzyme 11 (1-hydroxysteroid dehydrogenase (11(3-HSD) type 2 prevents illicit
occupation ofMR in mineralocorticoid-sensitive tissues such as the kidney and colon
(Seckl & Walker, 2001). Thus, physiological glucocorticoid effects are
predominantly mediated by binding to GR rather than MR in sites where 11|3-HSD2
is expressed. GR are a member of the nuclear hormone receptor superfamily that
includes receptors for steroids, thyroid hormones, retinoids and vitamin D. The
remainder of this discussion will concentrate on the action of glucocorticoids at GR.
1.2.2.1 Transcriptional effects
The important anti-inflammatory and immunomodulatory effects of glucocorticoids
are mediated predominantly by effects on gene transcription. Their main
characteristics are as follows: First, they are physiologically relevant and
therapeutically effective at very small doses, such as maintenance therapy for many
rheumatic diseases (Buttgereit et al., 2002). Second, the transcriptional action is
slow; significant changes in protein expression are not seen until at least 30 minutes
following receptor-ligand binding (Buttgereit et al., 2004). In the absence of ligand,
GR resides in the cytoplasm as part of a heat shock protein (HSP) complex (Pratt,
1993). Corticosterone binding activates GR where it dissociates from the complex,
interacts with the importin system, and translocates into the nucleus via nuclear pores
(Freedman & Yamamoto, 2004). Here, the steroid-bound receptor binds directly to
specific DNA recognition motifs known as glucocorticoid response elements (GREs)
or negative GREs (nGREs) (Dostert & Heinzel, 2004). These tend to be closely
associated with the promoter region of target genes (Yamamoto, 1985). Therefore,
upon interaction with the cell's transcriptional machinery, activated GRs are able to
either enhance or repress gene transcription (Yamamoto, 1985; Drouin et al., 1993;
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Webster & Cidlowski, 1999; Pelaia et al., 2003), a process termed 'transactivation'.
In keeping with the diverse array of actions of Cortisol, several hundred
glucocorticoid-responsive genes have been identified. Putting this in perspective, it
is estimated that glucocorticoids influence the transcription of approximately 1% of
the entire genome (Goulding NJ & Flower, 2001).
Recent research has uncovered more levels of complexity to this model. Pivotal to
this was the demonstration that glucocorticoids remained effective at suppressing
inflammatory responses in mice in which a point mutation was inserted into the GR
D-loop which prevented dimerisation and hence all transcriptional activation through
the classical pathway and did not rely upon DNA binding (Reichardt et al., 2001).
Consequently, focus shifted towards examination of direct interactions between the
ligand-GR complex and other transcriptional regulators such as nuclear factor-KB
(NF-kB), activating protein 1 (AP-1) and Smad3, which play a central role in the
induction of pro-inflammatory genes (Refojo et al., 2001; De Bosscher et al., 2003).
This 'transrepression' has now emerged as the dominant anti-inflammatory
mechanism of glucocorticoids (Goulding, 2004). Pharmacologically, this is a critical
area of research, as novel anti-inflammatory compounds that dissociate the
transactivating properties of GR from those which repress transcription are reported
to have a better side effect profile. Theoretically at least, these 'dissociated steroids'
possess strong transrepressional activities via inhibition of AP-1 or NF-kB, but weak
transactivation via GREs.
1.2.2.2 Non-transcriptional effects
Some regulatory effects of glucocorticoids arise within a few seconds or minutes and
cannot be explained by the above mentioned transcriptional actions because of the
time required for their occurrence (Cato et al., 2002; Falkenstein et al., 2000;
Croxtall et al., 2000; Hafezi-Moghadam et al., 2002). Much of the initial research
focused on neurophysiological and behavioural systems however, new evidence
suggest that these rapid effects may also impact upon inflammatory responses
(Buttgereit & Scheffold, 2002). One can postulate, therefore, that angiogenesis may
also be regulated in this way although evidence to support this is only just emerging.
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Three different rapid non-transcriptional actions of glucocorticoids are considered
below.
Non-specific actions in the form of physicochemical interactions with cell
membranes suggest that high concentrations of glucocorticoids are able to alter cell
function by influencing cation transport through the plasma membrane. The
resulting inhibition of calcium and sodium cycling across the plasma membrane is
thought to contribute to a 'dampening' of the inflammatory response (Schmid et al.,
2000).
Alternatively, glucocorticoids may also cause specific non-transcriptional actions
that are mediated through membrane-bound GR (mGR) (Bartholome et al., 2004).
The search for mGR has been hindered by a lack of sensitivity of conventional tools
for detecting membrane receptors expressed at low density. The advancement of
more sensitive immunofluorescence techniques and availability of more sensitive
antibodies that distinguish between cytosolic (cGR) and mGR has introduced a
primitive understanding of these receptors. Although there is a growing body of
evidence for their existence, no such data is available pertaining to specific signalling
pathways associated with mGR.
Finally, non-transcriptional effects could be mediated by cytosolic GR (cGR) with no
requirement for either nuclear translocation or effects on transcription. In this case,
chaperones (e.g. heat shock proteins, hsps) or co-chaperones (e.g. Src) act as
signalling components, and therefore, mediators of glucocorticoid effects. Examples
exist of rapid glucocorticoid effects on phospholipase A2 (PLA2) and
phosphoinositide-3-kinase (PI3K)-mediated eNOS release that are blocked by
antagonising ligand binding to GR, but not by transcriptional inhibition (Limbourg et
al., 2002; Hafezi-Moghadam et al., 2002).
Thus there are undeniably rapid effects of glucocorticoids that cannot be explained
by classical transcriptional mechanisms but their relevance to inflammation and
angiogenesis remains speculative.
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1.2.2.3 11 /3-Hydroxysteroid dehydrogenases
The ll(3-hydroxysteroid dehydrogenase (llp-HSD) enzymes catalyse the
inter-conversion of active and inactive glucocorticoids allowing local regulation of
corticosteroid receptor activation, a phenomenon described as pre-receptor
metabolism (Seckl & Walker, 2001). Two isozymes have been identified;
11(3-HSD2 is an exclusive dehydrogenase and converts Cortisol (corticosterone in
rodents) into its inactive metabolite, cortisone (11-dehydrocorticosterone, 11-DHC,
in rodents) (Agarwal el al., 1994), whereas 11(3-HSD1 is predominantly a reductase
in intact cells and whole organs and regenerates Cortisol from cortisone (Agarwal et
al., 1989).
1.2.2.4 Physiological roles of the 11 (3-hydroxysteroid dehydrogenases
11P-HSD1 is widely distributed in glucocorticoid target tissues including liver,
adipose tissue, skeletal muscle, vascular smooth muscle, lung, ovary and brain
(Monder & White, 1993; Stewart & Krozowski, 1999), where its role is to amplify
local glucocorticoid concentrations (Seckl & Walker, 2001) (Figure 1.4).
11P-HSD2 is expressed in the distal nephron of the kidney, colon and sweat glands
where it protects MR from inappropriate activation by glucocorticoids, thereby
allowing aldosterone selective access to otherwise non-selective MR (Edwards et al.,
1988). Congenital absence of this isozyme, as in the case of the syndrome of
apparent mineralocorticoid excess (SAME) (Ulick et al., 1979), or by inhibition with
liquorice or its derivatives (Stewart et al., 1987), causes glucocorticoids to occupy
MR illicitly, resulting in sodium retention, hypokalemia, and hypertension.
11P-HSD2 is also expressed in tissues which are not classic MR targets, including
the lung, lymph nodes, heart, blood vessel wall and placenta. In the placenta,
11P-HSD2 protects the foetus from excessive exposure to maternal glucocorticoids
(Brown et al., 1996), whereas cardiac 11P-HSD2 activity might have a role in
preventing fibrosis resulting from stimulation of MR by glucocorticoids (Konishi et
al., 2003).
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Figure 1.4 Physiological functions of the lip-hydroxysteroid dehydrogenase
isozymes
Diagram of the roles of the 11 P-hyrdroxysteroid dehydrogenase (11P-HSD) enzymes.
11P-HSD2 is an exclusive 11 p-dehydrogenase that acts in classical aldosterone target
tissues to exclude Cortisol from otherwise nonselective mineralocorticoid receptors.
Inactivation of Cortisol also occurs in placenta. 11P-HSD1 is a predominant 11 P-reductase in
vivo that acts in many tissues to increase local intracellular glucocorticoid concentrations and
thereby maintain adequate exposure of relatively low affinity glucocorticoid receptors to their
ligand. Figure taken from (Seckl & Walker, 2001).
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1.2.3 Physiological effects of glucocorticoids
Glucocorticoids influence many physiological systems including; metabolism, the
immune system, the cardiovascular system and growth and development. The
abundant physiological effects of glucocorticoids were first identified from the
clinical observations of the consequences of adrenal disease. Addison's disease, or
hypocortisolism, is a manifestation of glucocorticoid insufficiency and is
characterised by weight loss, decreased appetite, hypoglycaemia and hypotension
(Addison, 1855). Causes include inadequate production of ACTH by the pituitary, or
alternatively, the destruction of the adrenal cortex by the body's own immune system
(auto-immune disease). In contrast, Cushing's syndrome is caused by glucocorticoid
excess and is characterised by increased central fat deposition, impaired glucose
tolerance, hypertension, immunosuppression and impaired wound healing (Cushing,
1912; Gordon et al., 1994). It may be the result of an underlying disease (e.g.
tumour of the adrenal gland), or iatrogenic, e.g. in the case of patients given
long-term corticosteroid treatment for asthma. Since the subject of this thesis
concerns the influence of glucocorticoids on angiogenesis, some of the established
effects of glucocorticoids on the vasculature will be discussed.
1.2.3.1 Glucocorticoid effects on the vasculature
Corticosteroid receptors are present in the cells of the vessel wall supporting the idea
that glucocorticoids interact directly with the vasculature, reviewed in (Hadoke et al.,
2006). GR and MR have been identified in freshly isolated vessels (Christy et al.,
2003) and in cultured vascular cells (VSMCs (Meyer & Nicholls, 1981; Scott et al.,
1987) and endothelial cells (Inoue et al., 1999; Oberleithner et al., 2003)) from a
variety of species, however the distribution of these receptors may vary with vascular
territory. For example, MR were detected in rabbit aortic and pulmonary VSMCs
but not in small arteries (Lombes et al., 1992). Corticosteroid receptors are active in
the vasculature: GR antagonism (with RU38486) blocks dexamethasone-mediated
induction of angiotensin-converting enzyme (ACE) activity in rat aortic endothelial
cells (Sugiyama et al., 2005), and angiotensin II and aldosterone (an MR agonist)
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causes hypertrophy in VSMCs (Hatakeyama et al., 1994), and swelling in endothelial
cells (Oberleithner et al., 2003), respectively .
The downstream effects of GR activation in the vessel wall are imperfectly
understood. Glucocorticoids are essential for maintenance of blood pressure in
healthy individuals (Ullian, 1999) whilst their ability to increase peripheral resistance
in animals devoid of renal mass indicates that a non-renal mechanism contributes to
glucocorticoid-induced hypertension (Langford & Snavely, 1959). A considerable
body of evidence suggests that this non-renal mechanism may involve direct
glucocorticoid-mediated alteration of endothelial cell and VSMC function.
Consequently, regulation of glucocorticoid availability within the vessel wall is
thought to be an important influence on cardiovascular physiology and pathology
(Hadoke et al., 2006).
Glucocorticoids have been shown to influence many aspects of vascular function
including; vascular tone, haemostasis, inflammation, remodelling and angiogenesis
(Hadoke et al., 2006). Some of these properties are exploited clinically. For
example, large doses of glucocorticoids have been used to inhibit angiogenesis in
vascular tumours e.g. in the treatment of proliferating capillary haemangiomas of
infancy (Hasan et al., 2000; Hasan et al., 2003). The precise mechanism of this
glucocorticoid-induced angiostasis is unclear. Furthermore, the adverse effects of
systemic glucocorticoid therapy have restricted their use in this regard.
1.2.3.2 Intra-vascular glucocorticoid metabolism
The influence of 11P-HSD isozyme activity on cardiovascular physiology and
pathophysiology is well recognised (Krozowski & Chai, 2003) but details of the role
of lip-HSDs within the vessel wall have emerged only recently and remain
somewhat uncertain. Both 11P-HSD isozymes are expressed in the blood vessel wall
suggesting that they influence vascular function by regulating local availability of
active glucocorticoids (Ullian, 1999). The cellular distribution of vascular
11P-HSD1 and 11P-HSD2 is not completely clear, and may be both species and
site-specific. Studies from the Endocrinology Unit, University of Edinburgh, using
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rat and mouse aorta suggest that 11(3-HSD2 is localised to endothelial cells, whereas
11P-HSD1 is predominantly expressed in VSMCs (Walker et al., 1991; Christy et
al., 2003). Others have reported activity of both enzymes in human VSMC and
endothelial cells (Hatakeyama et al., 1999; Cai et al, 2001) and in rat aortic
endothelial cells (Brem et al., 1998). Furthermore, the literature suggests that
11P-HSD activity differs in vessels from distinct anatomical beds; in the rat
11P-HSD activity was higher in resistance arteries than in conduit arteries (Walker et
al., 1991), whereas in contrast, in the mouse, lip-reductase activity was higher in the
aorta than in femoral arteries (Dover et al., 2007). These variations in cellular
distribution and activity suggest that the role of intra-vascular glucocorticoid
metabolism is not the same in all blood vessels. Whilst these differences may be
attributable to species and site-specific differences, comparison between studies is
further complicated by the variety of experimental techniques employed (e.g. intact
vessels versus cultured cells, in situ hybridisation versus polymerase chain reaction).
Consequently, there is a need to resolve the contributions of these isozymes to
glucocorticoid metabolism in each experimental model when investigating the
influence of glucocorticoids on vascular function.
Recent studies in the Endocrinology Unit, University of Edinburgh, have
demonstrated that mice with genetic inactivation of lip-FISDl have enhanced
angiogenesis in vitro, in aortic rings, and in vivo (within implanted sponges,
cutaneous wounds and infarcted myocardium) (Small et al., 2005). These intriguing
data suggest that endogenous glucocorticoids, including those generated locally by
11P-HSD1, exert tonic inhibition of angiogenesis in physiology and
pathophysiology. The mechanisms underlying this inhibition, however, remain
unclear. Initial attempts to define this mechanism identified steroid-induced
histological changes in inflammation, cell migration, cell proliferation and ECM
integrity (Folkman & Ingber, 1987). This thesis focuses on the mechanisms of
glucocorticoid-mediated inhibition of angiogenesis, and therefore, a comprehensive
review of the proposed mechanisms is required.
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1.3 Regulation of angiogenesis by glucocorticoids
1.3.1 Discovery of the angiostatic steroids
Using complementary in vitro (chick chorioallantoic membrane assay, CAM) and in
vivo (rabbit cornea) assays, Folkman and colleagues were the first to demonstrate
that cortisone, in the presence of heparin, inhibits angiogenesis (Folkman et al.,
1983). Extending these findings, complete tumour regression was observed in mice
bearing subcutaneous tumours when both compounds were administered. This
activity was retained in nude mice, excluding the possibility that the
heparin-cortisone combination acts by promoting an immune response. Furthermore,
a role for the anti-coagulant function of heparin was ruled out as similar results were
obtained with the non-anti-coagulant hexasaccharide fragment of the heparin
molecule. Using a range of glucocorticoids and mineralocorticoids that lack classical
GR- and MR-mediated effects (deposition of glycogen in the liver, and sodium
excretion in urine, respectively) the same group showed that inhibition of
angiogenesis in the rabbit cornea was independent of these properties (Crum et al.,
1985). For example, 17a-hydroxyprogesterone has no glucocorticoid or
mineralocorticoid activity but has an anti-angiogenic activity equivalent to that of
hydrocortisone. Similarly, otherwise inert tetrahydro-S has twice the angiogenic
activity of hydrocortisone. Taken together, these studies demonstrated a class of
steroids for which inhibition of angiogenesis appears to be the principal function
which were thus named the 'angiostatic steroids' (Crum et al., 1985).
In the rat air-pouch model, tetrahydro-derivatives of cortisone and Cortisol (THE and
THF, respectively), which were amongst the first angiostatic agents to be identified
using the CAM assay (Crum et al., 1985), were unexpectedly shown to increase the
vascularity index (and hence angiogenesis) when administered in combination with
hyaluronan (Alam et al., 1998). Hyaluronan is an essential component of the ECM
that is important during wound healing and is commonly used as a topical drug
delivery system. Hyaluronan on its own does not modulate granulomatous tissue
angiogenesis, in contrast to THF which has an inhibitory effect. Therefore, a
possible explanation for this phenomenon is that tetrahydrosteroids and hyaluronan,
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when in combination, may modulate different cellular processes which converge to
promote angiogenesis. For example, it has been suggested that hyaluronan might
enable access of the steroid to a different cellular compartment than would normally
occur in isolated cell preparations (Alam et al., 1998). Consequently, it is important
to consider the in vivo tissue micro-environment, wherever possible, when
recapitulating angiogenesis in experimental models.
In the subsequent literature conventional glucocorticoids (i.e. GR agonists) and other
angiostatic steroids have often been used somewhat interchangeably. The potential
mechanisms identified are therefore reviewed together in the following section. As
is demonstrated below, however, a wide range of effects of steroids has been
observed, and there is a need to delineate which effects (if any) are mediated by
conventional GR signalling. Moreover, as discussed above, inflammation and
oxidative metabolisms play central roles in the initiation of angiogenesis, so that
there is a need to delineate which effects of steroids are mediated directly in the
vessel wall and which rely on systemic anti-inflammatory and/or metabolic effects.
1.3.2 Mechanisms of action: Experimental evidence
1.3.2.1 Actions on the basement membrane
The definitive mechanism(s) responsible for these angiostatic actions of steroids at
the cellular and molecular level remain imperfectly understood. At the time of their
discovery, Folkman hypothesised that physiologically, angiostatic steroids may act
synergistically with the heparin-like molecules on the surface of the endothelial cell
and within its basement membrane, to prevent capillary growth (Folkman & Ingber,
1987). This proposal was supported by subsequent experimental evidence. First, the
distribution of two major basement membrane components, laminin and fibronectin,
were studied using immunofluorescence microscopy in avascular regions induced by
angiostatic steroids in CAMs (Folkman & Ingber, 1987). As the avascular regions
developed over 48 hours, there was progressive loss of laminin and fibronectin.
Maragoudakis and colleagues showed that the effects of angiostatic steroids were
associated with decreased collagenous protein synthesis in vivo (Maragoudakis et al.,
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1989). Furthermore, regression of growing capillaries was induced
pharmacologically by proline analogues (such as L-azetidine carboxylic acid,
LACA) which interfere with triple helix formation and prevent collagen type IV
deposition (Ingber & Folkman, 1988). Combination of suboptimal doses of proline
analogues with either angiostatic steroids or heparin resulted in potentiation of their
angiostatic effects (avascular zones in 100% of CAMs and larger and more extensive
avascular zones than previously observed with steroid-heparin combinations). In
addition, protection of endogenous tissue heparin from degradation using a synthetic
arylsulfatase inhibitor appears to synergise with angiostatic steroids to induce
capillary regression even in the absence of exogenous heparin (Chen et al., 1988).
Thus, an imbalance in ECM turnover and loss of ECM structural integrity are
thought to play an important role in steroid-induced capillary regression.
Morphologically, degradation of basement membrane leads to gradual rounding, and
eventual detachment, of endothelial cells from the substratum and, ultimately, death
after only a few hours (Folkman & Moscona, 1978). This model also goes some way
towards explaining the specificity of angiostatic steroids for growing capillaries and
not for larger, more mature and quiescent vessels (since capillaries have a much
higher rate of basement turnover). Soon after the discovery of angiostatic steroids in
the CAM, this phenomenon was also shown for murine cerebral endothelial cells in
vivo (Beck et al., 1986) supporting a potential clinical application of these drugs.
Several mechanistic studies have further enhanced our understanding of the
angiostatic effects of steroids through interaction with the basement membrane. The
importance of the basement membrane protein laminin during the organisation of
isolated endothelial cells into tube-like structures (TLSs) is well established (Kubota
et al., 1988; Grant et al., 1989; Grant et al., 1992). Levels of laminin produced by
endothelial cells on an ECM substrate have been shown to be regulated by an
angiostatic steroid (medroxyprogesterone) (Tokida et al., 1990) which in turn, caused
inhibition of TLS formation.
Interactions between cells and the ECM during endothelial tube formation are
important because the matrix provides guidance cues for the establishment of
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endothelial tubes in the absence of cell-cell contacts. It is now clear that this process
is mediated, at the molecular level, via the matrix-integrin-cytoskeletal signalling
axis (Davis & Senger, 2005). Glucocorticoids can influence certain aspects of this
axis, such as regulation of integrin expression in inflammatory situations which are
driven by angiogenesis. In a rat arthritis model, RGD (Arg-Gly-Asp) peptides which
are linked to a carrier (liposome) containing dexamethasone, and targeted to av|33
integrins on endothelial cells, have proved to be efficacious in reducing inflammation
(Koning et al., 2006). Glucocorticoids have also been shown to alter expression
levels of various integrins in isolated cell cultures e.g. down-regulation of the a2
subunit in cytotrophoblasts (Ryu et al., 1999) and up-regulation of av|33 and av(55 in
osteoblasts (Cheng et al., 2000). However, the significance of this is not yet clear
since the pro- versus anti-angiogenic properties of the different integrin sub-units is
still under debate and it remains unclear whether altered integrin expression alone is
central to the angiostatic effects of glucocorticoids. Furthermore, expression of
TSP-1 (which is known to influence endothelial cell function by modulating
cell-matrix interactions (Bornstein, 2001)) may be stimulated by glucocorticoids
(Flugel-Koch et al., 2004) (Rae et al., manuscript submitted).
1.3.2.2 Protease production and activity
Considering that proteases are now accepted to play an essential role in an early, rate
limiting step in angiogenesis (Bellon et al., 2004; Mott & Werb, 2004), the
angiostatic effect of steroids may be mediated by the regulation of endothelial cell
protease production and activity. Steroid-induced inhibition of plasminogen
activator (PA) activity may occur as a result of 2 separate mechanisms: (i) PA
activity is increased in isolated endothelial cell monolayers when stimulated with
bFGF, and this effect is abrogated by the addition of an angiostatic steroid or
glucocorticoids (Blei et al., 1993; Yamamoto et al., 2004). This inhibition appears
primarily due to increased production of plasminogen activator inhibitor type-1
(PAI-1) production by endothelial cells, rather than to a decrease in PA production
(Blei et al., 1993; Yamamoto et al., 2004). (ii) In contrast, Wang and colleagues
showed that decreased invasion (Vitrogen collagen assay) of choroidal endothelial
cells (CECs) by triamcinolone acetate was due to an attenuation of MMP-2 activity
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(Wang et al., 2002b). Other reports support an inhibitory action of angiostatic
steroids on endothelial cell protease activity (Ashino-Fuse et al., 1989; Yamaji et al.,
1999), however in these studies, it was not reported whether this was due to
decreased PA activity, or increased protease turnover. Indeed, it is possible that a
combination of both mechanisms is important in vivo.
Following the in vitro observations of angiostatic steroid-induced PAI-1 activity,
Penn and colleagues provided the first evidence that angiostatic steroids may operate
by the same mechanism in pathophysiology (Penn et al., 2001). Retinopathy of
prematurity (ROP) is a pathologic condition of the retina in which abnormal
angiogenesis can lead to vitreal bleeding and retinal detachment. Increasing
incidence of ROP is linked to new neonatal care strategies that enhance the survival
of very low birth weight babies by supplementation of arterial oxygen (Phelps,
1993). Surgical intervention has limited success so there is; therefore, a need for
preventative therapy. It has been proposed that ROP can be prevented by angiostatic
steroid administration (Penn et al., 2001). Using a rat model of ROP (Penn et al.,
1994), treatment with angiostatic steroid was shown to produce a significant
reduction in the severity of abnormal retinal angiogenesis (Penn et al., 2001)
concomitant with an increase in PAI-1 production. The limited effect of anecortave
acetate (AA) on normal retinal vasculogenesis (Penn et al., 2001), in contrast to its
more profound effect on pathological angiogenesis, further improves its profile as a
potential therapeutic agent.
There may be a role for glucocorticoids in the treatment of other angiogenesis-related
ocular diseases such as choroidal neovascularisation in AMD (D'Amico et al., 2003).
In the developed world, AMD is the leading cause of blindness in individuals 50
years and older. In agreement with their in vitro effects (Wang et al., 2002b),
steroids (dexamethasone plus triamcinolone acetonide, (TA)) reduced the incidence
of experimentally-induced subretinal neovascularisation in monkeys (Ishibashi et al.,
1985) and, more recently, in humans (Hooper & Guymer, 2003; Danis et al., 2000).
Unlike anecortave acetate, TA has glucocorticoid activity and, consequently, it was
speculated that the angiostatic effect of this glucocorticoid in vivo was through dual
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pathways (inhibition of inflammation and altered vascular endothelial cell ECM
turnover) (Hooper & Guymer, 2003). Another report suggests that TA reduces
inflammatory cytokine production (IL-6 and IL-8 release from foetal calf
serum-stimulated fibroblast cultures) (Oddera et al., 2002), further supporting a dual
mode of action for this steroid.
Inhibition of matrix remodelling by steroids may contribute to delayed wound
healing since the MMPs are thought to play an important role throughout the entire
tissue repair process (Xue et al., 2006). However, excessive MMP activity
contributes to the development of chronic wounds and, therefore, selective control of
proteolysis may prove to be a valuable therapeutic approach to promote the healing
of chronic ulcers. In a rabbit ear model, granulation tissue formation (an early,
angiogenesis-dependent stage of wound healing) was not completed when TA was
administered at the time of injury (Hashimoto et al., 2002). In contrast, no
significant difference in healing was observed when the steroid was administered 10
days after injury. This time-dependence suggests that the effect of TA was due to
inhibition of angiogenic growth factor expression (such as VEGF, for example,
which becomes prominent 1 to 3 days after injury (Brown et al., 1992)) during the
early stages of wound healing, or inhibition of matrix synthesis (Hashimoto et al.,
2002). The mode of action of steroids in delayed wound healing, however, has yet to
be shown conclusively (and is likely to be multi-factorial).
1.3.2.3 Effects on growth factor production and growth factor receptors
Glucocorticoids may inhibit angiogenesis by suppressing VEGF production, a key
stimulus of endothelial cell proliferation and migration. Indeed, pharmacological
levels of glucocorticoids have been shown to have anti-mitotic (Beck et al., 1986;
Cariou et al., 1988; Kraling et al., 1999; Banciu et al., 2006; Zou et al., 2006) and
anti-migratory effects (Blei et al., 1993) on endothelial cells through an unknown
mechanism. VEGF from VSMCs is thought to act on endothelial cells in a paracrine
fashion to stimulate endothelial cell proliferation and migration. Glucocorticoids
inhibit VEGF mRNA expression and stability in different cell culture systems
(Nauck et al., 1998; Gille et al., 2001; Wen et al., 2003). In cultures of human aortic
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VSMCs, physiological concentrations of the corticosteroids hydrocortisone,
cortisone and dexamethasone abolished the PDGF-induced expression and secretion
of VEGF (Nauck et al., 1998). In contrast, the cholesterol precursors of these
corticosteroids (desoxycorticosterone and pregnenolone) which have no
anti-inflammatory activity did not have any significant effect in this concentration
range. Thus, in addition to inhibiting the 'classical' mediators of inflammation (such
as arachidonic acid, prostaglandins and leukotrienes) glucocorticoids act as a new
class of VEGF inhibitors. The field is currently expanding to investigate whether
this inhibitory effect is true of other growth factor-induced expression of VEGF, such
as bFGF, and in other cells such as primary fibroblasts from human skin and
pulmonary arteries (Nauck et al, 1998).
Similar findings were obtained using primary chondrocytes obtained from the tibial
growth plates of neonatal pigs (Koedam et al., 2002). This is a model of longitudinal
bone growth, a process that is often disturbed in children undergoing treatment with
glucocorticoids. VEGF protein secretion from these cells, as well as mRNA
transcript, were inhibited by dexamethasone, hydrocortisone and prednisolone. This
is strongly suggestive of a GR-mediated effect. In addition, the authors speculated
that a post-transcriptional regulatory mechanism is most likely to account for
GC-induced VEGF inhibition (Koedam et al., 2002).
Glucocorticoid-mediated inhibition of VEGF could have downstream effects on
other angiogenic factors. For example, VEGF up-regulates COX-2 mRNA, protein
and enzyme activity levels in human microvascular endothelial cells (HMEC-1) in a
dose- and time-dependent manner (Tamura et al., 2002). This effect was abolished
by pre-treatment of cells with a selective COX-2 inhibitor, NS-398, suggesting
specific up-regulation of COX-2 activity by VEGF. New insights into the COX-2
promoter regulatory region have identified several critical elements including: a
cyclic adenosine monophosphate response element (CRE); a nuclear factor for IL-6
expression (NF-IL-6); NF-kB; a polyoma enhancer activator (PEA)-3; and a zinc
finger protein family of transcription actors that recognise the consensus
(A/T)GATA(A/G) and related sequences (Tamura et al., 2002). Indeed, GATA
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binding sites are present in promoters of other genes that enhance endothelial cell
function including PECAM-1 (Gumina et al., 1997), endothelial nitric oxide synthase
(eNOS) (Zhang et al., 1995) and von Willebrand factor (vWF) (Jahroudi & Lynch,
1994).
Data collected from various animal models have validated these in vitro findings.
VEGF has been shown to accelerate gastric ulcer healing by enhancing angiogenesis
at the ulcer site (Jones et al., 2001) but until recently the mechanism was unclear.
Dexamethasone delayed ulcer healing in a rat model, by inhibition of angiogenesis,
and this effect was associated with a decrease in prostaglandin E2 (PGE2) levels and
down-regulation of VEGF (but not bFGF) protein expression (Luo et al., 2004).
Supplementation with PGE2 attenuated the inhibitory action of dexamethasone and
reversed the adverse effects on angiogenesis and ulcer healing. However, PGE2
treatment only partially abrogated the inhibitory action on VEGF expression
suggesting that other mechanisms are responsible. Similar findings were obtained in
larger animal models using other corticosteroids. For example, in a Gottingen
minipig model of osteoporosis, glucocorticoid-associated bone loss in animals that
received prednisolone orally for 8 weeks correlated with a reduction in VEGF
expression levels (Pufe et al., 2003). VEGF-mediated angiogenesis is considered
important in physiological bone turnover and during repair; for example, VEGF is
strongly expressed during the process of fracture healing (Pufe et al., 2002). The
ability of glucocorticoids to inhibit COX-2 activity (and, hence, PGE2 production)
combined with the ability of PGE2 to increase VEGF synthesis (Harada et al., 1994),
may explain the pathway underlying glucocorticoid-mediated reduction in VEGF
activity.
The endogenous oestradiol metabolite, 2-methoxyestradiol (2-ME), has now entered
into phase II clinical trials as an anti-tumour agent (Mooberry, 2003). Preclinical
studies have demonstrated significant efficacy of this agent against solid tumours and
attempts have been made to demonstrate its mechanism of action. In highly
angiogenic pituitary tumours in rats, 2-ME inhibited tumour growth and
angiogenesis, concomitant with a decrease in VEGF expression (Banerjeei et al.,
39
2000). In support of this, Mabjeesh and colleagues found similar efficacy of 2-ME
in vivo against human breast cancer cell (MDA-MB-231) xenografts growing in the
mammary fat-pad of immunodeficient mice (Mabjeesh et al., 2003). The mechanism
of action was further dissected in vitro and it was shown that 2-ME inhibits the
hypoxia-induced DNA binding and transcriptional activity of HIF suggesting that the
regulation of VEGF production may occur at the level of HIF.
The field has now widened to encompass research into glucocorticoid-induced
effects on the VEGF receptors and some recent evidence suggests that
down-regulation of VEGF-R2 contributes to glucocorticoid-induced angiostasis. In a
model of cutaneous wound healing in mice, VEGF-R2 expression was induced in the
wound tissue following full-thickness punch wounds (Zhang et al., 2004).
Bioluminescence from a luciferase reporter, under the control of the VEGF-R2
promoter, was imaged in real time in live animals to produce quantitative
measurements of luciferase activity, and hence VEGF-R2 expression, in the wounds.
Dexamethasone-treated mice had significantly less VEGF-R2 expression during the
healing period compared to saline-treated controls (Zhang et al., 2004). In addition,
histological analysis revealed that VEGF-R2 was predominantly expressed in
endothelial cells suggesting that the endothelium itself may be the site of action of
glucocorticoids. Macrophage infiltration into the damaged tissue was lower in
dexamethasone-treated mice suggesting that anti-inflammatory effects may also
contribute to the delayed wound healing in glucocorticoid-treated mice.
In physiology, lung development in humans involves the formation of pulmonary
alveoli (also known as septation) during the postnatal period. In rats, there is a
critical period for septation to occur, mainly between the 4th and 14th postnatal days,
which is impaired upon administration of corticosteroids (Massaro et al., 1985).
Until recently, the mechanism through which this effect occurs was unclear. It has
now been established that during normal lung development, VEGF and VEGF-R2
production increase in parallel over this period during normal lung development
(Bhatt et al., 2000). SU5416, a synthetic VEGF-R2 inhibitor currently in clinical
trials (Arora & Scholar, 2005), prevented septation and decreased arterial density
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indicating that angiogenesis is important in lung development (Jakkula et al., 2000).
In a study by Clerch and colleagues, dexamethasone-induced inhibition of alveolar
formation revealed that regulation of VEGF-R2 expression (by DNA microarray
analysis of neonatal mouse lung) was central to the angiostatic effects of
glucocorticoids in this system (Clerch et al., 2004). In the same study, validation of
the array data was achieved with concordant findings relating to VEGF-R2 protein,
by Western blotting. The significance of down-regulation of VEGF-R2 during
cutaneous wound healing and in lung development alike is likely to be a result of
attenuating the downstream effects of VEGF signalling of endothelial cell functions
such as survival, migration, proliferation and tube formation, all of which are key
components of the angiogenesis cascade.
1.3.2.4 Modulation of cytokine production
Angiogenesis is required for the progression of chronic inflammation and the
anti-inflammatory effects of glucocorticoids may, at least in part, explain their
angiostatic actions since the 2 processes share many common mediators
(Colville-Nash et al., 1995; Dostert & Fleinzel, 2004; Roman-Bias & Jimenez, 2006).
Common to both processes are vasodilatation, increased vascular permeability and
migration of inflammatory cells, which are mediated by NO, TNF-a, TGF-(J, IL-6,
COX-2 and NF-kB and these are suppressed by large concentrations of
glucocorticoids (Flori et al., 1996; Hasan et al., 2000; Beer et al., 2000; Yossuck et
al., 2001; Blomme et al., 2003).
Clinical studies in people with Cushing's syndrome and use of experimental animal
models suggest that vascular NO metabolism is impaired in the presence of excess
glucocorticoids (Saruta, 1996). This has been supported by evidence in vitro and the
underlying mechanisms are thought to be as a result of a direct effect on inducible
NOS (iNOS) enzyme levels, as well as an indirect effect on enzyme activity by
impairment of co-factor (tetrahydrobiopterin) and substrate (L-arginine) availability
(Whitworth et al., 2002).
41
Glucocorticoids have also been shown to inhibit TNF-a production by human
monocytes in vitro (Waage & Bakke, 1988) and astrocytes (Brenner et al., 1993).
This is of therapeutic importance since dexamethasone may provide a protection
against the development of retinopathy by decreasing the permeability of the
blood-retinal barrier and reducing the damaging inflammatory response. Indeed, this
hypothesis is supported by in vivo evidence; in a mouse model of oxygen-induced
retinopathy, dexamethasone decreased the injury response to hyperoxia (Rotschild et
al, 1999) and this protective effect on the vasculature correlated with a significant
decrease in TNF-a expression (Yossuck et al., 2001).
The differential effects of various angiostatic versus anti-inflammatory steroids on
local cytokine production has been investigated in rodents by subcutaneous
implantation of sterile polyether sponges which elicit a reproducible neovascular
response (Hori et al., 1996). Levels of IL-6 and TNF-a were measured in the
sponges at various timepoints. Among the angiostatic steroids tested, U-24067 and
tetrahydro-S caused a dose-dependent inhibition of sponge-induced angiogenesis but
did not influence the level of cytokine production compared with vehicle and had no
effect on spleen or thymus weight. In contrast, dexamethasone inhibited
angiogenesis concomitant with a marked reduction in the levels of IL-6 and TNF-a
and caused significant spleen and thymus weight loss indicative of a systemic
immunosuppressive effect. In the same study, the angiostatic steroids caused a
reduction in leukocyte infiltration into the sponges. Since these agents lack
'classical' anti-inflammatory glucocorticoid activity, it is feasible that they inhibit
infiltration as a result of their direct inhibition of neovascular growth.
Further evidence has accumulated to support the notion of an angiostatic effect of
glucocorticoids within the vessel wall independent of a systemic inflammatory
response. For example, in the presence of physiological or pharmacological levels of
glucocorticoids, mouse and rat aortic rings embedded in an ECM matrix produced
fewer angiogenic sprouts, respectively (Small et al., 2005; Nicosia & Ottinetti,
1990).
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1.3.2.5 Effects on the arachidonic acid cascade
Glucocorticoids have been shown to influence other facets of the inflammatory
cascade which, in turn may influence angiogenesis. The conversion of arachidonic
acid to PGE2, via COX-2, is induced at the inflammatory site in patients with
rheumatoid arthritis (Crofford et al., 1994) and in experimental animal models of
inflammation (Masferrer et al., 1994). Ghosh and colleagues analysed the role of
COX-2 in angiogenesis, during granulation tissue formation, using the rat air pouch
model (Colville-Nash et al., 1995). Sub-anti-inflammatory doses of either cortisone
or dexamethasone reduced VEGF protein levels, and inhibited angiogenesis, as
measured by an inhibition of the vascular network formation using a vascular casting
method. This effect was shown to be mediated via COX-2-derived PGE2 (Colville-
Nash et al., 1995). PGEi and PGE2 are also key mediators of angiogenesis in the
rabbit cornea and CAM assays (Form & Auerbach, 1983), which are also sensitive to
the effects of angiostatic steroids (Crum et al., 1985). Therefore it is feasible that
regulation of prostaglandin synthesis could be a central mechanism for inhibition of
angiogenesis by steroids.
Others have investigated the effects of steroidal (e.g. betamethasone) and
non-steroidal (e.g. ketoprofen) anti-inflammatory drugs (SAIDs and NSAIDs) on
angiogenesis in the CAM assay. A relatively low concentration (200 nM) of
betamethasone inhibited angiogenesis induced by tumour supernatant, indicating a
genomically-mediated effect (Lemus et al., 2001). Ketoprofen had a similar
angiostatic effect in the subcutaneous sponge implant model but, unlike
betamethasone, it was shown to induce apoptosis in stromal and endothelial cells
which partially may explain its angiostatic properties (Zuniga et al., 2003). Although
the specific mechanism underlying this cell death is not entirely clear, it is possible
that cell death receptor pathways (Fas/CD95, caspase 8) are involved (Kogianni et
al., 2004). NSAIDs may also act indirectly by regulating the balance of pro- and
anti-angiogenic factors locally within tissues. For example, prostaglandins stimulate
VEGF and bFGF expression (Cheng et al., 1998) and sulindac (a NSAID which
inhibits both COX isoforms) inhibi - angiogenesis in implanted sponges in mice
(Illanes et al., 2002). However, sulindac also has properties independent of COX
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inhibition in reducing growth of polyps and pre-cancerous lesions. Treatment of
mice with sulindac, at concentrations that inhibit colon tumour formation, has been
shown to increase TSP-1 production (Moon et al., 2005). Consequently, NSAIDs
may disrupt the normally tightly regulated balance of angiogenesis factors by
up-regulating angiostatic factors as well as inhibiting production of pro-angiogenic
factors.
1.3.2.6 Actions on endothelial cell-leukocyte interactions
Studies of leukocyte adhesion to endothelial cells reinforce the notion that separate
mechanisms exist for the anti-inflammatory and angiostatic properties of
glucocorticoids (Cronstein et al., 1992). The endothelium is known to play a critical
role in inflammation by directing circulating leukocytes into extravascular tissues by
expressing adhesive surface molecules for leukocytes e.g. endothelial-leukocyte
adhesion molecule (ELAM)-l, and intercellular adhesion molecule (ICAM)-l
(Bevilacqua et al., 1987; Walz et al., 1990). Pre-incubation of endothelial cells with
an inflammatory stimulus such as lipopolysaccharide (LPS) leads to an up-regulation
in expression of these markers, and, subsequently, an increase in adherence of
leukocytes (Cadepond et al., 1991). This effect was markedly attenuated by
treatment with dexamethasone (100 nM) and reversed with the GR antagonist
RU38486, indicating that these effects are mediated through GR. Furthermore, in the
study by Cadepond and colleagues Cortisol, but not inactive THF, inhibited
endothelial cell responses to LPS suggesting a GR mediated anti-inflammatory
mechanism (Cadepond et al., 1991). However, the absence of a GRE in the gene for
ELAM-1 transcription suggests that glucocorticoids must either interfere directly
with a regulator of ELAM-1 transcription (such as NF-kB) or a counter-regulatory
element (such as IkB) (Montgomery et al., 1991).
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In summary, glucocorticoids have well established anti-inflammatory effects which
may in part explain some indirect angiostatic effects on the vasculature. It is also
apparent, however, that additional mechanisms, independent of anti-inflammatory
effects, are of central importance.
1.3.2.7 Effects on vessel maturation and stabilisation
Glucocorticoids may inhibit the stabilisation and maturation of nascent angiogenic
sprouts. In support of this hypothesis, an observational study in a sheep model of
preterm labour, in which corticosteroids were administered to enhance foetal lung
maturation, revealed that the capillary tight junctions in the foetal sheep brain were
compromised, via an unknown mechanism (Huang et al., 2001). As described
(Section 1.1.2.1), Angl/Tie2 signalling is important in maintaining inter-endothelial
contacts (Thurston et al., 2000) and thus may be important in the regulation of vessel
maturation by glucocorticoids. In support of this, Feraud and colleagues investigated
Angl and Tie2 production in mouse adrenal atrophy whereby administration of
dexamethasone resulted in down-regulation of Angl and Tie2 mRNA and protein
levels (Feraud et al., 2003).
As well as vessel stabilisation via inter-endothelial contacts, deposition of a new
basement membrane is another sign of maturation of angiogenic sprouting, and may
be a potential target of glucocorticoid action. Indeed, in isolated endothelial cells,
treatment with glucocorticoids causes inhibition of MMP protein levels with a
concomitant increase in TIMP levels and activity (Kraling et al., 1999). This shift in
the proteolytic balance and deposition of a new basement membrane-type matrix has
been shown to reproducibly reduce proliferation of human dermal microvascular
endothelial cells (Kraling et al., 1999) and thus could explain their angiostatic
actions.
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1.3.2.8 Non-transcriptional effects ofglucocorticoids
Previous attention to glucocorticoid-induced inhibitory actions has mainly focused
on transcriptional mechanisms. More recently, post-transcriptional and translational
modes that regulate expression have been identified. Importantly, these effects may
explain similar angiostatic effects of steroids which do not share the same capacity to
activate GR. Glucocorticoids have been shown to play an important role in the
destabilisation of COX-2 transcripts during the IL-1-induced expression of COX-2
mRNA (Buttgereit et al., 1995). Furthermore, Gille and colleagues showed that
glucocorticoids increase VEGF mRNA turnover in keratinocytes indicating
post-transcriptional regulation of gene expression (Gille et al., 2001). In other
instances, glucocorticoids have been shown to inhibit gene expression at the level of
mRNA half-life (Peppel et al., 1991; Garcia-Gras et al., 2000). These effects were
rapid (mRNA was degraded in less than 2 hours) and did not appear to require de
novo protein synthesis since translation inhibition by cycloheximide did not attenuate
or block increased growth factor-induced mRNA turnover caused by dexamethasone.
The poly(A) tail and untranslated regions (UTRs) at the 5' and 3' ends of mRNA
sequences influence stability and have been shown to be involved in
glucocorticoid-mediated mRNA destabilisation in the case of IFN-p (Peppel et al.,
1991) and MCP-1 (Poon et al., 1999) which may explain, in part, the
anti-inflammatory actions of glucocorticoids. However, similar elements appear to
confer stability in the VEGF gene (Gille et al., 2001) and therefore a similar
mechanism may exist to regulate angiogenesis.
Following receptor activation by angiogenic factors (e.g. VEGF and integrins),
multiple signals from transmembrane RTKs form cascades which eventually lead to
gene transcription and a network of cross-talks that ultimately determine cellular
activity. As described previously (Section 1.1.3.2), the MAPK pathway is of
particular importance for transduction of soluble growth factor and ECM-derived
signals, in endothelial cells (Munoz-Chapuli et al., 2004), and MAPK signalling can
be modulated by steroids in a rapid non-genomic fashion in endothelial cells
(Nuedling et al., 1999; Simoncini et al., 2004). These intracellular pathways,
including MAPK, are important in mediating changes in endothelial cells (such as
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morphogenesis, migration, proliferation and survival) and consequently, may be a
target of glucocorticoid-mediated angiostasis. Signalling molecules downstream of
integrin-matrix interactions, such as the Rho guanosine triphosphatases (GTPases; in
the Ras superfamily), have been shown to control actin and microtubule cytoskeletal
networks (Zhao et al., 2006) and, therefore, regulate cell morphogenesis. Selective
glucocorticoid control of Rho kinase isoforms (ROCK1 and ROCK2) regulates
cell-cell interactions (Rubenstein et al., 2007) and it has been suggested that steroids
may control tight junction dynamics which are likely to be important in stabilisation
of angiogenic vessels.
The proposed angiostatic effects of glucocorticoids on endothelial cells are thought
to be dependent on stimulation of GR but may not always involve activation or
repression of GREs. For example, treatment of human endothelial cells with
dexamethasone (100 nM) stimulated eNOS activity, an effect which was blocked by
GR antagonism (RU38486), PI3K inhibition (wortmannin and LY294002) or eNOS
inhibition (N-nitro-L-arginine methylester, L-NAME), but was not blocked by
transcriptional inhibition (actinomycin D) (Hafezi-Moghadam et al., 2002). Again,
this indicates that some of the anti-inflammatory effects of corticosteroids occur via a
non-transcriptional mechanism. In the study by Hafezi-Moghadam and colleagues,
dexamethasone treatment increased the activity of the protein kinase, Akt, indicating
activation of downstream targets of PI3K. Akt has previously been shown to directly
phosphorylate and activate eNOS (Fulton et al., 1999). At present, it is unclear how
GR recruits and activates PI3K and the importance of these non-transcriptional
actions of glucocorticoids in vivo.
Transgenic mice expressing a mutant GR, GR°"n (by introducing a point mutation
into the GR gene), exhibit intact immunosuppressive responses to corticosteroids
(Reichardt et al., 1998). In mutant mice, GR cannot bind GRE and therefore impairs
GRE-dependent transactivation, whereas cross-talk (protein-protein interactions),
which results in the transrepression of AP-1-driven genes, remains intact. Although
several physiological functions are impaired in these mice (e.g. lung development
and depression of the HPA axis) the mutation does not reduce viability (in contrast to
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GR1 mice which die shortly after birth) (Cole et al., 1995). Consequently, these
mice offer an opportunity to dissect angiostatic mechanisms in vivo. Defining the
nuclear and non-nuclear actions of GR will be crucial in the development of selective
GR modulators which could distinguish between the beneficial and harmful effects
of corticosteroids. Discriminating between nuclear and non-nuclear effects of
glucocorticoids in angiogenesis will also be fundamental to understanding their
mechanisms of action.
1.3.2.9 Summary
Although there is a vast amount of evidence that glucocorticoids inhibit angiogenesis
by influencing anti-inflammatory, anti-migratory, anti-proliferative and
anti-basement membrane mechanisms, the relative significance of these interactions
requires further clarification. Further, the influence of physiologically-relevant
concentrations of glucocorticoids on cell function and molecular signalling pathways
has received little attention due to their widespread use as pharmacological
anti-inflammatory agents. Some of the evidence for glucocorticoid-mediated
angiostasis, introduced in this section, does rely on physiological levels of
glucocorticoids and, therefore, serves as a useful basis for investigating their
angiostatic mechanisms. Of particular note, lip-HSDl activity in the vessel wall
influences the angiostatic effects of glucocorticoids by altering the steroid
concentrations locally at sites of angiogenesis (Small et al., 2005) demonstrating that
endogenous glucocorticoids are also essential inhibitors of angiogenesis. However,
again, the cellular and molecular mechanisms that underpin this phenomenon remain
unclear. Finally, it is clear that glucocorticoids can influence diverse cell functions
including differentiation, proliferation and migration through an equally diverse
array of transcriptional and non-transcriptional mechanisms.
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1.4 Hypothesis and aims
Glucocorticoids are recognised inhibitors of angiogenesis although their mechanism
of action has not been establised. Previous studies have indicated that
glucocorticoids can directly alter the function of endothelial cells. Since changes in
endothelial cell function and structure are central to angiogenesis, this suggests that
glucocorticoids may inhibit angiogenesis by direct modulation of the vascular
endothelium.
1.4.1 Hypothesis
It was hypothesised that glucocorticoids act directly on GR on endothelial cells to
inhibit key steps of the angiogenesis cascade including; endothelial cell
morphogenesis, migration and proliferation. Glucocortioid-induced inhibition of
tube formation by endothelial cells is likely be mediated by altered production of
pro- and anti-angiogenic factors (including VEGF and TSP-1).
1.4.2 Aims
1) To establish and characterise an in vitro model of human endothelial TLS
formation and establish methods for assessing endothelial cell migration and
proliferation.
2) To investigate whether physiological glucocorticoids inhibit tube formation
by direct, GR-dependent action on the endothelium.
3) To determine whether glucocorticoids alter gene expression of
pro-angiogenic and angiostatic factors during endothelial TLS formation.
4) To investigate the influence of glucocorticoids on activation of signalling
proteins involved in transduction of VEGF and ECM-derived signals.








Unless otherwise stated all chemicals, reagents and drugs were purchased from
Sigma, Dorset, UK. All radioactivity was purchased from GE Healthcare,
Buckinghamshire, UK. HPLC grade solvents were purchased from Rathburn
Chemicals, Walkerburn, UK. Enzymes for molecular biology were purchased from
Promega, Southampton, UK.
2.2 Buffers and solutions
Bovine serum albumin (BSA) standard: 1 mg/ml in distilled water prepared
from lyophilised powder (supplied in Dc Protein Assay Kit II, Bio-Rad,
Hertfordshire, UK). 1 ml aliquots stored at -20°C.
DNA/RNA gel loading buffer: 20% Ficoll 400 w/v, 1% sodium dodecyl
sulphate (SDS) w/v, 0.25% bromophenol blue w/v, 0.25% xylene cyanol in 0.1M
EDTA, pH 8.0.
Mowiol mounting medium: 20% Mowiol-4-88 w/v (Calbiochem-Merck,
Nottingham, UK), 50% glycerol v/v in PBS. Incubated (overnight at 50°C) with
intermittent vortexing then centrifuged (for 10 minutes at 5000g). Aliquots stored at
-20°C.
20x NuPAGE MES-SDS running buffer: 50 mM 2-(iV-morpholino)
ethanesulfonic acid (MES), pH 7.2, 50 mM Tris-base, 1% SDS v/v, 1 mM EDTA
(ready mixed from Invitrogen, Paisley, UK).
20x Plate wash concentrate: PBS, surfactant, 2% chloroacetamide (ready mixed
from Calbiochem-Merck).
Phosphate buffered saline (PBS): 0.01 M phosphate buffer with 137 mM NaCl,
2.7 mM KC1 in distilled water, pH7.4. Stored at 4°C.
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5x Protein gel loading buffer: 300 mM Tris (pH 6.8), 50% glycerol v/v, 10%
SDS w/v, 12.5% p-mercaptoethanol v/v, 0.01% bromophenol blue w/v in distilled
water. Prepared in fume hood.
Protein lysis buffer: 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 10 mM EDTA,
0.6% Triton X-100 v/v, 10% glycerol v/v in distilled water, stored at 4°C. On day of
use, 1 Complete, Mini Protease Inhibitor Cocktail Tablet (Roche, Basel, Switzerland)
and 1 mM Na3V04 were added to 50 ml lysis buffer and kept on ice.
Reverse transcription lOx buffer: 0.1 M Tris-HCl (pH 9.0), 0.5 M KC1, 1%
Triton X-100 (ready mixed from Promega). Stored at -20°C.
Stripping buffer (for Western blots): 0.2 M glycine (pH 2.5), 1% SDS v/v in
distilled water.
lOx TBE (Tris/borate/EDTA) buffer: 0.9 M Tris-base, 0.9 M boric acid,
20 mM EDTA (pH 8.0) in distilled water, autoclaved before use.
Thermophilic DNA polymerase lOx reaction buffer: 0.1 M Tris-HCl (pH 9.0),
0.5 M KC1,1% Triton X-100 v/v (ready mixed from Promega). Stored at -20°C.
TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH 7.5, autoclaved before use.
5x TNS Tween buffer: 2.5 M NaCl, 100 mM Tris-HCl, 0.5% Tween 20 v/v, in
distilled water, autoclaved before use.
Transfer buffer (for Western blots): 25 mM Tris-base, 192 mM glycine,
20% methanol v/v, in distilled water.
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2.3 Drugs and radiolabeled steroids used in cell culture studies
[3H]4-Cortisol: 15.2 nM commercial stock solution of [3H]-Cortisol in
ethanol, stored at -20°C.
Cortisol: (FW: 362.46) 50 pM hydrocortisone, 0.2% ethanol v/v, 145 mM NaCl
in water, sterile-filtered (ready mixed from Sigma). 1 ml aliquots stored at -20°C.
[3H] 4-Cortisone: 22.2 nM commercial stock solution of [3H]-Cortisone in
ethanol, stored at -20°C.
Cortisone: (FW: 360.44) 36.04 mg cortisone was made up to 10 ml with ethanol
(102 M solution), then 10 pi was added to 10 ml deionised water (10~5 M solution).
1 ml aliquots stored at -20°C.
Fibroblast Growth Factor-Basic (bFGF): 25 pg human recombinant fibroblast
growth factor-basic (bFGF) was made up to 1 ml with 5 mM Trizma-HCl, pH 7.6
and filtered (0.2 pm, 25 pg/ml solution). 50 pi aliquots stored at -20°C.
PD98059: (FW: 267.28) 5 mg of PD98059 (Calbiochem-Merck) were dissolved
in 374 pi of DMSO (50 mM solution). 50 pi aliquots stored at -20°C and protected
from light.
Platelet factor 4: 72.4 pM of human platelet factor 4 in 20 mM Tris-HCl, 2 M
NaCl, pH 7.4 (Cambridge Biosciences, Cambridge, UK) were diluted in PBS to give
34.5 pM solution. 50 pi aliquots stored at -20°C.
Prostaglandin E2: (FW: 352.47) 5 mg of prostaglandin E2 were dissolved in
142 pi of ethanol (101 M solution), then 2 serial dilutions (1:100) in deionised water
(10~5 M solution). 1 ml aliquots stored at -20°C.
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Prostaglandin F2tt: (FW: 475.62) 1 mg of prostaglandin F2(X tris salt was dissolved
in 210 pi of ethanol (10~2 M solution), then 10 pi were added to 10 ml deionised
water (10~5 M solution). 1 ml aliquots stored at -20°C.
RU38486: (FW: 429.59) 42.96 mg RU38486 (mifepristone, a gift from Dr Roger
Brown, Endocrinology Unit, University of Edinburgh) were dissolved in 10 ml of
ethanol (10 2 M solution), then 100 pi were added to 10 ml deionised water (10 4 M
solution). 1 ml aliquots stored at -20°C.
Spironolactone: (FW: 416.57) 41.66 mg spironolactone were dissolved in
10 ml of ethanol (10 2 M solution), then 100 pi were added to 10 ml deionised water
(10 4M solution). 1 ml aliquots stored at -20°C.
SU5416: (FW: 238.28) 5 pg of SU5416 were dissolved in 1 ml of DMSO
(21 mM solution). 100 pi aliquots stored at -20°C.
Vascular Endothelial Growth Factor (VEGF): 10 pg human recombinant
vascular endothelial growth factor) 6s were dissolved in 100 pi of water (100 pg/ml
solution). 10 pi aliquots stored at -20°C.
2.4 Cell culture
2.4.1 Transfected Chinese Hamster Ovary cell culture
Chinese Hamster Ovary (CHO) cells transfected with human 11(3-HSD1 and
11|3-HSD2 (CHO-hlip-HSDl and CHO-hll|3-HSD2, respectively) were a gift from
Dr Scott Webster, Endocrinology Unit, University of Edinburgh. These were used as
positive controls for llp-HSD activity experiments. Cells were cultured in Ham's
F12 medium containing 10% foetal bovine serum (FBS), penicillin-streptomycin
(1 U/ml, 1 pg/ml) and 2 mM L-glutamine (all from Lonza Wokingham, Berkshire,
UK). Cell cultures were maintained at 37°C, 5% C02 in a humidified atmosphere
and growth medium was replaced every 2 days. At 90-95% confluency cells were
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washed twice in 4 ml PBS and detached from the flask by incubating with 3 ml
trypsin-versene (EDTA) (Lonza) at 37°C for up to 5 minutes with gentle agitation.
Trypsin-versene was neutralised by adding 15 ml of medium (containing serum) to
the flask and removed by centrifugation (at 1000 rpm for 5 minutes at room
temperature) and disposal of supernatant. Cells were resuspended in fresh medium
and divided into new 75 cm2 flasks using split ratios of between 1:10 and 1:15.
2.4.2 Human umbilical vein endothelial cell culture
Primary human umbilical vein endothelial cells (HUVECs) were obtained from
Promocell, Heidelberg, Germany. Each batch of cells had been pooled from multiple
donors by the supplier and arrived as proliferating cultures in 25 cm2 flasks. Cells
had been phenotypically characterised by the supplier and were positive (by
immunofluorescence) for endothelial markers (Platelet Endothelial Cell Adhesion
Molecule-1 (PECAM-1/CD31), von Willebrand Factor (vWF)) and showed uptake
of fluorescently-labelled acetylated low density lipoprotein (Dil-Ac-LDL) and were
negative for smooth muscle a-actin (a-SMA). Cells were used between passage
number (p) 2 and 6 in all experiments discussed in this thesis. Attempts to
cryopreserve HUVECs to extend the lifespan of a single batch proved unsuccessful;
therefore, cells were discarded after reaching p6. Cell cultures were maintained
according to the supplier's recommendations at 37°C, 5% CO2 in a humidified
atmosphere and growth medium was replaced every 2 days. HUVECs were
routinely cultured in endothelial cell growth medium-2 (EGM-2) Bullet Kit medium
(Lonza) supplemented with heparin, ascorbic acid, GA-1000, 2% FBS, hFGF-B,
VEGF, R3-IGF and hEGF as recommended by the supplier. Hydrocortisone
(Cortisol), however, was omitted. At 70-80% confluency cells were washed twice in
4 ml HEPES buffered saline solution and detached from the flask by incubating with
3 ml trypsin/EDTA (Reagent Pack subculture Reagent Kit, Lonza) at 37°C for up to
5 minutes with gentle agitation. Trypsin/EDTA was removed and neutralised by
adding 4 ml of trypsin neutralising solution (TNS) to the flask. Cells were divided
into new 75 cm2 flasks using split rat'os of between 1:4 and 1:10.
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2.4.3 Human aortic endothelial cell culture
Human aortic endothelial cell (HAoEC) culture was performed by Miss Sadaf Ali
under my supervision. Primary HAoECs were obtained from Promocell. A single
batch of cells from a 26 year old, Caucasian male arrived as a proliferating culture in
a 25 cm2 flask. Cells had been phenotypically characterised by the supplier and were
positive (by immunofluorescence) for endothelial markers PECAM-1/CD31 and
vWF, showed uptake of Dil-Ac-LDL and were negative for a-SMA. Cells were
used between p2 and p6. Cell cultures were maintained according to the supplier's
recommendations at 37°C, 5% C02 in a humidified atmosphere and growth medium
was replaced every 2 days. HAoECs were routinely cultured in EGM-MV medium
(Promocell) supplemented with 5% FBS, 0.4% endothelial cell growth
supplement/heparin (ECGS/H), 10 ng/ml hEGF, 50 pg/ml gentamicin and 50 mg/ml
amphotericin included in the supplement pack. Hydrocortisone (Cortisol), however,
was omitted. At 70-80% confluency cells were washed twice in 4 ml HEPES
buffered saline solution and detached from the flask by incubating with 3 ml
trypsin/EDTA (Reagent Pack subculture Reagent Kit, Lonza) at 37°C for up to 5
minutes with gentle agitation. Trypsin/EDTA was removed and neutralised by
adding 4 ml of trypsin neutralising solution (TNS) to the flask. Cells were divided
into new 75 cm2 flasks using split ratios of between 1:4 and 1:10.
2.4.4 Cell counting
In all cell culture assays cell counting was performed to ensure consistency of cell
density between experiments. Briefly, following trypsinisation, cells suspended in
TNS were pipetted into a sterile 15 ml Falcon tube centrifuged (at 1000 rpm for 5
minutes at room temperature), the supernatant drained and the pellet resuspended in
1 ml of the appropriate experimental medium (see relevant sections for details).
10 pi of cell suspension were added to 90 pi of 0.4% trypan blue solution, mixed by
gentle agitation and approximately 30 pi were placed into a haemocytometer and the
number of cells counted. The number of cells per ml was determined using the
standard formula:
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cells/ml = number of cells counted x dilution factor
number of squares counted x volume of 1 square
2.4.5 Endothelial tube-like structure formation assay
The endothelial tube-like structure (TLS) assay was chosen since it recapitulates one
of the key steps in the angiogenesis cascade, the differentiation of endothelial cells
into tubules, and is considered to resemble the in vivo process (Lawley & Kubota,
1989). Since the subject of this thesis was to dissect out the mechanisms of
glucocorticoid-induced angiostasis, a rapid, easy to perform, quantitative assay
amenable to protein and RNA extraction and immunostaining was required. The 2D
TLS assay has all of these attributes. Extensive methodological development
(discussed in Chapter 3) was undertaken to arrive at the following, final assay
conditions.
2.4.5.1 Culture conditions
HUVECs (4 x 104 cells/ml/well) resuspended in standard basal medium were seeded
into wells pre-coated with 250 pi of standard Matrigel (BD Biosciences, Oxford,
UK) in a 24-well, flat-bottomed microtiter plate (Cellstar-Greiner Bio-One,
Gloucestershire, UK). Standard basal medium comprised EGM-2 (Lonza)
supplemented with ascorbic acid, heparin and GA-1000; however, no growth factors
or serum supplied with the bullet kit were added. Growth factors, steroids and
established inhibitors were added immediately at the time of cell seeding, where
indicated in appropriate results chapters, and well contents were mixed by gentle
agitation. Plates were incubated for up to 24 hours at 37°C, 5% CO2, in a humidified
atmosphere.
2.4.5.2 Quantification of tube-like structure formation
Quantification of TLS formation was performed by inverted light microscopy (Carl
Zeiss Axiovert 25, Carl Zeiss, Hertfordshire, UK) and image analysis. Images at low
magnification (x5) at the centre of each well were captured after 4-5 hours and 21-24
hours of incubation and saved for analysis. Images were captured using the
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Microcomputer Imaging Device (MCID) from a live-feed camera (Pentax 250,
Pentax, Slough, UK) using MCID Basic v7.0 software (InterFocus Imaging, Linton,
UK). Image files were randomised by a different person to ensure quantification was
performed by an individual blind to treatment groups to ensure the integrity of the
results. Capillary connections, defined as the number of branch points between 2 or
more TLSs, were identified and marked using Adobe Photoshop cs (Adobe System
Inc, California, USA) software. Total numbers of capillary connections per field of
view were counted and tallied using a cell counter. In all experiments, each
condition was performed in triplicate wells.
2.4.5.3 Time-course oftube-like structure formation
To determine the time-course of TLS formation, the nature of the endothelial cellular
changes, and the mechanism through which Cortisol inhibits TLS formation,
time-lapse videomicroscopy was used. Technical assistance with time-lapse
equipment was provided by Mr Bob Morris and advice on videoclip preparation was
provided by Professor Adriano Rossi, Centre for Inflammation Research, University
of Edinburgh.
Sterile, polystyrene (9.0 cm2) SlideFlasks (Nunc, New York, USA) were pre-coated
with 750 pi Matrigel and allowed to set for approximately 60 minutes. HUVECs
(2 x 105 cells) in 2 ml of endothelial basal medium containing 5 mM HEPES
buffered saline solution were seeded onto the Matrigel. Treatments were added at
the time of cell seeding and immediately thereafter (within 10 minutes), stage
position settings and focus adjustments were made then image acquisition started.
Images were acquired with a Leica DM IRBE microscope using a xlO objective and
captured with a Leica Q500MC image processing system (Leica Cambridge Ltd.,
Cambridge, UK). Images were captured from 3 separate positions per flask at 4
minute intervals for 24 hours where possible. TLS counting was used to assess the
time course of TLS formation. From time-course graphs, time to reach peak number
of TLSs and maximum number of TLSs were determined.
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2.4.6 Characterisation of tube-like structures
2.4.6.1 Structural composition of tube-like structures
The structural composition of TLSs was assessed by immunofluorescent staining of
filamentous-actin (F-actin) and microtubules (a-tubulin), important components of
the cytoskeleton. Antibodies, expertise in immunofluorescence staining protocols,
and fluorescence microscopy were provided by Dr Kate Marshall, Centre
Cardivascular Science, University of Edinburgh.
HUVECs were resuspended (4 x 104 cells/ml) in 'experimental' medium and 1 ml
per well was seeded onto sterilised round coverslips (13 mm; 0 thickness) pre-coated
with 30 pi of phenol red-free Matrigel in a 24-well, flat-bottomed microtiter plate
(Cellstar-Greiner Bio-One, UK). Experimental medium consisted of EGM-2
medium (Lonza, UK) supplemented with heparin, ascorbic acid, GA-1000, and 2%
charcoal-stripped FBS (a gift from Miss Tijana Mitic, Endocrinology Unit,
University of Edinburgh); no growth factors from the Bullet kit were added. Cortisol
(600 nM) was added immediately at the time of cell seeding, as indicated. After 1, 4,
10 and 22 hours of incubation, medium was removed by gentle aspiration and
cultures fixed (for 3 minutes at room temperature) with 4% paraformaldehyde in
Dulbecco's PBS v/v. Cultures were rinsed (once for 2 minutes) in 0.05% Triton X
100 in PBS v/v, permeabilised (once for 3 minutes) in 0.1% Triton X 100 in PBS v/v,
blocked (for 1 hour at room temperature) in 3% BSA in PBS v/v, then rinsed again
(twice for 2 minutes). Cultures were incubated with (1:1000 in 0.3% BSA in PBS
v/v) mouse monoclonal anti-a-tubulin (clone B512) antibody (Sigma) for 1 hour at
room temperature then rinsed again (twice for 2 minutes). Cultures were incubated
with (1:500 in 0.3% BSA in PBS v/v) goat anti-mouse IgG (H+L) Alexa Fluor 594
secondary antibody (Molecular Probes-Invitrogen, Paisley, UK), for 1 hour at room
temperature, protected from light then rinsed again (twice for 2 minutes). Direct
fluorescent staining of F-actin was achieved with (1:500) phalloidin Alexa Fluor 488
(Molecular Probes-Invitrogen) and staining of DNA with 0.2 pg/ml
4',6-diamidino-2-phenylindole dihydrochloride (DAPI) which were included along
with the secondary antibody. Coverslips were carefully removed from the wells with
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tweezers, inverted, and mounted on Superfrost Plus microscope slides (VWR
International, Leicestershire, UK) using Mowiol mounting medium (approximately
30 pi) and stored protected from light. Slides were viewed by an Olympus AX-70
fluorescence microscope (Olympus Optical Company, London, UK) and images
captured with a Hamamatsu Orca-ER digital live-feed camera and controller
(Hamamatsu Photonics, Hertfordshire, UK) using Smart Capture 3 software (Digital
Scientific, Cambridge, UK).
2.4.6.2 Functional composition of tube-like structures
The endothelial nature of TLSs was assessed by immunocytochemistry for an
endothelium-specific cell surface marker (CD31). HUVECs (1 x 104) were cultured
in 250 pi of standard basal medium for 5 hours on 8-well permanox chamber slides
(Nalge-Nunc, Hereford, UK) pre-coated with 100 pi of standard Matrigel. Staining
was performed using Vectastain's avidin: biotinylated (peroxidase) enzyme complex
(ABC) Kit (Vector Laboratories, California, USA) as a secondary detection system
according to manufacturer's instructions. Briefly, culture medium was gently
removed by aspiration, TLSs rinsed with PBS and fixed with 10% formalin.
Quenching of endogenous peroxidase activity was achieved by incubating (for 30
minutes at room temperature) with 0.3% hydrogen peroxide in distilled water, v/v.
Cultures were incubated (for 30 minutes at room temperature) with diluted rabbit
serum then with rat anti-mouse CD31 (1 in 50 dilution, overnight at 4°C) monoclonal
antibody (BD Pharmingen, Oxford, UK). For negative control, the primary antibody
was omitted. The following day, cultures were rinsed (x3) with PBS then incubated
(for 30 minutes at room temperature) with biotinylated rabbit anti-rat secondary
antibody then further rinsing (x3) in PBS. Next, slides were incubated (for 30
minutes at room temperature) with Vectastain ABC reagent then further rinsing (x3)
in PBS. Finally, slides were incubated for 5 minutes with 3,3'-diaminobenzidine
(DAB) (Vector Laboratories) as a chromogenic substrate for the peroxidase moiety
with positive structures staining brown. The reaction was stopped with running tap
water and coverslips mounted using an aqueous medium. Slides were viewed by
light microscopy (Carl Zeiss Axioskop, Carl Zeiss, Hertfordshire, UK) and images
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2.4.7 Reverse transcription-polymerase chain reaction
Reverse-transcription-polymerase chain reaction (RT-PCR) allows the detection and
amplification of specific mRNA species from isolated total RNA and was used to
investigate expression of corticosteroid receptors and 1 lp-HSDs in endothelial cell
preparations. Using conditions provided by a commercially available kit (Reverse
Transcription System, Promega) the Avian myeloblastosis virus reverse transcriptase
(AMV-RT) enzyme transcribes mRNA into single stranded cDNA, the necessary
template for Taq polymerase (Taq bead Hot Start Polymerase, Promega).
Subsequent PCR amplification consists of a number of cycles during which the
cDNA template is repeatedly denatured, annealed with target-specific primers and
replicated using Taq polymerase. Following 20-40 cycles the amplified DNA can be
analysed for size and quantity using gel electrophoresis.
Only RNase-free, sterile solutions and equipment were used for RT-PCR in order to
prevent degradation of target RNA by exogenous RNases and contamination of
reactions with exogenous RNA or DNA. All reactions were prepared on ice unless
otherwise stated.
2.4.7.1 Tissue preparation
Intact tissues Livers from C57B16 mice aged 10-12 weeks were frozen on dry ice
immediately after dissection from the animal for use as a positive control for
lip-HSD l mRNA expression. Tissues were stored at -80°C until required. RNA
extracted from human kidney was a gift from Dr Elaine Marshall, Endocrinology
Unit, University of Edinburgh.
Undifferentiated cell monolayers Flasks of HUVECs and CHO-transfected cells
at 70-95% confluency were rinsed with PBS (2x4 ml) and were removed directly
from the culture flask by addition of 3-4 ml of TRIzol Reagent (Invitrogen). The
contents were transferred to a 15 ml sterile Falcon tube and stored at -80°C until
required.
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Endothelial tube-like structures The use of MatriSperse Cell Recovery Solution
(Matrisperse; BD Biosciences) is recommended by the manufacturer as a highly
reproducible method of recovering endothelial cells from Matrigel matrix for
subsequent biochemical analysis. Matrisperse depolymerises Matrigel at 2-8°C
without enzymatic digestion and/or lengthy incubation periods at high temperatures
thereby avoiding biochemical changes and digestion of extracellular portions of cell
surface receptors and adhesion molecules. The manufacturer's protocol was
followed in a pilot experiment but extremely low RNA yields necessitated method
optimisation and fewer PBS washes were used. These modifications improved
efficiency of cell recovery and resulted in improved RNA yields.
Briefly, medium was aspirated from TLS cultures on Matrigel-coated, 35 mm cell
culture dishes and structures were washed twice with cold PBS. Matrisperse (2 ml)
was added to each dish and the contents scraped and transferred to a 50 ml Falcon
tube sitting on ice. Dishes were rinsed with a further 3 ml of Matrisperse and
contents transferred to the tube. Tubes were inverted periodically (45 minutes to 1
hour) to aid dissolving of gel. After complete release from gel, cells were
centrifuged to a pellet (at 1200 rpm for 5 minutes at 4°C), washed once by gentle
resuspension in ice cold PBS and centrifugation, and the supernatant discarded. 1 ml
of Trizol was added to the cell pellet and the contents transferred to a cryovial for
storage at -80°C until required.
Endothelialprogenitor cells RNA extracted from endothelial progenitor cells was a
gift from Dr John McDermott, National University of Ireland, Galway, Republic of
Ireland. RNA was isolated from peripheral blood from 3 healthy human volunteers.
2.4.7.2 RNA extraction
RNA extraction was carried out using Trizol, a mono-phasic solution containing
phenol and guanidine isothiocyanate. This reagent maintains RNA integrity whilst
disrupting cells and dissolving cell components.
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Tissue homogenization Ice-cold Trizol (1 ml) was added to a 50-100 mg piece
of frozen liver dissected from the rest of the organ and placed in a 2 ml sterile
eppendorf tube. Samples were homogenised on ice using an Ystral mechanical
homogeniser (Scientific Instruments Centre, Hampshire, UK). Samples were
centrifuged (at 12,000g for 10 minutes at 4°C) to remove insoluble material and
small amounts of unhomogenised tissue. The resulting supernatant was removed to a
fresh eppendorf.
Phase separation Following homogenisation of tissue, and thawing of cells and
TLSs in Trizol, samples were allowed to equilibrate to room temperature then left for
5 minutes to allow complete dissociation of the nucleoprotein complexes.
Chloroform (0.25 ml for cells and TLSs, 0.3 ml for liver) was then added to each
sample. Samples were mixed vigorously by vortexing (15 seconds) then incubated
(at room temperature for 3 minutes). Samples were centrifuged (at 12,000g for 15
minutes at 4°C) resulting in a lower red phenol-containing phase (containing
proteins), an interface (containing DNA and denatured proteins) and an upper
aqueous phase (containing RNA).
RNA precipitation The upper aqueous phase from each sample was transferred
into a fresh eppendorf. RNA was precipitated by addition of 20 pi (for cells and
TLSs) and 30 pi (for liver) of well-resuspended RNaid matrix (Anachem,
Bedfordshire, UK). Following addition of matrix, samples were vortexed and mixed
by gentle agitation by hand for 5 minutes. Samples were centrifuged (at 12,000g for
1 minute at room temperature) and formed an obvious white pellet of matrix
containing RNA precipitate.
RNA wash Following centrifugation the supernatant was removed and the pellet
was washed with 0.5 ml of RNA wash buffer (containing 37.5% ethanol v/v) by
careful mixing with sterile 1 ml filter pipette tips. Once fully resuspended, samples
were vortexed for 15 seconds and centrifuged (at 12,000g for 1 minute at room
temperature) to pellet. The wash step was repeated a further 2 times and samples
were kept on ice, where possible, throughout.
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RNA resuspension Following the last RNA wash the pellet was resuspended in
18 pi (for cells and TLSs) and 30 pi (for liver) of nuclease-free water (Promega)
containing 10 mM dithiothriotol (DTT) and Recombinant RNasin Ribonuclease
Inhibitor (RNasin; Promega, Southampton, UK). Samples were then incubated at
55°C for 12 minutes (vortexing after 6 minutes) and quickly centrifuged (at 12,000g
for 1 minute at 4°C) to pellet. The supernatant containing RNA was carefully
removed by pipette, avoiding transfer of matrix, to a fresh eppendorf and stored at
-80°C until required.
RNA quantification and integrity Before use, RNA was quantified using a
GeneQuant RNA/DNA Calculator (Pharmacia Biotech, Uppsala, Sweden). RNA
was diluted 1:100 in nuclease-free water and the optical density at A,260nm and
A.280 nm was determined to assess concentration and purity.
To assess RNA integrity, RNA samples were run on a 1.2% agarose gel stained with
0.001% (v/v) of 10 mg/ml ethidium bromide. Intact total RNA run on an agarose gel
will have sharp, clear 28S and 18S ribosomal RNA (rRNA) bands. The 28S rRNA
band should be approximately twice as intense as the 18S rRNA band indicating that
the RNA is completely intact. All RNA samples were confirmed to have
approximately 2:1 ratio (28S:18S) before proceeding with RT-PCR.
2.4.7.3 Reverse transcription
First strand complementary DNA (cDNA) synthesis was performed using the
Reverse Transcription System (Promega, Southampton, UK). 0.5 pg of total RNA
was reverse transcribed in a reaction mixture containing 5 mM MgCl2, lx reverse
transcription buffer, 1 mM each of dATP, dCTP, dGTP and dTTP, 20 units (U)
RNasin, 0.5 pg oligo(dT)is primers and 15U AMV-Reverse Transcriptase made up
to 20 pi in nuclease-free water. The reactions were carried out on an Eppendorf
Mastercycler Gradient (Eppendorf, Hamburg, Germany) with a heated lid. The
programme consisted of incubation at 42°C for 45 minutes followed by 95 °C for 5
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minutes and finally chilled to 4°C to inactivate the enzyme and prevent binding to
DNA.
Negative control reactions for each experiment were performed in parallel with
samples. A reaction was performed as above using an RNA sample chosen at
random in the absence of AMV-reverse transcriptase in order to determine genomic
DNA contamination. Additionally, a negative control reaction containing
nuclease-free water instead of RNA was performed to determine RNA contamination
of the Reverse Transcriptase System reagents. Products from the RT reactions
(cDNA) were diluted 1:5 with nuclease-free water prior to PCR amplification.
2.4.7.4 Polymerase chain reaction
5 pi of cDNA template was used in each PCR reaction containing lx Thermophilic
DNA polymerase reaction buffer, 1.5 mM MgCl2, 0.2 mM dNTP mix (consisting of
dATP, dCTP, dGTP and dTTP), 40 pmol gene-specific upstream primer and 40 pmol
gene-specific downstream primer made up to 50 pi in nuclease-free water. One
TaqBead (1.25U) was added to each reaction tube before starting the required PCR
programme. A negative control reaction containing nuclease-free water rather than
cDNA was performed where necessary to determine contamination of PCR reagents.
PCRs were carried out on an Eppendorf Mastercycler Gradient with a heated lid.
Samples were heated to 95 °C for 5 minutes for initial denaturation then underwent
35 cycles of PCR amplification (denaturation at 90°C for 1 minute, primer annealing
at primer-specific temperature for 1 minute and elongation at 72°C for 2 minutes).
Upon completion of PCR programme, samples were incubated at 72°C for a further 5
minutes to ensure elongation of products to full length and chilled to 4°C prior to gel
electrophoresis. 35 cycles of amplification were used as standard throughout these
non-quantitative RT-PCR experiments, and were shown to enable detection of all of
the genes examined. Gene specific primer sequences and annealing temperatures are
detailed in Table 2.1.
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2.4.7.5 Gel electrophoresis
RT-PCR products were analysed by electrophoresis on a 1.2% agarose gel. Gels
were prepared by melting 1.2% (w/v) agarose (Lonza) in 0.5x Tris/Borate/EDTA
(TBE) buffer and adding 0.001% (v/v) of 10 mg/ml ethidium bromide to stain the
gel. After pouring the gel mould with appropriately sized combs in place, gels were
allowed to set at room temperature then placed in 0.5x TBE in a gel tank.
20 pi of DNA step ladder containing fragments ranging from 100 base pairs (bp) to
4000 bp in 100 bp increments were loaded into the first well on each gel to allow
determination of product size. 20 pi of each RT-PCR product were mixed with 4 pi
loading buffer and loaded into individual wells of the gel. Gels were electrophoresed
at 100V for 45 minutes-1hour, until the loading buffer migrated approximately 6 cm
from the well, and then photographed under UV light at X260 nm. It should be noted
that whilst PCR products were not sequenced due to time constraints, all RT-PCR
reactions resulted in the production of a single product which corresponded with size
predicted following primer design.
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Tie2 Forward: 5'-TCA CTC CAG TAT CAG CTC
AAG GG-3"
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11P-HSD2 Forward: 5'-TAG CTG CAT GGA GGT GAA
TTT CTT TGG-3'








GR Forward: 5'-TGT GGT TTA TAG AGG GCC
AAG ACT TGG-3'
Reverse: 5'-GGC ACA ACT TCC CTT TTC










Table 2.1 PCR primer sequences, positions and reaction conditions
Human tissue-specific Tie2 primer sequences were taken from Dr Clare Christy's PhD thesis
(Endocrinology Unit, University of Edinburgh, 2003). 11P-HSD1 primers were designed by
Dr Karen Chapman and GR primers by Dr Roger Brown (both Endocrinology Unit, University
of Edinburgh) and detect human and rodent mRNA. Human tissue-specific 11P-HSD2
primers were designed by Dr Roger Brown. The position of the forward primers (FP) and
reverse primers (RP) on each gene are shown schematically.
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2.4.8 Quantitative real time-polymerase chain reaction
To examine the influence of glucocorticoids and GR blockade on TLS gene
expression, quantitative real time-PCR (Qrt-PCR) was used. Qrt-PCR is used to
measure the quantity of cDNA present in a sample and is a modification of PCR
since the amount of double-stranded DNA product is measured after each round of
amplification (in "real-time") using gene sequence-specific primers, a fluorescent
reporter probe and light cycler detection system. These data can be analysed by
computer software to calculate cDNA copy number with reference to a standard
curve based on dilution standards from pooled samples from the same experiment.
Theoretically, equal amounts of RNA from each sample are reverse transcribed in the
first instance to cDNA. However, in order to correct for differences in abundance
and efficiencies in the RT reaction between samples, data are normalised against a
stably transcribed gene ("housekeeping gene" or internal control) to precisely
measure total amount of sample.
2.4.8.1 TLS preparation and treatment
HUVECs (200,000) in 2 ml of standard basal medium were seeded on 35 mm cell
culture dishes pre-coated with Matrigel (500 pi) and incubated in the presence of
Cortisol (600 nM), Cortisol plus RU38486 (1 pM), or left untreated (control). RNA
was recovered using Matrisperse solution (Section 2.4.7.1) after 1 hour, 4 hours, 8
hours and 22 hours of incubation to examine the timecourse of TLS gene expression.
1 ml of Trizol was added to the cell pellet and the contents transferred to a cryovial
for storage at -80°C until required.
2.4.8.2 RNA extraction and quantification
RNA extraction and quantification was performed using the Trizol method and
GeneQuant RNA/DNA Calculator (Pharmacia Biotech) as previously described
(Section 2.4.7.2). Due to the large quantity of samples, RNA extraction was
performed on batches of up to 40 samples on 2 separate occasions to prevent
degradation of RNA. Only RNase-free, sterile solutions and equipment were used
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for Qrt-PCR in order to prevent degradation of target RNA by exogenous RNases
and contamination of reactions with exogenous RNA or DNA.
2.4.8.3 Reverse transcription
First strand cDNA synthesis was performed using 0.5 pg of total RNA with the
Reverse Transcription System (Promega) as described previously (Section 2.4.7.3).
Again, negative control reactions for each batch of samples were performed in
parallel with samples. A reaction was performed as above using an RNA sample
chosen at random in the absence of AMV-reverse transcriptase in order to determine
genomic DNA contamination. Additionally, a negative control reaction containing
nuclease-free water instead of RNA was performed to determine RNA contamination
of the Reverse Transcriptase System reagents. Products from the RT reaction
(cDNA) were diluted 1:4 with nuclease-free water prior to Qrt-PCR amplification
based on reaction kinetics of serially-diluted pooled samples (1:4, 1:8, 1:16, 1:32,
1:64, 1:128).
2.4.8.4 Quantitative polymerase chain reaction
2 pi of cDNA template from each sample, pooled standard dilutions (prepared fresh
after 2-3 freeze-thaw cycles), and negative controls were added to a 384-well plate
(Roche) in triplicate.
Primer-probe master mix was prepared by mixing 5 pl/sample of (2X mix)
LightCycler 480 Probes Master (Roche) with 0.5 pl/sample of (20X mix) TaqMan
MGB primer probe mix plus 2.5 pl/sample of water (supplied with LightCycler 480
Probes Master, Roche). All TaqMan minor groove binder (MGB) probes and
primers supplied (TaqMan Gene Expression Assays, Applied Biosystems,
Warrington, UK) had been pre-mixed to a concentration of 18 pM for each primer
and 5 pM for the probe resulting in a 20X mix. TaqMan primer probe mixes were
supplied as pre-validated ready-to-use assays eliminating the need for primer design
or PCR optimisation. All assays were designed for use with human tissue, were exon
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spanning and will not detect genomic DNA. All probes had a FAM
(carboxyfluorescein) reporter dye at the 5' end and a non-fluorescent quencher at the
3' end and, consequently, were protected from light throughout. Master mix
(8 pl/sample) was added to each well using a digital multi-channel pipette to
minimise variation in volume added. Thus, final volume in each well was 10 pi.
Plates were sealed using a transparent sealing foil (Roche) and the contents of the
well brought to the bottom by centrifugation (at 2,000 rpm for 2 minutes at 4°C).
PCRs were carried out on a LightCycler 480 (Roche). Samples were heated to 95°C
for 5 minutes for pre-incubation then underwent 50 cycles of PCR amplification
(denaturation at 95°C for 10 seconds, primer annealing at 60°C for 30 seconds and
elongation at 72°C for 1 second) and finally underwent cooling at 40°C for a further
5 minutes. 50 cycles of amplification were used as standard for all reactions and
were shown to enable detection of all of the genes examined. TaqMan Gene
Expression Assays used are listed in Table 2.2.
2.4.8.5 Absolute quantification analysis
Absolute quantification analysis uses sample "crossing point" (Cp) to determine the
concentration of target DNA in unknown samples after amplification. The Cp value
is the point at which the fluorescence of a sample rises above the background
fluorescence. Data were analysed by LightCycler 480 software vl.2.0.169 (Roche).
Calibration curves were generated for each gene using crossing point (Cp) values as
a function of log of target copy number. Compared with expected standard
concentrations (1, 0.5, 0.25, 0.125, 0.0625 and 0.03125 arbitrary units), efficiencies
of the calibration curves (slope) were in the range 1.500 to 2.171 and error values
(mean squared error of the single data points fit to the regression line) were in the
range 0.0152 to 0.0728. By determining where the Cp of an unknown sample falls
on the standard curve, the initial concentration of target DNA in the samples can be
determined by the software. Sample concentrations, expressed as mean of triplicates,
were exported to Excel and normalised to corresponding cyclophilin A
concentrations, as a ratio, which served as an internal control.
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2.4.9 11 p-Hydroxysteroid dehydrogenase activity
Although lip-HSDs are present in the vessel wall their exact cellular localisation
remains controversial. To further validate the mRNA expression data, functional
activity assays were performed with undifferentiated HUVECs and TLSs to establish
llp-HSD activity in endothelium and ask whether activity is influenced by cell
differentiation state. To determine llfl-HSD activity in endothelial cells in vitro, a
published method was adapted using radio-labelled steroids as substrates for the
reactions (Cai et al., 2001).
2.4.9.1 In vitro 11J3-HSD activity assay
HUVECs (1.75 x 105 cells per well) were cultured in standard culture medium
(EGM-2 containing growth factors and 2% FBS) and standard basal medium
(EGM-2 containing only ascorbic acid, heparin and GA-1000) containing 3H-steroid
in 2 separate experiments. 11 (1-HSD1 activity was determined by adding 10 pmol/ml
[3H]4-cortisone (GE Healthcare) and 11(3-HSD2 activity was determined by adding
10 pmol/ml [3H]4-cortisol (GE Healthcare). Chinese hamster ovary (CHO) cells
stably transfected with human 11 fl-HSDl (CHO-hll (1-HSDl) and 11|3-HSD2
(CHO-hl 1(1-HSD2), a kind gift from Dr Scott Webster, Endocrinology Unit, were
used as positive controls. CHO cells (1.75 x 105 cells per well) were cultured in
Ham's F12 medium (containing 10% FBS, penicillin-streptomycin and 2 mM
L-glutamine). Medium alone served as a negative control. 11(!-HSD2 activity was
determined by adding 10 pmol/ml [3H]4-cortisol (GE Healthcare). HUVECs
(1.75 x 105 cells per well) cultured on Matrigel-coated plates were run in parallel
experiments to examine activity of both isozymes in TLSs under standard basal
conditions. Matrigel and media, without cells, were used as further negative
controls. After 5, 24 and 48 hours of incubation, 200 pi samples of media were
collected into glass tubes (Fisher Scientific, Leicestershire, UK) and stored at -20°C
until required.
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2.4.9.2 Radiolabelled steroid extraction from media
Steroids were extracted from media using Cig Sep-pak columns (Waters Millipore,
MA, USA). Briefly, samples of media were thawed and centrifuged to pellet any
loose cellular material. Columns were prepared by elution (under gravity) with 5 ml
of methanol (HPLC grade) then washed with 5 ml of water (HPLC grade; Rathburn
Chemicals). Samples were then run onto the column, washed with 5 ml of water and
eluted into glass tubes with 2 ml of methanol. Steroid-containing methanolic
samples were then dried down at 60°C under nitrogen gas.
2.4.9.3 High performance liquid chromatography
The high performance liquid chromatography (HPLC) system used to detect
[3H]4-cortisol and [3H]4-cortisone in samples was operated by Mrs Eileen Miller
(Endocrinology Unit, University of Edinburgh). The system comprised an
auto-sampler, mobile phase pump and symmetry shield RPig 5 pm column (Waters,
Hertfordshire, UK) and a radioactivity monitor linked to a scintillation fluid pump
(Berthold Technologies, Huddersfield, UK). The system was controlled by the
Winflow computer programme (JMBS Developments, Grenoble, France).
Briefly, samples were re-suspended in 1 ml mobile phase (60% water, 15%
acetonitrile, 25% methanol) and 180 pi of each sample was injected into the system
and quantified by on-line liquid scintillation counting (Dover et al., 2007).
Radioactive standards were injected at the start of each batch of samples to confirm
peak identity. Following chromatography, the area under each peak was integrated
using the Winflow software and used to quantify the percentage conversion of
[3H]4-cortisone to [3H]4-cortisol (ll(3-reductase activity) or [3H]4-cortisol to
[3H]4-cortisone (lip-dehydrogenase activity). Enzyme activity was expressed as
percentage conversion per 1.75 x 105 cells.
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2.4.10 Intracellular signal transduction
To assess the influence of glucocorticoids on focal adhesion kinase (FAK), and the
MAPK/ERK signal transduction pathway in endothelial cells, Western blotting was
used to detect FAK and phosphorylated (activated) ERK (pERK) in HUVEC protein
extracts after incubation with Cortisol, a GR antagonist (RU38486) and an
established inhibitor of MAPK signal transduction (PD98059). The method utilises
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins by
molecular weight. Proteins are transferred from the gel onto a membrane where they
are "probed" using specific labelled antibodies to the protein of interest. Quantitative
analysis is achieved by densitometry of fluorescent-probed bands and comparison
with an internal loading control. Training in methodology and antibodies were
provided by Dr Kurt Sales, MRC Human Reproductive Sciences Unit, Edinburgh).
2.4.10.1 Cell preparation
HUVECs (1 x 106 cells per dish) were harvested and seeded into 10 cm tissue culture
dishes (Cellstar-Greiner Bio-One) in standard culture medium (EGM-2 containing
growth factors, 2% FBS, ascorbic acid, heparin and GA-1000) and incubated for 24
hours to allow cells to adhere. The following day medium was replaced with EGM-2
containing 1% FBS, ascorbic acid, heparin and GA-1000 to provide serum-reduced
conditions for a further 24 hours incubation. Forty-eight hours after cell seeding,
medium was replaced with standard basal medium to provide serum-free conditions
for 1 hour prior to treatment and for the duration of the experiment. At this stage,
dishes were approximately 90% confluent which resulted in sufficient protein
recovery to run Western blots (preliminary findings from pilot experiments). On day
3, HUVECs were treated with 600 nM Cortisol for up to 4 hours in time-course
experiments. Vehicle (ethanol; 0.004% v/v) treated cells served as a control. For
inhibitor studies, HUVECs were pre-treated with inhibitor (RU38486, 1 pM or




Medium was removed from dishes and cells were washed once with PBS (2 ml) to
remove dead cells and cell debris. Fresh lysis buffer (containing a cocktail of
protease inhibitors) was prepared on each day of protein extraction and 200 pi were
added to each dish (kept on ice throughout) to minimise protein degradation by
endogenous proteases. Cells were detached from dishes using a cell scraper to aid
cell lysis and kept on ice (10 minutes) apart from occasional vortexing. Thereafter,
insoluble material was pelleted by centrifugation (at 13,000 rpm for 10 minutes at
4°C). The clarified lysate was removed to a new tube and stored at -20°C until
required for protein quantification and SDS-PAGE.
2.4.10.3 Protein quantification
Prior to Western blotting, it was necessary to determine protein content to ensure
equal gel loading. Protein concentration was measured using the Bio-Rad Dc protein
assay kit (Bio-Rad), based on the method of Lowry (Lowry el al., 1951). Briefly, the
reaction of protein with an alkaline copper tartrate solution and subsequently with
Folin reagent produces reduced species with characteristic blue colour.
To determine protein concentration in samples, a standard curve was prepared each
time the assay was performed. Bovine serum albumin (BSA, Bio-Rad) standards
were prepared by diluting 1 mg/ml stock to 200 pg/ml in distilled water followed by
6 serial dilutions (final concentrations; 100, 50, 25, 12.5, 6.25 and 3.125 pg/ml).
Samples were diluted 1:40 in distilled water which ensured protein concentrations
were within the range of the standard curve graph. Standards and diluted samples
(25 pi each) were added to a 96-well, flat-bottomed microtiter plate (Cellstar-Greiner
Bio-One) in duplicate. Reagents were prepared fresh on each occasion according to
manufacturer's instructions. Briefly, Reagents A and S were mixed (50:1) and added
(25 pi) to each well followed by Reagent B (100 pi). Plates were left for 15 minutes
(room temperature) to allow colour to develop then absorbance in each well was
measured using a Labsystems Multiskan EX photometer (Thermo LabSystems,
Cheshire, UK) at 690 nm. Sample protein concentrations were calculated from
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absorbance values using AssayZap v2.5 software (BioSoft, Cambridge, UK) and a
standard curve linear plot (Figure 2.2).
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Figure 2.2 Protein assay standard curve
Typical standard curve using Bio-Rad Dc protein assay kit based on the method of Lowry.
Representative graph of absorbance (at 690 nm) versus BSA concentration using 7
standards prepared by serial dilution and analysed in duplicate. A linear plot (shown above)
was used to estimate protein concentrations in samples from absorbance values using
AssayZap software.
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2.4.10.4 Immunoprecipitation and Western blot analysis
Immunoprecipitation For focal adhesion kinase (FAK) studies in which the protein
is of low abundance in cells, immunoprecipitation was used to enrich
phosphotyrosine-containing proteins in lysates. Lysates were first pooled from
treatment groups to provide sufficient protein for analysis. Equal amounts of total
protein (4 mg) in lysis buffer were incubated (overnight at 4°C) with (1:100 in
Odyssey blocking buffer) specific mouse monoclonal IgG2b anti-phosphotyrosine
antibody, p-Tyr (PY99) (Santa Cruz Biotechnology, California, USA) immobilised
onto agarose beads, with gentle rotation. Beads were washed extensively (x3) with
lysis buffer and centrifugation (at 15,000 rpm for 10 minutes at 4°C) and immune
complexes were eluted in 20 pi of 5x protein gel loading buffer, boiled for 5 minutes,
then kept on ice until required for gel electrophoresis.
Gel electrophoresis A total of 30 pg of protein (for MAPK studies) plus 5x protein
gel loading buffer were resuspended in 20 pi distilled water, boiled (for 5 minutes),
then kept on ice. Proteins were resolved on NuPAGE 4-12% Bis-Tris gels (1.5 mm x
15 wells; Invitrogen). Combs and tape were removed from the gels and wells rinsed
with distilled water. The gel apparatus was assembled and lx NuPAGE MES-SDS
running buffer added to the central reservoir to cover the top of the gel and outer
reservoir to cover the bottom of the gel. 10 pi of SeeBlue Pre-stained Protein
Standard (Invitrogen) containing 9 polypeptides ranging from 4 to 250 kiloDaltons
(kDa) were loaded into the first well on each gel to allow determination of sample
protein molecular weight. Samples were carefully loaded into wells using a
Hamilton syringe with a 22s gauge needle (Hamilton, Nevada, USA). Gels were
electrophoresed at 40 mA per gel for approximately 2 hours until the loading dye
front had migrated to the bottom of the gel.
Transfer In order to make proteins accessible to antibody detection, they were
moved from within the gel to an Immobilon-FL polyvinylidene difluoride (PVDF)
membrane (Millipore, Watford, UK) by electroblotting. Briefly, gels were removed
from the cassette and the top and bottom of the gels trimmed to a final size of
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8 cm x 6 cm. Membranes were soaked in methanol (30 seconds), distilled water (30
seconds), and then soaked in transfer buffer (5 minutes) to equilibrate. Stacks were
assembled comprising; 3 layers of Whatman 3MM (0.3 mm) chromatography
blotting paper (Fisher Scientific) pre-soaked in transfer buffer, wetted PVDF
membrane, gel (containing protein), and finally, another 3 layers of pre-soaked
blotting paper. Care was taken to avoid air bubbles between layers during assembly.
Stacks were blotted at a constant voltage (14 V for 2 hours) using a 20 cm x 20 cm
semi-dry blotting unit (Scie-Plas, Warwickshire, UK). As a result of the "blotting"
process, proteins are exposed on a thin surface layer for subsequent detection.
Blocking and detection A two-step detection method was used to detect target
proteins. First, to prevent interactions between the membranes and the antibody used
for detection, the PVDF membrane was blocked (for 1 hour at room temperature on
rocker) in Odyssey blocking buffer (Li-Cor Biosciences, Cambridge, UK) diluted 1:2
in PBS. Membranes were incubated with primary antibody (all 1:1000 in Odyssey
blocking buffer containing 0.01% sodium azide) overnight on rocker. For FAK
studies, rabbit polyclonal IgG anti-FAK (C-20) antibody (Santa Cruz Biotechnology)
was used. For MAPK studies, membranes were co-incubated with rabbit polyclonal
IgG anti-phospho-p44/p42 MAP kinase (to detect phosphorylated ERK1 and ERK2)
and mouse polyclonal IgG anti-p42 MAP kinase (3A7) (to detect total ERK2 protein)
(both Cell Signaling Technologies, Massachusetts, USA). Membranes were washed
(3 x 10 minutes at room temperature) in lx TNS Tween buffer on rocker then
incubated (for 1 hour at 4°C on rocker, protected from light) with secondary antibody
(both 1:5000 in Odyssey blocking buffer containing 0.01% sodium azide). For FAK
studies, goat anti-rabbit IgG (H+L) Alexa Fluor 680 (Molecular Probes-Invitrogen)
was used. For MAPK studies, membranes were co-incubated with goat anti-rabbit
IgG (H+L) Alexa Fluor 680 and goat anti-mouse IgG (H+L) IR dye 800 (Rockland
Immunochemicals, Pennsylvania, USA). Membranes were washed (3 x 10 minutes
at room temperature) in lx TNS Tween buffer on rocker then proteins were revealed
and quantified by Odyssey Li-Cor Infrared Imager. Target protein bands,
phosphorylated ERK1/2 and FAK, were determined from the relative mobility on
SDS-PAGE by comparison with molecular weight standards and were normalised as
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a ratio to total ERK2 protein and IgG, respectively, using Odyssey 2.1 software
(Li-Cor Biosciences).
2.4.11 Assessment of cell proliferation
Cell proliferation in HUVECs induced by VEGF and bFGF, and the effect of a range
of concentrations of Cortisol (3 nM to 1 pM) on the action of these growth factors,
was assessed by 2 independent methods; by measurement of cell viability and by
direct measurement of newly synthesised DNA.
2.4.11.1 Cell viability assay
The CellTiter-Glo Luminescent Cell Viability Assay (Promega) is an indirect method
of assessing the number of live cells based on quantitation of ATP present which
signals metabolically-active cells. Whether the cells are actively dividing or
quiescent is not distinguished but an increase in cell viability indicates cell growth.
The assay is designed for use with multi-well formats making it popular as a
high-throughput screening (HTS) tool to assess effects of test compounds on cell
proliferation and cytotoxicity. The protocol requires addition of a single reagent
(CellTiter-Glo Reagent) directly to cells in culture medium. Cell washing, removal
of medium or multiple pipetting steps are not required and, therefore, the assay is
highly sensitive. CellTiter-Glo Reagent contains recombinant firefly luciferase
which catalyses the mono-oxygenation of beetle luciferin to oxyluciferin in the
presence of Mg2+, ATP and oxygen in a reaction which emits light. There is a direct
relationship between the luminescent signal and the number of cells. Training in
methodology, validated culture conditions, and growth factor and reference
compound concentrations were provided by Dr Judith McKay and Mrs Julie Kellett,
Department of Pharmacology, Aptuit, Edinburgh, UK.
HUVECs were seeded in inner wells (to minimise edge effects) of an opaque 96-well
plate (Corning Fisher, Leicestershire, UK) at a density of 1.5 x 103 cells/well and
incubated (37°C; 95% 02:5% CO2) for 2 hours to allow cells to adhere to the plates.
This density was found to be sufficient to produce approximately 70% confluence in
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the individual wells after 96 hours of incubation with growth factor stimuli, but was
insufficient to produce 100% confluence, thereby avoiding cell-cell contact
inhibition of cell proliferation. Cells were incubated in 'experimental' medium
consisting of EGM-2 Bullet Kit medium (Lonza) supplemented with heparin,
ascorbic acid, GA-1000, and 2% charcoal-stripped FBS. No growth factors from the
kit were added. Serum-supplemented medium is necessary for the reaction but
charcoal stripping removes the majority of hormones (Leake et al., 1987), thereby
preventing influence of endogenous steroids. After the initial 2 hour period, cells
were incubated for a further 94 hours in the presence of: VEGF (25 ng/ml) or bFGF
(1 ng/ml), VEGF or bFGF plus established inhibitors (SU5416, 1 nM-1 pM; platelet
factor 4, 3 nM-1 pM, respectively), or VEGF or bFGF plus Cortisol (3 nM-1 pM).
The final volume in each well was 100 pi. Drug dilutions were prepared fresh on
each day of experimentation. Additionally, cells were incubated in the maximum
concentration of drug vehicles (ethanol, 0.004% v/v; DMSO, 0.167% v/v) or medium
alone as controls. Consequently it was possible to test the effect of Cortisol on
VEGF- and bFGF-induced proliferation in two steps. Firstly, comparing the effect of
growth factor alone with vehicle control, after establishing whether vehicle had an
effect by comparison with medium alone. Secondly, checking for inhibition of
growth by the steroid or reference substance by comparing proliferation in those
wells with the "growth factor alone" wells. At the end of the 96 hours, incubation
plates were equilibrated to room temperature (approximately 30 minutes) and 100 pi
of CellTiter-Glo Reagent were added to each well. Plates were incubated for a
further 10 minutes at room temperature to stabilise the luminescent signal before
being read on a Wallac 1420 VICTOR2 (Perkin-Elmer, Buckinghamshire, UK) plate
reader with a counting time of 1 second/well. Each condition was performed in
triplicate.
2.4.11.2 Bromodeoxyuridine incorporation assay
The 5-bromo-2'-deoxyuridine (BrdU) Cell Proliferation Assay (Calbiochem-Merck)
allows detection and quantification of BrdU, following partial denaturation of the
DNA double strand, by use of a detector monoclonal anti-BrdU antibody to bind to
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any BrdU incorporated into dividing cells during the S phase of the cell cycle.
Horseradish peroxidase-conjugated goat anti-mouse IgG antibody is then used to
bind to the detector antibody and catalyse the conversion of the chromogenic
substrate tetra-methylbenzidine (TMB) to form a coloured product that absorbs light
at dual wavelengths of 405 nm and 540 nm. The intensity of the coloured product is
directly proportional to the amount of incorporated BrdU present in the cells which,
in turn, should be directly proportional to the rate of cell division occurring in the
sample.
HUVECs were seeded in inner wells of a 96-well, flat-bottomed microtiter plate
(Cellstar-Greiner Bio-One) at a density of 3.5 x 103 cells/well and incubated (37°C;
95% 02:5% C02) for 2 hours to allow cells to adhere to the plates. Cells were
cultured in 'experimental' medium as described above. This density was found to be
sufficient to produce approximately 70% confluence in the individual wells after 48
hours of incubation with growth factor stimuli and, again, was insufficient to produce
100% confluence. After an initial 2 hour stabilisation period, cells were incubated
for a further 46 hours with the same growth factor and inhibitor conditions
previously described (see CellTiter-Glo assay) with the exception that BrdU was
added to the wells 1 hour after growth factors and inhibitors were added. The final
volume in each well was 125 pi. Drug dilutions were prepared fresh on each day of
experimentation. Additionally, cells were incubated in the maximum concentration
of drug vehicles (final concentration, 0.004% v/v ethanol or 0.167% v/v DMSO) or
medium alone as controls. Additional wells with cells but no BrdU were included to
obtain background absorbance measurements. At the end of the 48 hour incubation
period, cells were fixed (30 minutes at room temperature) and denatured according to
the assay kit instructions prior to incubation (1 hour at room temperature) with the
anti-BrdU antibody, followed by incubation (30 minutes at room temperature) with
horseradish peroxidase-conjugated goat anti-mouse IgG. Wells were washed
(3x300 pi of lx plate wash, prepared fresh on each occasion in distilled water)
between incubations to minimise background with an Anthos Labtec awl microplate
washer (ASYS Hitech, Eugendorf, Austria). Finally, the cells were incubated (15
minutes at room temperature in light-proof conditions) with TMB and the reaction
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was stopped by the addition of sulphuric acid (2.5 M). The optical densities (dual
wavelengths at 405 nm and 540 nm) were measured within 30 minutes of adding the
stop solution by a Multiskan Ascent plate reader and data captured using Ascent v2.6
software (Thermo LabSystems, UK). The absorbance of cells without the BrdU
label and that of the tissue culture medium, were measured and subtracted from each
reading. It was possible to test the effect of Cortisol on VEGF- and bFGF-induced
proliferation by comparing proliferation in those wells with the "growth factor alone"
wells after demonstrating growth factor alone had an effect by comparing with
vehicle control. Each condition was performed in triplicate.
2.4.12 Assessment of cell migration
Developed in 1962 by Stephen Boyden (Boyden, 1962), the Filter assay is still
employed in cell migration studies. This assay involves a two-compartment system
where cells may be induced to migrate from an upper compartment through a porous
polyethylene terephthalate (PET) membrane into a lower compartment, thus
following the gradient of a chemoattractant. Commercially available cell culture
inserts (ThinCerts; Greiner Bio-One) were used to test the effects of glucocorticoids
on basal-unstimulated, and VEGF-induced, endothelial cell migration. Migratory
cells can be rapidly and accurately measured by labelling with calcein-AM, a
non-fluorescent cell-permeable derivative of calcein which becomes fluorescent on
hydrolysis by cells. The amount of fluorescence and, hence, the number of
migratory cells can be measured using a fluorescence plate reader since relative
fluorescence units (RFU) correlate linearly with number of cells. An overview of the
individual steps of the migration assay is given in Figure 2.3.
Boyden chambers were prepared by immersing 8.0 pm ThinCerts into a 24-well,
flat-bottomed microtiter plate (Cellstar-Greiner Bio-One) containing either: 600 pi of
standard basal medium (EGM-2 containing only ascorbic acid, heparin and
GA-1000) as untreated control; medium with VEGF (10 ng/ml); medium with VEGF
plus inhibitor SU5416 (1 pM; positive control); or medium with VEGF plus Cortisol
(600 nM). HUVECs were harvested as described previously (Section 2.4.2) and
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seeded into the upper compartment at a density of 2 x 105 cells/insert in 200 pi of
standard basal medium. SU5416 (1 pM) or Cortisol (600 nM) were added
immediately to the upper compartment to maintain these final concentrations in both
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Plates were incubated for 24 hours to allow cells to migrate towards VEGF. Early
methodological development determined ThinCert pore size and duration of
incubation to allow sufficient migration of cells. Final concentration of VEGF
chosen was the EC50 value determined in pilot experiments. Following incubation
with chemoattractant, cell culture medium in the lower compartment was carefully
removed by gentle aspiration and replaced with 450 pi of standard basal medium
with calcein-AM dye (8 pM) and incubated for a further 45 minutes. Contents of the
upper chamber were then removed by gentle aspiration. ThinCerts were then
transferred into a freshly prepared 24-well cell culture plate containing 500 pi of
pre-warmed Trypsin-EDTA (Reagent Pack subculture Reagent Kit, Lonza) and
incubated for 10 minutes with periodic agitation to aid detachment of cells from the
underside. ThinCerts were discarded and 200 pi of Trypsin-EDTA solution (now
containing the labelled migratory cells) were transferred into a black flat-bottomed
96-well plate (Nalge-Nunc) to minimise background fluorescence between wells.
Fluorescence measurements (excitation wavelength, 485 nm; emission wavelength,
538 nm) were made by a Fluoroskan Ascent FL plate reader and data captured using
Ascent software (Thermo LabSystems, UK). Consequently, it was possible to test
the effect of Cortisol on unstimulated migration (by comparing with basal control
wells) and VEGF-induced migration (by comparing VEGF plus Cortisol with VEGF




All data are expressed as mean ± SEM, where indicates the number of different
assays performed. Treatment conditions in quantitative TLS, proliferation and
migration assays were performed in triplicate wells and TLS quantification was
performed by an individual blind to treatment groups. Statistical analysis was
performed by one-way analysis of variance (ANOVA) as indicated. Dunnett's
multiple comparison post hoc tests were used where appropriate. Repeated measures
ANOVA was used for the time-lapse imaging and two-way ANOVA for the
real-time PCR data-sets. For histological analysis, vessel counting was performed by
an individual blind to treatment groups and statistical analysis was performed by




Development of an in vitro Model of
Tube Formation in Human Endothelial




The recognition that glucocorticoids are potent inhibitors of angiogenesis has led to
this property being exploited clinically; for example in the treatment of capillary
haemangioma (Hasan et al., 2000). Despite extensive research, however, the cellular
and molecular mechanisms under-pinning this inhibition of angiogenesis are not well
understood. Since it is has been shown that glucocorticoids can alter vascular tone
by acting directly on endothelial cells (Ullian, 1999), it is possible that direct
interaction with the endothelium is also central to the angiostatic effects of these
steroids. Indeed, glucocorticoids can inhibit production of nitric oxide (NO) (Johns
et al., 2001), proteolytic activity (Pepper et al., 1994), migration (Wang et al.,
2002b) and proliferation (Cariou et al., 1988) in endothelial cells, all of which are
key components of angiogenesis.
In vitro models of tube formation by endothelial cells provide one of the most
appropriate methods for investigating the action of factors that influence
angiogenesis since they: are rapid to perform, are easy to quantify (Auerbach et al.,
2003), involve controlled cell populations and do not have confounding factors
characteristic of in vivo models (such as inflammatory and stromal cells). Advances
in isolation techniques have allowed investigators to isolate pure cell populations
from human sources (Jaffe et al., 1973) making results more directly applicable to a
human setting than those obtained using rodent models. Furthermore, molecular
signalling pathways can be dissected using single cell populations. Against this
background, we elected to study angiogenesis in vitro in the 2-dimensional (2D)
model of endothelial tube formation. This produces endothelial tubes with an
identifiable lumen and is thought to recapitulate the morphogenic component of tube
formation (Benelli & Albini, 1999). Assays that model this process in vitro have
become increasingly popular in recent years given that the formation of tubules is
considered similar to the in vivo situation (Lawley & Kubota, 1989). A limited
number of studies have investigated the effects of glucocorticoids on endothelial tube
formation in vitro but these have tended to use pharmacological concentrations of
synthetic glucocorticoids (Matsuda e. .il., 2005) or endothelial cells from non-human
species (Wang et al., 2002b). No previous study has addressed the influence of
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physiological levels of endogenous glucocorticoids on human endothelial cell
morphogenesis.
One potential complicating factor in assessing the impact of glucocorticoids on
endothelial cells in vitro is the possibility that added glucocorticoids may be
inter-converted by the isozymes of 11(3-HSD. Indeed, both lip-HSDl and
1 ip-HSD2 are present in the vessel wall (Hadoke et al., 2001; Christy el al., 2003;
Brem et al., 1998) and the former has been shown to regulate angiogenesis in tissue
explants ex vivo, in sponges in vivo, and in pathological models (Small et al., 2005).
Whether isozymes of lip-HSD are expressed in the endothelium, however, is still
controversial and, furthermore, it is not clear whether repeated passage of endothelial
cells (or tube formation itself) will induce expression of these isozymes.
3.1.1 Hypothesis
This study explored the hypothesis that glucocorticoids inhibit 2D tube-like structure
(TLS) formation by human endothelial cells cultured on Matrigel.
3.1.2 Aims
The specific aims were:
1) to establish and characterise an in vitro model of human endothelial TLS
formation.
2) to determine whether lip-HSD isozyme activity modulates glucocorticoid
activity in this system.
3) to investigate whether physiological glucocorticoids inhibit tube formation
by direct action on the endothelium.
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3.2 Methods
3.2.1 Development and characterisation of an endothelial tube formation
assay
Although the 2D model of endothelial tube formation is widely used for investigating
angiogenesis the methodology varies greatly between different groups (Table 3.1).
Using modifications of protocols from other authors (Cattaneo et al., 2003; Kuzuya
& Kinsella, 1994), several different incubation conditions, time courses and methods
of quantification were tested before a satisfactory experimental protocol was
established. These are outlined in the following sections.
3.2.1.1 Cells
Primary human umbilical vein endothelial cells (HUVECs) and human aortic
endothelial cells (HAoECs) were obtained from Promocell (Germany) and routinely
passaged as previously described (Section 2.4.2). Cells were used between p2 and
p6 in all experiments. Attempts to cryopreserve HUVECs to extend the lifespan of a
single batch proved unsuccessful; therefore, cells were discarded after reaching p6.
Where possible, cells were used at the same level of confluency (70-80%) to ensure
reproducibility of TLS formation. Cells were detached from the flasks with trypsin
and, in all assays, cell counting was performed to ensure consistency of cell density
between experiments (Section 2.4.4).
3.2.1.2 Culture medium
TLSs were incubated in endothelial cell growth medium-2 (EGM-2, Lonza, UK) a
specially formulated primary cell culture system developed for endothelial cell
growth in a low serum environment. Standard culture medium was prepared
according to the supplier's instructions; by adding the supplied growth factors and
serum to the basal medium. Although exact concentrations of growth factors
supplied with the Bullet kit medium were not revealed by the company for
commercial reasons, details regarding the final concentration range of most of the
contents have been obtained (Table 3.2).
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Preliminary experiments established the optimum medium for TLS formation and
defined the standard basal medium conditions to be used in subsequent experiments.
This comprised: EGM-2 basal medium supplemented with ascorbic acid, heparin and
GA-1000 supplied in the Bullet kit. No growth factors, serum or hydrocortisone
(Cortisol) were added (Table 3.2). Under these conditions sufficient TLS formation




































































































































































Ascorbic acid <200 ng/ml V V
Heparin 1-5 ng/ml V V
GA-1000 30 ng/ml gentamicin,
15 (xg/ml amphotericin
V V
FBS 2% V X
hFGF-B 5-20 ng/ml V X
VEGF <100 ng/ml V x !
Ra-IGF 5-50 ng/ml V X
hEGF <30 ng/ml V X
Hydrocortisone <50 mg/ml X X
Table 3.2 Contents of endothelial cell growth medium
Lonza (UK) revealed concentration ranges of Bullet kit components under commercial
constraints. Gentamicin and amphotericin B (GA-1000), foetal bovine serum (FBS), human
fibroblast growth factor-B (hFGF-B), vascular endothelial growth factor (VEGF), human
recombinant insulin like growth factor-1 (R3-IGF-1), human epidermal growth factor (hEGF).
(V) indicates addition of factor to medium, whereas (X) indicates factor was not added.
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3.2.1.3 Supporting matrix
A commercially available (BD Biosciences, UK) solubilised basement membrane
preparation (Matrigel) was used to support growth of endothelial cells into TLSs.
Matrigel is a gelatinous mixture of extracellular and basement membrane proteins
derived from the mouse Engelbreth-Holm-Swarm sarcoma.
A comparison was made of TLS formation on a solidified layer of Matrigel (2D)
versus cells dispersed throughout Matrigel and allowed to solidify (3-dimensional,
3D). As a result of this pilot study the 2D assay was used in subsequent
investigations. Based on previous reports (Table 3.1), tissue culture plates (24-well
format) were coated with 250 pi Matrigel per well which formed an even, solid layer
to act as substrate for TLS formation.
3.2.1.4 Quantification of tube-like structure formation
Quantification of TLS formation was performed by inverted light microscopy (Carl
Zeiss Axiovert 25) and image analysis. One image at low magnification (x5) at the
centre of each well was captured and saved for analysis. Images were captured from
a live-feed camera (Pentax 250, Pentax UK Ltd., UK) using MCID software. Image
files were randomised to ensure quantification was performed by an individual blind
to treatment groups to ensure integrity of the results. Three established methods
previously described in the literature were assessed to determine their accuracy and
consistency:
1) Capillary connections, defined as the number of branch points between 2 or
more TLSs, were identified and marked using Adobe Photoshop cs (Adobe
System Inc, USA) software. Total numbers of capillary connections per
field of view were counted and tallied using a cell counter (Figure 3.1A).
During method development, data were initially expressed as the mean
absolute number of connections (Donovan et al., 2001; Bussolati et al.,
2001). For the final, established method, data were expressed as a
percentage of the number of connections generated in concomitant control
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wells (Wilasrusmee et al., 2003). Consequently, control wells were run on
each plate.
Measurements of TLS length (Montanez et al., 2002; Yamagishi et al,
1999) were made digitally (in pixels) using Adobe Photoshop cs software.
Average length of TLSs intersecting gridlines in each field of view was
calculated (Figure 3.IB).
TLS density measurements (Grant et al., 1989) were derived by computer
analysis of pixel density using MCID software. Measurement of area
occupied by TLS networks was obtained using greyscale pixel threshold
(total grain count function) in each image.
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Figure 3.1 Methods of quantification of TLS formation
Light micrographs of TLSs demonstrating 2 different published methods of quantification. In
these images individual capillary connections (branch points) are marked with a white dot
(a) for counting and lengths of TLSs intersecting gridlines are measured (in pixels) and
identified with a white line, (b).
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3.2.1.5 Time-course of TLS formation
To determine the time-course of TLS formation, time-lapse video microscopy was
used. Technical assistance with time-lapse equipment was provided by Mr Bob
Morris and advice on movie-clip preparation was provided by Professor Adriano
Rossi, both Centre for Inflammation Research, University of Edinburgh.
SlideFlasks (Nunc, USA) were coated with 750 pi Matrigel and allowed to set for 60
minutes. HUVECs (200,000) in 2 ml standard basal medium containing 5 mM
Hepes buffered saline solution (Lonza, UK) were seeded onto Matrigel. Preliminary
experiments determined that these culture conditions were necessary to buffer
against pH changes in the flasks. Cells were incubated with lOng/ml VEGF,
600 nM Cortisol, or both. Immediately (within 10 minutes) after cell seeding onto
Matrigel, images were acquired with a Leica DM IRBE microscope using a xlO
objective and captured with a Leica Q500MC image processing system (Leica
Cambridge Ltd., UK). Images were captured from 3 separate positions per flask at 4
minute intervals for 24 hours, where possible. Movie-clips were reconstructed using
Apple QuickTime Player version 7.0 (Apple Inc., USA). Numbers of tubes per field
of view were counted at 2 hour interval in reconstructed movie-clips, and plotted
versus time in line graphs. From time-course graphs, time to reach peak TLS
number and maximum TLS number were determined and plotted as bar charts.
Based on this information, TLS formation was assessed at 4 hours, 8 hours and 22
hours after seeding, to test the influence of added factors. This is consistent with
time-points selected by others described in the literature (Bussolati et al., 2001;
Donovan et al., 2001; Lansink et al., 1998).
3.2.1.6 Characterisation of tube-like structures
The endothelial nature of TLSs was assessed using immunohistochemistry (detailed
in 2.4.6.1). Briefly, HUVECs (10,000) were cultured in 250 pi of standard basal
medium for 5 hours on 8-well permanox chamber slides (Nunc, USA) pre-coated
with 100 pi Matrigel. Culture medium was gently removed and TLSs rinsed once
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with PBS and fixed with 10% formalin. Staining was performed using the
Vectastain ABC Kit (Vector Lab., USA) according to the manufacturer's instructions
in combination with rat anti-mouse CD31 (1 in 50 dilution) monoclonal antibody
(BD Pharmingen, USA). Slides were incubated at room temperature for 5 minutes
with 3,3'-diaminobenzidine (DAB) (Vector Laboratories, USA) as substrate with
positive structures staining brown. For negative control, the primary antibody was
omitted. Slides were viewed by light microscopy (Carl Zeiss Axioskop, Carl Zeiss
Microimaging, Inc., USA) and images captured from a live-feed camera (3-CCD,
JVC Professional Europe Ltd, UK) using the Microcomputer Imaging Device
(MCID; InterFocus Imaging Ltd, UK).
The structural composition of TLSs was assessed by immunofluorescent staining of
F-actin and a-tubulin; important components of the cytoskeleton. Antibodies,
expertise in immunofluorescence staining protocols, and fluorescence microscopy
were provided by Dr Kate Marshall, Centre for Cardiovascular Science, University
of Edinburgh.
Briefly, HUVECs were resuspended (4 x 104 cells/ml) in experimental medium and
1 ml per well was seeded onto sterilised round coverslips (13 mm; 0 thickness)
pre-coated with 30 pi of phenol red-free Matrigel (to overcome the problem of signal
interference during immunofluorescence detection caused by standard Matrigel; Dr
Kate Marshall, personal communication) in a 24-well, flat-bottomed microtiter plate
(Cellstar-Greiner Bio-One, UK). Experimental medium consisted of EGM-2
medium (Lonza, UK) supplemented with heparin, ascorbic acid, GA-1000, and 2%
charcoal-stripped FBS; no growth factors from the Bullet kit were added.
Preliminary experiments determined that standard basal medium was not sufficient to
instigate formation of TLS networks in this set-up. Cortisol (600 nM) was added
immediately at the time of cell seeding. In time-course experiments, media were
removed after 1, 4, 10 and 22 hours of incubation and cultures fixed and stained as
described in (Section 2.4.6.2). Slides were viewed by an Olympus AX-70
fluorescence microscope (Olympus Optical Company, UK) and images captured
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with a Hamamatsu Orca-ER digital live-feed camera and controller (Hamamatsu
Photonics, UK) using Smart Capture 3 software (Digital Scientific, UK).
3.2.2 1ip-Hydroxysteroid dehydrogenases in endothelial cells and
tube-like structures
To further characterise the model it was important to determine l ip-HSD activity.
Since the subject of this thesis was to test the influence of glucocorticoids on
endothelial cells, it was important to determine whether glucocorticoids are
converted endogenously in the model between active and inactive forms by the
action of lip-HSD isozymes. Furthermore, the differentiation state of some cells
may determine the expression pattern of lip-HSDs; for example human monocyte
differentiation into macrophages causes an up-regulation of lip-HSDl (Thieringer et
al., 2001). Consequently, the presence of lip-HSDs in endothelial cells from 3
different stages of development; endothelial precursor cells, undifferentiated
HUVECs and mature endothelial TLSs was investigated.
3.2.2.1 11J3-HSD1 and 11J3-HSD2 mRNA expression
Expression of lip-HSDl and 11 (1-HSD2 mRNA was investigated in undifferentiated
HUVECs and mature TLSs by RT-PCR (Section 2.4.7). Mouse liver and human
kidney were used as positive controls for lip-HSDl and 11(3-HSD2 expression,
respectively. Tie2 is a common endothelial cell surface marker expressed almost
exclusively by endothelial cells (Dumont et al., 1992) and was included as a positive
control for the PCR reaction. To extend the expression profiling to an immature
endothelial precursor, lip-HSDl and 11(3-HSD2 expression was investigated by
RT-PCR in endothelial progenitor cells (EPCs) isolated from healthy human
volunteers (RNA was a gift from Dr John McDermott, National University of
Ireland, Galway, Republic of Ireland).
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3.2.2.2 11J3-HSD1 and 11J3-HSD2 activity
To determine lip-HSD activity in undifferentiated HUVECs and mature TLSs a
previously described method (Cai et al., 2001) was adapted. HUVECs (1.75 x 105
cells per well) in 2 ml of standard basal medium were seeded in 6 well-plates directly
on plastic and in dishes pre-coated with Matrigel. 11(3-HSD activity was established
by the conversion of 3H-steroid. 11 (3-reductase activity was determined by
incubating cells in the presence of 10 pmol/ml [3H]4-cortisone. Chinese hamster
ovary (CHO) cells stably transfected with human 11(3-HSD1 served as a positive
control. 11 (3-dehydrogenase activity was determined by incubating cells in the
presence of 10 pmol/ml [3H]4-cortisol. CHO cells stably transfected with human
11(3-HSD2 served as a positive control. Media alone, and Matrigel with medium
added but no cells, served as negative controls.
After 5 hours, 24 hours and 48 hours incubation, samples of media were taken and
stored at -20°C until analysis. Time-points to assess conversion for CHO cells were
in the range of 24 to 48 hours as recommended by Dr Scott Webster, Endocrinology
Unit (personal communication). An earlier time-point (5 hours) was also included in
view of the striking morphological changes observed in HUVECs on Matrigel at this
time. Steroids were purified from media samples by Sep Pak extraction and analysed
by HPLC (Section 2.4.9).
3.2.3 Influence of glucocorticoids on endothelial tube formation
Prior to experiments exploring the influence of glucocorticoids on endothelial tube
formation, the model was used to examine the effects of recognised pro-angiogenic
stimuli as positive controls to demonstrate responsiveness of the model under these
conditions, and to further validate the quantification method.
3.2.3.1 VEGF and prostanoid influence on endothelial tube formation
Studies were performed to examine the influence of the pro-angiogenic factors
VEGF (0.5, 5, 50, 500ng/ml) (Ferrara & Henzel, 1989) and 2 members of the
prostanoid family, PGF2a and PGE2. (10 nM, 100 nM, 500 nM, 1 pM) (Majima et
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al., 2000) in standard basal medium conditions. Conditions were performed in
triplicate wells.
3.2.3.2 Influence ofglucocorticoids on endothelial tube formation
The angiostatic effect of glucocorticoids was examined by incubating HUVECs on
Matrigel under standard basal medium conditions in the presence or absence of
Cortisol (300 nM, 600 nM or 1200 nM) or cortisone (300 nM, 600 nM or 1200 nM).
As steroids had been dissolved in ethanol and then diluted in aqueous solutions,
vehicle control conditions were established that contained equivalent aqueous
dilutions of ethanol (final concentration, 0.004% v/v). Vehicle or steroid was added
to the culture medium at time of cell seeding onto Matrigel. Conditions were
performed in triplicate wells.
3.2.3.3 Influence of glucocorticoids on endothelial tube formation by human
aortic endothelial cells
The influence of glucocorticoids on tube formation by another type of endothelial
cell was investigated using human aortic endothelial cells (HAoECs). These studies
were performed by a Pharmacology Honours project student, Miss Sadaf Ali, under
my supervision. Briefly, HAoECs were utilised in the TLS assay using the same
conditions previously described (Section 2.4.5.1). The angiostatic effect of
glucocorticoids was examined by incubating HAoECs on Matrigel under standard
basal medium conditions (control) or in the presence of Cortisol (600 nM). To
determine the receptors responsible for glucocorticoid-induced angiostasis, TLSs
were incubated with the glucocorticoid receptor (GR) selective, synthetic
glucocorticoid, dexamethasone (600 nM). To examine the effects of glucocorticoids
on VEGF-stimulated TLS formation, HUVECs and HAoECs were incubated with
VEGF (10 ng/ml) alone, or with VEGF in combination with Cortisol or
dexamethasone (both 600 nM).
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3.2.3.4 Identification of the receptor responsible for glucocorticoid-induced
angiostasis
To further investigate whether glucocorticoid-induced angiostasis was mediated by
glucocorticoid or mineralocorticoid receptors, HUVECs were cultured on Matrigel
under standard basal conditions in the presence of Cortisol (600 nM) and either the
GR antagonist RU38486 (1 pM) or the mineralocorticoid receptor (MR) antagonist
spironolactone (1 pM). In control wells, HUVECs were cultured with either
antagonist in the absence of Cortisol.
3.2.4 Statistics
Data are expressed as mean ± standard error, "ft" refers to number of different
experiments performed on separate occasions using different batches of HUVECs;
where possible all measurements of tube formation were made in triplicate wells and
the mean used for further analysis. Comparisons at selected timepoints were made
by one-way ANOVA and Dunnett's post hoc test. Inter-assay and intra-assay
coefficients of variation were 43% and 24% for number of connections after 4-5
hours in culture and 73% and 38% after 20-23 hours in culture (n=27). Time-lapse




3.3.1 Development and characterisation of an endothelial tube formation
assay
3.3.1.1 Cells
Initial observations indicated that HUVECs beyond p6 failed to form adequate
networks of TLSs (data not shown) and therefore cells beyond p6 were not used in
these studies. Untreated control cells between p2 and p6 showed similar,
reproducible tube formation after 4-5 hours and 21-23 hours on Matrigel (Figure
3.2). Therefore, cells were used between these passages in all further studies.
3.3.1.2 Culture medium
Initial experiments performed to determine the optimal conditions for tube formation
in vitro compared TLS formation by HUVECs cultured under basal conditions or in
the presence of growth factors (from the EGM-2 Bullet kit) and/or serum (see Table
3.2). TLS formation occurred in basal conditions and was enhanced by addition of
growth factors and serum (Figure 3.3). In the presence of serum and growth factors,
however, addition of further pro-angiogenic growth factor (VEGF in the range
25-75 ng/ml, exact concentration not disclosed by supplier) had no apparent effect on
TLS formation compared with controls. This suggests that HUVECs cultured under
these conditions were already maximally stimulated. In addition, under these
conditions, Cortisol (300 nM) did not impair TLS formation (Figure 3.4). Further
method refinement investigated the effects of glucocorticoids on TLS formation in
the absence of growth factors (hFGF-B, VEGF, R3-IGF-1, hEGF) or serum in
EGM-2 containing only ascorbic acid, heparin and GA1000. These conditions
produced sufficient, quantifiable TLS formation; ~150 connections were counted
after 4-5 hours and ~35 connections after 21-23 hours in culture. In addition, in the
presence of pro-angiogenic factors TLS formation was stimulated (Figure 3.5) and in
the presence of Cortisol (300 nM to 1200 nM) the number of connections was
reduced (compared with controls after 5 hours and 22-24 hours incubation TLS
formation was impaired) (Figure 3.15). Therefore, these conditions, "standard basal
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Figure 3.2 Influence ofHUVEC passage number on TLS formation
HUVECs seeded on Matrigel in standard basal medium in the absence of growth factors or
inhibitors. TLS formation was quantified at 2 time-points by counting the number of
connections between TLSs. Time-point 1 was 4-5 hours incubation; time-point 2 was 21-23
hours incubation. Data represent mean ± SEM (number of experiments as noted on bar
chart), no significant difference in TLS formation using HUVECs in this passage range was
detected using one-way ANOVA.
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Figure 3.3 Influence of culture conditions on TLS formation
HUVECs seeded on Matrigel for 21 hours in either standard basal medium (containing no
growth factors or serum), with growth factors; human fibroblast growth factor-B (hFGF-B),
vascular endothelial growth factor (VEGF), human recombinant insulin like growth factor-1
(R3-IGF-1), human epidermal growth factor (hEGF), with 2% foetal bovine serum (FBS) or
with 2% FBS plus growth factors. Tube formation was quantified as the number of
connections between tube-like structures (TLSs). Data represent mean ± SEM (n=1, each
condition was performed in triplicate wells).
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Figure 3.4 TLS formation in the presence of exogenous growth factors and
serum: Influence of VEGF and Cortisol
HUVECs seeded on Matrigel for 21 hours in endothelial cell growth medium-2 (EGM-2)
supplemented with Bullet kit growth factors (human fibroblast growth factor-B (hFGF-B),
vascular endothelial growth factor (VEGF), human recombinant insulin like growth factor-1
(R3-IGF-1), human epidermal growth factor (hEGF)) and 2% foetal bovine serum (FBS) but
excluding hydrocortisone (Cortisol). Tube formation was quantified as the number of
connections between tube-like structures (TLSs). A physiologically relevant concentration of
Cortisol (300 nM), and of the pro-angiogenic factor, vascular endothelial growth factor
(VEGF; 25-75 ng/ml, exact concentration not disclosed by supplier) had no effect on TLS
formation under these conditions. Data represent mean ± SEM (n=1 experiment, each
condition was performed in triplicate wells).
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3.3.1.3 Supporting matrix
Initial results obtained with standard Matrigel indicated that this was suitable for
generation of a practical number of TLSs by HUVECs. Previous studies using this
assay (Table 3.1) in 24-well plates have used 250-320 pi Matrigel, consistent with
the 250 pi used in these investigations.
3.3.1.4 Quantification of tube-like structure formation
Methods for quantification were assessed for reliability, reproducibility and
consistency. Computer generated measurement of TLS density proved to be
unreliable since undifferentiated cells and cell debris were indistinguishable from
TLS networks and, therefore, this method was discontinued at an early stage.
Quantification of TLS formation by measuring length or by counting connections
was more reliable and both methods detected enhanced angiogenesis in response to
VEGF. However, whereas measurement of TLS length only detected a modest
increase in response to VEGF (Figure 3.5B), counting TLS connections identified a
clear, consistent, concentration-dependent augmentation (Figure 3.5A). In addition,
TLS length was not altered in the presence of glucocorticoids (300 nM, 600 nM and
1200 nM Cortisol; n=3; data not shown). Therefore, since counting connections
identified changes in TLS formation, was reproducible and was technically less
demanding and less time-consuming, it was adopted for measurement of
angiogenesis in subsequent investigations.
3.3.1.5 Time-course of TLS formation
To understand the dynamic nature of the processes involved in TLS formation,
cultures were monitored repeatedly over 24 hours using time-lapse imaging. There
was little evidence from these movie-clips of cell migration or proliferation and TLS
formation consisted mainly of cell morphogenesis (see enclosed movie-clip).
Two distinct phases of TLS formation were identified in untreated control flasks
using this method (Figure 3.6A). Phase I consists of network assembly; TLS number
increased most rapidly during the first 4 hours after cell seeding, and continued to
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increase reaching a maximum number of TLSs after 8 hours on Matrigel in control
flasks. Phase II involves the degradation of the TLS network whereby cells detach
from the substratum and lift off, resulting in a decrease in TLS number from 8 hours
onwards. Most of the network was degraded after 24 hours under these conditions.
VEGF (10 ng/ml) caused an increase in the maximum effect (Emax; 14.4 ±1.2 TLSs
versus 11.6 ± 1.5 TLSs in controls; Figure 3.6B) but this did not reach statistical
significance. Furthermore, VEGF also caused a significant (p<0.05) decrease in the
time to reach peak TLS number (2.5 ± 0.5 hours versus 6.0 ± 0.5 hours in controls;
Figure 3.6C). Cortisol (600 nM) blocked the effects of 10 ng/ml VEGF (Emax,
9.6 ± 0.9 TLSs; time to peak, 4.8 ±1.0 hours) when in combination. Cortisol
(600 nM) alone caused a reduction in the amplitude of the TLS formation curve
(p<0.01, repeated measures ANOVA, effect of treatment) and a reduction in time to
reach peak number (4.4 ± 1.2 hours versus 6.0 ± 0.5 hours in controls; Figure 3.6C).
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Figure 3.5 Comparison of quantification methods using the pro-angiogenic
effects ofVEGF
HUVECs incubated on Matrigel in standard basal conditions for 5 hours in the presence of
vehicle (control) or a range (0.5-500 ng/ml) of concentrations of pro-angiogenic VEGF
(vascular endothelial growth factor). VEGF stimulated TLS formation consistently using 2
methods of quantification: (a) counting capillary connections (branch-points), or (b)
measuring TLS length. Data represent mean ± SEM (n=1 experiment, each condition was
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Figure 3.6 Dynamic nature of TLS formation identified by time-lapse imaging
HUVECs incubated on Matrigel in SlideFlasks in standard basal conditions for up to 24 hours
in the presence of 10 ng/ml vascular endothelial growth factor (VEGF), 600 nM Cortisol, or
both. Images captured (3 positions per flask, 4 minute intervals) using time-lapse video
microscopy, (a) Tube formation was quantified by counting the number of TLSs per frame,
indicated by arrows, in reconstructed movie-clips. Profiles of TLS formation were developed
plotting TLS number over time. Figure continued on next page.
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C) Time to peak formation
7-1
+ Cortisol
Figure 3.6 Dynamic nature of TLS formation identified by time-lapse imaging
(Continued)
From the time-lapse data set (a), the maximum effects of treatment, Emax (b), and time to
reach peak number of TLSs, (c), were determined. Data represent mean ± SEM (n=6
experiments). *p<0.05
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3.3.1.6 Characterisation of tube-like structures
Undifferentiated HUVEC monolayers (data not shown) and mature TLSs both
produced positive staining for the endothelial marker CD31 (Figure 3.7).
TLS staining of actin filaments (F-actin) and a-tubulin microtubules produced
specific staining of fibres in undifferentiated FlUVECs that appeared as well-formed,
parallel stress fibres throughout the cytoplasm and peri-nuclear space and was highly
concentrated just beneath the cell membrane. A similar staining pattern of fibres was
observed in TLSs which became apparent after 4 hours on Matrigel and was highly
concentrated in filopodia-like extensions after 10 hours (Figure 3.8). Staining for
F-actin, but not a-tubulin, appeared more diffuse and homogeneous after Cortisol
treatment (Figure 3.9) and correlated with a loss of TLS network integrity. Positive







Figure 3.7 Characterisation of TLSs by immunostaining with an endothelial
surface marker
Immunohistochemical confirmation that HUVECs retain an endothelial cell phenotype upon
differentiation into TLSs. HUVECs cultured on Matrigel for 4 hours, (a) Staining for CD31
immunoreactivity, x10 magnification. TLSs are indicated by thin arrows, (b) At x40
magnification, endothelial cell membranes are visible (thick arrows), (c) Negative control,
without primary antibody.
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Figure 3.8 Characterisation of TLSs composition by staining the cytoskeleton
HUVECs cultured on Matrigel-coated cover slips for up to 22 hours. Direct nuclear staining
of DNA with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, blue), Filamentous-actin
with phalloidin-488 (green) and a-tubulin with goat anti-mouse IgG Alexa Fluor 594
secondary antibody (red). TLSs consist of adjoining filopodia-like extensions that form
cell-cell contacts between neighbouring cells. Networks are evident from 4 hours and reach



















Figure 3.9 Glucocorticoids and the endothelial TLS cytoskeleton
HUVECs were cultured on Matrigel-coated cover slips for 1 hour and stained for DNA (blue),
filamentous (F)-actin (green) and a-tubulin (red). Exposure to Cortisol (600 nM) had no
apparent effect on microtubule staining but induced a more diffuse and homogenous
distribution of F-actin throughout the cells.
120
3.3.2 11 (3-Hydroxysteroid dehydrogenases in endothelial cells and
tube-like structures
3.3.2.111J3-HSD1 and 11 /3-HSD2 mRNA expression
Neither 11|3-HSD1 nor 11|3-HSD2 mRNA expression (n=5) were detected by
RT-PCR in undifferentiated cultured HUVECs, mature TLSs or EPCs (n=3) isolated
from human blood. Mouse liver strongly expressed 11(3-HSD1; human kidney and
CHO cells transfected with human 11 (3-HSD2 both expressed 11 [1-HSD2 as positive
controls for the PCR reaction. Expression of Tie2 and GR served as positive controls
for RNA integrity and both were detected in undifferentiated cultured HUVECs
(«=2), mature TLSs (n=5) and EPCs (n=3) isolated from human blood (Figure 3.10).
Furthermore, expression of the endothelial marker Tie2 was detected in HUVECs
and TLSs (data not shown).
3.3.2.2 11P-HSD1 and 11 J3-HSD2 activity
Neither ll(3-reductase nor 11(3-dehydrogenase activity were detected in either
undifferentiated HUVECs or TLSs after 5 hours, 24 hours or 48 hours in culture as
indicated by the failure to inter-convert [3H]4-cortisone and [3H]4-cortisol («=2-3).
This is consistent with a lack of mRNA expression for either of the isozymes of
lip-HSD. Positive control (CHO) cells transfected with 11(1-HSD1 converted
[3H]4-cortisone to [3H]4-Cortisol (Figure 3.11) and [3H]4-cortisol to [3H]4-cortisone
(Figure 3.11), demonstrating bi-directional activity, with the reductase activity being
predominant (10-fold higher). CHO cells transfected with 11|3-HSD2 converted
[3H]4-cortisol to [3H]4-cortisone (Figure 3.12), but not the reverse reaction,
demonstrating exclusive dehydrogenase activity (n=2).
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A) 11P-HSD1
CHO-h mouse -ve controls
EPCs EPCs EPCs HUVECs TLSs 11P-HSD2 liver -RT H20
™* 467 bp
B) 11p-HSD2
-ve controls CHO-h CHO-h human
-RT H20 EPCs EPCs EPCs HUVECs TLSs 11P-HSD2 11P-HSD2 kidney
490 bp
C) GR
CHO-h mouse -ve controls
EPCs EPCs EPCs HUVECs TLSs 11p-HSD2 liver -RT H20
354 bp
Figure 3.10 Expression of lip-HSDl, 11P-HSD2 and GR in endothelial cell
preparations
Specific primers were used to detect expression of (a) 11P-HSD1, (b) 11P-HSD2 and (c) GR
mRNA in human umbilical vein endothelial cells (HUVECs), endothelial tube-like structures
(TLSs) and human endothelial progenitor cells (EPC). Mouse liver, human kidney and
Chinese Hamster Ovary cells transfected with human 11P-HSD2 (CHO-h11P-HSD2) were
used as positive controls. 0.5 pg of total RNA were isolated from HUVECs, TLSs, mouse
liver, human kidney and CHO-h1ip-HSD2 whilst 0.075-0.245 pg of total RNA were isolated
from EPCs for RT-PCR. RT-PCR products were analysed by gel electrophoresis of 10 pi of
each sample (20 pi of each in 11P-HSD2 reaction) and were of the expected size (Table
2.1). Negative controls included a reaction carried out in the absence of the RT enzyme




Figure 3.11 lip-reductase activity in lip-HSDl-transfected Chinese hamster
ovary cells
11J3-HSD activity is expressed as the percentage conversion of fH^-cortisone to
fH^-cortisol by 1.75 x 105 cells. 1ip-HSD activity was measured after 5 hours, 24 hours
and 48 hours incubation. No conversion was detected in HUVECs growing on tissue culture
plastic (n=3) or HUVECs seeded on Matrigel in standard basal conditions (n=2) at any
time-point (data not shown). In contrast, Chinese hamster ovary cells transfected with
human 11P-HSD1 (CHO-h1 ip-HSD1, positive control) converted 21 ±11% after 5 hours,
88 ± 7% after 24 hours and 98 ± 3% after 48 hours incubation (n=2). Chinese hamster ovary
cells transfected with human 11p-HSD2 (CHO-h11P-HSD2) did not convert fH^-cortisone to
[3H]4-cortisol (n=3, data not shown). Results shown are the mean of 2 experiments.
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CHO-h11p-HSD1 CHO-h11p-HSD2
Figure 3.12 11 ^-dehydrogenase activity in lip-HSDl and
liP-HSD2-transfected Chinese hamster ovary cells
11P-HSD activity is expressed as the percentage conversion of fH^-cortisol to
^H^-cortisone by 1.75 x 105 cells. Iip-HSD activity was measured after 5 hours (data not
shown), 24 hours and 48 hours incubation. No conversion was detected in HUVECs
growing on tissue culture plastic (n=3) or HUVECs seeded on Matrigel in standard basal
conditions (n=2) at any time-point (data not shown). Chinese hamster ovary cells
transfected with human 11P-HSD1 (CHO-h1 ip-HSDI) converted 6 ± 3% after 24 hours and
8% after 48 hours incubation (n=2). Chinese hamster ovary cells transfected with human
11P-HSD2 (CHO-h1 ip-HSD2, positive control) converted 3% after 24 hours and 11 ±5%
after 48 hours incubation (n=2). Results shown are the mean of 2 experiments.
124
3.3.3 Influence of glucocorticoids on endothelial tube formation
3.3.3.1 VEGF and prostanoids enhance endothelial tube formation
As described, TLS formation was stimulated in a concentration-dependent manner
with VEGF (0.5 ng/ml, 143.5 ± 17.5; 5 ng/ml, 174.0 ± 4.0; 50 ng/ml, 200.0 ± 21.4
and 500 ng/ml 255.0 ± 15.3 connections) compared with control (117.3 ±9.6
connections) (Figure 3.5A) after 5 hours incubation (n=1). Following 22 hours of
incubation the number of connections were lower in all wells (including control)
compared with 5 hours, however, VEGF stimulated TLS formation at the lower
concentrations (0.5 ng/ml, 120.3 ± 4.3; 5 ng/ml, 107.7 ± 4.8 connections) compared
to control (88.0 ± 9.0 connections). At 50 ng/ml, the level of TLS formation was
similar to that of control (93.3 ±5.5 connections) and had reduced with
supra-physiological levels, 500 ng/ml (70.3 ± 10.3 connections).
Similarly, TLS formation was stimulated in a concentration-dependent manner with
both prostanoids. PGF2a at concentrations across the physiological range (10 nM to
1 pM) stimulated TLS formation after 4-5 hours (10 nM, 128 ± 25%; 100 nM,
140 ± 25%; 500 nM, 153 ± 33% and 1 pM, 167 ± 30% compared with control,
100%; Figure 3.13A) although this did not reach significance (n=5). After 20-23
hours, a similar concentration-dependent increase was observed that reached
significance (/?<0.05) at 1 pM (10 nM, 124 ± 18%; 100 nM, 208 ± 52%; 500 nM,
240 ± 44% and 1 pM, 309 ± 74% compared with control, 100%; Figure 3.13B).
Similar trends were observed with PGE2 at concentrations (10 nM to 1 pM) across
the physiological range (Figure 3.14). PGE2 stimulated TLS formation after 4-5
hours (10 nM, 98 ± 18%; 100 nM, 136 ± 23%; 500 nM, 146 ± 21% and 1 pM,
143 ± 21%) and after 20-23 hours (10 nM, 111 ± 36%; 100 nM, 251 ± 98%; 500 nM,
376 ± 155% and 1 pM, 332 ± 144%) and reached a maximum effect at 500 nM
although this did not reach significance («=4-5).
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A) 4-5 hours incubation
Figure 3.13 Influence of prostaglandin F2« on TLS formation
HUVECs incubated on Matrigel in standard basal conditions (control) or in the presence of
prostaglandin F2a (PGF2a, lOnM-lpM). PGF2a stimulated TLS formation in a
concentration-dependent manner with maximum effect observed at 1 p,M consistently (a)
after 4-5 hours (although this did not reach significance) and (b) after 20-23 hours of
incubation *p<0.05. Data represent mean ± SEM (n=5, each condition was performed in
triplicate wells).
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Figure 3.14 Influence of prostaglandin E2 on TLS formation
HUVECs incubated on Matrigel in standard basal conditions (control) or in the presence of
prostaglandin E2 (PGE2, 10nM-1^iM). PGE2 stimulated TLS formation in a
concentration-dependent manner with maximum effect observed at 500 nM consistently (a)
after 4-5 hours and (b) after 20-23 hours incubation although this did not reach statistical
significance. Data represent mean ± SEM (n=4-5, each condition was performed in triplicate
wells).
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3.3.3.2 Cortisol, but not cortisone, inhibits endothelial tube formation in
HUVECs
Incubation of TLSs with active (Cortisol), but not inactive (cortisone),
glucocorticoids inhibited TLS formation. At physiological concentrations Cortisol
(300 nM to 1200 nM), reduced the number of connections compared with controls
after 5 hours (300 nM, 85 ± 4%; 600 nM, 86 ± 7% and 1 pM, 84 ± 9%) and 22-24
hours (300 nM, 73 ± 8%; 600 nM, 59 ± 5% and 1 pM, 64 ± 12%) incubation
compared with control (100%). The angiostatic effect of Cortisol was greatest
(p<0.01) after 22-24 hours of incubation with 600 nM Cortisol (Figure 3.15). There
were no significant differences in mean TLS length between the different treatment
groups (data not shown). In contrast, the biologically inactive metabolite of Cortisol,
cortisone, failed to inhibit TLS formation across a range (300 nM to 1200 nM) of
physiological concentrations (Figure 3.16). These data are consistent with lack of
11|3-HSD1 mRNA expression and 11 [!-reductase activity in TLSs.
3.3.3.3 Cortisol and dexamethasone inhibit basal, and VEGF-stimulated,
endothelial tube formation in HUVECs and HAoECs
Extending these findings to another human endothelial cell type, TLS formation by
HAoECs on Matrigel was inhibited to a similar degree as HUVECs with 600 nM
Cortisol (4 hours, 54 ± 5%; 22 hours 45 ± 5%) and with the synthetic GR selective
glucocorticoid, dexamethasone (600 nM; 4 hours, 52 ± 3%; 22 hours 53 ± 6%)
compared with control (100%). Whereas the angiostatic effect of Cortisol on
HUVEC TLS formation was greatest after 22-24 hours in culture, the angiostatic
effect on HAoEC TLS formation was of similar magnitude and statistically
significant (p<0.01) after 4 hours (Figure 3.17A) and 22 hours (Figure 3.17B) in
culture.
Under VEGF-stimulated conditions, TLS formation by HUVECs (data not shown)
and HAoECs (Figure 3.17C&D) were inhibited by co-incubation with 600 nM
Cortisol or dexamethasone. Again, these effects were of similar magnitude and
significant (p<0.01) after 4 hours and 22 hours in culture.
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C) 5 hours incubation D) 22-24 hours incubation
Cortisol Cortisol
Figure 3.15 Influence of Cortisol on TLS formation
Light micrographs of HUVECs incubated on Matrigel under standard basal conditions
(control) or in the presence of Cortisol (600 nM) for 22 hours. In comparison with untreated
control wells, Cortisol (300-1200 nM) inhibited TLS formation after (a) 5 hours and (b) 22-24
hours incubation. The angiostatic effect of active Cortisol was greatest at the later time-point
(*p<0.05, **p<0.01). Data represent mean ± SEM (n=6, each condition was performed in
triplicate wells).
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A) 5 hours incubation B) 22-24 hours incubation
cortisone cortisone
Figure 3.16 Influence of cortisone on TLS formation
HUVECs incubated on Matrigel in standard basal conditions (control) or in the presence of
cortisone for (a) 5 hours and (b) 22-24 hours. Unlike active Cortisol, its biologically inert
metabolite, cortisone (300-1200 nM) had no effect on TLS formation compared with control
wells. Data represent mean ± SEM (n=3, each condition was performed in triplicate wells).
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Figure 3.17 Influence of glucocorticoids on basal and VEGF-stimulated TLS
formation in human aortic endothelial cells
Human aortic endothelial cells (HAoECs) incubated on Matrigel in standard basal conditions
in the presence of Cortisol (600 nM) or dexamethasone (600 nM) for (a) 4 hours and (b) 22
hours. Both steroids caused a significant (**p<0.01) inhibition of TLS formation. Vascular
endothelial growth factor (VEGF; 10ng/ml) stimulated TLS formation (**p<0.01) compared
with control, an effect that was blocked in the presence of Cortisol (600 nM) or
dexamethasone (600 nM; **p<0.01 compared with VEGF alone) (c) after 4 hours and (d)
after 22 hours. Data represent mean ± SEM (n=5, each condition was performed in triplicate
wells).
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3.3.3.4 Identification of the receptor responsible for glucocorticoid-mediated
inhibition of tube formation
Cortisol (600 nM) caused a 30% reduction in mean number of connections in GR
and MR antagonism experiments that did not reach statistical significance (69 ± 7%
compared with untreated control, 100%, n=4). The angiostatic effect of Cortisol
(600 nM) was reversed by co-incubation with the GR antagonist RU38486 (p<0.05,
n=4, Figure 3.18A) and there was a trend towards a similar effect by the MR
antagonist spironolactone (Figure 3.18B), however, the latter did not reach
significance (p=0.16). RU38486, spironolactone and vehicle did not influence TLS
formation in comparison to untreated control.
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A) GR antagonism B) MR antagonism
Figure 3.18 Glucocorticoid-induced angiostasis: Effects of GR and MR
antagonism
HUVECs incubated on Matrigel in standard basal conditions in the presence of Cortisol
(600 nM) alone, or Cortisol and the glucocorticoid receptor antagonist RU38486 (1 pM) or the
mineralocorticoid receptor antagonist spironolactone (1 pM) or either antagonist alone. The
angiostatic effect of Cortisol was reversed by GR antagonism (p<0.05; Cortisol plus RU38486
versus Cortisol) and by spironolactone, although the latter was not significant (Cortisol plus
spironolactone versus Cortisol, p=0.16). RU38486, spironolactone and vehicle control (data
not shown) had no effect on TLS formation compared with untreated control wells. Data
represent mean ± SEM (n=4, each condition was performed in triplicate wells).
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3.4 Discussion
In this chapter, through the development of an in vitro model of endothelial tube
formation, it was determined that physiologically-relevant concentrations of active
(but not inactive) glucocorticoids act directly on endothelial cells to inhibit a key
component of the angiogenesis cascade. Furthermore, evidence presented here
suggests that glucocorticoids inhibit angiogenesis by GR-dependent action on tube
formation by the endothelium.
3.4.1 Development of the endothelial TLS model
Endogenous glucocorticoids generated in the vessel wall by llp-reductase activity
are known to control angiogenesis by regulating local glucocorticoid availability
(Small et al., 2005), however it is not clear how they act. A major aim of the present
study was to develop an in vitro model to address this.
In vitro angiogenesis assays offer the opportunity to investigate angiogenic
mechanisms with speed and simplicity that cannot be achieved using in vivo assays
(Vailhe et al., 2001). Experiments involving controlled cell populations have
end-points that are easy to quantify, reproducible, and do not have confounding
factors of in vivo models such as stromal and inflammatory cells. For mechanistic
studies, recovery of cells to study gene and protein expression is another advantage.
A single cell population assay was chosen to investigate primarily whether
glucocorticoids have a direct effect on the endothelium rather than acting via an
intermediary cell type such as neighbouring SMCs. In the extensive literature on
angiogenesis assays (Auerbach et al., 2003), it is acknowledged that culturing
endothelial cells on basement membrane proteins promotes their morphologic
differentiation into mature capillary or tube-like structures (CLSs or TLSs) versus the
typical "cobblestone" appearance that they assume when grown on plastic (Lawley &
Kubota, 1989). Therefore the endothelial TLS assay offers the opportunity to study
the endothelial cell in a situation that more closely approximates its conformation
during angiogenesis in vivo.
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The endothelial tube formation model was selected because it is thought to
recapitulate the morphogenesis step of angiogenesis alone (Vailhe et al., 2001).
Potential effects of glucocorticoids on this step of angiogenesis in isolation could
therefore be examined. According to the literature, TLS formation occurs as a result
of endothelial cell differentiation and occurs in the absence of cell proliferation
(Kubota et al., 1988) and migration (Manoussaki et al., 1996).
One of the key requirements of the TLS model was that it should involve human
endothelial cells to extend the findings reported by Small and colleagues (Small et
al., 2005), which were restricted to mouse models. Strategies to stimulate, and
inhibit, angiogenesis have demonstrated efficacy in mice but fail to provide similar
results in humans (Rajagopalan et al., 2003; Oehler & Bicknell, 2000).
Consequently, it is best to use human cells or tissues, wherever possible, to avoid
species differences (Mestas & Hughes, 2004). An important consideration in the
choice of cell is that all endothelial cells are not alike, demonstrating phenotypic
differences. For example, differences in protease activity have been described
between large vessel-derived endothelial cells and endothelial cells of microvascular
origin (Jackson & Nguyen, 1997). Therefore, wherever possible, in vitro assays
should be carried out using endothelial cells from more than one source. In the
present study, HUVECs were used predominantly due to the availability of batches
from pooled donors, their rapid availability, and low cost compared with other
sources. For these reasons, HUVECs are by far the most common choice of cell used
in this assay (Table 3.1) and other in vitro endothelial cell assays. The observation in
the present study, that glucocorticoids inhibit TLS formation, was originally made in
HUVECs. Key observations were subsequently confirmed in another human
endothelial cell type, HAoECs, demonstrating that these findings are not limited to a
single vascular territory and extend the findings reported here to an arterial
endothelial cell-type. Furthermore, the angiostatic effects of physiological
concentrations of glucocorticoids in the TLS model have been described using
human cells of microvascular origin (by Dr Michael Rae, Centre for Reproductive
Biology, personal communication) and are significant since angiogenesis in vivo
occurs in microvascular beds.
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Attempts to extend the lifespan of each batch of cells by cryopreservation proved
unsuccessful as, although cells appeared healthy and underwent normal cell cycle
division upon revival, they failed to form TLS networks in the assay compared with
non-frozen cells. This suggests that irreversible damage to the cell is caused by
either the freezing process and/or storage conditions. It is not clear from the
literature whether cryopreservation of endothelial cells for extended use in the TLS
assay is routine but anecdotal evidence suggests that it is. A key advantage of using
multiple fresh batches of HUVECs as opposed to the extended use of a single batch
is that observations are made from a larger population base thereby minimising the
possibility of individual donor effects. Batch-specific variation in the degree of
control TLS formation was evident in these studies given the mean inter-assay
coefficients of variation; however, this was circumvented by performing control
groups on each occasion and normalising data to control.
Cell culture provides an approximation of the in vivo environment. For example, it is
documented that cells growing in isolated tissue culture for extended periods display
altered growth characteristics compared to those growing in situ in live tissues
(Cervenkova et al., 2001; Shi et al., 2004). To address whether this was an issue in
the present study, experiments were performed to assess the expression of CD31
(PECAM-1, platelet endothelial cell adhesion molecule-1) and Tie2, endothelial cell
surface markers involved in cell-cell interactions (Dumont et al., 1992; Newman et
al., 1990). Both cultured HUVECs and TLSs retained expression of both markers
after sub-culturing, suggesting that they do retain functional and biochemical
characteristics of endothelial cells in their normal environment. Furthermore, the use
of HUVECs within a similar passage range (p2-p6) to that used here is commonplace
according to the literature (Beckner & Liotta, 1996; Kuzuya & Kinsella, 1994;
Cattaneo et al., 2003); however, the basis for this choice is not made clear in these
reports. In the present study, the degree of TLS formation, and the presence of
markers of key endothelial functions, was found to be consistent within this passage
range and therefore use of cells within this range was reasonably justified.
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In this study, a 2D model of TLS formation was developed in which the TLSs form
directly upon the surface of the Matrigel. 2D models lend themselves more easily to
quantification than 3D models, in which cells or tissue explants are dispersed
through, or sandwiched between, layers of matrix since the latter model consists of
sprouting in multiple focal planes. Also, 3D models are more time-consuming and
may require several days or weeks for networks to develop (Nicosia & Ottinetti,
1990; Lansink et al., 1998; Nakatsu et al., 2003); in contrast endothelial cells plated
on Matrigel form TLSs within several hours as reported here and by others (Beckner
& Liotta, 1996; Cattaneo et al., 2003; Kuzuya & Kinsella, 1994). These were
important considerations in the final choice of assay since rapid and accurate
quantitation were prerequisites of the model. During method refinement, cells
dispersed throughout the matrix did not form adequate networks compared with cells
seeded on a solidified layer of Matrigel. Furthermore, recovery of cellular material
from TLSs in the 2D model was possible and allowed successful extraction of RNA
and protein for gene expression and signal transduction studies. In contrast, it has
been shown previously that aortic rings embedded in Matrigel do not allow for
successful recovery of RNA for gene expression studies (Mr Louis Chablis,
unpublished findings) and resistance of Matrigel to penetration by antibodies (Dr
Gary Small PhD thesis, University of Edinburgh 2006) precluded
immunohistochemical identification of component cells. An important facet of the
present study was to characterise the structural and functional components of TLSs
by direct staining methods. Consequently the 2D model was adopted for use in these
studies.
The use of EGM-2 culture medium in the TLS assay has been described by others
(Donovan et al., 2001; Wilasrusmee et al., 2003) but specific culture conditions with
regard to the inclusion of Bullet kit growth factors is not commonly reported.
Consequently, growth factor requirements for TLS formation were carefully
evaluated in the course of method development. Conditions were optimised to
produce sufficient networks that could be easily quantified and more importantly,
were responsive to angiogenic stimuli and inhibition. Preliminary studies revealed
that TLS formation in the presence of Bullet kit growth factors and serum was too
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prolific and further augmentation of growth with VEGF (positive control) could not
be achieved. Evidence from the literature suggests that further augmentation of TLS
formation with VEGF (100 ng/ml) can be achieved in the presence of serum, but
only at lower levels (1%) than those used in the present study (Kawasaki et al.,
2000). Furthermore, the angiostatic effect of Cortisol (300 nM) was not observed
under growth factor rich conditions and therefore any inhibitory effect is likely to
have been masked by the prolific network formation. This is consistent with a
previous report that dexamethasone (at micromolar concentrations) failed to inhibit
TLS formation under similar conditions (Wilasrusmee et al., 2003). It is feasible that
exogenous addition of factors was able to overcome glucocorticoid-induced
impairment of growth factor production and suggests an interaction between
glucocorticoids and growth factors. Under standard basal conditions (containing
only EGM-2 plus ascorbic acid, antibiotics and heparin), a level of TLS growth was
achieved that could be stimulated by growth factors and inhibited by glucocorticoids.
Ascorbic acid was included because of reports that it promotes angiogenesis in aortic
ring cultures and maintains new vessel structure (Nicosia et al., 1991) and heparin
was included since it is necessary for glucocorticoids to inhibit angiogenesis
(Folkman et al., 1983; Crum et al., 1985) in the CAM assay.
Choice of basement membrane matrices was decided as a result of careful
consideration of the literature. Matrigel has previously been shown to cause the
differentiation of endothelial cells into TLSs (Lawley & Kubota, 1989). Although
the composition of Matrigel is not completely characterised it appears highly
consistent since the results from Matrigel TLS assays are reproducible allowing
inter-lab experimental comparisons. Consequently, it has allowed the screening of
several anti-angiogenic molecules (Beckner & Liotta, 1996; Kuzuya & Kinsella,
1994; Morales et al., 1995; Stoltz et al., 1996). It has been determined that one of
the main signals responsible for TLS formation is laminin (Kubota et al., 1988)
which is the primary constituent of Matrigel, followed by collagen IV, heparin
sulphate proteoglycans, entactin and nidogen (Kleinman et al., 1982). However
TLS formation does not occur on laminin or collagen IV either alone or in
combination, but does when combined with collagen I, therefore interactions
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between the endothelium and multiple basement proteins is necessary to induce TLS
formation. Matrigel is an ideal choice of preparation since it is a preparation
extracted from a mouse tumour (EHS sarcoma) and contains the entire essential
extracellular matrix proteins involved in angiogenesis in vivo. Consequently,
Matrigel has been used in the TLS assay for almost 20 years (Lawley & Kubota,
1989) and is by far the most frequently used matrix to support growth.
Lack of a standard quantification method of TLS formation prompted a
comprehensive comparison of the most commonly described methods. Computer
analysis techniques have been used infrequently to count vessels in the TLS assay
(Sanz et al., 2002). In the present study, vessel density was not reliable or consistent
since it was not possible to set a binary threshold function to accurately distinguish
undifferentiated cells and cell debris from TLS networks as previously described
(Lansink et al., 1998; Donovan et al., 2001). This resulted in highly variable results
between replicate wells and, therefore, this method was excluded early on. Counting
capillary connections (or branch-points) and measurement of TLS length showed a
similar pattern of TLS formation in response to a pro-angiogenic stimulus (VEGF)
but counting connections was more sensitive. VEGF (10 ng/ml) has previously been
shown (Donovan et al., 2001) to have a significant effect on TLS length but only on
a growth-factor reduced substrate. This effect was not manifest on standard Matrigel
(Donovan et al., 2001), or in the present study. Thus, augmentation of TLS length
appears to be dependent on matrix type and could explain the lack of stimulation by
VEGF in the present study. Furthermore, TLS length was not altered in the presence
of glucocorticoids indicating that modulation of TLS length is not as sensitive to
modulation by exogenous angiogenic factors as counting connections. Counting
connections was reliable, technically less demanding, less time consuming, and most
importantly detected stimulation (VEGF; prostanoids) and inhibition (Cortisol,
dexamethasone) by exogenous factors. These advantages led to the adoption of
counting connections as the standard method for quantification of TLS formation.
Since connection counting was performed by an individual blind to the treatments
the integrity of the final data was ens ~sd.
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It is clear from the literature that early TLS formation is followed by detachment and
degradation of the network. Here, a pattern of TLS formation consistent with other
reports using similar conditions was observed (Kuzuya & Kinsella, 1994;
Wiedemann et al., 1996; Morales et ah, 1995; Bussolati et al., 2001) Briefly, after 1
to 2 hours on Matrigel, HUVECs attached to the matrix underwent elongation and
began to align with each other. After 4 to 5 hours, anastomosing networks were
obvious; after 8 to 10 hours, networks appeared to reach maturity and TLSs were
visible. During the regression phase, TLS networks disintegrated and cells began to
detach and lift off. By 24 hours, most of the TLS network had degraded and all that
remained were aggregates of cells that resembled apoptotic bodies although this was
not tested in this study. To address which phase, if any, was influenced by
glucocorticoids and to begin to explore potential angiostatic mechanisms, TLS
formation was initially assessed after 4 to 5 hours, and again after 20-24 hours of
incubation. This was consistent with time-points chosen to quantify TLS formation
in other studies (Morales et al., 1995; Tan et al., 2004; Wiedemann et al., 1996) but
the reasons for using these time-points are not made clear in these reports.
At the time these studies were performed quantitative studies in the literature were
limited to static morphometric approaches. However, consistent with the findings
from our own studies, a report has recently emerged describing extensive
characterisation of the dynamic process of TLS fomation (on fibrin gels) using
similar methodology (Stephanou et al., 2006). Time-lapse studies gave a more
dynamic insight into the time-course of TLS fomation and proved invaluable in
improving our understanding of the processes involved in the Matrigel model. These
studies revealed that the time course of TLS formation was consistent with those
previously observed at isolated time-points (4 hours and 22 hours) and enhanced our
understanding of the process by revealing that maximal TLS formation occurs at 8
hours. Indeed, this served as an important basis to plan gene expression studies
(explored in Chapter 4) and provide a useful justification for including 8 hour
time-points in future studies using this model. Time-lapse imaging also
demonstrated that TLS fomation occurs as a result of changes in cell morphology
with the absence of obvious signs of proliferation or migration, confirming claims
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that this serves as a useful model of endothelial cell differentiation in isolation from
these other processes (Taraboletti & Giavazzi, 2004). Furthermore, the effects of
glucocorticoids on the dynamic process of TLS formation have now been revealed.
'Snap-shots' data only revealed that fewer connections were present after
glucocorticoid treatment but it was not clear whether this was due to reduced
network formation or enhanced degradation. The time-lapse imaging studies indicate
that glucocorticoids can affect both; by reducing the magnitude of the initial
formation phase, and, accelerating the network degradation phase thus providing
further insight into their mechanism of action.
To validate the resemblance of TLSs to angiogenic networks in vivo, several studies
have examined their ultra-structural integrity. The presence of a lumen within TLSs
is considered evidence that the model recapitulates cell morphological changes that
lead to capillary formation in vivo (Taraboletti & Giavazzi, 2004) but this is an area
of controversy. Using TLS models similar to that described in this thesis (culturing
HUVECs on Matrigel), Lawley and Kubota reported hollow, lumen-like endothelial
tubes surrounded by cells in cross sections of TLSs (Lawley & Kubota, 1989).
Others have reported structures that are more like narrow clefts (Montanez et al.,
2002). In some instances lumen formation appeared to take place within individual
cells and in others involved remodelling of groups of cells; a pattern that is consistent
with that observed in the cytoskeleton studies reported in this chapter. The formation
of tight junctions between endothelial cells in the TLS assay has been described by
others (Auerbach et al., 2003), resembling those in vivo, further validating the
relevance of the model used in the present study.
3.4.2 11|3-Hydroxysteroid dehydrogenases in endothelial cells and
tube-like structures
The rationale for determining the presence of llp-HSDs in this model was that both
isozymes are present in the vessel wall (Hadoke et al., 2001; Christy et al., 2003;
Brem et al., 1998) although the cellular localisation is controversial. Since
11(3-HSD1 has been shown to have a role in regulating angiogenesis in vitro and in
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vivo (Small et al., 2005), determining the source of this activity in the vessel wall is
important. Studies have demonstrated expression of both isozymes in primary
human vascular SMC cultures (Cai et al., 2001) and in primary cultures of rat aortic
endothelial cells (Brem et al., 1998) whereas histological studies in rat vessels
suggest that immunoreactivity for 11 (1-HSD1 is restricted to vascular smooth muscle
(Walker et al., 1991). Other studies have revealed that 11|3-HSD2 is localised to the
endothelium in human renal artery (Kataoka et al., 2002) and in mouse aortic media
(Miss Danielle Armour, unpublished findings). Direct comparison of studies is
difficult, given the use of vessels from different species and anatomical locations
combined with a variety of techniques for detecting llfl-HSDs. Another
confounding factor to explain disparities in expression is that they may vary
according to culture conditions. For instance, the expression of lip-HSDl in
hepatocytes growing in culture is sensitive to culture conditions (Jamieson et al.,
1995). Furthermore, 11 (5-HSD1 is induced upon differentiation of human monocytes
into macrophages (Thieringer et al., 2001) and in adipocytes (Napolitano et al.,
1998). This indicates that llfl-HSD expression, and activity, in isolated cells
growing in culture may vary depending on culture condition. Thus it was necessary
to determine lip-HSD status in the TLS assay prior to embarking on studies
exploring the effects of substrates for these enzymes (i.e. glucocorticoid effects).
In the present study neither of the llp-HSD isozymes was expressed or active in
undifferentiated HUVECs and the expression and activity profiles did not change
upon differentiation of cells into mature TLSs. In contrast, stably transfected CHO
cells acted as robust positive controls with reductase and dehydrogenase activity
detected in line with previous in vitro studies from our department (Dr Scott
Webster, personal communication). A published study demonstrated ll(!-reductase
activity in cultured vascular smooth muscle cells incubated with substrate over the
same time period (Cai et al., 2001). The finding that lip-HSDl acted as both a
reductase and dehydrogenase in transfected CHO cells is not surprising given that
this has been previously reported (Bujalska et al., 2005). Indeed, in most cell
models, stably transfected with human llfl-HSDl cDNA into HEK293 cells
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(Bujalska et al., 1997) or transiently transfected with rat lip-HSDl into CHO cells
(Agarwal et al., 1989), both reductase and dehydrogenase activity were reported.
Further, there is some evidence that llp-HSDl has bi-directional capability in intact
vascular tissue; llp-dehydrogenase was detected in endothelium-denuded aorta and
smooth muscle cells apparently devoid of 11(3-HSD2 expression (Brem et al., 1995).
Absence of expression of 1 ip-HSDs from isolated human circulating endothelial
precursor cells in the present study is consistent with these findings from isolated
resident endothelial cells. This suggests that the expression of these isozymes is not
determined by developmental stage. However, there are data to suggest that activity
of lip-HSDs in the vasculature is territory-dependent as higher activity was reported
in rat mesenteric arteries compared with aorta (Walker et al., 1991). Consequently, it
will be important in future studies to validate these findings using human endothelial
cells from other physiologically relevant microvascular sources (e.g. human dermal
microvascular endothelial cells, HuDMECs).
A role for intra-vascular generation of endogenous glucocorticoids in modulation of
angiogenesis was indicated recently by our demonstration that lip-HSDl in vascular
smooth muscle catalyses local production of active glucocorticoid (Dover et al.,
2007; Small et al., 2005). This process was maintained in vivo and influenced the
angiogenic response to healing in the myocardium and cutaneous wounds (Small et
al., 2005). It was not clear, however, whether glucocorticoids generated by medial
lip-HSDl were inhibiting angiogenesis by an autocrine action on the vascular
smooth muscle or a paracrine action on the endothelium. In the present study, a lack
of lip-reductase activity in endothelial TLSs suggests that lip-HSDl regulates
angiogenesis by active glucocorticoids generated by another cell type in the vessel
wall such as neighbouring SMCs (Cai et al., 2001). Indeed, a lack of endogenous
glucocorticoid-generating capacity in endothelial tubes may negate a possible role
for this isozyme in regulating angiogenesis autonomously in the endothelium.
Alternatively, activated macrophages have also been shown to express lip-HSDl
(Thieringer et al., 2001) suggesting that generation of active glucocorticoids within
these cells may contribute to regulation of inflammation. However, these findings
could not be confirmed in an in vivo setting (Dover et al., 2007). These are
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hypotheses that need to be addressed more rigorously and future projects are planned
to adapt the TLS model to a co-culture system. Alternatively, HUVECs are
amenable to transfection (Ear et al., 2001) and therefore lip-HSD activity could be
added into the model in this way. In summary, 1 lfl-HSDs are not expressed in this
system and therefore the effects of glucocorticoids could be dissected without the
confounding factor of local metabolism, but the role of lip-HSDs could not be
dissected further in this model.
3.4.3 Influence of glucocorticoids on TLS formation
Prior to testing the effects of glucocorticoids in this system, assessment of the
responsiveness of the model was demonstrated first of all using pro-angiogenic
stimuli as positive controls. VEGF and prostaglandins all reproducibly stimulated
TLS formation in keeping with their physiological role in stimulating angiogenesis in
vitro and in vivo (Bussolati et al., 2001; Ferrara & Henzel, 1989; Majima et al.,
2000; Tamura et al., 2006). The pro-angiogenic effects of prostaglandins may be
due to enhanced VEGF synthesis which has been demonstrated in vitro (Pai et al.,
2001; Fukuda et al., 2003) and in vivo. Thus, since the precursor to endogenous
prostaglandin synthesis, (COX-2) is down-regulated by glucocorticoids (Crofford et
al., 1994; Ghosh et al., 2000); this may represent part of the angiostatic molecular
mechanism of glucocorticoids. The stimulatory effect of VEGF on TLS formation
was observed after only 4 to 5 hours of incubation compared with both
prostaglandins which exerted maximal effects at the later time-point of 20 to 23
hours incubation. Differing modes of action to induce TLS formation may underpin
the difference in timescales. TLS formation was consistently enhanced by 3 different
angiogenic factors demonstrating the responsiveness of the model to exogenous
stimuli and further validating the quantification method.
Physiologically-relevant concentrations of Cortisol inhibited TLS formation (Figure
3.15), demonstrating that Cortisol has a direct inhibitory effect on endothelial tube
formation in the absence of peri-vascular cell types. Glucocorticoid-mediated
inhibition of VEGF-induced TLS formation (Figure 3.17) suggests an inhibitory
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effect on the downstream signalling events elicited by the action of VEGF on the
endothelium and supports a previous study which demonstrated a role for
glucocorticoids inhibiting VEGF-induced calcium flux in HUVECs (Dr Gary Small,
unpublished findings). Cortisol blocked VEGF effects in order that, in the presence
of Cortisol, VEGF had no effect. Consequently, there may be elements of Cortisol
action which are VEGF independent, or alternatively, that there is endogenous VEGF
being blocked by Cortisol. These angiostatic actions of Cortisol in the TLS assay are
consistent with, and extend, the angiostatic effects of the rodent equivalent,
corticosterone (30 to 600 nM), in the aortic ring model (Small et al., 2005; Nicosia &
Ottinetti, 1990) and in a model of cutaneous wound repair (Beer et al., 2000).
Preliminary data from the cytoskeleton studies would suggest that glucocorticoids
may alter the cytoskeleton of endothelial TLSs; however, further investigation is
required to confirm this. This hypothesis is supported by the literature in endothelial
cell monolayers (Criscuolo & Balledux, 1996) and interfering with microfilaments or
microtubules suppresses key angiogenic cellular responses including migration and
rearrangement into TLSs (Grant et al., 1991; Shen et al., 2007). However, a direct
effect of glucocorticoids on the cytoskeleton of TLSs has not been reported thus far
and would be a novel finding.
From the initial observation of endothelial cells exposed to pharmacological
concentrations of steroids a description of cellular "rounding-up" with retraction of
cytoplasmic extensions and detachment from the basement membrane was reported
(Folkman & Ingber, 1987). A patho-physiological concentration (1.2 pM) of Cortisol
did not exceed the magnitude of inhibition in the present study using 600 nM and is
consistent with studies in the chick chorioallantoic membrane (CAM) assay in which
various steroids generated bell-shaped concentration-response curves (Crum et al.,
1985). In addition, findings from the CAM assay (Crum et al., 1985), mouse aortic
rings (Small et al., 2005), and the data presented in this chapter all support a role for
glucocorticoid suppression of angiogenesis independent of inflammation and
immunity. The inhibitory effect of physiological glucocorticoids reported here is
significant as it correlates with hum _n fasting plasma Cortisol levels (Wake et al.,
2003). Although the angiostatic effect of endogenous glucocorticoids in human
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pathophysiology has not been investigated, impaired wound healing (an angiogenesis
associated process) is seen in Cushing's disease patients with excess endogenous
glucocorticoids (Gordon et al., 1994) and in patients on extended glucocorticoid
therapy (Green, 1965).
In contrast to the angiostatic effect of Cortisol, the inability of cortisone at similar
concentrations to inhibit TLS formation contrasts with the angiostatic effects seen in
in vivo angiogenesis models (Folkman et al., 1983; Maragoudakis et al., 1989; Small
et al., 2005). A likely explanation for this is due to lack of lip-HSDl activity in
TLSs and is further evidence that active glucocorticoids are not generated in the
endothelium. Cortisone does inhibit VEGF production in cultured human SMCs
(Nauck et al., 1998), which also possess lip-HSDl activity (Cai et al., 2001).
Consequently cortisone may confer angiostasis in the vessel wall following
regeneration to Cortisol, by lip-HSDl, and blocking the action of VEGF.
Cortisol may inhibit tube formation via GR or MR, both of which may be expressed
in endothelial cells. GR are expressed in endothelial cells (Yang & Zhang, 2004) but
levels may vary between endothelial cell types (Inoue et al., 1999). MR expression
has previously been reported in HUVECs (Oberleithner et al., 2003) but the
expression of MR in TLSs is not clear and would be worth checking in future
studies. Expression of GR was confirmed in the present study in undifferentiated
HUVECs and expression was not altered upon differentiation into mature TLSs. At
relevant concentrations neither GR nor MR antagonism influenced TLS formation,
consistent with previous reports (Yamamoto et al., 1994). The angiostatic effect of
glucocorticoids on TLS formation appears to be mediated via GR since inhibition
occurred with the GR selective glucocorticoid dexamethasone. The receptor
antagonism studies were also indicative of GR dependency since the inhibitory effect
of Cortisol was reversed by GR antagonism. However, since MR antagonism also
tended to reverse the Cortisol effect, albeit not statistically significantly, MR may
also be involved and further studies aimed at elucidating its presence in TLSs will be
required to resolve this issue. Since progestogens were not added to the assay, the
progesterone receptor-blocking effects of RU38486 (Schreiber et al., 1983) cannot
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account for this mechanism. The GR-mediated inhibition of endothelial tube
formation is of pathophysiological significance since wound repair is impaired in
mice with a defective GR mutation (Grose et al., 2002).
3.4.4 Conclusion
The data in this chapter provide evidence for the establishment of an in vitro assay of
endothelial tube formation as a useful tool to examine the influence of
glucocorticoids on the endothelium and to dissect angiostatic mechanisms
independently of systemic anti-inflammatory and metabolic changes. Given that
11P-HSD activity is absent from this system, the influence of exogenous
glucocorticoids at physiologically relevant concentrations could be faithfully tested.
These studies demonstrated that endogenous and synthetic glucocorticoids inhibit
endothelial tube formation and that this effect occurs via glucocorticoid receptors.
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This may represent one of the key components of glucocorticoid-mediated
angiostasis in vivo and in pathological situations. The TLS model will serve as a
useful tool to examine the molecular signalling pathways through which









The demonstration that glucocorticoids inhibit tube formation by endothelial cells in
vitro (Chapter 3) suggests that their anti-angiogenic action in vivo may be due, at
least in part, to direct interaction with the endothelium. These studies have not
shown, however, the mechanism(s) through which this glucocorticoid
receptor-dependent inhibition is mediated. A careful review of the literature suggests
that regulation of angiogenesis by glucocorticoids is due to: effects on growth factor
production and their receptors, inhibition of endothelial cell-ECM interactions,
degradation of the basement membrane, and/or effects on the arachidonic acid
cascade (Section 1.3.2). Moreover, the time-lapse studies from Chapter 3 highlight
altered VEGF signalling as a likely mechanism since VEGF loses its stimulatory
effect in the presence of glucocorticoids (Section 3.3.1.5). In addition, the literature
suggests that altered intracellular signalling cascades might play a role.
4.1.1 VEGF signalling
Glucocorticoids inhibit TLS formation in the presence of VEGF (Chapter 3) and this
is consistent with other studies in the literature describing glucocorticoid effects on
angiogenesis. Glucocorticoids can influence VEGF production (Nauck et al., 1998),
stability (Gille et al., 2001) and action (Matsuda et al., 2005; Wu et al., 2006). In
isolated HUVECs, VEGF-induced intracellular calcium flux was inhibited by
Cortisol treatment (Small et al., unpublished findings) suggesting a role in
glucocorticoid-mediated angiostasis. In vivo, patterns of expression of VEGF and
VEGF receptors in steroidogenic, and steroid responsive, tissues in mice, suggest a
role in hormonally-regulated angiogenesis in vivo (Shweiki et al., 1993). Also, in
various disease models, glucocorticoid treatment suppresses VEGF production (Pufe
et al., 2003; Luo et al., 2004).
Notch signalling plays a fundamental role in the determination of cell fate {e.g. cell
proliferation or differentiation) (Artavanis-Tsakonas et al., 1995) and is known to be
involved in VEGF signalling. The Notch pathway is highly conserved and is known
to play important roles in development in both invertebrates and in vertebrate tissues,
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recently reviewed by Roca & Adams, 2007. However, the angiogenic signalling that
controls Notch and its ligands' activity is only partially understood (Liu et al., 2003).
A series of studies have shown that one ligand for the Notch receptors, D114, is
normally induced by VEGF and is a negative-feedback regulator that restrains
vascular sprouting and branching (Hellstrom et al., 2007; Siekmann & Lawson,
2007; Leslie et al., 2007). Consistent with this role, the deletion or inhibition of D114
results in excessive, non-productive angiogenesis in tumours (Thurston et al., 2007).
4.1.2 Endothelial cell-ECM interactions
The extracellular matrix (ECM) provides guidance cues for the establishment of
endothelial tubes in the absence of cell-cell contacts via the
matrix-integrin-cytoskeletal signalling axis (Davis & Senger, 2005). The
involvement of particular integrins is dependent on the matrix environment to which
endothelial cells are exposed (Davis et al., 2002). In laminin-rich matrices, such as
Matrigel, a6 and pi subunits are thought to play a critical role in regulating tube
formation (Bauer et al., 1992; Davis & Camarillo, 1995; Da Silva et al., 2003). It is
not entirely clear from the literature how expression of integrins translates into cues
for endothelial tube formation but over-expression of pi subunits, when unligated, is
enough to induce apoptosis (Stupack et al., 2001).
Matricellular proteins, such as TSP-1 are secreted proteins that influence cell
function by modulating cell-matrix interactions (Bornstein, 2001). TSP-1, and
fragments of TSP-1, can act directly on endothelial cells to inhibit angiogenesis by
interactions with cell surface proteins CD36 (a member of the class B scavenger
receptor family of proteins), CD47 (which is involved in the increase of intracellular
calcium upon cell adhesion to the ECM) and integrins on the surface of the cell.
Binding of TSP-1 to CD36 mediates inhibition of endothelial cell migration (Dawson
et al., 1997) and tube formation (Iruela-Arispe et al., 1991; DiPietro et al., 1994) and
leads to induction of apoptosis (Jimenez et al., 2000).
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Caveolins are prominently expressed in most adherent mammalian cells and their
main function is in the formation of invaginations, termed caveolae, in the plasma
membrane (Williams & Lisanti, 2004). Caveloae have a role in signal transduction
(via the ERK-MAPK pathway) and caveolin-1 has been shown to play a role in
integrin signalling (Wary et al., 1998) and is, therefore, important in cell-matrix
interactions. Recent studies have proposed a role for caveolin-1 in the regulation of
angiogenesis; over-expression of caveolin-1 accelerates capillary tube formation by
endothelial cells in 3D models (Liu et al., 2002) and vice versa (Griffoni et al.,
2000). However, it is not fully understood what regulates caveolin expression.
Glucocorticoids induce caveolin-1 expression and the formation of caveolae, via GR,
in isolated epithelial cells (Barar et al., 2007), but no study to date has investigated
glucocorticoid effects on caveolin-1 expression in the endothelium.
4.1.3 Intra-cellular signal transduction
Intra-cellular signal transduction pathways convey the necessary signals which
determine the final behaviour of endothelial cells during angiogenesis; including
proliferation, migration and differentiation (Munoz-Chapuli et al., 2004).
4.1.3.1 Focal adhesion kinase
FAK is a cytoplasmic tyrosine kinase that plays a key role in integrin-mediated
signal transduction (Parsons, 2003) and has an important role in endothelial cell
activities associated with angiogenesis including proliferation, migration and
differentiation (Ilic et al., 2003; Shen et al., 2005). Members of the FAK family link
transmembrane glycoproteins to the actin cytoskeleton and, therefore, have a crucial
role in mediating cell shape and motility induced by cell-matrix interactions. Other
studies have implicated FAK in the transduction of soluble signals including VEGF
(Qi & Claesson-Welsh, 2001). There is a limited literature on rapid,
non-transcriptional activation of FAK by glucocorticoids (Koukouritaki et al., 1999;
Koukouritaki & Lianos, 1999) while other studies have demonstrated that
glucocorticoids attenuate cytokine in 'need FAK expression (Jee et al., 2007), at least
in non-endothelial cell types.
151
4.1.3.2 Mitogen-activated protein kinases
Further downstream of receptor tyrosine kinases and the FAK relay, multiple signals
from transmembrane receptors (such as VEGF-R and integrins) form cascades which
eventually lead to gene transcription and a network of cross-talks that ultimately
determine cellular activity. The Ras-ERK-MAPK pathway is of particular
importance in the transduction of differentiation/morphogenesis signals in
endothelial cells (Meadows et al., 2001) and involves a series of phosphorylation
steps which confer activity of the pathway. Since previous studies have shown that
the phosphorylation state of ERK1/2 is reduced during endothelial tube formation, in
the absence of significant changes in their transcript levels (Grove et al., 2002),
post-translational modification is just as important for investigating influence of
glucocorticoids on angiogenesis as changes in gene transcription. Also,
glucocorticoid-mediated inhibition of intracellular calcium flux in HUVECs (Small
et al., unpublished findings) implicates the MAPK pathway since calcium flux is
known to play an important role in the activation of ERK/MAPK signalling
(Munaron, 2002; Kupzig et al., 2005).
4.1.4 Regulation of angiogenic molecular signalling by glucocorticoids
Glucocorticoids exert some of their actions through binding to receptors that are
hormone-regulated transcription factors that may activate or repress gene expression
(Webster & Cidlowski, 1999). A careful review of the existing literature suggested
that GC-mediated inhibition of angiogenesis is due to a reduced generation or action
of pro-angiogenic factors (e.g. VEGF), increased activation of angiostatic factors
(e.g. TSP-1, Notch signalling) and/or altered endothelial cell-extracellular matrix
(ECM) interactions (e.g. integrins, caveolae). A relatively new concept of
non-transcriptional action of glucocorticoids has emerged where activated GR
initiate signalling without a direct effect on gene transcription (Limbourg & Liao,
2003) and inhibition of MAPK signalling (e.g. ERK, JNK) has been implicated in the
regulation of angiogenesis.
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Previous investigations of glucocorticoid effects on angiogenic factor gene
expression have tended to use; pharmacological, synthetic glucocorticoids (e.g.
dexamethasone) (Wu et al., 2006); a variety of human (Tong et al., 2006) and
non-human (Machein et al., 1999), endothelial (Gallicchio et al., 2006) and
non-endothelial cell types (Wu et al., 2006). Furthermore, these previous studies
were limited to isolated, proliferating cells growing on tissue culture plastic. These
studies demonstrated that glucocorticoids tended to decrease the synthesis of
pro-angiogenic factors such as VEGF (Koedam et al., 2002; Tong et al., 2006),
whilst they induce expression of angiostatic factors such as TSP-1 (Flugel-Koch et
al., 2004) and tissue inhibitors of metalloproteases (TIMPs) (Forster et al., 2007);
thus shifting the balance of factors in the direction of angiostasis. Similarly,
pharmacological levels of synthetic glucocorticoids have been suggested to inhibit
activation of MAPK proteins (JNK, ERK and p38) (Pelaia et al., 2001; Gonzalez el
al., 1999) in isolated endothelial cell monolayers.
Together, these studies have given some insight into the molecular mechanism(s) of
action of glucocorticoids in the regulation of angiogenesis. It is not clear, however,
whether regulation of transcription of these factors, or regulation of activated protein
levels can account for glucocorticoid-mediated inhibition of endothelial tube
formation and angiogenesis. Lastly, it is not clear whether any modulation of
molecular signalling, in this way, is dependent on glucocorticoid receptors.
4.1.5 Hypothesis
The investigations described in this chapter address the hypotheses that
glucocorticoids inhibit endothelial tube formation by down-regulation of the
expression of pro-angiogenic factors (VEGF, VEGF-R2, a6-integrin, caveolin-1,
FAK, ERK, p38, JNK and Akt) and/or up-regulation of the expression of angiostatic
factors (TSP-1, Notch-1 and D114). These studies also addressed the hypothesis that
glucocorticoid-mediated changes in endothelial gene, and protein, expression levels
are mediated via GR.
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4.1.6 Aims
The specific aims were:
1) to determine whether glucocorticoids alter gene expression of VEGF,
VEGF-R2, TSP-1, a6-integrin, Notch-1, D114 and caveolin-1 during
endothelial TLS formation.
2) to investigate the influence of glucocorticoids on activation of FAK, ERK,
p38, JNK and Akt proteins in endothelial cell monolayers to provide a tool
for investigating signal transduction in endothelial TLSs.
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4.2 Methods
4.2.1 Influence of glucocorticoids on angiogenic factor gene expression in
TLSs
The influence of glucocorticoids on the expression of angiogenic factors during TLS
formation was examined using quantitative real-time PCR (QrtPCR). This required
recovery of tube-like structures from Matrigel, isolation of RNA, reverse
transcription and QrtPCR using primers for genes of interest. Since few studies to
date have addressed modulation of gene expression in endothelial TLSs, some
method development was necessary. Pharmacological GR antagonism was used to
confirm, and extend, the demonstration (Chapter 3) that glucocorticoid-mediated
inhibition of TLS formation is dependent on GR binding.
4.2.1.1 TLS preparation and glucocorticoid treatment
Initial experiments demonstrated that using the 24-well plate set-up for TLS
formation did not yield sufficient cells for isolation of RNA. Consequently, TLS
formation was expanded to enable tube generation in a 35 mm dish. Briefly,
HUVECs (200,000) in 2 ml of standard basal medium were seeded on 35 mm cell
culture dishes pre-coated with Matrigel (500 pi) and incubated in the presence of
Cortisol (600 nM), Cortisol plus RU38486 (1 pM), or left untreated (control). RNA
was recovered using Matrisperse solution (Section 2.4.7.1) after incubation for 1, 4, 8
or 22 hours to examine both the time-course of gene expression in TLSs and effects
of treatment on the expression of these genes. Trizol (1 ml) was added to the cell
pellet and the contents transferred to a cryovial for storage at -80°C until required.
4.2.1.2 RNA extraction and reverse transcription
RNA extraction (Section 2.4.7.2) and reverse transcription (Section 2.4.7.3) were
performed as described previously. Due to the large number of samples, RNA
extraction was performed on batches of up to 40 samples on 2 separate occasions to
prevent degradation of RNA. Only RNase-free, sterile solutions and equipment were
used in order to prevent degradation of target RNA by exogenous RNases and
contamination of reactions with exogenous RNA or DNA. Briefly, first strand
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cDNA synthesis was performed using 0.5 pig of RNA with the Reverse Transcription
System (Promega, UK) in a reaction containing 5 mM MgCl2, lx reverse
transcription buffer, 1 mM each of dATP, dCTP, dGTP and dTTP, 20U RNasin,
0.5 pig oligo(dT)i5 primers and 15U AMV-Reverse Transcriptase. 01igo(dT)15
primers were used to prime RT reactions, rather than short random oligonucleotides
to ensure that poly (A) containing mRNAs were selectively reverse transcribed;
thereby ensuring less variation in the QrtPCR results (Hembruff et al., 2005). The
reactions were carried out on an Eppendorf Mastercycler Gradient (Eppendorf,
Germany) consisting of incubation at 42°C for 45 minutes followed by 95°C for 5
minutes and finally chilled to 4°C. Negative control reactions (no RT enzyme; no
RNA) were performed in parallel for each batch of samples. Products from the RT
reaction (cDNA) were diluted 1:4 with nuclease-free water prior to Qrt-PCR
amplification based on reaction kinetics of serially-diluted, pooled samples from the
gene expression experiment. Prior to running large numbers of samples on real-time
plates, randomly selected cDNA samples and negative controls, were run on standard
PCR using Tie2 primers (Table 2.1) to establish quality of cDNA and determine
potential contamination.
4.2.1.3 Quantitative real-time polymerase chain reaction
QrtPCR was used to determine the relative concentration of mRNA present in
samples using primers for genes of interest (Table 2.2) as detailed in Section 2.4.8.
Cyclophilin A was used as an internal (loading) control (Horiuchi et al., 2006;
Maresh et al., 2004). TaqMan primer probe mixes were supplied as pre-validated
ready-to-use assays. All assays were designed for use with human tissue, were exon
spanning and will not detect genomic DNA. All probes had a FAM reporter dye at
the 5' end and a non-fluorescent quencher at the 3' end and, consequently, required
protection from light throughout the procedure.
Briefly, 2 pi of cDNA template from each sample, pooled standard dilutions
(prepared fresh after 2 to 3 freeze-thaw cycles), and negative controls were added to
a 384-well plate (Roche, Switzerland) in triplicate wells. Primer-probe master mix
was prepared by mixing a 5 pl/sample of LightCycler 480 Probes Master (Roche)
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with 0.5 ul/sample of TaqMan MGB primer probe mix plus 2.5 pl/sample of water.
Master mix (8 pl/sample) was added to each well using a digital multi-channel
pipette to minimise variation in volume added. Thus, the final volume in each well
was 10 pi. PCRs were carried out on a LightCycler 480 (Roche) as detailed
previously (Section 2.4.8.4).
To determine the concentration of target DNA in unknown samples after PCR
amplification, absolute quantification analysis was used (as described in Section
2.4.8.5). Data were analysed by LightCycler 480 software vl.2.0.169 (Roche). By
determining where the Cp value of an unknown sample falls on the standard curve,
the initial concentration of target DNA in the samples were determined by the
software. Sample concentrations, expressed as a mean of triplicates, were exported
to Excel and normalised to corresponding cyclophilin A concentrations, as a ratio,
which served as an internal control.
4.2.2 Influence of glucocorticoids on VEGF protein production during TLS
formation
Preliminary investigations in the Endocrinology Unit (University of Edinburgh),
using a VEGF ELISA kit, demonstrated production of soluble VEGF (VEGFm and
VEGF165) protein by mouse aortic rings cultured in Matrigel (Small et al.,
unpublished findings). The possibility that glucocorticoids inhibit TLS formation by
inhibiting VEGF production by endothelial cells was addressed using a similar
approach. Briefly, HUVECs (4 x 104 cells/ml) in standard basal medium (EGM-2
with no growth factors or FBS) in the presence of Cortisol (600 nM), vehicle
(ethanol, 0.0006% v/v) or untreated (control) were seeded directly onto uncoated,
and Matrigel-coated, 24-well tissue culture plates. Conditioned media were collected
1, 5 and 22 hours after cell seeding, and soluble VEGF protein levels determined
using a human VEGF ELISA kit (Calbiochem-Merck, UK) according to the
manufacturer's instructions. Plates were read using a spectrophotometric plate
reader at dual wavelengths of 450 rm and 540 nm (MRX, Dynatech Laboratories,
UK).
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4.2.3 Influence of glucocorticoids on activation of signal transduction
proteins in endothelial cells
The influence of glucocorticoids on signal transduction pathways in endothelial cells
was assessed using a biochemical approach. Western blotting was used to detect
FAK and phosphorylated (activated) ERK (pERK) in HUVEC protein extracts to
examine the influence of Cortisol, GR antagonism (RU38486) and an established
inhibitor of MAPK signal transduction (PD98059). Training in methodology and
antibodies were provided by Dr Kurt Sales, MRC Human Reproductive Sciences
Unit, Edinburgh).
4.2.3.1 Optimisation of culture conditions
Developing an in vitro system with which to determine the effects of glucocorticoids
on signal transduction in endothelial cells required extensive development of existing
methodology being used in endometrial carcinoma (Ishikawa) cells (Sales et al.,
2005). To reduce background MAPK activity, serum withdrawal from culture
medium is routine prior to stimulation of cells (Russell et al., 2000; Wang et al.,
2002a). Furthermore, since confluence of isolated endothelial cells in culture
induces cell cycle exit by inhibiting MAPK activity (Vinals & Pouyssegur, 1999),
sub-confluent cultures were required.
Pilot experiments revealed that complete serum starvation overnight (serum-free
conditions) resulted in prolific cell death and poor protein yields. Consequently,
HUVECs were harvested and initially cultured in standard culture medium (EGM-2
containing growth factors, 2% FBS, ascorbic acid, heparin and GA-1000) for 24
hours to allow cells (1 x 106 cells per dish) to adhere. The following day medium
was replaced with EGM-2 containing 1% FBS, ascorbic acid, heparin and GA-1000
to provide serum-reduced conditions for a further 24 hours incubation. Forty-eight
hours after cell seeding, medium was replaced with standard basal medium (EGM-2
with no growth factors or FBS) to provide serum-free conditions for 1 hour prior to
treatment and for the duration of the experiment. At this stage, dishes were
approximately 90% confluent which resulted in sufficient protein recovery to run
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Western blots. During the refinement of the final protocol, it was necessary to vary
the number of cells, size of cell culture dish, and volume of lysis buffer to provide
sufficient protein for analysis. The final conditions are described in Section (Section
2.4.10.1).
4.2.3.2 Time-course of effects of glucocorticoids on activation of signal
transduction proteins
To determine the effects of glucocorticoids on phosphorylation of signal transduction
proteins, HUVECs were treated (on day 3 following serum reduction and serum
starvation) with Cortisol (600 nM), or vehicle (ethanol; 0.004% v/v) for 5, 10,15, 30,
60, 120, 180 and 240 minutes. Incubation times were consistent with MAPK
signalling studies in Ishikawa (Sales et al., 2005) and endothelial (Gonzalez et al.,
1999; Pelaia et al., 2001) cells.
4.2.3.3 ERK1/2 activation by glucocorticoid treatment and blockade by
pathway and receptor inhibitors
To further dissect the mechanism through which Cortisol stimulates phosphorylation
of p44/p42 MAPK (ERK1/2) activity, HUVECs were pre-treated for 1 hour with the
GR antagonist, RU38486 (1 pM), or with the specific p44/p42 MAPK (MEK)
inhibitor, PD98059 (50 pM), for 1 hour prior to stimulation with Cortisol (600 nM)
for a further 4 hours. For negative control, cells received either inhibitor or
antagonist alone for 5 hours. As a further control, cells received Cortisol (600 nM) or
vehicle (ethanol, 0.004% v/v), for 4 hours, to validate the previous time-course
findings.
4.2.3.4 Western blotting for signal transduction proteins
Protein extraction Following treatment with Cortisol and/or inhibitors, protein
was extracted from cell monolayers as described previously (Section 2.4.10.2).
Briefly, 200 pi of fresh lysis buffer (containing a cocktail of protease inhibitors;
Complete Protease Inhibitor Tablet, Roche, Switzerland) were added to each dish
(kept on ice throughout) to prevent protein degradation by endogenous proteases.
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Cells were detached from dishes using a cell scraper to aid cell lysis. Thereafter,
insoluble material was pelleted by centrifugation. The clarified lysate was removed
to a new tube and stored at -20°C until required for protein quantification and
SDS-PAGE.
Protein quantification To ensure equal gel loading, protein concentration was
measured using the Bio-Rad Dc protein assay kit (Bio-Rad, UK), based on the
method of Lowry (Lowry et al., 1951), as described previously (Section 2.4.10.3).
Immunoprecipitation For focal adhesion kinase (FAK) studies, in which the protein
is of low abundance in cells, immunoprecipitation was used to enrich
phosphotyrosine-containing proteins in lysates (Section 2.4.10.4). Briefly, lysates
were first pooled from treatment groups to provide sufficient protein for analysis
(from 9 experiments). Equal amounts of total protein in lysis buffer were incubated
(overnight) with specific mouse monoclonal IgG2b anti-phosphotyrosine antibody,
p-Tyr (PY99) (Santa Cruz Biotechnology, USA) immobilised onto agarose beads.
Beads were washed extensively with lysis buffer and immune complexes were eluted
in 20 pi of 5x protein gel loading buffer, boiled for 5 minutes, then kept on ice until
required for gel electrophoresis.
Gel electrophoresis Pilot experiments revealed that loading of 15 and 20 pg of
protein did not result in detectable bands. Consequently, a total of 30 pg protein
were resolved (Section 2.4.10.4) on NuPAGE 4-12% Bis-Tris gels (Invitrogen, UK).
SeeBlue Pre-stained Protein Standard (Invitrogen) was loaded into the first well on
each gel to allow determination of sample protein molecular weight. Gels were
electrophoresed at 40 mA per gel for approximately 2 hours until the loading dye
front had migrated to the bottom of the gel.
Transfer In order to make proteins accessible to antibody detection, they were
moved from within the gel to an Immobilon-FL polyvinylidene difluoride (PVDF)
membrane (Millipore, UK) by electroblotting (Section 2.4.10.4). Briefly, stacks
were assembled comprising; 3 layers of Whatman chromatography blotting paper
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(Fisher Scientific) pre-soaked in transfer buffer, wetted PVDF membrane, gel
(containing protein), and finally, another 3 layers of pre-soaked blotting paper. Care
was taken to avoid air bubbles between layers during assembly. Stacks were blotted
at a constant voltage (14 V for 2 hours) using a semi-dry blotting unit (Scie-Plas).
Secondary probing and chemiluminescence-based detection Initially, proteins
of interest were detected using a multi-step chemiluminescent-based method as
previously described (Sales et al., 2004). Briefly, gels were blotted onto a PVDF
membrane (Immobilon-P, Millipore, UK) and blocked for 1 hour in 4% BSA in TBS
Tween and 0.1% sodium azide. Blots were then incubated with primary antibodies
against phosphorylated (activated) forms of MAPK subgroups; p44/p42 (ERK1/2),
p38 and c-jun N-terminal kinase (JNK), and the cell survival protein, protein kinase
B (Akt). All primary antibodies were diluted 1:1000 (in 4% BSA) and were made in
rabbit. Membranes were washed (in TNS Tween) then incubated with secondary
antibody (1:30,000, goat anti-rabbit alkaline phosphatase, Sigma, UK). Membranes
were washed again, then immunoreactive proteins were visualised using the ECF
chemiluminescence system (GE healthcare, UK) following the manufacturer's
instructions. Proteins were revealed and quantified by Typhoon 9400
Phosphorlmager analysis (Amersham Biosciences, UK). Blots were then "stripped"
to remove immune complexes and substrate (in 40% methanol for 1 hour followed
by 45 minutes in stripping buffer on rocker) before being re-probed with primary
antibodies (1:1000, made in rabbit) against total ERK1/2, p38, JNK and Akt to act as
a loading control. Blots were then incubated with the same secondary antibody as
before, and detected in the same manner. Target protein bands; phosphorylated
ERK1/2, p38, JNK and Akt, were determined from the relative mobility on
SDS-PAGE by comparison with molecular weight standards and were normalised to
total ERK2, p38, JNK and Akt proteins, as a ratio, using the STORM 860 system
(Molecular Dynamics, Amersham Pharmacia Biotech, Little Chalfont, UK).
Two-step Fluorescence-based detection During the present studies, a move
towards a fluorescence-based method was made where the secondary antibody is
directly conjugated to a fluorescent probe. Since primary antibodies made in
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different species are available, the protein of interest and the loading control can be
detected simultaneously; thereby removing the membrane-stripping and re-probing
stages. A two-step detection method was used to detect target proteins as detailed in
Section 2.4.10.4. Briefly, gels were blotted onto a PVDF membrane (Immobilon-FL,
Millipore, UK) and blocked in Odyssey blocking buffer (Li-Cor Biosciences, UK)
before being incubated with primary antibody (1:1000). For FAK studies, rabbit
polyclonal IgG anti-FAK (C-20) antibody (Santa Cruz Biotechnology, USA) was
used. For MAPK studies, membranes were co-incubated with rabbit polyclonal IgG
anti-phospho-p44/p42 MAPK and mouse polyclonal IgG anti-p42 MAP kinase (3A7)
(both Cell Signaling Technologies, USA). Membranes were washed (in TNS
Tween) then incubated with secondary antibody (1:5000). For FAK studies, goat
anti-rabbit IgG (H+L) Alexa Fluor 680 (Molecular Probes-Invitrogen, UK) was used.
For MAPK studies, membranes were co-incubated with goat anti-rabbit IgG (H+L)
Alexa Fluor 680 and goat anti-mouse IgG (H+L) IR dye 800 (Rockland
Immunochemicals, USA). Membranes were washed again and proteins were
revealed and quantified by Odyssey Li-Cor Infrared Imager. Target protein bands,
phosphorylated ERK1/2 and FAK were determined from the relative mobility on
SDS-PAGE by comparison with molecular weight standards and were normalised as
a ratio to total ERK2 protein and IgG, respectively, using Odyssey v2.1 software
(Li-Cor Biosciences).
4.2.4 Statistics
Data are expressed as mean ± standard error, "n" refers to number of different
experiments performed on separate occasions using different batches of HUVECs.
For ELISA and QrtPCR studies, all conditions were performed in triplicate wells.
Comparisons at selected timepoints were made by one-way ANOVA and Dunnett's




4.3.1 Influence of glucocorticoids on angiogenic factor gene expression in
endothelial tube-like structures
4.3.1.1 Cyclophiliri A expression is not modulated by treatment but does
change with time
Expression of cyclophilin A mRNA was not modulated significantly by treatment
with Cortisol (600 nM) but there was a trend towards a decrease in expression after 8
hours (Figure 4.1). Cyclophilin A expression decreased with time in treatment and
control groups (p=0.005, two-way ANOVA, effect of time). Changes in expression
levels with time of all of the angiogenic factors examined were observed (TSP-1,
p<0.05; a6-integrin, /?<0.005, Figure 4.2; VEGF, p<0.05; VEGF-R2, p<0.0001,
Figure 4.3; Notch-1, /?<0.05; D114, />=0.0001, Figure 4.4 and caveolin-1, /?<0.01,
Figure 4.5).
4.3.1.2 Cortisol up-regulates expression of thrombospondin-1 during TLS
formation
QrtPCR measurements indicated a significant (p<0.05) 2.3-fold increase in
thromobospondin-1 mRNA level in TLSs 8 hours following treatment with Cortisol
(600 nM) (Figure 4.2A). No differences in expression levels of thrombospondin-1
mRNA were observed following Cortisol treatment at earlier (1 hour and 4 hours) or
later (22 hours) timepoints.
4.3.1.3 Cortisol does not regulate expression of other key angiogenic factors
during TLS formation
There were no significant differences in mRNA levels of the other angiogenic factors
examined (a6-integrin, Figure 4.2B; VEGF, Figure 4.3A; VEGF-R2, Figure 4.3B;
Dll-4, Figure 4.4A; Notch-1, Figure 4.4B; caveolin-1,Figure 4.5) in response to
treatment with Cortisol (600 nM).
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4.3.1.4 Effects of Cortisol and GR antagonism on gene expression
The number of replicates in the Cortisol plus RU38486 treatment groups were low
(n=l-3). However, the effect of Cortisol on TSP-1 expression (5.2 ± 1.1 arbitrary
units, AU) was blocked by GR antagonism since thrombospondin-1 mRNA returned
to a level similar to that of control (2.3 ± 0.4 AU) in the presence of RU38486
(1.7±0.3 AU) p=0.11, n=3). Cortisol plus RU38486 resulted in increased
expression of VEGF (1.5-fold, /?<0.05, n=3), VEGF-R2 (2.0-fold, ^><0.01, n=3) and
Notch-1 (1.9-fold, p<0.01, n=3) after 1 hour, and decreased expression of caveolin-1
(7.1-fold,/><0.05, n=3) after 22 hours, versus Cortisol treatment alone. The effects of




Figure 4.1 Cyclophilin A expression in endothelial TLSs
Cyclophilin A mRNA expression in human umbilical vein endothelial cells (HUVECs) on
Matrigel during tube-like structure (TLS) formation. Cortisol (600 nM) was added to the
culture medium at time of cell seeding, or left untreated (control). Quantitative real-time PCR
(QrtPCR) measurements (mean concentration ± SEM) were determined from a standard
curve (data not shown) using crossing point (Cp) values. Significant (p<0.01) effects of time,
but not treatment, were observed (n=8-9, each condition was performed in triplicate wells)
which is consistent with changes in expression of all the genes examined, with time. Since
the key question was whether Cortisol treatment affects gene expression (rather than an












































Figure 4.2 TSP-1 and a6-integrin expression studies in endothelial TLSs and
the influence of Cortisol
Effects of Cortisol on (a) thrombospondin-1 (TSP-1) and (b) a6-integrin mRNA expression in
human umbilical vein endothelial cells (HUVECs) on Matrigel during tube-like structure (TLS)
formation. Cortisol (600 nM) was added to the culture medium at time of cell seeding, or left
untreated (control). Quantitative real-time PCR (QrtPCR) measurements (mean
concentration ± SEM) were expressed as a ratio of concentration of mRNA of gene of
interest to internal control (cyclophilin A). Significant effects of time (p<0.05, TSP-1;
p<0.005, a6-integrin) and Cortisol treatment (p<0.05, TSP-1, 8 hours) were observed (n=8-9,











Figure 4.3 VEGF and VEGF-R2 expression studies in endothelial TLSs and the
influence of Cortisol
Effects of Cortisol on (a) vascular endothelial growth factor A (VEGF-A, VEGF) and (b) VEGF
receptor 2 (VEGF-R2) mRNA expression in human umbilical vein endothelial cells
(HUVECs) on Matrigel during tube-like structure (TLS) formation. Cortisol (600 nM) was
added to the culture medium at time of cell seeding, or left untreated (control). Quantitative
real-time PCR (QrtPCR) measurements (mean concentration ± SEM) were expressed as a
ratio of concentration of gene of interest to internal control (cyclophilin A). Significant effects
of time (p<0.05, VEGF; p<0.0001, VEGF-R2) but no effects of Cortisol were observed (n=8-9,
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Figure 4.4 D114 and Notch-1 expression studies in endothelial TLSs and the
influence of Cortisol
Effects of Cortisol on (a) delta-like ligand 4 (DLL-4) and (b) Notch-1 mRNA expression in
human umbilical vein endothelial cells (HUVECs) on Matrigel during tube-like structure (TLS)
formation. Cortisol (600 nM) was added to the culture medium at time of cell seeding, or left
untreated (control). Quantitative real-time PCR (QrtPCR) measurements (mean
concentration ± SEM) were expressed as a ratio of concentration of gene of interest to
internal control (cyclophilin A). Significant effects of time (p<0.05, Notch-1; p=0.0001, DII4)






















Figure 4.5 Caveolin-1 expression studies in endothelial TLSs and the influence
of Cortisol
Effects of Cortisol on caveolin-1 mRNA expression in human umbilical vein endothelial cells
(HUVECs) on Matrigel during tube-like structure (TLS) formation. Cortisol (600 nM) or
Cortisol and RU38486 (1 pM, GR antagonist) were added to the culture medium at time of
cell seeding, or left untreated (control). Quantitative real-time PCR (QrtPCR) measurements
(mean concentration ± SEM) were expressed as a ratio of concentration of gene of interest
to internal control (cyclophilin A). A significant effect of time (p<0.01) but no effects of
Cortisol was observed (n=8-9, each condition was performed in triplicate wells).
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4.3.2 Influence of glucocorticoids on VEGF protein production during TLS
formation
In this pilot experiment, no VEGF was detected in any of the sample media despite
detection of VEGF standards included in the kit (data not shown).
4.3.3 Influence of glucocorticoids on activation of signal transduction
proteins in endothelial cells
4.3.3.1 Immunoprecipitation and Western blotting for FAK in HUVECs
FAK protein expression was detected (Figure 4.6A) in enriched
phosphotyrosine-containing protein lysates (from 9 experiments) by a strong band at
125 kDa. Densitometry measurements (Figure 4.6B) indicated a 2-fold increase in
FAK expression after 4 hours of vehicle treatment versus untreated control (no
incubation). There was an increase in expression of FAK in the presence of Cortisol
(600 nM) but less so compared with 4 hour vehicle-treated cells. A 4 hour control of
untreated cells was absent from this study, to determine whether the effect of vehicle
was due to vehicle or an environmental effect.
4.3.3.2 Western blotting for activation of signal transduction proteins in
HUVECs
Expression of phosphorylated and total p44/p42 (ERK1/2) protein was detected
(Figure 4.8A) in lysates with strong dual bands at 44 and 42 kDa. In contrast,
reliable bands could not be detected for p38, JNK, and Akt, at the expected
molecular weights, even after high exposure times (Figure 4.7).
4.3.3.3 Cortisol induces activation of ERK after 3 to 4 hours in HUVECs
Densitometry measurements (Figure 4.8B) indicated an increase in phosphorylation
of ERK with time, in both vehicle and cortisol-treated cells (p<0.005). There were
1.5 to 2.3-fold increases in phosphorylation of ERK between 5 and 15 minutes of
incubation with either vehicle or Cortisol treatment. However, no differences were
observed between Cortisol and vehicle treatment groups at these early time-points
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(data not shown). In contrast, there was a 1.5-fold increase in phosphorylation of
ERK in cortisol-treated cells versus vehicle-treated cells, after 3 hours and 4 hours,
although this difference did not reach statistical significance (p=0.1).
4.3.3.4 ERK activation by glucocorticoid treatment and blockade by pathway
and receptor inhibitors
The trend towards an increase in phosphorylation of ERK in cortisol-treated cells
(600 nM, 4 hours) (p=0.1 versus vehicle-treated cells) was inhibited by co-incubation
with the MEK inhibitor, PD98059 (50 pM) (p<0.01, Figure 4.9A), or with the GR
antagonist, RU38486 (1 pM) (/?<0.01, (Figure 4.9B) versus Cortisol treatment alone.
Phosphorylation of ERK with the inhibitor or antagonist alone was not different to
either untreated or vehicle controls (p=not significant).
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A) Western Blot



































Figure 4.6 Influence of Cortisol on focal adhesion kinase (FAK) protein in
HUVECs
Effect of Cortisol on focal adhesion kinase (FAK) in isolated human umbilical vein endothelial
cells (HUVECs). Cortisol (600 nM) or vehicle (ethanol; 0.004% v/v) were added to HUVECs
in serum-free endothelial cell growth medium-2 (EGM-2), incubated for 4 hours, or left
untreated (control). Cell lysates were subject to immunoprecipitation with a phosphotyrosine
antibody and immunoblot analysis using an antibody against FAK. (a) A representative
Western blot is shown, (b) Relative density in immunoblots was calculated by dividing the
value obtained from the FAK band by the value obtained from the IgG band and expressed






Figure 4.7 Lack of a specific detection method for phosphorylation of p38, JNK
and Akt proteins in HUVECs
Cell lysates from Cortisol (600 nM), vehicle (ethanol; 0.004% v/v) or untreated HUVECs (15
minutes to 4 hours) were subject to immunoblot analysis using polyclonal (made in rabbit, all
1:1000 dilution) antibodies against phosphorylated (activated) (a) p38, (b) c-jun N-terminal
kinase (JNK) and (c) Akt proteins. Secondary probing was performed using goat anti-rabbit
alkaline phosphatase antibody (1:30,000) then immunoreactive proteins were attempted to
be visualised using the ECF chemiluminescence system (GE healthcare, UK). Bands at the
expected molecular weight, as indicated in the immunoblots, could not be detected.
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A) Western blot
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Figure 4.8 Influence of Cortisol on phosphorylation of p44/p42 (ERK1/2)
protein in HUVECs
Effect of Cortisol on extracellular signal-regulated kinase 1/2 (ERK1/2) signalling in isolated
human umbilical vein endothelial cells (HUVECs). Cortisol (600 nM) or vehicle (ethanol;
0.004% v/v) were added to HUVECs in serum-free endothelial cell growth medium-2
(EGM-2), incubated for up to 4 hours, or left untreated (control). Cell lysates were subject to
immunoblot analysis using an antibody against phosphorylated (activated) ERK1/2 and total
ERK (as a loading control), (a) A representative Western blot of ERK expression is shown,
(b) Relative density in immunoblots was calculated by dividing the value obtained from the
phosphorylated blots by the value obtained from total protein blots and expressed as fold
above untreated control. Data are mean ± SEM; r?=6-10 where indicated on the bar chart. A
significant effect of time (p<0.005) was observed and there was a trend towards an effect of
Cortisol treatment after 180 minutes (p-0.1) and 240 minutes (p=0.1) although this did not
reach statistical significance (ns).
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A) MEK inhibition B) GR antagonism
Figure 4.9 Glucocorticoid-induced activation of p44/p42 (ERK1/2): Effects of a
pathway inhibitor and GR antagonist
HUVECs incubated in serum-free endothelial cell growth medium-2 (EGM-2) for 4 hours in
the presence of vehicle (ethanol; 0.004% v/v), Cortisol (600 nM), Cortisol and the MAPK/ERK
kinase (MEK) inhibitor PD98059 (50 pM), Cortisol and the glucocorticoid receptor antagonist
RU38486 (1 pM), or either inhibitor/antagonist alone. Activation of ERK1/2 was determined
by immunoblot analysis using antibodies against phosphorylated (activated) ERK1/2 and
total ERK (as a loading control). The stimulatory effect of Cortisol on phosphorylation of ERK
(p=0.1 versus vehicle control) was abolished with (a) a MAPK inhibitor (p<0.01; Cortisol plus
PD98059 versus Cortisol), and by (b) GR antagonism (p<0.01; Cortisol plus RU38486 versus
Cortisol). PD98059 and RU38486 alone had no effect but vehicle caused a (non-significant)
1.5-fold increase in phosphorylation of ERK versus untreated control. Data represent
mean ± SEM (n=8, control, vehicle and Cortisol, n=3, Cortisol plus inhibitor/antagonist).
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4.4 Discussion
The intention of these studies was to investigate the molecular mechanisms through
which endogenous glucocorticoids inhibit endothelial tube formation. Using the in
vitro model developed for these investigations (Chapter 3), it was determined that
glucocorticoids up-regulate expression of angiostatic thrombospondin-1, which
occurs concurrently with the degradation of TLS networks described previously
(Chapter 3). Consequently, glucocorticoids may serve to inhibit angiogenesis in vivo
by favouring a net generation of angiostatic factors which inhibit cellular
morphogenesis. In addition, it was shown that glucocorticoids directly stimulate
MAPK signalling, via the ERK pathway, in undifferentiated endothelial cells raising
the possibility that this pathway is activated as a stress response mechanism. This
method development will serve as a tool to determine whether similar stimulation of
the ERK pathway by Cortisol occurs during inhibition of endothelial tube formation
and angiogenesis. Modulation of molecular signalling by glucocorticoids, during
endothelial tube formation, was dependent on GR, consistent with a role for these
receptors in glucocorticoid-mediated inhibition of tube formation.
It is known that tube formation by endothelial cells requires gene transcription and de
novo protein synthesis (Grove et al., 2002; Grant et al., 1991). Furthermore, it is
important to study gene expression and signal transduction during endothelial tube
formation since endothelial cells growing on Matrigel are likely to be synthesising
many other specific proteins distinct from those synthesised on plastic (Grant et al.,
1991). The 2D model of TLS formation is an ideal model to study the influence of
glucocorticoids on molecular signalling during endothelial tube formation since cells
resemble their conformational state in vivo (Lawley & Kubota, 1989) whilst they can
be recovered from the substrate to isolate RNA and protein. Also, soluble growth
factors (e.g. VEGF), secreted from developing endothelial tubes into the culture
medium, can also be easily analysed. Consequently, quantitative PCR, Western
blotting and ELISA are the most appropriate technologies to study changes in gene
and protein expression, and soluble protein production, respectively.
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4.4.1 Influence of glucocorticoids on angiogenic factor gene expression in
TLSs
QrtPCR is, at present, the most sensitive method for the detection of changes in
abundance of mRNAs (Bustin et al., 2005). This proved to be a sensitive method to
detect changes in mRNA expression, in the present study, given the low intra-assay
variation between replicate samples. The reactions were specific for the genes of
interest since all primers were exon spanning and, therefore, will not detect genomic
DNA. For QrtPCR, there is a general consensus on using a single control gene for
normalisation purposes (Vandesompele et al., 2002) but the choice of internal control
must be made after careful consideration. Ideally, the abundance of internal control
mRNA should not vary in the tissues or cells under investigation, or in response to
experimental treatment to correct for possible differences in RNA quantity or quality
across experimental samples. However, according to the literature, very few
house-keeping genes fit this criterion as all are regulated to some extent and many
vary in expression levels across a range of different conditions (reviewed in (Thellin
et al., 1999; Bustin, 2000; Nolan et al., 2006)). There is no consensus in the
literature on which internal control to use for primary human endothelial cell gene
expression studies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Forster
et al., 2007; Murthi et al., 2007), |3-actin (Matsuda et al., 2005; Yan et al., 2005) and
cyclophilin A (Zlot et al., 2003; Lucerna et al., 2007) have all been documented in
the literature, with the latter reported for use in HUVEC studies. Ribosomal RNAs
(rRNAs), are another popular choice of internal control in QrtPCR studies but, as
rRNA subunits are not poly-adenylated, they cannot be used when dealing with
cDNA derived from total RNA using oligo(dT) primers in the RT reaction (Nicot et
al., 2005). Another drawback to the use of rRNA as an internal standard is its high
abundance compared with target RNA transcripts making it difficult to subtract the
baseline value in data analysis accurately (Vandesompele et al., 2002). In the
present study, cyclophilin A was of similar abundance to the other genes of interest
(similar Cp values) and was, therefore, a good internal control candidate. Although
cyclophilin A expression varied with time, it did not vary with the effects of
treatment apart from a non-significant change at 8 hours in the Cortisol treatment
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group. These apparent changes in genes expression are more likely due to changes in
RNA stability due to the culture conditions (e.g. serum starvation), differences in
starting amounts of RNA due to inherent errors in the RNA quantification method,
and differences in efficiencies of the RT step. Since one of the primary aims of the
study was to determine the influence of Cortisol on TLS formation at selected
time-points, the use of cyclophilin A was justified on this basis.
4.4.1.1 Endothelial cell-ECM interactions
TSP-1 was the only factor to be significantly regulated by Cortisol out of all those
examined in the present study. A significant decrease in TSP-1 mRNA over time in
untreated control TLSs is consistent with the literature (Lane et al., 1992) and fits
with a role for TSP-1 as a negative regulator of endothelial tube formation (Iruela-
Arispe et al., 1991; DiPietro et al., 1994). The induction of TSP-1 mRNA
expression in TLSs, by Cortisol, could explain the mechanism through which
glucocorticoids inhibit TLS formation.
The time-course of induction of TSP-1 synthesis by Cortisol is consistent with the
time-course of morphological changes observed by time-lapse imaging (Chapter 3)
and is also consistent with a previous study (100 nM dexamethasone; trabecular
meshwork cells which have vascular endothelial cell properties) (Flugel-Koch et al.,
2004). The highest level of TSP-1 mRNA occurred after 8 hours of Cortisol
treatment which coincides with the time at which the greatest effect of Cortisol on
TLS number was observed in time-lapse imaging studies (Chapter 3).
TSP-1, and fragments of TSP-1, can act directly on endothelial cells to inhibit
angiogenesis by interactions with CD36, CD47 and integrins on the surface of the
cell. Binding of TSP-1 to CD36 mediates inhibition of endothelial cell migration
(Dawson et al., 1997) and tube formation (Iruela-Arispe et al., 1991; DiPietro et al.,
1994) and leads to induction of apoptosis (Jimenez et al., 2000). Thus, the delay
between peak induction of TSP-1 mRNA (at 8 hours) by Cortisol, and the complete
degradation of the TLS network observed at 18 hours (Figure 3.6), may explain the
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time required for 1) the cells' translational machinery to be employed, 2) the protein
to be secreted, 3) it to act through its cell receptor, and 4) activation of intracellular
signalling cascades and, ultimately, tube degradation. In addition, Cortisol does not
induce TSP-1 mRNA earlier than 8 hours and this may explain why Cortisol
(600 nM) does not completely prevent the formation of TLS networks. These data
support the hypothesis that glucocorticoids accelerate the degradation phase of TLS
formation, consistent with studies in the literature where TSP-1 is counter-adhesive
when added to fibronectin and causes disassembly of focal adhesions and stress
fibres formed by vascular endothelial cells (Greenwood & Murphy-Ullrich, 1998).
Indeed, glucocorticoid-mediated inhibition of tube formation was shown to occur
with morphological changes in stress fibres (Chapter 3) and there is preliminary
evidence to support a role for FAK (Figure 4.6).
The magnitude of induction of TSP-1 transcription induced by glucocorticoids, in the
present study, is similar to a previous report in isolated trabecular meshwork cells
(Flugel-Koch et al., 2004). The increase in TSP-1 mRNA levels induced by Cortisol
treatment was blocked in the presence of RU38486 (although small numbers)
suggesting that glucocorticoid-mediated regulation of TSP-1 is dependent on
glucocorticoid receptors. Again, this is consistent with the GR-dependent effects of
Cortisol on inhibition of TLS formation described in Chapter 3. The potential effect
of RU38486 alone on TSP-1 levels during TLS formation was not tested in these
studies, however, in other studies, RU38486 (1-50 pm) treatment did not alter TSP-1
mRNA expression in isolated endometrial epithelial (Ishikawa) (Mirkin & Archer,
2004) or stromal (Iruela-Arispe et al., 1996) cells. The presence of GREs on the
TSP-1 promoter has not been reported so far but analysis of the human TSP-1 gene
has revealed the presence of 2 progesterone-responsive elements in the progesterone
receptor promoter (Iruela-Arispe et al., 1996). Since the glucocorticoid and
progesterone receptors share the same nucleotide binding sequence (Beato, 1989) it
is likely that the TSP-1 gene may also contain GREs and this will be addressed in a
future study.
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In support of a role for TSP-1 in aberrant angiogenesis in vivo, overexpression of
TSP-1 results in abnormal wound angiogenesis in mice (Streit et al., 2000), when
tissue remodelling is necessary. The possibility that the TSP-1 gene might be
responsive to steroids in vivo has not yet been fully elucidated and the literature to
date is limited to a few studies on progesterone and reproductive function (Iruela-
Arispe et al., 1996; Espey et al., 2000) or dexamethasone in glaucomatous eyes
(Flugel-Koch et al., 2004) and the influence on angiogenesis per se in these studies is
difficult to ascertain.
Any full assessment of the biological consequences of variable mRNA levels must
include information regarding regulatory RNAs, protein levels and protein activity
(Nolan et al., 2006). Lack of protein availability prevented studies investigating the
possibility that the increase in TSP-1 mRNA synthesis by TLSs is translated into
increased protein production. However, very recent evidence now suggests that
glucocorticoids (nM) exert a direct angiostatic effect in the endometrium
concurrently with an increase in TSP-1 production (Rae et al., manuscript
submitted).
The reciprocal pattern of integrin expression and tube formation in the present study;
where high expression is seen during peak tube formation and low expression during
degradation, may be critical for tube formation per se. The fact that Cortisol was
without effect on a6-integrin expression suggests that this is not an important facet
of glucocorticoid-mediated inhibition of tube formation. Also, it is more likely that
multiple integrins act together in regulating endothelial tube formation (Davis &
Senger, 2005; Davis et al., 2002). Furthermore, signalling molecules downstream of
integrin-matrix interactions, such as the Rho guanosine triphosphatases (GTPases; in
the Ras superfamily), have been shown to control actin and microtubule cytoskeletal
networks (Zhao et al., 2006) and, therefore, regulate cell morphogenesis. It might be
interesting to follow up on this lead in future studies. Therefore, on balance, there is
insufficient evidence presented here to conclude that glucocorticoids do not regulate
the integrin signalling axis but regulation of a6-integrin at the level of gene
expression can now be ruled out.
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Glucocorticoids did not significantly alter levels of caveolin-1 mRNA suggesting
that this does not play a significant role in glucocorticoid-mediated inhibition of TLS
formation in this system. It is important to note that caveolin-1 can be tyrosine
phosphorylated under certain conditions such as oxidative stress (Aoki et al., 1999),
and post-translational modification may play an important role in regulation of active
protein levels.
4.4.1.2 VEGF signalling
In the present study, glucocorticoids do not appear to regulate levels of VEGF
mRNA during TLS formation. It is feasible that glucocorticoids regulate levels of
specific VEGF-A isoforms but this was not examined in the present study. For
example, triamcinolone acetate caused a significant decrease specifically in VEGF165
levels in HUVEC monolayers (Tong et al., 2006). Nonetheless, VEGF165 is the most
abundantly expressed VEGF isoform (Houck et al., 1992) and would have been
detected using the current primers (along with the other isoforms), and so substantial
changes in its expression level should have been detected in the present study.
There may be different mechanisms of regulation of VEGF gene expression and
these may differ between cell types. For example, glucocorticoids were shown to
decrease growth factor-regulated VEGF gene expression, via GR, in keratinocytes
(Gille et al., 2001), chondrocytes (Koedam et al., 2002) and vascular smooth muscle
cells (Nauck et al., 1998). In these previous studies, however, cells were stimulated
with other angiogenic stimuli (HGF, FCS and PDGF, respectively), in contrast to the
present study which examined effects on basal, unstimulated VEGF expression. This
is supported by the fact that, hypoxia-induced VEGF mRNA levels are less sensitive
to glucocorticoid-mediated inhibition than in normoxic conditions (Machein et al.,
1999). Consequently, it seems unlikely that glucocorticoids regulate expression of
endogenous VEGF production when the only stimulus is the endothelial cells'
interaction with the matrix.
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The lack of effect of Cortisol on VEGF-R2 mRNA levels, in the present study, is
consistent with a previous study in cell monolayers using dexamethasone (Machein
et al., 1999). However, during cutaneous wound healing (Zhang et al., 2004) and in
neonatal lung development (Clerch et al., 2004), VEGF-R2 expression is suppressed
by administration of glucocorticoids. This difference between the present in vitro
and previous in vivo findings may be explained by different regulatory mechanisms
depending on the context of the surrounding tissue microenvironment. Nevertheless,
the results presented here demonstrate that modulation of VEGF and VEGF-R2
expression does not play a significant role in glucocorticoid-mediated inhibition of
endothelial tube formation.
In conclusion, the present evidence indicates that glucocorticoids are more likely to
block the downstream actions of VEGF following receptor activation, during tube
formation, rather than altering its synthesis within the endothelium. The fact that
glucocorticoids inhibit the expression of VEGF in human vascular smooth muscle
cells (Nauck et al., 1998), but not in endothelial cells, also supports the notion of a
paracrine mechanism of inhibition. Co-cultures and conditioned media studies
support this hypothesis since glucocorticoids suppress VEGF production (by
fibroblasts and epithelial cells) and TLS formation by HUVECs cultured on Matrigel
(Matsuda et al., 2005; Wu et al., 2006). This is also supported by the fact that
glucocorticoids blocked VEGF-induced TLS formation (Chapter 3).
The relatively low abundance of D114 in control TLSs at 4 and 8 hours, when TLS
number peaks, is consistent with a role of D114 as a negative regulator of
angiogenesis. In support of this, D114-induced expression in HUVECs inhibited
vessel sprouting in a 3D TLS assay (Harrington et al., 2007). It is less obvious why
Notch-1 expression increased during TLS formation, in the present study (in a
time-dependent manner) in the absence of exogenous VEGF. It is possible that
Notch-1 production is switched on as a negative feedback regulator of endogenous
VEGF production.
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The lack of effect of Cortisol on transcription of either D114 or Notch-1 demonstrates
that these are not likely to play an important role in glucocorticoid-mediated
inhibition of TLS formation. Since these studies were performed another report has
described the influence of glucocorticoids on Notch signalling (in endothelial cell
monolayers); expression of Notch-4 was induced by Cortisol but only in the presence
of growth factors (EGF and bFGF) (Wu & Bresnick, 2007). The complexity of
Notch signalling in endothelial cells was highlighted with the finding that Notch has
effects on the cell cycle independent of VEGF activity (Sainson et al., 2005).
Consequently, it is likely that Matrigel contains soluble growth factors sufficient to
induce expression of Notch-1. Alternatively, this pathway may be regulated by
signals from direct endothelial cell-ECM interaction (e.g. integrins, TSP-1). In
conclusion, glucocorticoids might regulate Notch signalling in the endothelium but
this is strongly dependent on the environmental conditions and does not appear to be
important in the present system.
In summary, these studies have highlighted the complexity of examining regulation
of angiogenic factor gene expression during TLS formation. Nevertheless, these
studies have implicated the involvement of TSP-1 induction by glucocorticoids
which could explain the molecular basis of their angiostatic effect on tube formation.
4.4.2 Influence of glucocorticoids on VEGF protein production in HUVECs
The failure to detect VEGF protein in unstimulated HUVECs using an ELISA is
most likely due to levels below the limits of detection of the assay. This may be in
part due to the serum-free conditions used as serum is recommended by the
manufacturer for the stability of the protein. Undetectable protein production from
HUVECs is consistent with previous studies (Dupuy et al., 2003; Nanobashvili et al.,
2003). In other studies where VEGF was detected (Belgore et al., 2003; Yoon et al.,
2006), the levels were very low and towards the lower limit of detection. In the
present study, VEGF protein production did not appear to be stimulated by culturing
cells on Matrigel and this is consistent with the relatively low levels of mRNA
detected in QrtPCR studies. Consequently, it is likely that cell-matrix interaction
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alone is not a sufficient stimulus to promote VEGF secretion. Method refinement
such as increasing the number of cells, inclusion of (charcoal-stripped) serum and/or
stimulation of cells with a growth factor (e.g. bFGF) or hypoxia may prove useful in
future studies. However, since glucocorticoids have already been shown to block the
stimulatory effect of VEGF on TLS formation under the same, serum-free conditions
(Chapter 3), it seems more likely that Cortisol blocks the downstream signalling
actions of exogenous VEGF on the endothelium rather than preventing synthesis of
new protein and attenuating an autocrine effect of VEGF.
4.4.3 Influence of glucocorticoids on activation of signal transduction
proteins in endothelial cells
4.4.3.1 Focal adhesion kinase
In the present study, preliminary data suggest there may be a slight inhibitory effect
of Cortisol on activation of FAK protein in endothelial cells. However the low
abundance of this protein required samples to be pooled from multiple experiments
which prevented statistical analysis to strengthen interpretations. These data offer
some insight into an important relay mechanism that may well be a target of
glucocorticoid-induced inhibition of endothelial tube formation. This positive
method development will provide a useful basis for future studies investigating
glucocorticoid effects on FAK activation during endothelial tube formation. The
possibility of regulation of FAK by Cortisol would fit with a mechanistic role in
inhibition of tube formation, since FAK activation acts as a signal relay between
endothelial cell contacts and the ECM (Burridge et al., 1992).
4.4.3.2 Mitogen-activated protein kinases
The failure to reliably detect p38, JNK, and Akt protein in the present study most
likely reflects the need for further method optimisation (e.g. increasing antibody
titration, different primary antibody) since all 3 proteins have been detected
previously in HUVECs (Pelaia et al., 2001; Gonzalez et al., 1999; Hermann et al.,
2000). Alternatively, it is possible that under the conditions used in the present
study, these proteins are not constitutively active. In contrast, the reproducible and
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quantifiable detection of both phosphorylated and total forms of ERK protein, in
untreated and cortisol-treated cell lysates, demonstrates that this is a useful system to
study glucocorticoid-mediated regulation of ERK activation in isolated endothelial
cells.
Activation of ERK by Cortisol treatment may indicate the cellular response to stress
in the system. Indeed, MAPK cascades are key components of the signalling
networks that sense cellular exposure to environmental stress (Kyriakis & Avruch,
2001) and in some cellular systems, activation of the ERK pathway confers
protection against stress and apoptosis (Cuda et al., 2002). An effect of vehicle
(ethanol) was apparent in these studies but it could not be determined whether this
was due to vehicle per se, or whether it was an environmental effect; for example,
from the stress of serum-starvation. Consequently, it would not be surprising if there
was a basal activation of this pathway by serum starvation which was exacerbated, to
a lesser extent by vehicle, and by a greater extent to the stress hormone, Cortisol.
Glucocorticoids induce oxidative stress in the intact vasculature (Schafer et al., 2005)
and ERK1/2 has been proposed as a key regulator of the signalling cascade triggered
by oxidative stress (Cuda et al., 2002). There is a limited literature on
glucocorticoids and ERK signalling in endothelial cells. However, the present
findings are fully consistent with a previous study (in trabecular meshwork cells)
where dexamethasone treatment caused activation of the ERK/MAPK pathway,
which was reversed by GR antagonism and MEK inhibition (Jeon et al., 2003). The
present findings contrast with previous studies in endothelial cells where
glucocorticoids have been shown to inhibit ERK (Pelaia et al., 2001; Gonzalez et al.,
1999). In these 2 published studies, however, cells were pre-treated with steroid then
activated by VEGF or pro-inflammatory cytokines (IL-lp and TNF-a); whereas the
present study investigated Cortisol effects on basal-unstimulated ERK activation.
Other studies demonstrated no effect of synthetic corticosteroids; triamcinolone
acetonide (Ebrahem et al., 2006) or dexamethasone (Kasselman et al., 2007) on
VEGF-induced phosphorylation in HUVECs. In conclusion, direct ERK activation
by Cortisol is probably not responsible for attenuating responses to VEGF, since in
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the presence of VEGF, blockade rather than potentiation of the ERK response was
observed (Chapter 3).
Although MAPK signalling can be modulated by steroids in a rapid
non-transcriptional way in endothelial cells (Nuedling et al., 1999; Simoncini el al.,
2004), the time-course of cortisol-induced induction of ERK protein expression in
the present study is likely to be due to a transcriptional effect of
glucocorticoid-activated GR. This is supported by the fact that GR antagonism
blocked cortisol-induced activation of ERK. This has been described previously in
vitro in a non-endothelial cell type (Revest et al., 2005) and was supported by studies
in vivo where ERK has been shown to be activated concomitantly with GR after
behavioural stress (Meller et al., 2003; Yang et al., 2004).
In the present study, transcriptional activation of this pathway by glucocorticoids is
likely to have occurred either at the level of ERK itself, or by upstream components
of the cascade such as Ras or Raf-1 (Figure 1.2). Pharmacological blockade ofMEK
(with PD98059), which is immediately upstream of ERK1/2, blocked the effect of
Cortisol suggesting that induction of this pathway occurs either at the level of
Ras/Raf-1; or further upstream e.g. at the level of phospholipase C (PLC), protein
kinase C (PKC) or, phosphoinositide 3-kinase (PI3K). The former is supported by
findings that activated GR can stimulate the transcription of Ras and Raf-1 directly
and glucocorticoid-responsive elements (GREs) have been identified on the
promoters of Ras (Strawhecker et al., 1989) and Raf (Lee et al., 1996) family
members. However, it is also worth noting that TSP-1 signalling of focal adhesion
disassembly and reorganisation of the endothelial actin cytoskeleton requires
activation of PI3K (Greenwood et al., 1998; Short et al., 2005). Consequently,
glucocorticoid-induced TSP-1 synthesis, and glucocorticoid-activation of MAPK
signalling, may feature as 2 components of the same mechanism of inhibition of
endothelial tube formation.
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In summary, these novel data provide a solid foundation for future investigation of
the levels and activation state of other members of the ERK/MAPK pathway to
further dissect out the effect of glucocorticoids on endothelial cell signal transduction
during tube formation and angiogenesis.
4.4.4 Conclusion
The studies described in this Chapter implicate altered gene expression (TSP-1) and
signal transduction pathways (ERK/MAPK) as possible targets of
glucocorticoid-mediated inhibition of tube formation by endothelial cells.
Furthermore, inhibition of VEGF mRNA and protein synthesis by endothelial cells
undergoing this morphogenesis can now be excluded as an angiostatic mechanism.
This supports the contention that VEGF action on the endothelium, rather than
production, may be attenuated by glucocorticoids.
Since VEGF can also facilitate other key angiogenic changes in endothelial cells;
such as proliferation and migration, it is possible that these other processes, in
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The work in Chapter 3 showed that glucocorticoids can inhibit tube formation by
direct interaction with the endothelial cells. In this 2-dimensional model, inhibition
of tube formation appeared to be due to an alteration in endothelial cell
morphogenesis, rather than to changes in cellular proliferation or migration. This,
however, does not exclude the possibility that direct modulation of endothelial cell
proliferation and migration may contribute to glucocorticoid-mediated inhibition of
angiogenesis in vivo. Indeed, assessment of the intra-cellular mechanism(s) through
which glucocorticoids alter endothelial cells (Chapter 4) suggested aberrant growth
factor signalling. It was important, therefore, to use alternative approaches to
determine whether inhibition of endothelial cell proliferation or migration may
contribute to the angiostatic effect of these steroids.
The literature on glucocorticoids and endothelial cell migration and proliferation is
limited. An inhibitory effect of angiostatic steroids on cell protease activity (Blei et
al., 1993) suggests that glucocorticoids could potentially inhibit endothelial cell
migration since degradation of the ECM is a pre-requisite for cell motility in vivo.
This indirect evidence was supported by a study using the more direct Boyden
chamber assay (migration of cells through pores towards a chemoattractant) with
high concentrations of triamcinolone acetonide (Wang et al., 2002b) but could not be
supported in another study using (400 nM) dexamethasone (Polytarchou &
Papadimitriou, 2005). In the latter study, however, only effects of glucocorticoids on
undirected (i.e. no stimulus) cell migration were tested. No previous study has tested
the effects of physiological glucocorticoids on endothelial cell migration in response
to VEGF.
Previous studies of glucocorticoid influence on cell proliferation have been difficult
to interpret, collectively, since a variety of cell proliferation assays exist (both direct
and indirect) and a variety of different species of endothelial cells have been used.
The ability of synthetic glucocorticoids to inhibit cellular proliferation (Berk et al.,
1988; Longenecker et al., 1982; Longenecker et al., 1984) and migration (Pross et
al., 2002b) has been demonstrated using rat and bovine vascular smooth muscle
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cells. These properties have prompted their assessment as anti-atherosclerotic
(Cavallero et al., 1976) and anti-restenotic (Berk et al., 1991; Versaci el al., 2002)
agents. The fact that these inhibitory effects have not translated well into the clinic
highlights the existence of important species-specific responses to glucocorticoids.
Pharmacological levels of synthetic corticosteroids inhibit human endothelial cell
proliferation in vitro (Kraling et al., 1999; Banciu et al., 2006; Zou et al., 2006). In
contrast, dexamethasone (1010 to 10"5 M) has no effect on bovine corneal endothelial
cell proliferation under basal, unstimulated conditions (Chen et al., 2006). The
effects of physiological levels of glucocorticoids on endothelial cell proliferation,
driven by VEGF or bFGF, which are known to be important endothelial cell
mitogens in vivo, have thus far not been explored.
5.1.1 Hypothesis
This study explored the hypotheses that glucocorticoids inhibit endothelial cell
migration and proliferation and block the stimulatory actions of VEGF and/or bFGF
on these key angiogenic processes.
5.1.2 Aims
The specific aims were to:
1) establish assays of endothelial cell migration and proliferation using isolated
human endothelial cells.
2) investigate the influence of glucocorticoids on endothelial cell migration and




Primary HUVECs were obtained from Promocell (Germany) and routinely passaged,
as described previously (Section 2.4.2). Cells were used between p2 and p6 in all
migration and proliferation experiments. Where possible, cells were used at the
same level of confluency (70-80%) to ensure reproducibility of results. Cells were
detached from the flasks with trypsin and, in all assays, cell counting was performed
to ensure consistency of cell density between experiments (Section 2.4.4).
5.2.2 Development of an endothelial cell migration assay
To test the effects of glucocorticoids on basal (unstimulated) and VEGF-induced
endothelial cell migration, commercially available cell culture inserts (ThinCerts;
Cellstar-Greiner Bio-One, UK) were used. Based on the Boyden Filter assay, this
involves a two-compartment system where cells may be induced to migrate from an
upper compartment through a porous membrane into a lower compartment, thus
following the gradient of a chemoattractant (Boyden, 1962). Migratory cells can
measured by labelling with a fluorescent dye (calcein-AM) and measured using a
fluorescence plate reader since relative fluorescence units (RFU) correlate linearly
with number of cells. Some degree of method development was required to generate
the final protocol as described in the following sections.
5.2.2.1 Culture conditions and pore size
Pore size and duration of incubation have previously been shown to be important
determinants of endothelial cell (Matsuda & Nakayama, 1996) and neutrophil (Stein
et al., 1983) migration. Therefore, a pilot study was performed; comparing 3.0 pm
versus 8.0 pm porous ThinCerts (Cellstar-Greiner Bio-One, UK), and comparing 5
hours versus 24 hours of incubation.
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5.2.2.2 Determination of EC50 of VEGF as a chemoattractant
VEGF is commonly used as a chemoattractant in the Boyden chamber assay but
there is no consensus on the ideal concentration. Yoshida and colleagues used 1
ng/ml VEGF (Yoshida et al., 1996), whilst others have reported using higher
concentrations; e.g. 10 ng/ml (Gallicchio et al., 2005) and 50 ng/ml (Cattaneo et al.,
2003). Therefore, in pilot studies, concentration-response curves were generated
using VEGF. To determine the half-maximal effective concentration (EC50) of
VEGF, HUVECs in standard basal medium (EGM-2 medium containing only
ascorbic acid, heparin and GA-1000) were seeded into the upper chamber of cell
culture inserts (8.0 pm pores). The lower chamber contained standard basal medium
with VEGF as a chemoattractant at a range of concentrations; 0.5 ng/ml to 500 ng/ml
and 7.5 ng/ml to 60 ng/ml in 2 separate experiments. After 24 hours, migratory cells
were quantified by labelling with calcein-AM (8 pM) and the amount of fluorescence
was measured in a plate reader (Section 2.4.12). EC50 was determined by non-linear
regression with sigmoidal concentration: response curves shown generated using
GraphPad Prism v4.02 (GraphPad Software, USA). The EC50 values from 2
experiments were determined and the average value was used in the final protocol.
Each condition was performed in triplicate wells.
5.2.3 Influence of glucocorticoids on endothelial cell migration
The effects of Cortisol on basal-unstimulated, and VEGF-induced, endothelial cell
migration were tested using the final protocol detailed in Section 2.4.12. Briefly,
Boyden chambers were prepared by immersing 8.0 pm ThinCerts into a 24-well
plate containing either standard basal medium (untreated control), medium with
VEGF (10 ng/ml), medium with VEGF plus inhibitor, SU5416 (1 pM; positive
control), medium with VEGF plus Cortisol (600 nM) or medium with SU5416 or
Cortisol. HUVECs were harvested and seeded into the upper compartment at a
density of 2 x 105 cells/insert. SU5416 or Cortisol were added immediately to the
upper compartment to maintain these final concentrations in both compartments
whereas VEGF was only present in the lower chamber to produce a gradient of
chemoattractant. Plates were incubated for 24 hours to allow cells to migrate, then
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labelled with calcein-AM dye (8 pM). Contents of the upper chamber were then
removed by gentle aspiration. ThinCerts were then transferred into a new 24-well
cell culture plate and the labelled migratory cells were detached from the underside
using Trypsin-EDTA with periodic agitation. Trypsin-EDTA solution (200 pi)
containing the labelled, migratory cells, was transferred into a black 96-well plate to
minimise background fluorescence between wells. Fluorescence measurements were
made using a Fluoroskan Ascent FL plate reader and data captured using Ascent
software (Thermo LabSystems, UK). Consequently, it was possible to test the effect
of Cortisol on unstimulated migration (by comparing with basal control wells) and
VEGF-induced migration (by comparing VEGF plus Cortisol with VEGF alone wells
after demonstrating VEGF had an effect). Each condition was performed in triplicate
wells.
5.2.4 Influence of glucocorticoids on endothelial cell proliferation
Cell proliferation induced by VEGF and bFGF in HUVECs, plus the ability of
Cortisol (3 nM to 1 pM) to inhibit the action of these growth factors, was assessed
using two independent methods; (1) measurement of cell viability and (2) direct
measurement of newly synthesised DNA. Both methods involved the use of
commercially available kits and involved some degree of method optimisation,
discussed in the following sections, to generate the final protocols.
5.2.4.1 Bromodeoxyuridine (BrdU) incorporation assay (direct method):
Optimisation of culture conditions
The BrdU Cell Proliferation Assay (Calbiochem-Merck, UK) allows detection and
quantification of BrdU, following partial denaturation of the DNA double strand by
use of a detector monoclonal anti-BrdU antibody to bind to any BrdU incorporated
into dividing cells. An enzyme-linked immunosorbent assay (ELISA) is then used to
form a coloured product that absorbs light at dual wavelengths. The intensity of the
coloured product is directly proportional to the amount of incorporated BrdU present
in the cells.
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The manufacturer's instructions were followed (as described in Section 2.4.11.2)
with some method refinement during the initial experiments. To produce an optimal
level of cell confluency (around 70-90% at fixation stage); cell density (1.5 x 103
cells/well to 5 x 103 cells/well) and total duration of incubation (24 to 96 hours) were
varied. In addition, duration of BrdU incubation (3 to 72 hours) was varied.
5.2.4.2 Influence ofglucocorticoids on BrdU incorporation
As detailed in Section 2.4.11.2, HUVECs were seeded in inner wells of a 96-well
plate at a density of 3.5 x 103 cells/well and incubated for 2 hours to allow cells to
adhere to the plates. Cells were cultured in 'experimental' medium consisting of
EGM-2 Bullet Kit medium (Lonza, UK) supplemented with heparin, ascorbic acid,
GA-1000, and 2% charcoal-stripped FBS. No growth factors from the kit were
added. This density was found to be sufficient to produce approximately 70%
confluency in the individual wells after 48 hours of incubation with growth factor
stimuli and was insufficient to produce 100% confluency, thereby avoiding cell-cell
contact inhibition of proliferation. After an initial 2 hour stabilisation period, cells
were incubated for a further 46 hours in the presence of; VEGF (25 ng/ml) or bFGF
(1 ng/ml), VEGF or bFGF plus established inhibitors (SU5416, 1 nM-1 pM; platelet
factor 4, 3 nM-1 pM, respectively), or VEGF or bFGF plus Cortisol (3 nM-1 pM).
BrdU was added to the wells 1 hour after growth factors and inhibitors were added.
Fresh drug dilutions were prepared on each day of experimentation. Additionally,
control cells were incubated in the maximum concentration of vehicle (ethanol,
0.004% v/v; DMSO, 0.167% v/v) or in medium alone. Additional wells with cells
but with no BrdU were included to obtain background absorbance measurements. At
the end of the 48 hour incubation period, cells were fixed and denatured according to
the assay kit instructions prior to incubation with the anti-BrdU antibody, followed
by incubation with horseradish peroxidase-conjugated goat anti-mouse IgG. Wells
were washed (lx plate wash) between incubations to minimise background with an
Anthos Labtec awl microplate washer (ASYS Hitech, Austria). Finally, the cells
were incubated with TMB and the reaction was stopped by the addition of sulphuric
acid. Optical densities were measured using a Multiskan Ascent plate reader and
data captured using Ascent v2.6 software (Thermo LabSystems, UK). The
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absorbance of cells without the BrdU label and of the tissue culture medium, were
measured and subtracted from each reading. It was possible to test the effect of
Cortisol on VEGF- and bFGF-induced proliferation by comparing proliferation in
those wells with the "growth factor alone" wells after demonstrating growth factor
alone had an effect by comparing with vehicle control. Each condition was
performed in triplicate wells.
5.2.4.3 Cell viability assay (indirect method)
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, UK) is an indirect
method of assessing the number of live cells based on quantitation of ATP which
indicates metabolically-active cells. Whether the cells are actively dividing or
quiescent is not distinguished but an increase in cell viability indicates cell growth.
CellTiter-Glo Reagent contains recombinant firefly luciferase which catalyses the
mono-oxygenation of luciferin to oxyluciferin in the presence of Mg2+, ATP and
oxygen in a reaction which emits light. There is a direct relationship between the
luminescent signal and the number of cells. Training in methodology, validated
culture conditions, and growth factor and reference compound concentrations were
provided by Dr Judith McKay and Mrs Julie Kellett, Department of Pharmacology,
Aptuit, Edinburgh, UK, therefore limited method development was required.
5.2.4.4 Influence ofglucocorticoids on cell viability
As detailed in Section 2.4.11.1, HUVECs were seeded in a 96-well plate at a density
of 1.5 x 103 cells/well and incubated for 2 hours to allow cells to adhere to the plates.
This density was found to be sufficient to produce approximately 70% confluency in
the individual wells after 96 hours of incubation with growth factor stimuli, but was
insufficient to produce 100% confluency. Cells were incubated in 'experimental'
medium consisting of EGM-2 Bullet Kit medium (as above). Serum-supplemented
medium is necessary for the reaction but charcoal stripping removes the majority of
hormones (Leake et al., 1987), thereby preventing influence of endogenous steroids.
After the initial 2 hour period, cells were incubated for a further 94 hours in the
presence of growth factors and inhibitors, as described for the BrdU method. Fresh
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drug dilutions were prepared on each day of experimentation. Additionally, cells
were incubated in the maximum concentration of vehicle or in medium alone to act
as controls. At the end of the 96 hours, incubation plates were equilibrated to room
temperature and CellTiter-Glo Reagent (100 pi) was added to each well. Plates were
incubated for a further 10 minutes at room temperature to stabilise the luminescent
signal before being read on a Wallac 1420 VICTOR2 (Perkin-Elmer, UK) plate
reader. Each condition was performed in triplicate wells.
5.2.5 Statistics
Data are expressed as mean ± standard error, "n" refers to number of different
experiments performed on separate occasions using different batches of HUVECs;
where possible all measurements of migration and proliferation were made in
triplicate wells. During method development, cell migration data were initially
expressed as the mean relative fluorescence units (RFU). For the final established
method, data were expressed as a percentage of the RFU generated in concomitant
control wells. Comparisons were made using Student's t-test and one way ANOVA
followed by Dunnett's post hoc test, where appropriate. For migration assays,
inter-assay and intra-assay coefficients of variation were 49% and 19% respectively
(n=16). For proliferation assays, inter-assay and intra-assay coefficients of variation
were 75% and 26%, respectively, (n=6) using the BrdU assay, and 68% and 16%,




Preliminary data from control wells containing cells between p2 and p6 showed
similar, reproducible migration after 24 hours (Figure 5.1). There was a trend,
however, towards a correlation of enhanced migration with lower passage number
(p=0.09). Consequently, cells were used at the earliest passage number (p2-p3)
where possible. To maintain consistency with the migration assays, and with the
TLS assay, proliferation assays were performed with cells between passages 2 and 6.
The number of proliferation assays performed (n=6 of each) was insufficient for
statistical analysis of correlation of proliferation with passage number.
5.3.2 Development of an endothelial cell migration assay
5.3.2.1 Culture conditions and pore size
Pilot studies demonstrated that VEGF-induced endothelial cell migration was not
apparent after 5 or 24 hours of incubation using inserts with 3.0 pm pores (Figure
5.2). In contrast, whilst no migration was observed after 5 hours incubation using
8.0 pm pores, a 3.9-fold increase in VEGF (10 ng/ml)-induced migration was
observed (VEGF, 28.4 ± 0.8 RFU; versus control, 7.2 ± 0.4 RFU) after 24 hours of
incubation.
To determine whether glucocorticoids inhibit VEGF-induced HUVEC migration,
preliminary experiments used concentrations of VEGF consistent with previous
studies; 25 ng/ml (Kim et al., 2002) and 50 ng/ml (Ali et al., 2005; Cattaneo et al.,
2003), as a chemoattractant. Under these conditions, Cortisol (600 nM) induced
modest reductions (18.5% at 25 ng/ml and 15.0% at 50 ng/ml VEGF) in the degree
of migration but these differences were not significant {p=0.82 and p=0.68,
respectively; Figure 5.3).
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5.3.2.2 Determination of EC50 of VEGF as a chemoattractant
EC50 values for VEGF were determined as 5 ng/ml and 15 ng/ml from 2 independent






Figure 5.1 Influence of HUVEC passage number on cell migration
Human umbilical vein endothelial cells (HUVECs) in standard basal medium (endothelial cell
growth medium-2, EGM-2) were seeded into the upper chamber of cell culture inserts
(8.0 pm pores) in a Boyden chamber assay of cell migration. After 24 hours, migratory cells
were quantified by labelling with calcein-AM and the amount of fluorescence (relative to cell
number) was measured in a plate reader. Data represent mean ± SEM (number of
experiments noted on bar chart), each condition was performed in triplicate wells. HUVECs
at relatively low passage number demonstrated a greater migratory potential (p=0.09),
therefore cells at low passage number (p2 or p3) were used where possible.
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Figure 5.2 Development of a cell migration assay: Effects of pore size and
incubation time
Human umbilical vein endothelial cells (HUVECs) in standard basal medium (endothelial cell
growth medium-2, EGM-2) were seeded into the upper chamber of cell culture inserts
(3.0 p,m or 8.0 |xm pores). The lower chamber contained EGM-2 (control), or vascular
endothelial growth factor (VEGF, 10 ng/ml) as a chemoattractant. After 5 hours or 24 hours,
migratory cells were quantified by labelling with calcein-AM and the amount of fluorescence
(relative to cell number) was measured in a plate reader. 3.0 pores and 5 hours of
incubation were both insufficient to produce a stimulatory effect of VEGF. Consequently,
8.0 pm pores and 24 hours of incubation were used in the final protocol. Data are from a
single pilot experiment (where error bars represent SEM where each condition was















Figure 5.3 Development of a cell migration assay: Effects of VEGF and Cortisol
HUVECs in standard basal medium (endothelial cell growth medium-2, EGM-2) were seeded
into the upper chamber of cell culture inserts (8.0 pm pores). The lower chamber contained
EGM-2 (control) or vascular endothelial growth factor (VEGF, 25 ng/ml or 50 ng/ml) as a
chemoattractant. Upper and lower chambers contained Cortisol (600 nM) where indicated.
After 24 hours, migratory cells were quantified by labelling with calcein-AM and the amount
of fluorescence was measured in a plate reader. No significant differences were observed
between Cortisol and VEGF wells (p=0.82, 25 ng/ml and p=0.68, 50 ng/ml VEGF and Cortisol
versus VEGF alone). Data represent mean ± SEM (n=2-6), each condition was performed in
triplicate wells.
201
Figure 5.4 Development of a cell migration assay: Determination of EC50 of
VEGF
HUVECs in standard basal medium (endothelial cell growth medium-2, EGM-2) were seeded
into the upper chamber of cell culture inserts (8.0 pm pores). The lower chamber contained
vascular endothelial growth factor (VEGF) as a chemoattractant at a range of
concentrations; 0.5 ng/ml to 500 ng/ml and 7.5 ng/ml to 60 ng/ml in 2 separate experiments.
After 24 hours, migratory cells were quantified by labelling with calcein-AM and the amount
of fluorescence was measured in a plate reader. The half-maximal effective concentration
(EC50) was determined by non-linear regression with a representative sigmoidal
concentration: response curve shown above. The EC50 values from 2 experiments were
determined and the average value (10 ng/ml) was used in the final protocol. Data represent
mean ± SEM from 1 experiment, each condition was performed in triplicate wells.
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5.3.3 Influence of glucocorticoids on endothelial cell migration
Endothelial cell migration was stimulated with 10 ng/ml VEGF (262 ± 59%;
/><0.05), compared with control (100%); Figure 5.5). This VEGF-induced migration
was blocked (91 ± 4%) with the VEGF receptor inhibitor SU5416 (1 pM; positive
control; p<0.01; VEGF plus SU5416 versus VEGF) whereas this compound had only
a modest effect (86 ± 5%; p=not significant) on basal-unstimulated migration (Figure
5.5A). In contrast, Cortisol (600 nM) had no effect on either VEGF-induced
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Figure 5.5 Effect of Cortisol on endothelial cell migration
HUVECs in standard basal medium (endothelial cell growth medium-2, EGM-2) were seeded
into the upper chamber of cell culture inserts (8.0 pm pores). The lower chamber contained
vascular endothelial growth factor (VEGF, 10 ng/ml) as a chemoattractant. Upper and lower
chambers contained the selective VEGF receptor inhibitor, SU5416 (1 pM, positive control),
or Cortisol (600 nM), or EGM-2 medium (negative control). After 24 hours, migratory cells
were quantified by labelling with calcein-AM and the amount of fluorescence was measured
in a plate reader. The stimulatory effect of VEGF (*p<0.05) was (a) blocked by co-incubation
with SU5416 (**p<0.01 VEGF and SU5416 versus VEGF) whilst (b) Cortisol had no effect
(p=0.95). SU5416 or Cortisol alone had no effect on cell migration. Data represent
mean ± SEM; n=6. Each condition was performed in triplicate wells.
control VEGF VEGF SU5416
+ SU5416
control VEGF VEGF Cortisol
+ Cortisol
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5.3.4 Influence of glucocorticoids on endothelial cell proliferation
5.3.4.1 Bromodeoxyuridine (BrdU) incorporation assay (direct method):
Optimisation of culture conditions
Cell seeding density was found to be an important factor in the sensitivity of the
assay; 1.5 x 103 cells/well resulted in only a modest augmentation of proliferation by
25 ng/ml VEGF (140% compared with vehicle-treated control), whereas 5 x 10
cells/well caused cultures to overgrow with little or no effect of growth factor
detected. Cultures incubated for a total of 24 hours, or with BrdU during the final 3
hours of the protocol, exhibited insufficient proliferation and low absorbance
readings in control wells. Cultures incubated for up to 96 hours resulted in
overgrowth of cells. This important method refinement culminated in the final,
established culture conditions described in Section 2.4.11.2.
5.3.4.2 Influence ofglucocorticoids on BrdU incorporation
Drug vehicles (ethanol, 0.004% v/v; DMSO, 0.167% v/v) had no impact on cell
proliferation compared with untreated control wells (p=0.97 and p=0.93,
respectively; Figure 5.6).
HUVEC proliferation was induced by incubation with either growth factor; VEGF
(25 ng/ml) stimulated 1.6 to 1.9-fold increases (p<0.01) in relative luminescence
(Figure 5.7); bFGF (1 ng/ml) stimulated 2.0 to 2.7-fold increases (p<0.05; Figure
5.8).
VEGF-induced cell proliferation was inhibited in the presence of SU5416 (positive
control) in a concentration-dependent manner (100 nM, 114 ± 14%, £><0.05; 300 nM,
98 ± 10%, p<0.01 and 1 pM, 71 ± 10%, £><0.01 compared with VEGF plus
vehicle-treated control, 185 ± 24%) (Figure 5.7A). Platelet factor 4 (positive control)
had little effect on bFGF-induced cell proliferation within a 3 nM to 100 nM range
but proliferation was inhibited at 300 nM (181 ± 34%) and 1 pM (103 ± 17%,
£><0.05) compared with bFGF-treatec amtrol, 273 ± 42%) (Figure 5.8A).
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In contrast to the described effects of the positive controls, Cortisol (3 nM to 1 pM)
had no effect on cell proliferation induced by either growth factor (Figure 5.7B and
Figure 5.8B).
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A) Ethanol B) DMSO
300-, 250i p=0.93
untreated control ethanol-vehicle untreated control DMSO-vehicle
Figure 5.6 Effects of ethanol and DMSO (drug vehicles) on endothelial cell
proliferation
HUVECs were seeded into 96-well plates in standard experimental medium (endothelial cell
growth medium-2, EGM-2, plus 2% charcoal-stripped foetal bovine serum) or in the
presence of: drug vehicles (ethanol, 0.004% v/v; dimethyl sulfoxide, DMSO, 0.167% v/v).
Bromodeoxyuridine (BrdU) was added to the wells, and after 48 hours of incubation, BrdU
incorporation (relative to the amount of cell proliferation) was quantified by enzyme-linked
immunosorbent assay (ELISA) and absorbance was measured in a plate reader. Ethanol
and DMSO vehicles had no effect on HUVEC proliferation (p=0.97 andp=0.93, respectively.
Data represent mean ± SEM; n=6-13. Each condition was performed in triplicate wells.
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A) VEGF-R2 inhibitor (positive control)
VEGF plus SU5416, nM
B) Cortisol
VEGF plus Cortisol, nM
Figure 5.7 Effect of Cortisol on VEGF-induced endothelial cell proliferation
(BrdU method)
HUVECs in standard experimental medium (endothelial cell growth medium-2, EGM-2, plus
2% charcoal-stripped foetal bovine serum) were seeded into 96-well plates in the presence
of: vascular endothelial growth factor (VEGF, 25 ng/ml), VEGF plus an established inhibitor
(SU5416, 1 nM-1 pM), or VEGF plus Cortisol (3 nM-1 |iM). Cells were incubated in drug
vehicles (final concentration, 0.004% v/v ethanol or 0.167% v/v DMSO) or medium alone as
controls. Bromodeoxyuridine (BrdU) was added to the wells, and after 48 hours of
incubation, BrdU incorporation (relative to the amount of cell proliferation) was quantified by
enzyme-linked immunosorbent assay (ELISA) and absorbance was measured in a plate
reader. The stimulatory effect of VEGF (**p<0.01) was (a) blocked by co-incubation with
SU5416 (100 nM, *p<0.05; 300 nM and 1 p,M, **p<0.01), while (b) Cortisol had no effect on
VEGF-induced HUVEC proliferation. Data represent mean ± SEM; n=6. Each condition was
performed in triplicate wells.
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A) bFGF inhibitor (positive control)
400-1
bFGF plus platelet factor 4, nM
B) Cortisol
300-1
bFGF plus Cortisol, nM
Figure 5.8 Effect of Cortisol on bFGF-induced endothelial cell proliferation
(BrdU method)
HUVECs in standard experimental medium (endothelial cell growth medium-2, EGM-2, plus
2% charcoal-stripped foetal bovine serum) were seeded into 96-well plates in the presence
of: basic fibroblast growth factor (bFGF, 1 ng/ml), bFGF plus an established inhibitor (platelet
factor 4, 3 nM-1 p,M), or bFGF plus Cortisol (3 nM-1 jiM). Cells were incubated in vehicle
(final concentration, 0.004% v/v ethanol) or in medium alone as controls.
Bromodeoxyuridine (BrdU) was added to the wells and, after 48 hours of incubation, BrdU
incorporation (relative to the amount of cell proliferation) was quantified by enzyme-linked
immunosorbent assay (ELISA) and absorbance was measured in a plate reader. The
stimulatory effect of bFGF (*p<0.05) was (a) blocked by co-incubation with platelet factor 4
(300 nM, p<0.12; 1 fiM, *p<0.05), whilst (b) Cortisol had no effect on bFGF-induced HUVEC
proliferation. Data represent mean ± SEM; n=5. Each condition was performed in triplicate
wells.
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5.3.4.3 Influence ofglucocorticoids on cell viability
HUVEC proliferation was induced with both growth factors; VEGF (25 ng/ml)
resulted in 2.5 to 4.4-fold increases (p<0.01) in relative luminescence (Figure 5.9);
bFGF (1 ng/ml) resulted in 3.8 to 6.7-fold increases (Figure 5.10).
VEGF-induced cell proliferation was inhibited in the presence of SU5416 (positive
control) in a concentration-dependent manner (300 nM, 100 ± 6%, pcO.Ol and
1000 nM, 54 ± 9%, p<0.01 compared with VEGF plus vehicle-treated control,
438 ± 82%) (Figure 5.9A). Basic-FGF-induced cell proliferation was augmented in
the presence of 3 nM and 10 nM platelet factor 4 (positive control) and was inhibited
at the higher concentrations (ANOVA, /?<0.()1; Dunnett's post hoc test, 300 nM,
90 ± 8%, p=0.07 and 1 pM, 86 ± 18%, p-0.07 compared with bFGF-treated control,
669 ± 281%) (Figure 5.10A).
In contrast to the described effects of the positive controls, Cortisol had little effect on
cell proliferation induced by either growth factor at 3 nM to 600 nM. With 1 pM
Cortisol, however, there was a trend towards inhibition of bFGF-induced proliferation
but this did not reach statistical significance (bFGF and Cortisol, 190 ± 57%
compared with bFGF plus vehicle-treated control, 383 ± 84%, /?=0.09) (Figure 5.9B
and Figure 5.10B).
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Figure 5.9 Effect of Cortisol on VEGF-induced endothelial cell proliferation
(cell viability method)
HUVECs in standard experimental medium (endothelial cell growth medium-2, EGM-2, plus
2% charcoal-stripped foetal bovine serum) were seeded into 96-well plates in the presence
of: vascular endothelial growth factor (VEGF, 25 ng/ml), VEGF plus an established inhibitor
(SU5416, 1 nM-1 p,M), or VEGF plus Cortisol (3 nM-1 pM). Cells were incubated in vehicles
(ethanol, 0.004% v/v; DMSO, 0.167% v/v) or medium alone as controls. After 96 hours of
incubation, Cell-Titer Glo reagent (Promega) was added to the wells, and ATP production
(relative to the number of viable cells) was measured in a plate reader by luminescence.
The stimulatory effect of VEGF was (a) blocked by co-incubation with SU5416 (300 nM and
1 pM, **p<0.01), while (b) Cortisol had no effect on VEGF-induced HUVEC proliferation.
Data represent mean ± SEM; n=6. Each condition was performed in triplicate wells.
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A) bFGF inhibitor (positive control)
bFGF plus platelet factor 4, nM
B) Cortisol
5001
bFGF plus Cortisol, nM
Figure 5.10 Effect of Cortisol on bFGF-induced endothelial cell proliferation
(cell viability method)
HUVECs in standard experimental medium (endothelial cell growth medium-2, EGM-2 plus
2% charcoal-stripped foetal bovine serum) were seeded into 96-well plates in the presence
of: basic fibroblast growth factor (bFGF, 1 ng/ml), bFGF plus an established inhibitor (platelet
factor 4, 3 nM-1 ^M), or bFGF plus Cortisol (3 nM-1 ^M). Cells were incubated in vehicle
(ethanol, 0.004% v/v) or medium alone as controls. After 96 hours of incubation, Cell-Titer
Glo reagent (Promega) was added to the wells, and ATP production (relative to the number
of viable cells) was measured in a plate reader by luminescence. The stimulatory effect of
bFGF was (a) blocked by co-incubation with platelet factor 4 (p<0.01). In contrast, Cortisol
had little effect in the 3 nM-600 nM range (b), however at 1 p.M, Cortisol caused a 50%
inhibition in proliferation, but again, this did not reach significance (p=0.09). Data represent
mean ± SEM; n=6. Each condition was performed in triplicate wells.
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5.4 Discussion
The intention of these studies was to determine whether glucocorticoids inhibit
endothelial cell migration and proliferation, and whether they do so by inhibiting
cellular responses to angiogenic growth factors relevant to these two processes. The
results suggest that physiologically-relevant concentrations of glucocorticoids do not
inhibit endothelial cell migration or proliferation in vitro. Indeed this is consistent
with the fact that glucocorticoids inhibit TLS formation which does not encompass
cell migration or proliferation. It is unlikely, therefore, that glucocorticoid-mediated
inhibition of angiogenesis in vivo is due to direct inhibition of endothelial cell
migration or proliferation.
5.4.1 Development of an endothelial cell migration assay
A wide spectrum of assays exist for assaying cell migration; from simple 2D surface
migration assays such as phagokinetic tracks (Albrecht-Buehler, 1977) (measuring
displacement of colloidal gold by cell movement), to more qualitative methods
which include time-lapse imaging of cells migrating in 3D matrices, reviewed in
(Entschladen et al., 2005). The 2 most popular methods for assaying endothelial cell
migration include the Boyden chamber (or filter) and scratch (or 'wound' healing)
assays. In the Boyden chamber assay (Boyden, 1962) endothelial cells move along a
gradient of angiogenesis-inducing factors such as VEGF. In the scratch assay a
'wound' is created in a monolayer of confluent cells and the motility of endothelial
cells on a flat (2D) surface is analysed (Taraboletti & Giavazzi, 2004). In the scratch
assay, the repair process is considered to involve a combination of migration and
proliferation (Coomber & Gotlieb, 1990; Zahm et al, 1997; Yarrow et al., 2004)
which, thus, limits its use in mechanistic studies where the action of an agent on the
migration step alone is required. Since a major aim of these studies was to examine
the influence of glucocorticoids on directed cell migration, the Boyden chamber
assay was most appropriate. Furthermore, in the scratch migration assay, problems
are associated with the requirement to run control and experimental groups under
identical growth conditions and levels of confluency. These concerns can be avoided
with the Boyden chamber assay where the same population of cells (from the same
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flask) is analysed in all treatment groups (Auerbach et al., 1991). Another major
advantage of the Boyden chamber assay over other migration assays is the high
sensitivity to small differences in concentration gradients (Falk et al., 1980; Staton et
al., 2004) making it a useful tool to examine potentially subtle effects of
physiological concentrations of glucocorticoids.
The Boyden chamber assay lends itself to testing concentrations gradients and, thus,
may reflect the conditions that operate in vivo (Auerbach et al., 2003). However, in
vitro assays are only a rough approximation of the in vivo situation. It has been
suggested that equilibrium of the chemoattractant between the two chambers is
quickly formed, thus, making it difficult to discriminate between chemotaxis (i.e.
directed cell movement) and chemokinesis (i.e. undirected increase of migratory
activity) (Entschladen et al., 2005). This has been circumvented by checkerboard
analysis studies (Zigmond & Hirsch, 1973). These distinguish chemotaxis (increased
migration towards a chemoattractant in the lower compartment) from chemokinesis
(with the same concentration of attractant applied to the upper, or the upper and
lower, compartments) (Entschladen et al., 2005). Chemokinesis would produce
increased cell migration regardless of whether the chemoattractant was placed in the
upper, lower or both compartments (Entschladen et al., 2005). VEGF has been
shown to have predominantly chemotactic properties in this assay, whereas bFGF
has been shown to produce a predominantly chemokinetic pattern (Yoshida et al.,
1996). Consequently, in the present study, it was possible to test the effects of
glucocorticoids on directed cell migration.
Evaluation of the effects of cell passage number on basal migration levels
demonstrated that early passage cells (p2-p3) have greater chemokinetic ability than
later passage cells (p4-p6) and suggests they are more likely to be responsive to an
angiogenic stimulus. These findings contrast with a lack of effect of passage number
across the p2-p6 range in the TLS assay and suggest that migration is more sensitive
to passage than TLS formation. For this reason, cells at p2 and p3 were used in cell
migration assays, where possible. This is consistent with other reports in the
literature which have used endothelial cells at pi (Polytarchou & Papadimitriou,
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2005), p2 (Herve et al, 2005) or p2-p3 (Ahmad & Ahmed, 2004). In these studies,
however, the rationale for using cells at low passage was not explained. In contrast,
several studies have used endothelial cells as high as p6 (Cattaneo et al, 2003; Ali et
al., 2005) and even p8 (Isenberg et al, 2006). In the present study, 5 fresh batches of
pooled HUVECs from multiple donors were used; thereby minimising the possibility
of individual donor effects. Batch-specific variation in the degree of basal (control)
migration was evident in these studies given the mean inter-assay coefficients of
variation; this was circumvented, however, by performing control groups on each
occasion and normalising data to control.
Relative to the size of the investigated cells, the size of the pores in the filter
membrane must be small enough to avoid the passive passage of cells, but large
enough to allow their active migration. The most common pore size used in the
Boyden chamber assay with HUVECs is 8.0 pm (Hotchkiss et al, 2002; Cattaneo et
al, 2003), but there have been studies using 5.0 pm pores (Nissen et al, 1998;
Gallicchio et al, 2005). Furthermore, whilst 4-6 hours of incubation is commonly
used for this assay (Kim et al, 2002; Ali et al, 2005), longer incubation times (16
hours) have also been reported (Herve et al, 2005). Consequently, a lack of standard
experimental conditions prompted an evaluation of the effects of pore size and
duration of incubation during method refinement. The fact that relatively little
migration was observed with 3.0 pm pores in response to VEGF indicates that the
pore size was too small for HUVEC trans-migration. A lack of effect of VEGF on
cell migration after 5 hours of incubation contrasts with previous reports but these
studies used between 2-fold (Kim et al, 2002; Ischenko et al, 2007) and 5-fold (Ali
et al, 2005) higher concentrations of VEGF. Furthermore, the use of serum-free
medium in the present study contrasts with most previous reports which generally
use serum-reduced media (Lee et al, 2000; Kim et al, 2002; Gallicchio et al, 2005).
Although it was not tested, it is possible that the combination of chemoattractant,
along with growth factors present in serum, may act synergistically to induce a
quicker chemotactic response. This could explain the longer duration of incubation
required in the present study (24 hours) compared with previous studies (4-6 hours)
(Kim et al, 2002; Ali et al, 2005). To maintain consistency with the endothelial
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TLS formation studies, and to exclude effects from undetermined factors present in
serum as possible confounding factors, basal (serum and growth factor-free) medium
was used in the present study. This combination of pore size, culture conditions and
duration of incubation proved sufficient to produce a measurable effect of
chemoattractant on HUVEC chemotaxis, thereby providing a useful tool to test the
effects of glucocorticoids.
Given the observations in previous chapters, VEGF was an obvious choice as a
chemoattractant in these studies. The use of VEGF as a chemoattractant in this assay
is common (Cattaneo et al., 2003; Gallicchio et al., 2005; Herve et al., 2005)
probably mainly due to its recognised chemotactic properties in physiological
(Autiero et al., 2005) and pathophysiological (Nissen et al., 1998) models. The most
abundant VEGF-A splice variant, VEGF]65, was used in the present study since it has
been shown to have stronger migration-inducing effects than longer isoforms (e.g.
VEGF189) which require protease activation and cleavage in vivo (Ferrara & Davis-
Smyth, 1997). Studies to determine the EC50 value of VEGF were prompted by a
lack of consensus in the literature with quoted values ranging from 1 ng/ml (Ahmad
& Ahmed, 2004) up to 50 ng/ml (Cattaneo et al., 2003). It is also likely that the
concentration required to produce a sub-maximal chemotactic response will vary
depending on the culture conditions used. In preliminary studies, a lack of
significant inhibitory effect of Cortisol using 25 and 50 ng/ml VEGF could be
interpreted as over-stimulation of the cells which could mask any potential effect of
glucocorticoids. Accordingly, determination of the EC50 value for VEGF was an
important step of method development.
Fluorescence-based measurements proved rapid, reliable and not technically
demanding; advantages which led to the adoption of this method of quantification.
In the original assay, developed in 1962, quantification was performed by counting,
under a microscope, 5 to 10 random fields for each filter. Various alternatives have
been developed subsequently including; metabolic labelling with X-gal substrate or
similar compounds (Klemke et al., 1998), colorimetric detection (Saito et al., 1997),
or fluorescence-based detection of stained cells. The results obtained using a dye
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method of quantification are said to vary less than those obtained from counting cells
directly (Grotendorst, 1987) but the reasons for this are unclear. A possible
explanation is that dye methods take into account the total number of cells that
migrate through the pores, whereas the counting method measures a sample of cells
in random fields that might not be representative of the whole filter. Also, assays
which involve a plate reader for end-point analysis are less prone to investigator bias
than cell counting which requires selection of fields for enumeration (Frevert et al.,
1998; Wang et al., 2007). In comparative studies using leukocytes, the fluorescence
end-point assay was shown to be more rapid and more sensitive than the counting
assay (De Gendt et al., 1996; Frevert et al., 1998). Importantly, others have shown
that relative fluorescence intensity correlates significantly with cell counts (Sunder-
Plassmann et al., 1996) and that calcein-AM does not influence cell functions, such
as chemotaxis, at least in leukocytes (De Clerck et al., 1994). In the present study,
method development demonstrated that the fluorescence-based quantification method
was sensitive in detecting stimulation of cell migration using narrow and wide VEGF
concentration ranges on different occasions. Consistent with other studies using
plate-reader measurements (Klemke et al., 1998; Erzurum et al., 2003), each
condition was performed in triplicate and data were expressed as a percentage
relative to control wells, to avoid intra- and inter-assay variability, respectively.
5.4.2 Influence of glucocorticoids on endothelial cell migration
Glucocorticoids can inhibit migration of leukocytes (Yamada et al., 1993;
Yamaguchi et al., 1994; Hofbauer et al., 1999) and smooth muscle cells (Pross et al.,
2002b). There is at least indirect evidence to suggest that glucocorticoids and
synthetic angiostatic steroids may modulate endothelial cell migration, for example
by inhibiting growth factor-induced proteolytic activity (Blei et al., 1993; Pepper et
al., 1994), which is intimately related to cell motility and essential for angiogenesis
(Blasi, 1997). Furthermore, a possible effect of glucocorticoids on the endothelial
cytoskeleton (Chapter 3) is suggestive of a potential effect on VEGF-induced
motility since regulation of actin reorganisation and cytoskeleton remodelling is
responsible for this process (Rousseau et al., 2000). Any direct effect of
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physiological glucocorticoids on growth factor-induced endothelial cell migration
per se remained to be determined.
The demonstration that glucocorticoids do not inhibit endothelial cell migration,
either in the presence or absence of angiogenic stimuli suggests that this is not a
mechanism through which they inhibit angiogenesis. Demonstration of a lack of
effect of glucocorticoids in this model were strengthened by the blockade of VEGF
action by the specific VEGF signalling inhibitor, SU5416, which acted as a robust
positive control. SU5416 has previously been shown to inhibit endothelial cell
migration (Hirata et al., 2002; Abdollahi et al., 2003; Dolle et al., 2005). Only one
other study to date has examined the influence of glucocorticoids on endothelial cell
migration, in the absence of additional chemoattractant, showing, surprisingly, that
dexamethasone (400 nM) stimulated HUVEC migration (Polytarchou &
Papadimitriou, 2005). Flowever, the presence of high (15%) serum levels in the
culture medium, which in itself is chemotactic (English et al., 2000) could potentially
have overcome any inhibitory effect of dexamethasone (Polytarchou &
Papadimitriou, 2005). Interestingly, dexamethasone-mediated stimulation of
migration in this previous study (Polytarchou & Papadimitriou, 2005) was
accompanied by activation of eNOS which is consistent with activation of the
ERK/MAPK signalling pathway (Chapter 4). This suggests that culture conditions
are likely to play a pivotal role in the interpretation of these data.
5.4.3 Influence of glucocorticoids on endothelial cell proliferation
Endothelial cells are normally quiescent in the adult vasculature but readily undergo
rapid proliferation during angiogenesis. This process is recapitulated, to some
extent, by growing isolated cells on tissue culture plastic. Cell proliferation assays
are easy to perform, highly reproducible, and lend themselves to precise
quantification and high sample throughput (Auerbach et al., 1991). There are two
major classes of proliferation assay: those that determine net cell number (i.e.
indirect) and those that evaluate cell-cycle kinetics (i.e. direct). Cell number can be
determined by direct cell counting or by cell viability measurements (e.g. ATP or
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tetrazolium salts) as an indicator for healthy cells. Whether the cells are actively
dividing or quiescent is not distinguished in cell viability assays but a decrease in cell
viability may indicate cytotoxicity, rather than anti-proliferative activity, of an agent.
In contrast, direct proliferation assays (such as BrdU or [3H]-thymidine
incorporation) measure actively dividing cells, since incorporation of the labelled
precursor into DNA is directly proportional to the rate of cell division (Dean et al.,
1984). Quiescent, non-dividing, but otherwise healthy cells, are not detected by cell
proliferation assays. Combining data from multiple different types of proliferation
assay will yield a more accurate picture of endothelial cell responses to a given agent
(Staton et al., 2004). Thus, in the present study, two commercially-available kits
were used to determine the influence of glucocorticoids on both endothelial cell
proliferation and viability. Finally, it is important to bear in mind that inhibition of
cell proliferation is not a requisite for anti-angiogenic activity of an angiostatic agent
and a lack of anti-proliferative activity could indicate an alternative mode of action
(e.g. inhibition of cell migration, invasiveness etc.) (Taraboletti & Giavazzi, 2004).
Both the BrdU (Nanobashvili et al., 2004; Park et al., 2006) and the Cell-Titer Glo
(Mendoza et al., 2002) assays have previously been described in the literature. The
Cell-Titer Glo assay has been validated for commercial use by our collaborators in
the pharmaceutical industry; thus reducing the need for method development. To
maintain consistency with the TLS and migration assays, and in keeping with the
literature (Dou et al., 2004; Nanobashvili et al., 2004), HUVECs were used at
relatively low passage number (up to p4 in 75% of the assays). Method refinement
demonstrated that cells were more responsive to angiogenic stimuli at lower passage
number (data not shown). It was necessary to vary cell seeding densities and
incubation times for each assay, in order to produce a level of confluency at a point
of logarithmic cell growth, thus mimicking endothelial cells undergoing angiogenic
proliferation.
The influence of Cortisol on the action of VEGF and bFGF-induced proliferation
were tested since glucocorticoids can interfere with both of these signalling
pathways, and importantly, both are important mediators of angiogenesis in vivo
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(Bohnsack & Hirschi, 2004). Although 2.5-fold higher concentrations of VEGF
were required to produce the desired mitogenic effect compared with the chemotactic
response, this is consistent with another report where 10-fold higher levels of VEGF
were required in proliferation, compared with migration, assays (Kanno et al., 2000).
The reason for this is not clear but may reflect different mechanisms of regulation of
these endothelial cell processes which involve overlapping but distinct signalling
pathways (Becker et al., 2001). However, the concentrations of VEGF and bFGF
used in the current experiments were sufficient to reliably produce significant
stimulation of HUVEC proliferation in both systems to allow the influence of
glucocorticoids to be tested.
The inclusion of serum in the culture medium was necessary for the reaction to
measure cell viability, according to the manufacturer's instructions, and was included
in the BrdU assay to maintain consistency between proliferation assays. The
inclusion of serum is also necessary for experiments which rely on extended periods
of culture (several days) to prevent apoptosis induced by serum starvation. Indeed
the inclusion of serum in these assays is commonplace in the literature with between
5% (Marks et al., 2002) and 10% (Nanobashvili et al., 2004) reported whilst
maintaining significant stimulatory effects with exogenous stimuli. To avoid the
possibility of steroid hormones present in FBS masking any effect of exogenous
Cortisol treatments, charcoal-stripped serum was used: charcoal stripping removes
the majority of hormones from serum (Leake et al., 1987).
Findings from the present study consistently demonstrate that endogenous
glucocorticoids, across a physiological range of concentrations, do not influence
mitogen-induced HUVEC proliferation. This interpretation was strengthened by the
fact that the same results were obtained using 2 different methods of assaying
proliferation, and that proliferation was inhibited using relevant positive controls.
SU5416 and platelet factor 4 have previously been shown to inhibit HUVEC
proliferation in response to VEGF, (Mendel et al., 2000) and bFGF (Yoshida et al.,
1996; Gentilini et al., 1999), respectively, using similar experimental conditions.
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There may be species differences in the vascular response to glucocorticoids. For
example, glucocorticoids have well-documented anti-proliferative effects on rodent
vascular smooth muscle cells (Berk et al., 1988) and endothelial cells (Heffernan et
al., 1978; Derbyshire et al., 1996) which have not translated well into the clinic as
potential anti-atherosclerotic and anti-restenotic agents (Hadoke et al., 2006). There
have been mixed reports in vitro of the effects of glucocorticoids on endothelial cell
proliferation. For example, inhibitory effects (Cariou et al., 1988; Kraling el al.,
1999; Banciu et al., 2006; Zou et al., 2006), stimulatory effects (Polytarchou &
Papadimitriou, 2005) and no effect on unstimulated (Chen et al., 2006) or
TNFa-induced (Yamamoto et al., 2004), human endothelial cell proliferation have
been reported. The reasons for these conflicting data may reflect differences in;
endothelial cell type (species and vascular territory), steroid (synthetic or
endogenous; concentration), culture conditions (presence of serum and/or growth
factors; charcoal stripping; duration of incubation), and the method used to assay for
proliferation (e.g. direct cell counting, MTT, BrdU or [3H]-thymidine incorporation).
The fact that at the same concentration and culture conditions, Cortisol has divergent
effects on endothelial cell proliferation (present study) versus endothelial sprouting
(which comprises cell proliferation) (Small et al., 2005), highlights the differential
effects of physiological glucocorticoids on the individual components of the
angiogenesis cascade. This is supported by the fact that Cortisol (600 nM) inhibits
TLS formation (Chapter 3) without an apparent effect on cell viability, findings
which parallel that of another study in which blockade of pi-integrin function
destroys the integrity of capillary tubes without a loss of cell viability (Da Silva et
al., 2003). In other words, cell death is not a pre-requisite for disruption of
endothelial tube formation.
The trend towards an inhibitory effect of 1 pM Cortisol on bFGF-induced HUVEC
proliferation suggests that, in contrast with physiological levels of glucocorticoids,
pharmacological levels might exert direct anti-proliferative effects on isolated
endothelial cells. Indeed, this may be one element of their actions in vivo e.g. when
administered therapeutically for the treatment of capillary haemangioma. For
example, bFGF is elevated in the lesions (Takahashi et al., 1994) and urine (Marler
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et al., 2005) of infants with proliferating baemangioma, however, transcript or
protein levels do not decrease with signs of response to corticosteroids (Hasan et al.,
2000). Therefore, inhibition of bFGF action on endothelial cell proliferation (e.g. by
inhibition of signal transduction), despite unaltered bFGF levels, may account in part
for the angiostatic actions of pharmacological steroids. Further studies are required
to confirm this possibility.
5.4.4 Conclusion
The data in this chapter provide evidence for the establishment of in vitro assays of
endothelial cell migration and proliferation as useful tools to examine the influence
of glucocorticoids on the endothelium and to dissect angiostatic mechanisms. The
results presented in this Chapter clearly demonstrate that concentrations of Cortisol
which cause the disruption of endothelial tube formation, in contrast, do not inhibit
endothelial cell migration or proliferation. This supports the contention that the
ability of glucocorticoids to inhibit angiogenesis through direct interaction with
endothelial cells is due, at least in part, to a reduction of tube formation, rather than






Against the background that pharmacological glucocorticoids are known to inhibit
angiogenesis (Folkman et al., 1983; Nicosia & Ottinetti, 1990), and that
physiological concentrations of endogenous glucocorticoids generated by 11(3-HSD1
contribute to regulation of angiogenesis in vivo (Small et al., 2005), the potential role
of glucocorticoids in the pathophysiology and therapy of deregulated angiogenesis is
highly topical and important. The mechanisms through which glucocorticoids inhibit
angiogenesis, however, remain obscure. Advances in our understanding of the
nature of the interaction between glucocorticoids and the vascular wall make it
possible to propose mechanisms that explain the anti-angiogenic actions of these
steroids. At a cellular level, for example, glucocorticoids can alter vascular tone by
acting directly on endothelial cells suggesting that direct interaction with the
endothelium might also underpin their angiostatic effects. Indeed, this is plausible as
endothelial cell morphogenesis, migration and proliferation are key stages in the
multi-step angiogenic pathway, and furthermore, glucocorticoids (at least at
pharmacological levels) can interfere with each of these functions. The
mechanism(s) underlying these anti-angiogenic effects of glucocorticoids likely
centre on their ability to regulate the expression and/or action of angiogenic factors
(e.g. VEGF and TSP-1) and intra-cellular signalling cascades (e.g. MAPK) within
the endothelium. Thus, the major aims of this thesis were to examine whether
physiological glucocorticoids can act directly on endothelial cells to account for their
angiostatic effects in vivo and to explore the cellular and molecular mechanism
through which this phenomenon occurs.
6.1 Methodology
Fundamental to the work described in this thesis was the necessity to use in vitro
models to investigate possible mechanisms of glucocorticoid-mediated angiostasis.
Firstly, this approach allows the use of isolated endothelial cells, thus enabling the
investigation of direct effects of glucocorticoids in the absence of confounding
influences of other cell types (such as SMCs, perivascular cells and inflammatory
cells). Secondly, the models described in this thesis produced results which were
consistently reliable (in terms of response to positive controls), reproducible, and
readily quantifiable. The use of HUVECs as the predominant endothelial cell type of
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choice was based predominantly on their widespread use in the relevant literature
(which, in turn reflects their ready availability, low cost and relative robust nature in
cell cultures). Thus use of HUVECs was important as it enabled direct comparison
of data produced during the course of the PhD with published results. It has to be
acknowledged, however, that results obtained in HUVECs cannot necessarily be
extrapolated to systemic endothelial cells making it necessary to validate these data
using a more representative cell type. Human aortic endothelial cells were chosen
for reproducing key observations made in HUVECs, as they are perhaps more
relevant to adult physiology and pathophysiology. By examining various structural
and functional markers of healthy, intact endothelial cells (e.g. CD31 and Tie2
expression), and demonstrating that these did not alter with limited passaging, or by
the process of differentiation, this also validated the cell culture models used.
Furthermore, in each of the studies presented here careful consideration of the
choices of in vitro assay, culture conditions, time-points and quantification methods
were made by first consulting the literature and then testing the influence of each of
these different parameters during the course of method refinement to produce
well-reasoned protocols.
A possible complicating factor in examining the effects of glucocorticoids on cell
function is the action of the isozymes of 11 [1-HSD which exert an important
regulatory control mechanism of glucocorticoid-mediated inhibition of angiogenesis
locally in the vessel wall (Small et al., 2005). The contentious issue of the precise
cellular localisation of these isozymes within the vascular wall, however, made it
necessary to investigate their presence within both undifferentiated HUVECs and the
TLS model. The absence of 1 l(3-HSDs in HUVECs and TLSs meant that both single
cells and the tube-formation assay could be used to test the influence of exogenous
glucocorticoids on endothelial cell function without complication by steroid
metabolism within the cells. However, it precluded further investigation of the role
of llp-HSDs in modulating this process.
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6.2 Application of methods
6.2.1 Glucocorticoids influence endothelial cell morphogenesis
The observations described in Chapter 3 advance the field of
glucocorticoid-mediated inhibition of angiogenesis by firstly, demonstrating that
physiological glucocorticoids can act directly on the endothelium, via GR, and
secondly, by demonstrating how they inhibit angiogenesis with regard to their effects
on cellular function. One of the key steps of angiogenesis in vivo is the process of
endothelial tube formation which is recapitulated in the cell morphogenesis (TLS
formation) model. The studies in Chapter 3 explored the hypothesis that
glucocorticoids inhibit angiogenesis by altering the remodelling of undifferentiated
and, otherwise uniform, endothelial cells into a mature network of endothelial tubes
that resembles a new capillary bed in vivo. Limited evidence in the literature
suggested that pharmacological levels of glucocorticoids are angiostatic in this model
but no studies to date had examined the influence of physiological glucocorticoids or
focussed on human endothelial cells in any detail. In addition to the demonstration
in the present study that glucocorticoids inhibit TLS formation in two different
endothelial cell types (HUVECs and HAoECs), collaboration with other groups has
led to similar observations in primary EPCs (McDermott et al., unpublished findings)
and endometrial endothelial cells (Rae et al., manuscript submitted). Therefore, a
growing body of evidence now suggests that physiological glucocorticoids might
exert a tonic angiostatic effect in vivo, via GR, by influencing endothelial cell
morphogenesis.
When the time-lapse studies were performed, no other reports had previously
described the use of this methodology to examine endothelial TLS formation. These
studies were useful not only for confirming the 'snap-shot' data that glucocorticoids
inhibit the formation of new tubules, but also in advancing our understanding of the
nature of this inhibition. Time-lapse sequences demonstrated that TLS formation
occurs in the absence of obvious cell migration or proliferation (which is evident in
some other endothelial tube formation models), confirming that this methodology
provides a model of endothelial cell morphogenesis. Furthermore, these studies
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demonstrated that glucocorticoids reduce TLS formation by both inhibiting
formation of new tubes and by actively degrading the existing network. This
demonstrates a complexity in the angiostatic effect of glucocorticoids not previously
apparent from data obtained at single time-points. Although the use of time-lapse
imaging is not widespread at present, this dynamic approach to investigating the
mechanism of TLS formation represents an important tool for future investigations.
These studies provided a useful basis for planning time-points in subsequent studies
(Chapter 4). Furthermore, time-lapse data were also complementary with the
cytoskeleton studies which, although preliminary in nature, point towards an
attenuation of cell-matrix interactions and subsequent downstream
matrix-integrin-cytoskeleton signalling pathway (e.g. FAK, ERK, p38, JNK) that led
to the studies described in Chapter 4.
The fact that physiological glucocorticoid concentrations inhibit TLS formation
under basal (unstimulated) conditions as well us under growth-factor stimulated
conditions reveals other facets of their angiostatic mechanisms of action. Firstly, it
demonstrates that there are likely to be multiple molecular mechanisms of action e.g.
inhibition of growth factor signalling, either by altering the balance of pro- to
anti-angiogenic factor generation within the endothelium, by influencing the action
of angiogenic factors (both soluble and ECM-based) on TLS formation, and/or by
inhibition of downstream post-receptor signalling pathways. Secondly, it
demonstrates that although glucocorticoids can alter TLS formation directly within
endothelial cells themselves, it also strongly suggests that other cell types are likely
to be important in glucocorticoid-mediated inhibition of angiogenesis. For example,
blocking the action of exogenous VEGF on TLS formation suggests that other cell
types (e.g. SMCs, macrophages) as a source of these factors, may be important in
vivo and points towards a paracrine mechanism of action. Indeed, this mechanism of
regulation of angiogenesis is well accepted in the contexts of physiological
angiogenesis in wound healing and in tumour pathophysiology (Hanahan &
Folkman, 1996; Carmeliet, 2000).
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Although glucocorticoids can influence endothelial TLS formation directly, the idea
of an additional paracrine mechanism of action in vivo is supported by the studies
(Chapter 3) assessing the presence of lip-HSDs. Whilst it is feasible that
endothelial cells could maintain lip-HSDs activity in the intact vessel wall, the
inability of cortisone to inhibit TLS formation, despite the efficacy of cortisone to
inhibit angiogenesis e.g. in aortic rings (Small et al., 2005), is significant as it
suggests that glucocorticoid regeneration probably occurs in another vascular cell
type. Although cortisone can inhibit angiogenesis in vivo via the action of
llp-HSDl (Small et al., 2005), the lack of expression and activity of lip-HSDl (in
isolated endothelial cells, EPCs and TLSs), and lack of an effect of cortisone in TLS
preparations, when taken together demonstrates that an alternative source of
glucocorticoid regeneration in the vessel wall exists outside the endothelium. This is
important as it advances our current understanding of a role for these enzymes as it
has previously been suggested that they act as a mechanism for controlling
intracellular glucocorticoid action. However, these findings now suggest that the
lip-HSDs can control glucocorticoid action in the vasculature between different cell
types. Whether or not physical contact between cell types is required and the
mechanism of glucocorticoid secretion and action on neighbouring cell types are
both important questions for future studies which could be addressed by co-culture
experiments (Section 6.4.2).
6.2.2 Glucocorticoids stimulate generation of an angiostatic factor during
endothelial tube formation
The studies in Chapter 4 extend the observation of glucocorticoid-mediated
inhibition of endothelial tube formation, via GR, by implicating the possible
involvement of the angiostatic factor TSP-1. Although the present studies were
limited to mRNA expression levels, the results are supported by evidence that
Cortisol, at 600 nM, causes up-regulation of TSP-1 protein levels that translates into
an angiostatic effect in ex vivo (primary endometrial tissue) explants in Matrigel (Rae
et al., manuscript submitted). Furthermore, in the studies by Rae and colleagues, the
angiostatic effect of Cortisol was shown, using a small interfering (si)RNA approach,
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to be a direct result of TSP-1 up-regulation. Emerging evidence from the literature,
concerning the regulation of angiogenesis in vivo and in pathological models by
glucocorticoids, suggests that they act by altering the balance of pro-angiogenic (e.g.
VEGF) (Pufe et al., 2003; Luo el al., 2004) to anti-angiogenic (e.g. TSP-1 and
TIMP-1) factors (Flugel-Koch et al., 2004; Forster et al., 2007). The data presented
here are consistent with this idea and extend our current knowledge by demonstrating
that endothelial cells themselves are a source of TSP-1. This might be important for
drug delivery strategies aimed at targeting aberrant angiogenesis in disease.
Gene selection (such as VEGF, a6-integrin) for the current work was based on
preliminary evidence from Small and colleagues (altered calcium influx in HUVECs;
Small et al., unpublished findings) and careful evaluation of the literature. This does
not, however, exclude the possibility that interaction with additional genes may
contribute to the angiostatic effects of glucocorticoids on endothelial cells.
Lack of a significant effect of Cortisol on VEGF and VEGF-R2 mRNA levels should
not be taken as a lack of involvement of VEGF signalling in glucocorticoid-mediated
inhibition of TLS formation. On the contrary, TLS formation driven by VEGF is
blocked by glucocorticoids (Chapter 3), suggesting that it may play a role. However,
it is likely that a post-receptor signal transduction mechanism is involved. Limited in
vitro evidence suggests that MAPK signalling is inhibited in endothelial cells by
pharmacological glucocorticoids in angiogenic (Ebrahem et al., 2006) and
inflammatory situations (Pelaia et al., 2001). Consequently, it was hypothesised that
physiological levels of Cortisol would attenuate activation of ERK. However, trends
were observed suggesting activation of this pathway by physiological levels of
glucocorticoids in unstimulated, undifferentiated cells (Chapter 4), demonstrating the
complexity of regulation of this pathway by glucocorticoids. The sensitivity of ERK
signalling to the extra-cellular environment, which is the physiological purpose of
this pathway, necessitates close consideration of the culture conditions when
interpreting these novel data. Whether or not activation of ERK/MAPK is important
during the process of tube formation will require studies to be performed on protein
recovered from TLSs on Matrigel. The difficulty in obtaining sufficient protein from
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TLSs for this purpose highlights the importance of this methodological development.
The preliminary work described in this thesis will serve as a useful basis for planning
future studies since protocols (e.g. for measurement of pERK) are now well
established. In conclusion, whether or not activation of ERK signalling is involved
in glucocorticoid-mediated angiostasis can be determined in future studies now that
relevant, validated tools are available.
6.2.3 Glucocorticoids do not inhibit angiogenesis by influencing endothelial
cell migration or proliferation
As described in the introduction (Chapter 1) angiogenesis is a multi-step process,
prompting investigation into the effects of glucocorticoids on endothelial cell
migration and proliferation. Although it was demonstrated that glucocorticoids
consistently inhibit endothelial cell morphogenesis (Chapter 3) additional
investigations (Chapter 5) showed that they do not inhibit proliferation or migration
of these cells. Pharmacological levels of glucocorticoids are known to inhibit
migration (Pross et al., 2002a) and proliferation (Berk el al., 1988) of vascular
smooth muscle and endothelial cells in rodents, but whether they inhibit these
processes at physiological levels in human endothelial cells was unclear.
Furthermore, since glucocorticoids block some of the actions of VEGF on the
endothelium in other in vitro systems, and VEGF-induced migration and
proliferation are required during angiogenesis in vivo, these studies addressed the
hypotheses that glucocorticoids inhibit VEGF-induced migration and proliferation.
Since no effects on either migration or proliferation were noted in these studies,
despite using a range of well validated, relevant models, it was concluded that
glucocorticoid-mediated inhibition of angiogenesis is not a result of effects on either
of these endothelial cell processes. Indeed, this is consistent with the fact that TLS
formation occurs in the absence of any obvious signs of cell proliferation or
migration. This is important because a similar physiological level of Cortisol inhibits
endothelial tube formation in the intact vessel wall (Small et al., 2005) (which
encompass endothelial cell morphogenesis, migration and proliferation), in spite of a
possible lack of effect on either migration of proliferation (Figure 6.1).
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6.3 Summary
In summary, the research presented in this thesis demonstrates that physiological
levels of glucocorticoids, via GR, are sufficient to inhibit tube formation by direct
interaction with human endothelial cells. Exposure of endothelial cells to
glucocorticoids undergoing this morphogenesis (or remodelling) revealed some new
insights into their molecular mechanisms of action, however, glucocorticoid
interactions with the endothelium may be even more complex than previously
appreciated. Furthermore, the work in this thesis does not exclude the possibility that
glucocorticoid-mediated inhibition of angiogenesis in vivo may also include effects
on inflammatory and smooth muscle cells. Finally, since physiological
glucocorticoids inhibit tube formation in the absence of an effect on either
endothelial cell migration or proliferation, this demonstrates that glucocorticoids act
selectively in mediating their angiostatic effects.
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B) Regulation by glucocorticoids
morphogenesis
tube formation
Figure 6.1 Schematic of proposed cellular mechanism of
glucocorticoid-mediated inhibition of endothelial tube formation
The proposed mechanism of action of glucocorticoids on angiogenesis (note, diagram is not
to scale). A) Endothelial tube formation, a key component of angiogenesis in vivo is
comprised of multiple cell functions including; endothelial cell morphogenesis, migration and
proliferation. These processes are regulated by various angiogenic signals from the
surrounding microenvironment including vascular endothelial growth factor,
thrombospondin-1, integrins and other unknown factors. B) The findings from this thesis
demonstrate that glucocorticoids, via GR, regulate endothelial cell morphogenesis, but not
the migration or proliferation steps.
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6.4 Future work
Further studies are planned, as a basis for a new PhD project, with the aim of
advancing some of the key findings from this thesis. Some of the key questions
arising from the present work, and the relevant methodologies to address these, are
proposed as follows:
6.4.1 Characterisation of endothelial TLS integrity and influence of
glucocorticoids
• Which components of endothelial cell morphogenesis (e.g. cell polarisation or
lumen formation) are influenced by glucocorticoids?
The influence of glucocorticoids on the ultra-structural integrity of TLSs could be
addressed with the use of electron microscopy. This would allow examination of the
presence of a lumen in TLSs that would add to the body of evidence reported in this
study that the model recapitulates, to an extent, endothelial tube formation in vivo.
Electron microscopy studies of the cytoplasmic (filopodia-like) extensions that
contribute to TLSs, will allow a more qualitative analysis of the cell-cell and
cell-matrix interactions.
6.4.2 Glucocorticoid effects on physiological endothelial tube formation
• Do glucocorticoids inhibit tube formation during invasive sprouting
angiogenesis?
• Is tube formation inhibited by glucocorticoids when driven by physiological
stimuli?
• Do glucocorticoids influence the production of angiogenic factors by
neighbouring smooth muscle cells, and if so, does this in turn have an influence on
endothelial TLS formation?
• Is the inter-conversion of cortisone to Cortisol by 11J3-HSD1 -active cells sufficient
to confer angiostatic effects on nearby tubes?
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Glucocorticoid-mediated inhibition of TLS formation could be investigated in more
physiologically-relevant, 'qualitative', variations of the existing model. For
example, the influence of glucocorticoids on endothelial cell invasion in combination
with cell morphogenesis, migration and proliferation could be investigated using a
3D system in which endothelial cell-coated beads cultured within fibrin gels have
been described as producing branching tubes with 'tip cells' resembling angiogenic
sprouts in vivo (Nakatsu et al., 2003). Alternatively, culturing endothelial tubes in a
hypoxia chamber (Ben-Yosef et al., 2005), or co-culturing endothelial cells directly
onto confluent monolayers of matrix-producing cells (e.g. fibroblasts) (Donovan et
al., 2001) has been suggested to produce a more heterogeneous pattern of TLS
formation (long and short TLSs) that more closely resembles capillaries in vivo.
Given that circulating EPCs contribute to angiogenesis in vivo (Asahara et al., 1997)
it would be worthwhile testing the possible influence of glucocorticoids on isolated
precursor cells in a variation of the TLS model. Preliminary evidence suggests that
exposure of EPCs to a physiological concentration of Cortisol inhibits TLS formation
through an unknown mechanism (McDermott et al., unpublished findings) which is
tantalizing and warrants further investigation.
The influence of 11(3-HSD1 on endothelial tube formation will be an important issue
to address since it is known to regulate endothelial tube formation by the intact
vessel wall (Small et al., 2005). Consequently, introducing 11(3-HSD1 back into an
in vitro system will allow the opportunity to study communication between human
vascular cell types and to address further a possible paracrine mechanism of action.
This could be achieved using cell culture inserts and culturing llp-HSDl-active cells
(e.g. activated smooth muscle cells (Cai et al., 2001) or macrophages (Thieringer et
al., 2001)) and endothelial cells together, by transfection of endothelial cells, or
using conditioned media from 11 (1-HSD1-expressing cells.
234
6.4.3 Molecular mechanisms of glucocorticoid-mediated angiostasis
• Is up-regulation of TSP-1 the cause of glucocorticoid-mediated inhibition of
endothelial tube formation?
• How important is VEGF signalling in glucocorticoid-mediated inhibition of
endothelia I tube forma tion ?
• Are there other molecular mediators central to the angiostatic action of
glucocorticoids ?
The functional consequence of up-regulated TSP-1 could by explored by testing
whether blockade (e.g. by blocking with antibodies (Desai et al., 2005) or siRNA) of
TSP-1, or its receptor (CD36), counteracts the angiostatic effect of glucocorticoids
on TLS formation. In addition, it will be important to determine some of the
downstream actions of switching-on TSP-1. The literature suggests that the
counter-adhesive properties of TSP-1 lead to disassembly of focal adhesions and
stress fibres, and eventually apoptosis. This could be addressed by
immunocytochemical staining and fluorescence microscopy using markers of focal
adhesion kinase (FAK), stress fibres (F-actin) and apoptosis (caspases). A firm
foundation for these studies is already in place with the preliminary work described
in Chapter 3.
Similarly, blocking VEGF signalling e.g. using VEGF-Trap or a similar neutralising
antibody would allow determination of whether the angiostatic effect of
glucocorticoids is mediated by aberrant VEGF signalling.
More global approaches to studying changes in gene expression (e.g. by RNA
microarrays) during endothelial TLS formation are emerging in the literature (Glesne
et al., 2006). Since angiogenesis is regulated by an enormous number of factors, and
likewise, glucocorticoids regulate expression of various factors, this technology
offers an efficient means of identifying new targets. No studies to date, however,
have used microarrays to examine glucocorticoid effects on angiogenic factors in
endothelial tubes and this technology offers an area of opportunity for the future.
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Finally, with each of these strategies of identifying molecular targets of
glucocorticoids on angiogenesis, it will be important to take these findings and test
them in angiogenesis models in vivo (e.g. subcutaneous sponges (Hori etal., 1996) or





Abdollahi, A., Lipson, K. E., Sckell, A., Zieher, H., Klenke, F., Poerschke, D., Roth,
A., Han, X., Krix, M., Bischof, M., Hahnfeldt, P., Grone, H. J., Debus, J., Hlatky, L.,
& Huber, P. E. (2003). Combined therapy with direct and indirect angiogenesis
inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Research
63,8890-8898.
Addison, T. (1855). On the constitutional and local effects of disease of the supra¬
renal capsules reprinted by S Highley, London.
Agarwal, A. K., Monder, C., Eckstein, B., & White, P. C. (1989). Cloning and
expression of rat cDNA encoding corticosteroid ll(3-dehydrogenase. Journal of
Biological Chemistry 264, 18939-18943.
Agarwal, A. K., Mune, T., Monder, C., & White, P. C. (1994). NAD+-dependent
isoform of ll(3-hydroxysteroid dehydrogenase. Cloning and characterisation of
cDNA from sheep kidney. Journal ofBiological Chemistry 269, 25959-25962.
Ahmad, S. & Ahmed, A. (2004). Elevated placental soluble vascular endothelial
growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circulation Research
95, 884-891.
Alam, C., Colville-Nash, P., Seed, M. P., & Willoughby, D. (1998). Tetrahydro-
derivatives of cortisone promote granulomatous tissue angiogenesis in vivo on
topical application in hyaluronan. Angiogenesis. 1, 185-191.
Albrecht-Buehler, G. (1977). The phagokinetic tracks of 3T3 cells. Cell 11, 395-404.
Ali, N., Yoshizumi, M., Fujita, Y., Izawa, Y., Kanematsu, Y., Ishizawa, K.,
Tsuchiya, K., Yano, S., Sone, S., & Tamaki, T. (2005). A novel Src kinase inhibitor,
M475271, inhibits VEGF-induced human umbilical vein endothelial cell
proliferation and migration. J.Pharmacol.Sci. 98,130-141.
Antoniotti, S., Fiorio, P. A., Pregnolato, S., Mottola, A., Lovisolo, D., & Munaron, L.
(2003). Control of endothelial cell proliferation by calcium influx and arachidonic
acid metabolism: a pharmacological approach. J.Cell Physiol 197, 370-378.
Aoki, T., Nomura, R., & Fujimoto, T. (1999). Tyrosine phosphorylation of caveolin-
1 in the endothelium. Exp.CellRes. 253, 629-636.
Arora, A. & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer
therapy. Journal ofPharmacology and Experimental Therapeutics 315, 971-979.
Artavanis-Tsakonas, S., Matsuno, K., & Fortini, M. E. (1995). Notch signaling.
Science 268, 225-232.
238
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der, Z. R., Li, T.,
Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997). Isolation of putative
progenitor endothelial cells for angiogenesis. Science 275, 964-967.
Ashino-Fuse, H., Takano, Y., Oikawa, T., Shimamura, M., & Iwaguchi, T. (1989).
Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the
plasminogen activator in bovine endothelial cells. IntJ.Cancer 44, 859-864.
Auerbach, R., Auerbach, W., & Polakowski, I. (1991). Assays for angiogenesis: a
review. Pharmacol.Ther. 51,1-11.
Auerbach, R., Lewis, R., Shinners, B., Kubai, L., & Akhtar, N. (2003). Angiogenesis
assays: a critical overview. Clinical Chemistry 49, 32-40.
Autiero, M., De, S. F., Claes, F., & Carmeliet, P. (2005). Role of neural guidance
signals in blood vessel navigation. Cardiovascular Research 65, 629-638.
Azzouz, M., Ralph, G. S., Storkebaum, E., Walmsley, L. E., Mitrophanous, K. A.,
Kingsman, S. M., Carmeliet, P., & Mazarakis, N. D. (2004). VEGF delivery with
retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature
429, 413-417.
Bagavandoss, P., Kaytes, P., Vogeli, G., Wells, P. A., & Wilks, J. W. (1993).
Recombinant truncated thrombospondin-1 monomer modulates endothelial cell
plasminogen activator inhibitor 1 accumulation and proliferation in vitro.
Biochemical andBiophysical Research Communications 192, 325-332.
Banai, S., Jaklitsch, M. T., Shou, M., Lazarous, D. F., Scheinowitz, M., Biro, S.,
Epstein, S. E., & Unger, E. F. (1994). Angiogenic-induced enhancement of collateral
blood flow to ischemic myocardium by vascular endothelial growth factor in dogs.
Circulation 89, 2183-2189.
Banciu, M., Schiffelers, R. M., Fens, M. H., Metselaar, J. M., & Storm, G. (2006).
Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in
mice. J.Control Release 113,1-8.
Banerjeei, S. K., Zoubine, M. N., Sarkar, D. K., Weston, A. P., Shah, J. H., &
Campbell, D. R. (2000). 2-Methoxyestradiol blocks estrogen-induced rat pituitary
tumor growth and tumor angiogenesis: possible role of vascular endothelial growth
factor. Anticancer Res. 20, 2641-2645.
Barar, J., Campbell, L., Hollins, A. J., Thomas, N. P., Smith, M. W., Morris, C. J., &
Gumbleton, M. (2007). Cell selective glucocorticoid induction of caveolin-1 and
caveolae in differentiating pulmonary alveolar epithelial cell cultures. Biochemical
andBiophysical Research Communications 359, 360-366.
239
Bartholome, B., Spies, C. M., Gaber, T., Schuchmann, S., Berki, T., Kunkel, D.,
Bienert, M., Radbruch, A., Burmester, G. R., Lauster, R., Scheffold, A., &
Buttgereit, F. (2004). Membrane glucocorticoid receptors (mGCR) are expressed in
normal human peripheral blood mononuclear cells and up-regulated after in vitro
stimulation and in patients with rheumatoid arthritis. FASEB Journal 18, 70-80.
Bates, D. O., Heald, R. I., Curry, F. E., & Williams, B. (2001). Vascular endothelial
growth factor increases Rana vascular permeability and compliance by different
signalling pathways. J.Physiol 533, 263-272.
Battegay, E. J., Rupp, J., Iruela-Arispe, L., Sage, E. H., & Pech, M. (1994). PDGF-
BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-
receptors. J.Cell Biol. 125, 917-928.
Bauer, J., Margolis, M., Schreiner, C., Edgell, C. J., Azizkhan, J., Lazarowski, E., &
Juliano, R. L. (1992). In vitro model of angiogenesis using a human endothelium-
derived permanent cell line: contributions of induced gene expression, G-proteins,
and integrins. J.Cell Physiol 153, 437-449.
Bauer, K. S., Cude, K. J., Dixon, S. C., Kruger, E. A., & Figg, W. D. (2000).
Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated
nitric-oxide synthase-vascular endothelial growth factor pathway. Journal of
Pharmacology and Experimental Therapeutics 292, 31-37.
Bayless, K. J., Salazar, R., & Davis, G. E. (2000). RGD-dependent vacuolation and
lumen formation observed during endothelial cell morphogenesis in three-
dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(l)
integrins. Am.J.Pathol. 156,1673-1683.
Beato, M. (1989). Gene regulation by steroid hormones. Cell 56, 335-344.
Beck, D. W., Olson, J. J., & Linhardt, R. J. (1986). Effect of heparin, heparin
fragments, and corticosteroids on cerebral endothelial cell growth in vitro and in
vivo. J.Neuropathol.Exp.Neurol. 45, 503-512.
Becker, P. M., Verin, A. D., Booth, M. A., Liu, F., Birukova, A., & Garcia, J. G.
(2001). Differential regulation of diverse physiological responses to VEGF in
pulmonary endothelial cells. AmJ.Physiol Lung Cell Mol.Physiol 281, L1500-
L1511.
Beckner, M. E. & Liotta, L. A. (1996). AAMP, a conserved protein with
immunoglobulin and WD40 domains, regulates endothelial tube formation in vitro.
Lab Invest 75, 97-107.
Beer, H. D., Fassler, R., & Werner, S. (2000). Glucocorticoid-regulated gene
expression during cutaneous wound repair. Vitam.Horm. 59, 217-239.
240
Belgore, F., Lip, G. Y., & Blann, A. D. (2003). Basic fibrobrast growth factor
induces the secretion of vascular endothelial growth factor by human aortic smooth
muscle cells but not by endothelial cells. EurJ.Clin.Invest 33, 833-839.
Bellon, G., Martiny, L., & Robinet, A. (2004). Matrix metalloproteinases and
matrikines in angiogenesis. Crit Rev.Oncol.Hematol. 49, 203-220.
Ben-Yosef, Y., Miller, A., Shapiro, S., & Lahat, N. (2005). Hypoxia of endothelial
cells leads to MMP-2-dependent survival and death. AmJ.Physiol Cell Physiol 289,
C1321-C1331.
Benelli, R. & Albini, A. (1999). In vitro models of angiogenesis: the use of Matrigel.
IntJ.Biol.Markers 14, 243-246.
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999). Selective
ablation of immature blood vessels in established human tumors follows vascular
endothelial growth factor withdrawal. J.Clin.Invest 103,159-165.
Bergers, G. & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch.
Nat.Rev. Cancer 3, 401-410.
Berk, B. C., Gordon, J. B., & Alexander, R. W. (1991). Pharmacologic roles of
heparin and glucocorticoids to prevent restenosis after coronary angioplasty. Journal
of theAmerican College ofCardiology 17,111B-117B.
Berk, B. C., Vallega, G., Griendling, K. K., Gordon, J. B., Cragoe, E. J., Canessa,
M., & Alexander, R. W. (1988). Effects of glucocorticoids on Na/H exchange and
growth in cultured vascular smooth muscle cells. Journal ofCellular Physiology 137,
391-401.
Bevilacqua, M. P., Pober, J. S., Mendrick, D. L., Cotran, R. S., & Gimbrone, M. A.,
Jr. (1987). Identification of an inducible endothelial-leukocyte adhesion molecule.
Proc.NatlAcad.Sci.U.S.A 84, 9238-9242.
Bhatt, A. J., Amin, S. B., Chess, P. R., Watkins, R. H., & Maniscalco, W. M. (2000).
Expression of vascular endothelial growth factor and Flk-1 in developing and
glucocorticoid-treated mouse lung. Pediatric Research 47, 606-613.
Blasi, F. (1997). uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and
chemotactic highways? Immunol.Today 18, 415-417.
Blei, F., Wilson, E. L., Mignatti, P., & Rifkin, D. B. (1993). Mechanism of action of
angiostatic steroids: suppression of plasminogen activator activity via stimulation of
plasminogen activator inhibitor synthesis. J.Cell Physiol 155, 568-578.
Blomme, E. A., Chinn, K. S., Hardy, M. M., Casler, J. J., Kim, S. H., Opsahl, A. C.,
Hall, W. A., Trajkovic, D., Khan, K. N., & Tripp, C. S. (2003). Selective
cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness
incisional wounds in SKH-1 mice. British Journal ofDermatology 148, 211-223.
241
Bohnsack, B. L. & Hirschi, K. K. (2004). Red light, green light: signals that control
endothelial cell proliferation during embryonic vascular development. Cell Cycle 3,
1506-1511.
Bompais, H., Chagraoui, J., Canron, X., Crisan, M., Liu, X. H., Anjo, A., Tolla-Le,
P. C., Leboeuf, M., Charbord, P., Bikfalvi, A., & Uzan, G. (2004). Human
endothelial cells derived from circulating progenitors display specific functional
properties compared with mature vessel wall endothelial cells. Blood 103, 2577-
2584.
Bomstein, P. (2001). Thrombospondins as matricellular modulators of cell function.
J.Clin.Invest 107, 929-934.
Boyden, S. (1962). The chemotactic effect of mixtures of antibody and antigen on
polymorphonuclear leucocytes. J.Exp.Med. 115, 453-466.
Brem, A. S., Bina, R. B., King, T., & Morris, D. J. (1995). Bidirectional activity of
11 (1-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids 60,
406-410.
Brem, A. S., Bina, R. B., King, T. C., & Morris, D. J. (1998). Localization of 2
llbeta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension
31, 459-462.
Brem, H. & Folkman, J. (1975). Inhibition of tumor angiogenesis mediated by
cartilage. J.Exp.Med. 141, 427-439.
Brenner, T., Yamin, A., Abramsky, O., & Gallily, R. (1993). Stimulation of tumor
necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone
in cultured astrocytes. Brain Research 608, 273-279.
Brew, K., Dinakarpandian, D., & Nagase, H. (2000). Tissue inhibitors of
metalloproteinases: evolution, structure and function. Biochim.Biophys.Acta 1477,
267-283.
Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., & Cheresh, D. A.
(1998). Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase
fragment with integrin binding activity. Cell 92, 391-400.
Brown, L. F., Yeo, K. T., Berse, B., Yeo, T. K., Senger, D. R., Dvorak, H. F., & Van
de, W. L. (1992). Expression of vascular permeability factor (vascular endothelial
growth factor) by epidermal keratinocytes during wound healing. J.Exp.Med. 176,
1375-1379.
Brown, R. W., Diaz, R., Robson, A. C., Kotelevtsev, Y. V., Mullins, J. J., Kaufman,
M. H., & Seckl, J. R. (1996). The ontogeny of llbeta-hydroxysteroid dehydrogenase
type 2 and mineralocorticoid receptor gene expression reveal intricate control of
glucocorticoid action in development. Endocrinology 137, 794-797.
242
Bujalska, I., Shimojo, M., Howie, A., & Stewart, P. M. (1997). Human llbeta-
hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms and
localization of the type 2 isozyme within renal tissue. Steroids 62, 77-82.
Bujalska, I. J., Draper, N., Michailidou, Z., Tomlinson, J. W., White, P. C.,
Chapman, K. E., Walker, E. A., & Stewart, P. M. (2005). Hexose-6-phosphate
dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid
dehydrogenase type 1 .Journal ofMolecular Endocrinology 34, 675-684.
Burridge, K., Turner, C. E., & Romer, L. H. (1992). Tyrosine phosphorylation of
paxillin and ppl25FAK accompanies cell adhesion to extracellular matrix: a role in
cytoskeletal assembly. J.Cell Biol. 119, 893-903.
Bussolati, B., Dunk, C., Grohman, M., Kontos, C. D., Mason, J., & Ahmed, A.
(2001). Vascular endothelial growth factor receptor-1 modulates vascular endothelial
growth factor-mediated angiogenesis via nitric oxide. Am.J.Pathol. 159, 993-1008.
Bustin, S. A. (2000). Absolute quantification of mRNA using real-time reverse
transcription polymerase chain reaction assays. Journal ofMolecular Endocrinology
25,169-193.
Bustin, S. A., Benes, V., Nolan, T., & Pfaffl, M. W. (2005). Quantitative real-time
RT-PCR—a perspective. Journal ofMolecular Endocrinology 34, 597-601.
Buttgereit, F., Brink, I., Thiele, B., Burmester, G. R., Hiepe, F., & Hall, E. D. (1995).
Effects of methylprednisolone and 21-aminosteroids on mitogen-induced interleukin-
6 and tumor necrosis factor-alpha production in human peripheral blood
mononuclear cells. Journal of Pharmacology and Experimental Therapeutics 275,
850-853.
Buttgereit, F., da Silva, J. A., Boers, M., Burmester, G. R., Cutolo, M., Jacobs, J.,
Kirwan, J., Kohler, L., Van Riel, P., Vischer, T., & Bijlsma, J. W. (2002).
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment
regimens: current questions and tentative answers in rheumatology. Ann.Rheum.Dis.
61, 718-722.
Buttgereit, F. & Scheffold, A. (2002). Rapid glucocorticoid effects on immune cells.
Steroids 67, 529-534.
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. R. (2004).
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms
of action. Arthritis Rheum. 50, 3408-3417.
Cadepond, F., Schweizer-Groyer, G., Segard-Maurel, I., Jibard, N., Hollenberg, S.
M., Giguere, V., Evans, R. M., & Baulieu, E. E. (1991). Heat shock protein 90 as a
critical factor in maintaining glucocorticosteroid receptor in a nonfunctional state.
Journal ofBiological Chemistry 266, 5834-5841.
243
Cai, T. Q., Wong, B. M., Mundt, S. S., Thieringer, R., Wright, S. D., &
Hermanowski-Vosatka, A. (2001). Induction of llbeta-hydroxysteroid
dehydrogenase type 1 but not type 2 in human aortic smooth muscle cells by
inflammatory stimuli. Journal ofSteroidBiochemistry 77,117-122.
Cariou, R., Harousseau, J. L., & Tobelem, G. (1988). Inhibition of human endothelial
cell proliferation by heparin and steroids. Cell Biol.Int.Rep. 12,1037-1047.
Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat.Med. 6,
389-395.
Carmeliet, P. (2003). Angiogenesis in health and disease. Nat.Med. 9, 653-660.
Carmeliet, P. (2004). Manipulating angiogenesis in medicine. Journal of Internal
Medicine 255, 538-561.
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M.,
Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J.,
Moons, L., Collen, D., Risau, W., & Nagy, A. (1996). Abnormal blood vessel
development and lethality in embryos lacking a single VEGF allele. Nature 380,
435-439.
Carmeliet, P. & Jain, R. K. (2000). Angiogenesis in cancer and other diseases.
Nature 407, 249-257.
Carmeliet, P. & Tessier-Lavigne (2005). Common mechanisms of nerve and blood
vessel wiring. Nature 436,193-200.
Cato, A. C., Nestl, A., & Mink, S. (2002). Rapid actions of steroid receptors in
cellular signaling pathways. Sci.STKE. 2002, RE9.
Cattaneo, M. G., Pola, S., Deho, V., Sanguini, A. M., & Vicentini, L. M. (2003).
Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug
assay. British Journal ofPharmacology 138, 377-385.
Cavallero, C., Di, T. U., Mingazzini, P. L., Nicosia, R., Pericoli, M. N., Sarti, P.,
Spagnoli, L. G., & Villaschi, S. (1976). Cell proliferation in the atherosclerotic
plaques of cholesterol-fed rabbits. Part 3. Histological and radioautographic
observations on glucocorticoids-treated rabbits. Atherosclerosis 25,145-152.
Cervenkova, K., Belejova, M., Vesely, J., Chmela, Z., Rypka, M., Ulrichova, J.,
Modriansky, M., & Maurel, P. (2001). Cell suspensions, cell cultures, and tissue
slices-important metabolic in vitro systems. Biomed.Pap.Med.Fac.Univ
Palacky.Olomouc.Czech.Repub. 145, 57-60.
Chambers, R. C., Leoni, P., Kaminski, N., Laurent, G. J., & Heller, R. A. (2003).
Global expression profiling of fibroblast responses to transforming growth factor-
betal reveals the induction of inhibitor of differentiation-1 and provides evidence of
smooth muscle cell phenotypic switching. Am.J.Pathol. 162, 533-546.
244
Chang, E., Yang, J., Nagavarapu, U., & Herron, G. S. (2002). Aging and survival of
cutaneous microvasculature. J.InvestDermatol. 118, 752-758.
Chen, N. T., Corey, E. J., & Folkman, J. (1988). Potentiation of angiostatic steroids
by a synthetic inhibitor of arylsulfatase. Lab Invest 59, 453-459.
Chen, W. L., Lin, C. T., Yao, C. C., Huang, Y. H., Chou, Y. B., Yin, H. S., & Hu, F.
R. (2006). In-vitro effects of dexamethasone on cellular proliferation, apoptosis, and
Na+-K+-ATPase activity of bovine corneal endothelial cells. Ocul.Immunol.Inflamm.
14, 215-223.
Cheng, S. L., Lai, C. F., Fausto, A., Chellaiah, M., Feng, X., McHugh, K. P.,
Teitelbaum, S. L., Civitelli, R., Hruska, K. A., Ross, F. P., & Avioli, L. V. (2000).
Regulation of alphaVbeta3 and alphaVbeta5 integrins by dexamethasone in normal
human osteoblastic cells. J.Cell Biochem. 77, 265-276.
Cheng, T., Cao, W., Wen, R., Steinberg, R. H., & LaVail, M. M. (1998).
Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast
growth factor mRNA expression in cultured rat Muller cells. Invest
Ophthalmol.Vis.Sci. 39, 581-591.
Christy, C., Hadoke, P. W. F., Paterson, J. M., Mullins, J. J., Seckl, J. R., & Walker,
B. R. (2003). Glucocorticoid action in mouse aorta; localisation of llbeta
Hydroxysteroid dehydrogenase type 2 and effects on response to glucocorticoid in
vitro. Hypertension 42, 580-587.
Clerch, L. B., Baras, A. S., Massaro, G. D., Hoffman, E. P., & Massaro, D. (2004).
DNA microarray analysis of neonatal mouse lung connects regulation of KDR with
dexamethasone-induced inhibition of alveolar formation. AmJ.Physiol Lung Cell
Mol.Physiol 286, L411-L419.
Cole, T. J., Blendy, J. A., Monaghan, A. P., Krieglstein, K., Schmid, W., Aguzzi, A.,
Fantuzzi, G., Hummler, E., Unsicker, K., & Schutz, G. (1995). Targeted disruption
of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development
and severely retards lung maturation. Genes Dev. 9,1608-1621.
Colville-Nash, P. R., Alam, C. A., Appleton, I., Brown, J. R., Seed, M. P., &
Willoughby, D. A. (1995). The pharmacological modulation of angiogenesis in
chronic granulomatous inflammation. Journal of Pharmacology and Experimental
Therapeutics 274,1463-1472.
Conway, E. M., Collen, D., & Carmeliet, P. (2001). Molecular mechanisms of blood
vessel growth. Cardiovascular Research 49, 507-521.
Conway, E. M., Zwerts, F., Van, E., V, DeVriese, A., Nagai, N., Luo, W., & Collen,
D. (2003). Survivin-dependent angiogenesis in ischemic brain: molecular
mechanisms of hypoxia-induced up-regulation. AmJ.Pathol. 163, 935-946.
245
Coomber, B. L. & Gotlieb, A. I. (1990). In vitro endothelial wound repair.
Interaction of cell migration and proliferation. Arteriosclerosis 10, 215-222.
Criscuolo, G. R. & Balledux, J. P. (1996). Clinical neurosciences in the decade of the
brain: hypotheses in neuro-oncology. VEG/PF acts upon the actin cytoskeleton and is
inhibited by dexamethasone: relevance to tumor angiogenesis and vasogenic edema.
YaleJ.Biol.Med. 69, 337-355.
Crofford, L. J., Wilder, R. L., Ristimaki, A. P., Sano, H., Remmers, E. F., Epps, H.
R., & Hla, T. (1994). Cyclooxygenase-1 and -2 expression in rheumatoid synovial
tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J.Clin.Invest
93,1095-1101.
Cronstein, B. N., Kimmel, S. C., Levin, R. I., Martiniuk, F., & Weissmann, G.
(1992). A mechanism for the antiinflammatory effects of corticosteroids: the
glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and
expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion
molecule 1. Proc.NatlAcad.Sci.U.SA 89, 9991-9995.
Crottogini, A., Meckert, P. C., Vera, J. G., Lascano, E., Negroni, J., Del Valle, H.,
Dulbecco, E., Werba, P., Cuniberti, L., Martinez, V., De Lorenzi, A., Telayna, J.,
Mele, A., Fernandez, J. L., Marangunich, L., Criscuolo, M., Capogrossi, M. C., &
Laguens, R. (2003). Arteriogenesis induced by intramyocardial vascular endothelial
growth factor 165 gene transfer in chronically ischemic pigs. Hum.Gene Ther. 14,
1307-1318.
Croxtall, J. D., Choudhury, Q., & Flower, R. J. (2000). Glucocorticoids act within
minutes to inhibit recruitment of signalling factors to activated EGF receptors
through a receptor-dependent, transcription-independent mechanism. British Journal
ofPharmacology 130, 289-298.
Crum, R., Szabo, S., & Folkman, J. (1985). A new class of steroids inhibits
angiogenesis in the presence of heparin or a heparin fragment. Science 230, 1375-
1378.
Cuda, G., Paterno, R., Ceravolo, R., Candigliota, M., Perrotti, N., Perticone, F.,
Faniello, M. C., Schepis, F., Ruocco, A., Mele, E., Cassano, S., Bifulco, M., Santillo,
M., & Avvedimento, E. V. (2002). Protection of human endothelial cells from
oxidative stress: role of Ras-ERKl/2 signaling. Circulation 105, 968-974.
Cushing, H. (1912). The pituitary body and its disorders, pp. 217. Lippincott,
Philadelphia and London.
D'Amico, D. J., Goldberg, M. F., Hudson, H., Jerdan, J. A., Krueger, D. S., Luna, S.
P., Robertson, S. M., Russell, S., Singerman, L., Slakter, J. S., Yannuzzi, L., &
Zilliox, P. (2003). Anecortave acetate as monotherapy for treatment of subfoveal
neovascularization in age-related ...acular degeneration: twelve-month clinical
outcomes. Ophthalmology 110, 2372-2383.
246
Da Silva, M. S., Siddiqui, J., Halverson, A., Wilasrusmee, C., Bruch, D., & Kittur, D.
S. (2003). betal-integrin-ligand disengagement induces in vitro capillary tube
disruption mediated by p38 MAPK activity. Surgery 134,164-168.
Danis, R. P., Ciulla, T. A., Pratt, L. M., & Anliker, W. (2000). Intravitreal
triamcinolone acetonide in exudative age-related macular degeneration. Retina 20,
244-250.
Davis, G. E., Bayless, K. J., & Mavila, A. (2002). Molecular basis of endothelial cell
morphogenesis in three-dimensional extracellular matrices. Anat.Rec. 268, 252-275.
Davis, G. E. & Camarillo, C. W. (1995). Regulation of endothelial cell
morphogenesis by integrins, mechanical forces, and matrix guidance pathways.
Exp.Cell Res. 216,113-123.
Davis, G. E. & Senger, D. R. (2005). Endothelial extracellular matrix: biosynthesis,
remodeling, and functions during vascular morphogenesis and neovessel
stabilization. Circulation Research 97,1093-1107.
Dawson, D. W., Pearce, S. F., Zhong, R., Silverstein, R. L., Frazier, W. A., & Bouck,
N. P. (1997). CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on
endothelial cells. J.Cell Biol. 138, 707-717.
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003). The interplay
between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1:
molecular mechanisms for gene repression. Endocrine Reviews 24, 488-522.
De Clerck, L. S., Bridts, C. H., Mertens, A. M., Moens, M. M., & Stevens, W. J.
(1994). Use of fluorescent dyes in the determination of adherence of human
leucocytes to endothelial cells and the effect of fluorochromes on cellular function.
J.Immunol.Methods 172, 115-124.
De Gendt, C. M., De Clerck, L. S., Bridts, C. H., & Stevens, W. J. (1996). The use of
calcein acetomethylester (AM)-labelled polymorphonuclear cells in a polycarbonate
filter chemotaxis assay. Clinica Chimica Acta 249,189-195.
de la Torre, J. C. (2004). Is Alzheimer's disease a neurodegenerative or a vascular
disorder? Data, dogma, and dialectics. Lancet Neurol. 3,184-190.
de Muinck, E. D. & Simons, M. (2004). Re-evaluating therapeutic
neovascularization. Journal ofMolecular and Cellular Cardiology 36, 25-32.
Dean, P. N., Dolbeare, F., Gratzner, H., Rice, G. C., & Gray, J. W. (1984). Cell-cycle
analysis using a monoclonal antibody to BrdUrd. Cell Tissue Kinet. 17, 427-436.
Derbyshire, E. J., Yang, Y. C., Li, S., Comin, G. A., Belloir, J., & Thorpe, P. E.
(1996). Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid
activities inhibit the proliferation of vascular endothelial cells. Biochim.Biophys.Acta
1310, 86-96.
247
Desai, A., Victor-Vega, C., Gadangi, S., Montesinos, M. C., Chu, C. C., & Cronstein,
B. N. (2005). Adenosine A2A receptor stimulation increases angiogenesis by down-
regulating production of the antiangiogenic matrix protein thrombospondin 1.
Mol.Pharmacol. 67, 1406-1413.
DiPietro, L. A., Nebgen, D. R., & Polverini, P. J. (1994). Downregulation of
endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J.Vasc.Res. 31,
178-185.
Distler, J. H., Hirth, A., Kurowska-Stolarska, M., Gay, R. E., Gay, S., & Distler, O.
(2003). Angiogenic and angiostatic factors in the molecular control of angiogenesis.
QJ.Nucl.Med. 47,149-161.
Dolle, J. P., Rezvan, A., Allen, F. D., Lazarovici, P., & Lelkes, P. I. (2005). Nerve
growth factor-induced migration of endothelial cells. Journal of Pharmacology and
Experimental Therapeutics 315, 1220-1227.
Donovan, D., Brown, N. J., Bishop, E. T., & Lewis, C. E. (2001). Comparison of
three in vitro human 'angiogenesis' assays with capillaries formed in vivo.
Angiogenesis. 4, 113-121.
»
Dostert, A. & Heinzel, T. (2004). Negative glucocorticoid receptor response
elements and their role in glucocorticoid action. Curr.Pharm.Des 10, 2807-2816.
Dou, L., Bertrand, E., Cerini, C., Faure, V., Sampol, J., Vanholder, R., Berland, Y.,
& Brunet, P. (2004). The uremic solutes p-cresol and indoxyl sulfate inhibit
endothelial proliferation and wound repair. Kidney International 65, 442-451.
Dover, A. R., Hadoke, P. W., Macdonald, L. J., Miller, E., Newby, D. E., & Walker,
B. R. (2007). Intravascular glucocorticoid metabolism during inflammation and
injury in mice. Endocrinology 148, 166-172.
Drouin, J., Sun, Y. L., Chamberland, M., Gauthier, Y., De Lean, A., Nemer, M., &
Schmidt, T. J. (1993). Novel glucocorticoid receptor complex with DNA element of
the hormone-repressed POMC gene. EMBOJ. 12, 145-156.
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S.,
Zimmermann, J., & Lydon, N. B. (1996). Effects of a selective inhibitor of the Abl
tyrosine kinase on the growth of Bcr-Abl positive cells. Nat.Med. 2, 561-566.
Dumont, D. J., Yamaguchi, T. P., Conlon, R. A., Rossant, J., & Breitman, M. L.
(1992). tek, a novel tyrosine kinase gene located on mouse chromosome 4, is
expressed in endothelial cells and their presumptive precursors. Oncogene 7, 1471-
1480.
Dupuy, E., Habib, A., Lebret, M., Yang, R., Levy-Toledano, S., & Tobelem, G.
(2003). Thrombin induces angiogenesis and vascular endothelial growth factor
expression in human endothelial cells: possible relevance to HIF-1alpha.
J.Thromh.Haemost. 1,1096-1102.
248
Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A.,
Manseau, E. J., Van de, W. L., & Senger, D. R. (1991). Distribution of vascular
permeability factor (vascular endothelial growth factor) in tumors: concentration in
tumor blood vessels. J.Exp.Med. 174,1275-1278.
Ear, T., Giguere, P., Fleury, A., Stankova, J., Payet, M. D., & Dupuis, G. (2001).
High efficiency transient transfection of genes in human umbilical vein endothelial
cells by electroporation. J.Immunol.Methods 257, 41-49.
Ebrahem, Q., Minamoto, A., Hoppe, G., Anand-Apte, B., & Sears, J. E. (2006).
Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream
of the IL-6 and VEGF receptors. Invest Ophthalmol.Vis.Sci. 47, 4935-4941.
Edwards, C. R. W., Stewart, P. M., Burt, D., Brett, L., Mclntyre, M. A., Sutanto, W.
S., DeKloet, E. R., & Monder, C. (1988). Localisation of 11p-hydroxysteroid
dehydrogenase- tissue specific protector of the mineralocorticoid receptor. Lancet ii,
986-989.
Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A.
(1999). Selective requirement for Src kinases during VEGF-induced angiogenesis
and vascular permeability. Mol.Cell 4, 915-924.
English, D., Welch, Z., Kovala, A. T., Harvey, K., Volpert, O. V., Brindley, D. N., &
Garcia, J. G. (2000). Sphingosine 1-phosphate released from platelets during clotting
accounts for the potent endothelial cell chemotactic activity of blood serum and
provides a novel link between hemostasis and angiogenesis. FASEB Journal 14,
2255-2265.
Entschladen, F., Drell, T. L., Lang, K., Masur, K., Palm, D., Bastian, P., Niggemann,
B., & Zaenker, K. S. (2005). Analysis methods of human cell migration. Exp.Cell
Res. 307, 418-426.
Eriksson, U. & Alitalo, K. (1999). Structure, expression and receptor-binding
properties of novel vascular endothelial growth factors.
Curr.Top.Microbiol.Immunol. 237, 41-57.
Erzurum, V. Z., Bian, J. F., Husak, V. A., Ellinger, J., Xue, L., Burgess, W. H., &
Greisler, H. P. (2003). R136K fibroblast growth factor-1 mutant induces heparin-
independent migration of endothelial cells through fibrin glue. J.Vasc.Surg. 37,
1075-1081.
Espey, L. L., Yoshioka, S., Russell, D. L., Robker, R. L., Fujii, S., & Richards, J. S.
(2000). Ovarian expression of a disintegrin and metalloproteinase with
thrombospondin motifs during ovulation in the gonadotropin-primed immature rat.
Biol.Reprod. 62, 1090-1095.
Falk, W., Goodwin, R. H., Jr., & Leonard, E. J. (1980). A 48-well micro chemotaxis
assembly for rapid and accurate measurement of leukocyte migration.
J.Immunol.Methods 33, 239-247.
249
Falkenstein, E., Norman, A. W., & Wehling, M. (2000). Mannheim classification of
nongenomically initiated (rapid) steroid action(s). J.Clin.Endocrinol.Metab 85, 2072-
2075.
Feraud, O., Mallet, C., & Vilgrain, I. (2003). Expressional regulation of the
angiopoietin-1 and -2 and the endothelial-specific receptor tyrosine kinase Tie2 in
adrenal atrophy: a study of adrenocorticotropin-induced repair. Endocrinology 144,
4607-4615.
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003). The biology of VEGF and its
receptors. NatureMedicine 9, 669-676.
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-
Braxton, L., Hillan, K. J., & Moore, M. W. (1996). Heterozygous embryonic lethality
induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
Ferrara, N. & Davis-Smyth, T. (1997). The biology of vascular endothelial growth
factor. Endocrine Reviews 18, 4-25.
Ferrara, N. & Henzel, W. J. (1989). Pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular endothelial cells. Biochemical and
Biophysical Research Communications 161, 851-858.
Flugel-Koch, C., Ohlmann, A., Fuchshofer, R., Welge-Lussen, U., & Tamm, E. R.
(2004). Thrombospondin-1 in the trabecular meshwork: localization in normal and
glaucomatous eyes, and induction by TGF-betal and dexamethasone in vitro.
Exp.Eye Res. 79, 649-663.
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. New England
Journal ofMedicine 285,1182-1186.
Folkman, J. (2001). Angiogenesis. In Principles of Internal Medicine, eds.
Braunwald, E., Hauser, S. L., Fauci, A. C., Longo, D. L., Jameson J.L., & Kasper
D.L., pp. 517-530. McGraw-Hill, New York.
Folkman, J. & D'Amore, P. A. (1996). Blood vessel formation: what is its molecular
basis? Cell 87,1153-1155.
Folkman, J. & Ingber, D. E. (1987). Angiostatic steroids. Method of discovery and
mechanism of action. Annals ofSurgery 206, 374-383.
Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C., & Taylor, S. (1983).
Angiogenesis inhibition and tumor regression caused by heparin or a heparin
fragment in the presence of cortisone. Science 221, 719-725.
Folkman, J. & Moscona, A. (1978). Role of cell shape in growth control. Nature 273,
345-349.
250
Fong, G. H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995). Role of the Flt-
1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.
Nature 376, 66-70.
Form, D. M. & Auerbach, R. (1983). PGE2 and angiogenesis. Proceedings of the
Society ofExperimental Biology andMedicine 172, 214-218.
Forster, C., Kahles, T., Kietz, S., & Drenckhahn, D. (2007). Dexamethasone induces
the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular
endothelial cell line cEND. J.Physiol 580, 937-949.
Freedman, N. D. & Yamamoto, K. R. (2004). Importin 7 and importin alpha/importin
beta are nuclear import receptors for the glucocorticoid receptor. Mol.Biol.Cell 15,
2276-2286.
Frevert, C. W., Wong, V. A., Goodman, R. B., Goodwin, R., & Martin, T. R. (1998).
Rapid fluorescence-based measurement of neutrophil migration in vitro.
J.Immunol.Methods 213, 41-52.
Fukuda, R., Kelly, B., & Semenza, G. L. (2003). Vascular endothelial growth factor
gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by
hypoxia-inducible factor 1. Cancer Research 63, 2330-2334.
Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T.
F., Papapetropoulos, A., & Sessa, W. C. (1999). Regulation of endothelium-derived
nitric oxide production by the protein kinase Akt. Nature 399, 597-601.
Gale, N. W. & Yancopoulos, G. D. (1999). Growth factors acting via endothelial
cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular
development. Genes Dev. 13,1055-1066.
Gallicchio, M., Mitola, S., Valdembri, D., Fantozzi, R., Varnum, B., Avanzi, G. C.,
& Bussolino, F. (2005). Inhibition of vascular endothelial growth factor receptor 2-
mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105,
1970-1976.
Gallicchio, M., Rosa, A. C., Benetti, E., Collino, M., Dianzani, C., & Fantozzi, R.
(2006). Substance P-induced cyclooxygenase-2 expression in human umbilical vein
endothelial cells. British Journal ofPharmacology 147, 681-689.
Garcia-Gras, E. A., Chi, P., & Thompson, E. A. (2000). Glucocorticoid-mediated
destabilization of cyclin D3 mRNA involves RNA-protein interactions in the 3'-
untranslated region of the mRNA. Journal of Biological Chemistry 275, 22001-
22008.
Gentilini, G., Kirschbaum, N. E., Augustine, J. A., Aster, R. H., & Visentin, G. P.
(1999). Inhibition of human umbilical vein endothelial cell proliferation by the CXC
chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of
p21(Cipl/WAFl). Blood 93, 25-33.
251
Gerber, H. P., Dixit, V., & Ferrara, N. (1998a). Vascular endothelial growth factor
induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial
cells. Journal ofBiological Chemistry 273, 13313-13316.
Gerber, H. P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G. A., Rangell, L.,
Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999). VEGF is required for
growth and survival in neonatal mice. Development 126,1149-1159.
Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., &
Ferrara, N. (1998b). Vascular endothelial growth factor regulates endothelial cell
survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.
Requirement for Flk-l/KDR activation. Journal ofBiological Chemistry 273, 30336-
30343.
Ghosh, A. K., Hirasawa, N., Niki, H., & Ohuchi, K. (2000). Cyclooxygenase-2-
mediated angiogenesis in carrageenin-induced granulation tissue in rats. Journal of
Pharmacology andExperimental Therapeutics 295, 802-809.
Gille, J., Reisinger, K., Westphal-Varghese, B., & Kaufmann, R. (2001). Decreased
mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular
endothelial growth factor gene expression by cultured keratinocytes. J.Invest
Dermatol. 117, 1581-1587.
Glesne, D. A., Zhang, W., Mandava, S., Ursos, L., Buell, M. E., Makowski, L., &
Rodi, D. J. (2006). Subtractive transcriptomics: establishing polarity drives in vitro
human endothelial morphogenesis. Cancer Research 66, 4030-4040.
Gonzalez, M. V., Gonzalez-Sancho, J. M., Caelles, C., Munoz, A., & Jimenez, B.
(1999). Hormone-activated nuclear receptors inhibit the stimulation of the JNK and
ERK signalling pathways in endothelial cells. FEBS Lett. 459, 272-276.
Gordon, C. B., Li, D. G., Stagg, C. A., Manson, P., & Udelsman, R. (1994). Impaired
wound healing in Cushing's syndrome: the role of heat shock proteins. Surgery 116,
1082-1087.
Goulding NJ & Flower, R. J. (2001). Glucocorticoids: Milestones in drug therapy,
pp. 5. Springer-Verlag Telos.
Goulding, N. J. (2004). The molecular complexity of glucocorticoid actions in
inflammation - a four-ring circus. Curr.Opin.Pharmacol. 4, 629-636.
Grant, D. S., Kinsella, J. L., Fridman, R., Auerbach, R., Piasecki, B. A., Yamada, Y.,
Zain, M., & Kleinman, H. K. (1992). Interaction of endothelial cells with a laminin A
chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo.
J.Cell Physiol 153, 614-625.
Grant, D. S., Lelkes, P. I., Fukude K., & Kleinman, H. K. (1991). Intracellular
mechanisms involved in basement membrane induced blood vessel differentiation in
vitro. In Vitro Cell Dev.Biol. 27A, 327-336.
252
Grant, D. S., Tashiro, K., Segui-Real, B., Yamada, Y., Martin, G. R., & Kleinman,
H. K. (1989). Two different laminin domains mediate the differentiation of human
endothelial cells into capillary-like structures in vitro. Cell 58, 933-943.
Green, J. P. (1965). Steroid Therapy and Wound Healing in Surgical Patients. British
Journal ofSurgery 52, 523-525.
Greenwood, J. A. & Murphy-Ullrich, J. E. (1998). Signaling of de-adhesion in
cellular regulation and motility. Microsc.Res.Tech. 43, 420-432.
Greenwood, J. A., Pallero, M. A., Theibert, A. B., & Murphy-Ullrich, J. E. (1998).
Thrombospondin signaling of focal adhesion disassembly requires activation of
phosphoinositide 3-kinase. Journal ofBiological Chemistry 273, 1755-1763.
Gridley, T. (2007). Notch signaling in vascular development and physiology.
Development 134, 2709-2718.
Griffoni, C., Spisni, E., Santi, S., Riccio, M., Guarnieri, T., & Tomasi, V. (2000).
Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in
vitro and in vivo. Biochemical and Biophysical Research Communications 276, 756-
761.
Grose, R., Werner, S., Kessler, D., Tuckermann, J., Huggel, K., Durka, S., Reichardt,
H. M., & Werner, S. (2002). A role for endogenous glucocorticoids in wound repair.
EMBORep. 3,575-582.
Grotendorst, G. R. (1987). Spectrophotometric assay for the quantitation of cell
migration in the Boyden chamber chemotaxis assay. Methods Enzymol. 147, 144-
152.
Grove, A. D., Prabhu, V. V., Young, B. L., Lee, F. C., Kulpa, V., Munson, P. J., &
Kohn, E. C. (2002). Both protein activation and gene expression are involved in early
vascular tube formation in vitro. Clin.Cancer Res. 8, 3019-3026.
Gumina, R. J., Kirschbaum, N. E., Piotrowski, K., & Newman, P. J. (1997).
Characterization of the human platelet/endothelial cell adhesion molecule-1
promoter: identification of a GATA-2 binding element required for optimal
transcriptional activity. Blood 89,1260-1269.
Hadoke, P. W., Macdonald, L., Logie, J. J., Small, G. R., Dover, A. R., & Walker, B.
R. (2006). Intra-vascular glucocorticoid metabolism as a modulator of vascular
structure and function. CellMol.Life Sci. 63, 565-578.
Hadoke, P. W. F., Christy, C., Kotelevtsev, Y. V., Williams, B. C., Kenyon, C. J.,
Seckl, J. R., Mullins, J. J., & Walker, B. R. (2001). Endothelial cell dysfunction in
mice after transgenic knockout of type 2, but not type 1, 11 (l-hydroxysteroid
dehydrogenase. Circulation 104, 2832-2837.
253
Hafezi-Moghadam, A., Simoncini, T., Yang, E., Limbourg, F. P., Plumier, J. C.,
Rebsamen, M. C., Hsieh, C. M., Chui, D. S., Thomas, K. L., Prorock, A. J., Laubach,
V. E., Moskowitz, M. A., French, B. A., Ley, K., & Liao, J. K. (2002). Acute
cardiovascular protective effects of corticosteroids are mediated by non-
transcriptional activation of endothelial nitric oxide synthase. Nat.Med. 8, 473-479.
Hammond, G. L., Smith, C. L., Paterson, N. A. M., & Sibbald, W. J. (1990). A role
for corticosteroid-binding globulin in delivery of Cortisol to activated neutrophils.
Journal ofClinical Endocrinology andMetabolism 71, 34-39.
Hanahan, D. (1997). Signaling vascular morphogenesis and maintenance. Science
211, 48-50.
Hanahan, D. & Folkman, J. (1996). Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell 86, 353-364.
Harada, S., Nagy, J. A., Sullivan, K. A., Thomas, K. A., Endo, N., Rodan, G. A., &
Rodan, S. B. (1994). Induction of vascular endothelial growth factor expression by
prostaglandin E2 and El in osteoblasts. J.Clin.Invest 93, 2490-2496.
Harper, J. & Moses, M. A. (2006). Molecular regulation of tumor angiogenesis:
mechanisms and therapeutic implications. EXS 223-268.
Harrington, L. S., Sainson, R. C., Williams, C. K., Taylor, J. M., Shi, W., Li, J. L., &
Harris, A. L. (2007). Regulation of multiple angiogenic pathways by D114 and Notch
in human umbilical vein endothelial cells. Microvascular Research.
Hasan, Q., Tan, S. T., Gush, J., Peters, S. G., & Davis, P. F. (2000). Steroid therapy
of a proliferating hemangioma: histochemical and molecular changes. Pediatrics
105,117-120.
Hasan, Q., Tan, S. T., Xu, B., & Davis, P. F. (2003). Effects of five commonly used
glucocorticoids on haemangioma in vitro. Clin.Exp.Pharmacol.Physiol 30,140-144.
Hashimoto, I., Nakanishi, H., Shono, Y., Toda, M., Tsuda, H., & Arase, S. (2002).
Angiostatic effects of corticosteroid on wound healing of the rabbit ear. J.Med.Invest
49, 61-66.
Hatakeyama, H., Inaba, S., & Miyamori, I. (1999). llbeta-Hydroxysteroid
dehydrogenase in cultured human vascular cells: Possible role in the development of
hypertension. Hypertension 33,1179-1184.
Hatakeyama, H., Miyamori, I., Fujita, T., Takeda, Y., Takeda, R., & Yamamoto, H.
(1994). Vascular aldosterone. Biosynthesis and a link to angiotensin Il-induced
hypertrophy of vascular smooth muscle cells. Journal of Biological Chemistry 269,
24316-24320.
254
Heffernan, J. T., Futterman, S., & Kalina, R. E. (1978). Dexamethasone inhibition of
experimental endothelial cell proliferation in retinal venules. Invest
Ophthalmol.Vis.Sci. 17, 565-568.
Hellstrom, M., Phng, L. K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P.,
Alva, J., Nilsson, A. K., Karlsson, L., Gaiano, N., Yoon, K., Rossant, J., Iruela-
Arispe, M. L., Kalen, M., Gerhardt, H., & Betsholtz, C. (2007). D114 signalling
through Notchl regulates formation of tip cells during angiogenesis. Nature 445,
776-780.
Hembruff, S. L., Villeneuve, D. J., & Parissenti, A. M. (2005). The optimization of
quantitative reverse transcription PCR for verification of cDNA microarray data.
Anal.Biochem. 345, 237-249.
Hench, P. (1950). Effects of cortisone in the rheumatic diseases. Lancet 2, 483-484.
Henry, S. P., Marcusson, E. G., Vincent, T. M., & Dean, N. M. (2004). Setting sights
on the treatment of ocular angiogenesis using antisense oligonucleotides. Trends in
Pharmacological Sciences 25, 523-527.
Hermann, C., Assmus, B., Urbich, C., Zeiher, A. M., & Dimmeler, S. (2000).
Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling
cascade for endothelial cells. Arterioscler.Thromb.Vasc.Biol. 20, 402-409.
Herve, M. A., Buteau-Lozano, H., Mourah, S., Calvo, F., & Perrot-Applanat, M.
(2005). VEGF189 stimulates endothelial cells proliferation and migration in vitro
and up-regulates the expression of Flk-l/KDR mRNA. Exp.Cell Res. 309, 24-31.
Heymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L.,
Dyspersin, G. D., Cleutjens, J. P., Shipley, M., Angellilo, A., Levi, M., Nube, O.,
Baker, A., Keshet, E., Lupu, F., Herbert, J. M., Smits, J. F., Shapiro, S. D., Baes, M.,
Borgers, M., Collen, D., Daemen, M. J., & Carmeliet, P. (1999). Inhibition of
plasminogen activators or matrix metalloproteinases prevents cardiac rupture but
impairs therapeutic angiogenesis and causes cardiac failure. Nat.Med. 5,1135-1142.
Hirata, A., Ogawa, S., Kometani, T., Kuwano, T., Naito, S., Kuwano, M., & Ono, M.
(2002). ZD1839 (Iressa) induces antiangiogenic effects through inhibition of
epidermal growth factor receptor tyrosine kinase. Cancer Research 62, 2554-2560.
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., & Shibuya, M. (1998). Flt-1 lacking
the tyrosine kinase domain is sufficient for normal development and angiogenesis in
mice. Proc.Natl.Acad.Sci.U.S.A 95, 9349-9354.
Hofbauer, R., Gmeiner, B., Handler, S., Speiser, W., Kapiotis, S., & Frass, M.
(1999). Dexamethasone inhibits leukocyte migration through endothelial cells
towards smooth muscle cells. Life Sciences 64, 671-679.
Hooper, C. Y. & Guymer, R. H. (2003). New treatments in age-related macular
degeneration. Clin.Experiment.Ophthalmol. 31, 376-391.
255
Hori, Y., Hu, D. E., Yasui, K., Smither, R. L., Gresham, G. A., & Fan, T. P. (1996).
Differential effects of angiostatic steroids and dexamethasone on angiogenesis and
cytokine levels in rat sponge implants. British Journal of Pharmacology 118, 1584-
1591.
Horiuchi, K., Umetani, M., Minami, T., Okayama, H., Takada, S., Yamamoto, M.,
Aburatani, H., Reid, P. C., Housman, D. E., Hamakubo, T., & Kodama, T. (2006).
Wilms' tumor 1-associating protein regulates G2/M transition through stabilization of
cyclin A2 mRNA. Proc.NatLAcad.Sci.U.SA 103,17278-17283.
Hotchkiss, K. A., Ashton, A. W., Mahmood, R., Russell, R. G., Sparano, J. A., &
Schwartz, E. L. (2002). Inhibition of endothelial cell function in vitro and
angiogenesis in vivo by docetaxel (Taxotere): association with impaired
repositioning of the microtubule organizing center. Mol.Cancer Ther. 1,1191-1200.
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992). Dual
regulation of vascular endothelial growth factor bioavailability by genetic and
proteolytic mechanisms. Journal ofBiological Chemistry 267, 26031-26037.
Huang, W. L., Harper, C. G., Evans, S. F., Newnham, J. P., & Dunlop, S. A. (2001).
Repeated prenatal corticosteroid administration delays astrocyte and capillary tight
junction maturation in fetal sheep. IntJ.Dev.Neurosci. 19, 487-493.
Humphries, M. J. (2000). Integrin structure. Biochem.Soc.Trans. 28, 311-339.
Ilic, D., Kovacic, B., McDonagh, S., Jin, F., Baumbusch, C., Gardner, D. G., &
Damsky, C. H. (2003). Focal adhesion kinase is required for blood vessel
morphogenesis. Circulation Research 92, 300-307.
Illanes, J., Dabancens, A., Acuna, O., Fuenzalida, M., Guerrero, A., Lopez, C., &
Lemus, D. (2002). Effects of betamethasone, sulindac and quinacrine drugs on the
inflammatory neoangiogenesis response induced by polyurethane sponge implanted
in mouse. Biol.Res. 35, 339-345.
Ingber, D. & Folkman, J. (1988). Inhibition of angiogenesis through modulation of
collagen metabolism. Lab Invest 59, 44-51.
Inoue, H., Umesono, K., Nishimori, T., Hirata, Y., & Tanabe, T. (1999).
Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-
2 gene is modulated by expression of its receptor in vascular endothelial cells.
Biochemical andBiophysical Research Communications 254, 292-298.
Iruela-Arispe, M. L., Bornstein, P., & Sage, H. (1991). Thrombospondin exerts an
antiangiogenic effect on cord formation by endothelial cells in vitro.
Proc.Natl.Acad.Sci. U.S.A 88, 5026-5030.
Iruela-Arispe, M. L., Lombardo, M., Krutzsch, H. C., Lawler, J., & Roberts, D. D.
(1999). Inhibition of angiogenesis by thrombospondin-1 is mediated by 2
independent regions within the type 1 repeats. Circulation 100,1423-1431.
256
Iruela-Arispe, M. L., Porter, P., Bornstein, P., & Sage, E. H. (1996).
Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the
human endometrium. J.Clin.Invest 97, 403-412.
Ischenko, I., Guba, M., Yezhelyev, M., Papyan, A., Schmid, G., Green, T., Fennell,
M., Jauch, K. W., & Bruns, C. J. (2007). Effect of Src kinase inhibition on metastasis
and tumor angiogenesis in human pancreatic cancer. Angiogenesis. 10,167-182.
Isenberg, J. S., Ridnour, L. A., Thomas, D. D., Wink, D. A., Roberts, D. D., &
Espey, M. G. (2006). Guanylyl cyclase-dependent chemotaxis of endothelial cells in
response to nitric oxide gradients. Free Radic.Biol.Med. 40,1028-1033.
Ishibashi, T., Miki, K., Sorgente, N., Patterson, R., & Ryan, S. J. (1985). Effects of
intravitreal administration of steroids on experimental subretinal neovascularization
in the subhuman primate. Arch.Ophthalmol. 103, 708-711.
Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield,
K., Razvi, S., Walsh, K., & Symes, J. F. (1996). Clinical evidence of angiogenesis
after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet
348, 370-374.
Izumi, Y., Xu, L., di, T. E., Fukumura, D., & Jain, R. K. (2002). Tumour biology:
herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280.
Jackson, C. J. & Nguyen, M. (1997). Human microvascular endothelial cells differ
from macrovascular endothelial cells in their expression of matrix
metalloproteinases. IntJ.Biochem.CellBiol. 29,1167-1177.
Jaffe, E. A., Nachman, R. L., Becker, C. G., & Minick, C. R. (1973). Culture of
human endothelial cells derived from umbilical veins. Identification by morphologic
and immunologic criteria. J.Clin.Invest 52, 2745-2756.
Jahroudi, N. & Lynch, D. C. (1994). Endothelial-cell-specific regulation of von
Willebrand factor gene expression. Mol.Cell Biol. 14, 999-1008.
Jain, R. K. (2003). Molecular regulation of vessel maturation. Nat.Med. 9, 685-693.
Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R. (2007).
Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a
potential strategy for plaque stabilization. Nat.Clin.Pract.Cardiovasc.Med. 4, 491-
502.
Jakkula, M., Le Cras, T. D., Gebb, S., Hirth, K. P., Tuder, R. M., Voelkel, N. F., &
Abman, S. H. (2000). Inhibition of angiogenesis decreases alveolarization in the
developing rat lung. AmJ.Physiol Lung Cell Mol.Physiol 279, L600-L607.
257
Jamieson, P. M., Chapman, K. E., Edwards, C. R. W., & Seckl, J. R. (1995). 11(3-
Hydroxysteroid dehydrogenase is an exclusive lip-reductase in primary cultures of
rat hepatocytes: effect of physicochemical and hormonal manipulations.
Endocrinology 136, 4754-4761.
Jee, B. K., Surendran, S., Park, K. M., Lee, W. K., Han, C. W., Kim, Y. Y.,
Patinharayil, G., Kim, Y. H., & Lee, K. H. (2007). Role of tumor necrosis factor-
alpha, interleukin-8, and dexamethasone in the focal adhesion kinase expression by
human nucleus pulposus cells. Spine 32, 30-35.
Jeon, J. W., Lee, S. J., Kim, J. B., Kang, J. J., Lee, J. H., Seong, G. J., & Kim, E. K.
(2003). Cellular proliferative effect of dexamethasone in immortalized trabecular
meshwork cell (TM5) line. YonseiMedJ. 44, 299-306.
Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., &
Bouck, N. (2000). Signals leading to apoptosis-dependent inhibition of
neovascularization by thrombospondin-1. Nat.Med. 6, 41-48.
Johns, D. G., Dorrance, A. M., Tramontini, N. L., & Webb, R. C. (2001).
Glucocorticoids inhibit tetrahydrobiopterin-dependent endothelial function.
Experimental Biology and Medicine 226, 27-31.
Jones, M. K., Kawanaka, H., Baatar, D., Szabo, I. L., Tsugawa, K., Pai, R., Koh, G.
Y., Kim, I., Sarfeh, I. J., & Tamawski, A. S. (2001). Gene therapy for gastric ulcers
with single local injection of naked DNA encoding VEGF and angiopoietin-1.
Gastroenterology 121, 1040-1047.
Kanno, S., Oda, N., Abe, M., Terai, Y., Ito, M., Shitara, K., Tabayashi, K., Shibuya,
M., & Sato, Y. (2000). Roles of two VEGF receptors, Flt-1 and KDR, in the signal
transduction of VEGF effects in human vascular endothelial cells. Oncogene 19,
2138-2146.
Kasahara, Y., Tuder, R. M., Taraseviciene-Stewart, L., Le Cras, T. D., Abman, S.,
Hirth, P. K., Waltenberger, J., & Voelkel, N. F. (2000). Inhibition of VEGF receptors
causes lung cell apoptosis and emphysema. J.Clin.Invest 106,1311-1319.
Kasselman, L. J., Kintner, J., Sideris, A., Pasnikowski, E., Krellman, J. W., Shah, S.,
Rudge, J. S., Yancopoulos, G. D., Wiegand, S. J., & Croll, S. D. (2007).
Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced
angiogenesis in adult brain. J.Vasc.Res. 44, 283-291.
Kataoka, S., Kudo, A., Hirano, H., Kawakami, H., Kawano, T., Higashihara, E.,
Tanaka, H., Delarue, F., Sraer, J. D., Mune, T., Krozowski, Z. S., & Yan, K. (2002).
llbeta-hydroxysteroid dehydrogenase type 2 is expressed in the human kidney
glomerulus. J.Clin.Endocrinol.Metab 87, 877-882.
258
Kawasaki, J., Hirano, K., Hirano, M., Nishimura, J., Nakatsuka, A., Fujishima, M., &
Kanaide, H. (2000). Dissociation between the Ca(2+) signal and tube formation
induced by vascular endothelial growth factor in bovine aortic endothelial cells.
European Journal ofPharmacology 398,19-29.
Kim, I., Kim, H. G., Moon, S. O., Chae, S. W., So, J. N., Koh, K. N., Ahn, B. C., &
Koh, G. Y. (2000). Angiopoietin-1 induces endothelial cell sprouting through the
activation of focal adhesion kinase and plasmin secretion. Circ.Res. 86, 952-959.
Kim, Y. M., Kim, Y. M., Lee, Y. M., Kim, H. S., Kim, J. D., Choi, Y., Kim, K. W.,
Lee, S. Y., & Kwon, Y. G. (2002). TNF-related activation-induced cytokine
(TRANCE) induces angiogenesis through the activation of Src and phospholipase C
(PLC) in human endothelial cells. Journal ofBiological Chemistry 277, 6799-6805.
Kimura, FL, Weisz, A., Ogura, T., Hitomi, Y., Kurashima, Y., Hashimoto, K.,
DAcquisto, F., Makuuchi, M., & Esumi, H. (2001). Identification of hypoxia-
inducible factor 1 ancillary sequence and its function in vascular endothelial growth
factor gene induction by hypoxia and nitric oxide. Journal of Biological Chemistry
276, 2292-2298.
Kinnaird, T., Stabile, E., Epstein, S. E., & Fuchs, S. (2003). Current perspectives in
therapeutic myocardial angiogenesis. J.Interv.Cardiol. 16, 289-297.
Kleinman, H. K., McGarvey, M. L., Liotta, L. A., Robey, P. G., Tryggvason, K., &
Martin, G. R. (1982). Isolation and characterization of type IV procollagen, laminin,
and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 21, 6188-
6193.
Klemke, R. L., Leng, J., Molander, R., Brooks, P. C., Vuori, K., & Cheresh, D. A.
(1998). CAS/Crk coupling serves as a "molecular switch" for induction of cell
migration. J.Cell Biol. 140, 961-972.
Koedam, J. A., Smink, J. J., & Buul-Offers, S. C. (2002). Glucocorticoids inhibit
vascular endothelial growth factor expression in growth plate chondrocytes. Mol.Cell
Endocrinol. 197, 35-44.
Kogianni, G., Mann, V., Ebetino, F., Nuttall, M., Nijweide, P., Simpson, H., &
Noble, B. (2004). Fas/CD95 is associated with glucocorticoid-induced osteocyte
apoptosis. Life Sciences 75, 2879-2895.
Koning, G. A., Schiffelers, R. M., Wauben, M. H., Kok, R. J., Mastrobattista, E.,
Molema, G., ten Hagen, T. L., & Storm, G. (2006). Targeting of angiogenic
endothelial cells at sites of inflammation by dexamethasone phosphate-containing
RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 54, 1198-
1208.
259
Konishi, A., Tazawa, C., Miki, Y., Darnel, A. D., Suzuki, T., Ohta, Y., Suzuki, T.,
Tabayashi, K., & Sasano, H. (2003). The possible roles of mineralocorticoid receptor
and 1 lbeta-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the
spontaneously hypertensive rat. Journal of Steroid Biochemistry and Molecular
Biology 85, 439-442.
Koukouritaki, S. B., Gravanis, A., & Stournaras, C. (1999). Tyrosine
phosphorylation of focal adhesion kinase and paxillin regulates the signaling
mechanism of the rapid nongenomic action of dexamethasone on actin cytoskeleton.
Mol.Med. 5, 731-742.
Koukouritaki, S. B. & Lianos, E. A. (1999). Glucocorticoid effect on human
mesangial cell cytoskeletal proteins. J.Lab Clin.Med. 133, 378-383.
Koyama, S., Sato, E., Haniuda, M., Numanami, H., Nagai, S., & Izumi, T. (2002).
Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid
of normal smokers and patients with pulmonary fibrosis. AmJ.Respir.Crit Care Med.
166, 382-385.
Rraling, B. M., Wiederschain, D. G., Boehm, T., Rehn, M., Mulliken, J. B., &
Moses, M. A. (1999). The role of matrix metalloproteinase activity in the maturation
of human capillary endothelial cells in vitro. J.Cell Sci. 112 (Pt 10), 1599-1609.
Krozowski, Z. & Chai, Z. (2003). The role of 1 lbeta-hydroxysteroid dehydrogenases
in the cardiovascular system. EndocrJ. 50, 485-489.
Krupinski, J., Kaluza, J., Kumar, P., Kumar, S., & Wang, J. M. (1994). Role of
angiogenesis in patients with cerebral ischemic stroke. Stroke 25,1794-1798.
Kubota, Y., Kleinman, H. K., Martin, G. R., & Lawley, T. J. (1988). Role of laminin
and basement membrane in the morphological differentiation of human endothelial
cells into capillary-like structures. J.Cell Biol. 107,1589-1598.
Kumar, R., Yoneda, J., Bucana, C. D., & Fidler, I. J. (1998). Regulation of distinct
steps of angiogenesis by different angiogenic molecules. Int.J.Oncol. 12, 749-757.
Kumar, S. & Rajkumar, S. V. (2005). Thalidomide and dexamethasone: therapy for
multiple myeloma. Expert.RevAnticancer Ther. 5, 759-766.
Kupzig, S., Walker, S. A., & Cullen, P. J. (2005). The frequencies of calcium
oscillations are optimized for efficient calcium-mediated activation of Ras and the
ERK/MAPK cascade. Proc.Natl.Acad.Sci.U.S.A 102, 7577-7582.
Kurz, H. (2000). Physiology of angiogenesis. J.Neurooncol. 50,17-35.
Kuzuya, M. & Kinsella, J. L. (1994). Reorganization of endothelial cord-like
structures on basement membrane complex (Matrigel): involvement of transforming
growth factor beta 1. J.Cell Physiol 161, 267-276.
260
Kyriakis, J. M. & Avruch, J. (2001). Mammalian mitogen-activated protein kinase
signal transduction pathways activated by stress and inflammation. Physiol Rev. 81,
807-869.
Lane, T. F., Iruela-Arispe, M. L., & Sage, E. H. (1992). Regulation of gene
expression by SPARC during angiogenesis in vitro. Changes in fibronectin,
thrombospondin-1, and plasminogen activator inhibitor-1. Journal of Biological
Chemistry 267, 16736-16745.
Langford, H. G. & Snavely, J. R. (1959). Effect of DCA on development of
renoprival hypertension. AmJ.Physiol 196, 449-450.
Lansink, M., Koolwijk, P., van, H., V, & Kooistra, T. (1998). Effect of steroid
hormones and retinoids on the formation of capillary-like tubular structures of human
microvascular endothelial cells in fibrin matrices is related to urokinase expression.
Blood 92, 927-938.
Lawler, J. (2000). The functions of thrombospondin-1 and-2. Curr.Opin.Cell Biol.
12, 634-640.
Lawley, T. J. & Kubota, Y. (1989). Induction of morphologic differentiation of
endothelial cells in culture. J.InvestDermatol. 93, 59S-61S.
Lazarous, D. F., Shou, M., Stiber, J. A., Hodge, E., Thirumurti, V., Goncalves, L., &
Unger, E. F. (1999). Adenoviral-mediated gene transfer induces sustained pericardial
VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovascular
Research 44, 294-302.
Leake, R. E., Freshney, R. I., & Munir, I. (1987). Steroid response in vivo and in
vitro. In Steroid hormones; a practical approach, eds. Green, B. & Leake, R. E., pp.
205-208. IRL Press, Oxford.
LeCouter, J., Lin, R., & Ferrara, N. (2002). Endocrine gland-derived VEGF and the
emerging hypothesis of organ-specific regulation of angiogenesis. Nat.Med. 8, 913-
917.
Lee, J. E., Beck, T. W., Wojnowski, L., & Rapp, U. R. (1996). Regulation of A-raf
expression. Oncogene 12,1669-1677.
Lee, O. H., Bae, S. K., Bae, M. H., Lee, Y. M., Moon, E. J., Cha, H. J., Kwon, Y. G.,
& Kim, K. W. (2000). Identification of angiogenic properties of insulin-like growth
factor II in in vitro angiogenesis models. Br.J.Cancer 82, 385-391.
Lemus, D., Dabancens, A., Illanes, J., Fuenzalida, M., Guerrero, A., & Lopez, C.
(2001). Antiangiogenic effect of betamethasone on the chick cam stimulated by TA3
tumor supernatant. Biol.Res. 34, 227-236.
261
Leslie, J. D., riza-McNaughton, L., Bermange, A. L., McAdow, R., Johnson, S. L., &
Lewis, J. (2007). Endothelial signalling by the Notch ligand Delta-like 4 restricts
angiogenesis. Development 134, 839-844.
Li, Y., Hazarika, S., Xie, D., Pippen, A. M., Kontos, C. D., & Annex, B. H. (2007).
In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating
transcription factor modulates VEGF signaling and induces therapeutic angiogenesis
after hindlimb ischemia. Diabetes 56, 656-665.
Limbourg, F. P., Huang, Z., Plumier, J. C., Simoncini, T., Fujioka, M., Tuckermann,
J., Schutz, G., Moskowitz, M. A., & Liao, J. K. (2002). Rapid nontranscriptional
activation of endothelial nitric oxide synthase mediates increased cerebral blood flow
and stroke protection by corticosteroids. J.Clin.Invest 110,1729-1738.
Limbourg, F. P. & Liao, J. K. (2003). Nontranscriptional actions of the
glucocorticoid receptor. J.Mol.Med. 81,168-174.
Lindner, V. & Reidy, M. A. (1991). Proliferation of smooth muscle cells after
vascular injury is inhibited by an antibody against basic fibroblast growth factor.
Proc.Natl.Acad.Sci.U.S.A 88, 3739-3743.
Liu, J., Wang, X. B., Park, D. S., & Lisanti, M. P. (2002). Caveolin-1 expression
enhances endothelial capillary tubule formation. Journal of Biological Chemistry
277, 10661-10668.
Liu, Z. J., Shirakawa, T., Li, Y., Soma, A., Oka, M., Dotto, G. P., Fairman, R. M.,
Velazquez, O. C., & Herlyn, M. (2003). Regulation of Notchl and D114 by vascular
endothelial growth factor in arterial endothelial cells: implications for modulating
arteriogenesis and angiogenesis. Mol.Cell Biol. 23,14-25.
Lombes, M., Oblin, M. F., Gasc, J. M., Baulieu, F. E., Farman, N., & Bonvalet, J. P.
(1992). Immunohistochemical and biochemical evidence for a cardiovascular
mineralocorticoid receptor. Circulation Research 71, 503-510.
Longenecker, J. P., Kilty, L. A., & Johnson, L. K. (1982). Glucocorticoid influence
on growth of vascular wall cells in culture. Journal ofCellular Physiology 113, 197-
202.
Longenecker, J. P., Kilty, L. A., & Johnson, L. K. (1984). Glucocorticoid inhibition
of vascular smooth muscle cell proliferation: influence of homologous extracellular
matrix and serum mitogens.J.Cell Biol. 98, 534-540.
Lopez, J. J., Laham, R. J., Stamler, A., Pearlman, J. D., Bunting, S., Kaplan, A.,
Carrozza, J. P., Sellke, F. W., & Simons, M. (1998). VEGF administration in chronic
myocardial ischemia in pigs. Cardiovascular Research 40, 272-281.
Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein
measurement with the Folin phenol reagent. Journal of Biological Chemistry 193,
265-275.
262
Lucerna, M., Zernecke, A., de, N. R., de Jager, S. C., Bot, I., van der, L. C., Kholova,
I., Liehn, E. A., van Berkel, T. J., Yla-Herttuala, S., Weber, C., & Biessen, E. A.
(2007). Vascular endothelial growth factor-A induces plaque expansion in ApoE
knock-out mice by promoting de novo leukocyte recruitment. Blood 109,122-129.
Luo, J. C., Shin, V. Y., Liu, E. S., Ye, Y. N., Wu, W. K., So, W. H., Chang, F. Y., &
Cho, C. H. (2004). Dexamethasone delays ulcer healing by inhibition of angiogenesis
in rat stomachs. European Journal ofPharmacology 485, 275-281.
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M.,
Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P.
(2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules
and dysregulating HIF. Cancer Cell 3, 363-375.
Machein, M. R., Kullmer, J., Ronicke, V., Machein, U., Krieg, M., Damert, A.,
Breier, G., Risau, W., & Plate, K. H. (1999). Differential downregulation of vascular
endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma
cells. NeuropathoLAppl.Neurobiol. 25, 104-112.
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J.,
Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly,
T. J., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1997). Angiopoietin-2, a natural
antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60.
Majima, M., Hayashi, I., Muramatsu, M., Katada, J., Yamashina, S., & Katori, M.
(2000). Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced
angiogenesis through induction of vascular endothelial growth factor in rat sponge
implants. British Journal ofPharmacology 130, 641-649.
Manoussaki, D., Lubkin, S. R., Vernon, R. B., & Murray, J. D. (1996). A mechanical
model for the formation of vascular networks in vitro. Acta Biotheor. 44, 271-282.
Maragoudakis, M. E., Sarmonika, M., & Panoutsacopoulou, M. (1989).
Antiangiogenic action of heparin plus cortisone is associated with decreased
collagenous protein synthesis in the chick chorioallantoic membrane system. Journal
ofPharmacology and Experimental Therapeutics 251, 679-682.
Maresh, J. G., Xu, H., Jiang, N., & Shohet, R. V. (2004). In vivo transcriptional
response of cardiac endothelium to lipopolysaccharide.
Arterioscler.Thromb.Vasc.Biol. 24, 1836-1841.
Marks, M. G., Shi, J., Fry, M. O., Xiao, Z., Trzyna, M., Pokala, V., Ihnat, M. A., &
Li, P. K. (2002). Effects of putative hydroxylated thalidomide metabolites on blood
vessel density in the chorioallantoic membrane (CAM) assay and on tumor and
endothelial cell proliferation. Biol.Pharm.Bull. 25, 597-604.
263
Marler, J. J., Fishman, S. J., Kilroy, S. M., Fang, J., Upton, J., Mulliken, J. B.,
Burrows, P. E., Zurakowski, D., Folkman, J., & Moses, M. A. (2005). Increased
expression of urinary matrix metalloproteinases parallels the extent and activity of
vascular anomalies. Pediatrics 116, 38-45.
Martin, C., Yu, A. Y., Jiang, B. H., Davis, L., Kimberly, D., Hohimer, A. R., &
Semenza, G. L. (1998). Cardiac hypertrophy in chronically anemic fetal sheep:
Increased vascularization is associated with increased myocardial expression of
vascular endothelial growth factor and hypoxia-inducible factor 1.
Am.J.Obstet.Gynecol. 178, 527-534.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith,
W. G., Isakson, P. C., & Seibert, K. (1994). Selective inhibition of inducible
cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Proc.Natl.Acad.Sci. U.S.A 91, 3228-3232.
Massaro, D., Teich, N., Maxwell, S., Massaro, G. D., & Whitney, P. (1985).
Postnatal development of alveoli. Regulation and evidence for a critical period in
rats.J.Clin.Invest 76,1297-1305.
Matsuda, S., Gomi, F., Oshima, Y., Tohyama, M., & Tano, Y. (2005). Vascular
endothelial growth factor reduced and connective tissue growth factor induced by
triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol.Vis.Sci. 46,
1062-1068.
Matsuda, T. & Nakayama, Y. (1996). Surface microarchitectural design in
biomedical applications: in vitro transmural endothelialization on microporous
segmented polyurethane films fabricated using an excimer laser.
J.Biomed.Mater.Res. 31, 235-242.
McDonald, D. M. & Choyke, P. L. (2003). Imaging of angiogenesis: from
microscope to clinic. Nat.Med. 9, 713-725.
Meadows, K. N., Bryant, P., & Pumiglia, K. (2001). Vascular endothelial growth
factor induction of the angiogenic phenotype requires Ras activation. Journal of
Biological Chemistry 276, 49289-49298.
Meller, E., Shen, C., Nikolao, T. A., Jensen, C., Tsimberg, Y., Chen, J., & Gruen, R.
J. (2003). Region-specific effects of acute and repeated restraint stress on the
phosphorylation ofmitogen-activated protein kinases. Brain Research 979, 57-64.
Mendel, D. B., Schreck, R. E., West, D. C., Li, G., Strawn, L. M., Tanciongco, S. S.,
Vasile, S., Shawver, L. K., & Cherrington, J. M. (2000). The angiogenesis inhibitor
SU5416 has long-lasting effects on vascular endothelial growth factor receptor
phosphorylation and function. Clin.Cancer Res. 6, 4848-4858.
Mendoza, N., Phillips, G. L., Silva, I, Schwall, R., & Wickramasinghe, D. (2002).
Inhibition of ligand-mediated HER2 activation in androgen-independent prostate
cancer. Cancer Research 62, 5485-5488.
264
Mestas, J. & Hughes, C. C. (2004). Of mice and not men: differences between mouse
and human immunology. J.Immunol. 172, 2731-2738.
Meyer, W. J. & Nicholls, N. R. (1981). Mineralocorticoid binding on cultured
smooth muscle cells and fibroblasts from rat aorta. Journal of Steroid Biochemistry
14,1157-1168.
Mirkin, S. & Archer, D. F. (2004). Effects of mifepristone on vascular endothelial
growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the
endometrial effects ofmifepristone. Contraception 70, 327-333.
Monder, C. & White, P. C. (1993). ll|3-Hydroxysteroid dehydrogenase. Vitamins
and Hormones 47,187-271.
Montanez, E., Casaroli-Marano, R. P., Vilaro, S., & Pagan, R. (2002). Comparative
study of tube assembly in three-dimensional collagen matrix and on Matrigel coats.
Angiogenesis. 5, 167-172.
Montgomery, K. F., Osborn, L., Hession, C., Tizard, R., Goff, D., Vassallo, C., Tarr,
P. I., Bomsztyk, K., Lobb, R., Harlan, J. M., & . (1991). Activation of endothelial-
leukocyte adhesion molecule 1 (ELAM-1) gene transcription.
Proc.Natl.Acad.Sci. U.S.A 88, 6523-6527.
Mooberry, S. L. (2003). New insights into 2-methoxyestradiol, a promising
antiangiogenic and antitumor agent. Curr.Opin.Oncol. 15, 425-430.
Moon, Y., Bottone, F. G., Jr., McEntee, M. F., & Eling, T. E. (2005). Suppression of
tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1
via the early growth response gene Egr-1. Mol.Cancer Ther. 4,1551-1558.
Morales, D. E., McGowan, K. A., Grant, D. S., Maheshwari, S., Bhartiya, D., Cid,
M. C., Kleinman, H. K., & Schnaper, H. W. (1995). Estrogen promotes angiogenic
activity in human umbilical vein endothelial cells in vitro and in a murine model.
Circulation 91, 755-763.
Mott, J. D. & Werb, Z. (2004). Regulation of matrix biology by matrix
metalloproteinases. Curr.Opin Cell Biol. 16, 558-564.
Moulton, K. S., Vakili, K., Zurakowski, D., Soliman, M., Butterfield, C., Sylvin, E.,
Lo, K. M., Gillies, S., Javaherian, K., & Folkman, J. (2003). Inhibition of plaque
neovascularization reduces macrophage accumulation and progression of advanced
atherosclerosis. Proc.NatlAcad.Sci.U.S.A 100, 4736-4741.
Munaron, L. (2002). Calcium signalling and control of cell proliferation by tyrosine
kinase receptors (review). Int.J.Mol.Med. 10, 671-676.
Munoz-Chapuli, R., Quesada, A. R., & Medina, M. A. (2004). Angiogenesis and
signal transduction in endothelial cells. CellMol.Life Sci. 61, 2224-2243.
265
Murthi, P., So, M., Gude, N. M., Doherty, V. L., Brennecke, S. P., & Kalionis, B.
(2007). Homeobox genes are differentially expressed in macrovascular human
umbilical vein endothelial cells and microvascular placental endothelial cells.
Placenta 28, 219-223.
Nakatsu, M. N., Sainson, R. C., Aoto, J. N., Taylor, K. L., Aitkenhead, M., Perez-
del-Pulgar, S., Carpenter, P. M., & Hughes, C. C. (2003). Angiogenic sprouting and
capillary lumen formation modeled by human umbilical vein endothelial cells
(HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvascular
Research 66,102-112.
Nanobashvili, J., Jozkowicz, A., Neumayer, C., Spom, F. E., Polterauer, P., & Huk,
I. (2003). Comparison of angiogenic potential of human microvascular endothelial
cells and human umbilical vein endothelial cells. European Surgery 35, 214-218.
Nanobashvili, J., Prager, M., Jozkowicz, A., Neumayer, C., Fugl, A., Blumer, R.,
Cabaj, A., Wrba, F., Polterauer, P., & Huk, I. (2004). Positive effect of treatment
with synthetic steroid hormone tibolon on intimal hyperplasia and restenosis after
experimental endothelial injury of rabbit carotid artery. Eur.Surg.Res. 36, 74-82.
Napolitano, A., Voice, M. W., Edwards, C. W., Seckl, J. R., & Chapman, K. E.
(1998). llbeta-Hydroxysteroid dehydrogenase 1 in adipocytes: Expression is
differentiation-dependent and hormonally regulated. Journal ofSteroid Biochemistry
andMolecular Biology 64, 251-260.
Nauck, M., Karakiulakis, G., Perruchoud, A. P., Papakonstantinou, E., & Roth, M.
(1998). Corticosteroids inhibit the expression of the vascular endothelial growth
factor gene in human vascular smooth muscle cells. European Journal of
Pharmacology 341, 309-315.
Neufeld, G., Cohen, T., Gengrinovitch, S., & Poltorak, Z. (1999). Vascular
endothelial growth factor (VEGF) and its receptors. FASEBJ. 13, 9-22.
Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O., & Herzog, Y. (2002). The
neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon
guidance and angiogenesis. Trends Cardiovasc.Med. 12,13-19.
Newman, P. J., Berndt, M. C., Gorski, J., White, G. C., Lyman, S., Paddock, C., &
Muller, W. A. (1990). PECAM-1 (CD31) cloning and relation to adhesion molecules
of the immunoglobulin gene superfamily. Science 247,1219-1222.
Nicosia, R. F., Belser, P., Bonanno, E., & Diven, J. (1991). Regulation of
angiogenesis in vitro by collagen metabolism. In Vitro Cell Dev.Biol. 27A, 961-966.
Nicosia, R. F. & Ottinetti, A. (1990). Growth of microvessels in serum-free matrix
culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63, 115-
122.
266
Nicot, N., Hausman, J. F., Hoffmann, L., & Evers, D. (2005). Housekeeping gene
selection for real-time RT-PCR normalization in potato during biotic and abiotic
stress. J.Exp.Bot. 56, 2907-2914.
Ninomiya, M., Koyama, H., Miyata, T., Hamada, H., Miyatake, S., Shigematsu, H.,
& Takamoto, S. (2003). Ex vivo gene transfer of basic fibroblast growth factor
improves cardiac function and blood flow in a swine chronic myocardial ischemia
model. Gene Ther. 10,1152-1160.
Nissen, N. N., Polverini, P. J., Koch, A. E., Volin, M. V., Gamelli, R. L., & DiPietro,
L. A. (1998). Vascular endothelial growth factor mediates angiogenic activity during
the proliferative phase of wound healing. Am.J.Pathol. 152,1445-1452.
Nolan, T., Hands, R. E., & Bustin, S. A. (2006). Quantification of mRNA using real¬
time RT-PCR. Nat.Protoc. 1,1559-1582.
Nuedling, S., Kahlert, S., Loebbert, K., Meyer, R., Vetter, H., & Grohe, C. (1999).
Differential effects of 17beta-estradiol on mitogen-activated protein kinase pathways
in rat cardiomyocytes. FEBSLett. 454, 271-276.
Oberleithner, H., Schneider, S. W., Albermann, L., Hillebrand, U., Ludwig, T.,
Riethmuller, C., Shahin, V., Schafer, C., & Schillers, H. (2003). Endothelial cell
swelling by aldosterone. J.Membr.Biol. 196,163-172.
Oddera, S., Cagnoni, F., Mangraviti, S., Giron-Michel, J., Popova, O., & Canonica,
G. W. (2002). Effects of triamcinolone acetonide on adult human lung fibroblasts:
decrease in proliferation, surface molecule expression and mediator release.
Int.Arch.Allergy Immunol. 129, 152-159.
Oehler, M. K. & Bicknell, R. (2000). The promise of anti-angiogenic cancer therapy.
Br.J.Cancer 82, 749-752.
Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa,
S., Sasazuki, T., & Kerbel, R. S. (1998). Impact of oncogenes in tumor angiogenesis:
mutant K-ras up-regulation of vascular endothelial growth factor/vascular
permeability factor is necessary, but not sufficient for tumorigenicity of human
colorectal carcinoma cells. Proc.NatLAcad.Sci.U.SA 95, 3609-3614.
Pai, R., Szabo, I. L., Soreghan, B. A., Atay, S., Kawanaka, H., & Tamawski, A. S.
(2001). PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1
signaling pathways. Biochemical and Biophysical Research Communications 286,
923-928.
Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F.,
Altieri, D. C., & Sessa, W. C. (2000). Angiopoietin-1 inhibits endothelial cell
apoptosis via the Akt/survivin pathway. J.Biol.Chem. 275, 9102-9105.
267
Park, K., Lee, G. Y., Kim, Y. S., Yu, M., Park, R. W., Kim, I. S., Kim, S. Y., &
Byun, Y. (2006). Heparin-deoxycholic acid chemical conjugate as an anticancer drug
carrier and its antitumor activity. J.Control Release 114, 300-306.
Parsons, J. T. (2003). Focal adhesion kinase: the first ten years. J.Cell Sci. 116,1409-
1416.
Pelaia, G., Cuda, G., Vatrella, A., Fratto, D., Grembiale, R. D., Tagliaferri, P.,
Maselli, R., Costanzo, F. S., & Marsico, S. A. (2003). Effects of transforming growth
factor-[beta] and budesonide on mitogen-activated protein kinase activation and
apoptosis in airway epithelial cells. AmJ.Respir.Cell Mol.Biol. 29,12-18.
Pelaia, G., Cuda, G., Vatrella, A., Grembiale, R. D., De, S. G., Maselli, R., Costanzo,
F. S., Avvedimento, V. E., Rotiroti, D., & Marsico, S. A. (2001). Effects of
glucocorticoids on activation of c-jun N-terminal, extracellular signal-regulated, and
p38 MAP kinases in human pulmonary endothelial cells. Biochemical Pharmacology
62,1719-1724.
Penn, J. S., Henry, M. M., & Tolman, B. L. (1994). Exposure to alternating hypoxia
and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatric
Research 36, 724-731.
Penn, J. S., Rajaratnam, V. S., Collier, R. J., & Clark, A. F. (2001). The effect of an
angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.
Invest Ophthalmol. Vis.Sci. 42, 283-290.
Peppel, K., Vinci, J. M., & Baglioni, C. (1991). The AU-rich sequences in the 3'
untranslated region mediate the increased turnover of interferon mRNA induced by
glucocorticoids. J.Exp.Med. 173, 349-355.
Pepper, M. S., Vassalli, J. D., Wilks, J. W., Schweigerer, L., Orci, L., & Montesano,
R. (1994). Modulation of bovine microvascular endothelial cell proteolytic properties
by inhibitors of angiogenesis. J.Cell Biochem. 55, 419-434.
Phelps, D. L. (1993). Retinopathy of prematurity. Pediatr.Clin.North Am. 40, 705-
714.
Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P., & Smith, L. E. (1995).
Vascular endothelial growth factor/vascular permeability factor expression in a
mouse model of retinal neovascularization. Proc.Natl.Acad.Sci. U.S.A 92, 905-909.
Polverini, P. J. (2002). Angiogenesis in health and disease: insights into basic
mechanisms and therapeutic opportunities. J.Dent.Educ. 66, 962-975.
Polytarchou, C. & Papadimitriou, E. (2005). Antioxidants inhibit human endothelial
cell functions through down-regulation of endothelial nitric oxide synthase activity.
European Journal ofPharmacology 510, 31-38.
268
Poon, M., Liu, B., & Taubman, M. B. (1999). Identification of a novel
dexamethasone-sensitive RNA-destabilizing region on rat monocyte chemoattractant
protein 1 mRNA. Mol.Cell Biol. 19, 6471-6478.
Pozzi, A., Moberg, P. E., Miles, L. A., Wagner, S., Soloway, P., & Gardner, H. A.
(2000). Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1
knockout mice cause reduced tumor vascularization. Proc.NatlAcad.Sci.U.SA 97,
2202-2207.
Pratt, W. B. The role of heat shock proteins in regulating the function, folding, and
trafficking of the glucocorticoid receptor. Journal of Biological Chemistry 268,
21455-21458. 1993.
Pross, C., Farooq, M. M., Angle, N., Lane, J. S., Cerveira, J. J., Xavier, A. E.,
Freischlag, J. A., Law, R. E., & Gelabert, H. A. (2002a). Dexamethasone inhibits
vascular smooth muscle cell migration via modulation of matrix metalloproteinase
activity. J.Surg.Res. 102, 57-62.
Pross, C., Farooq, M. M., Lane, J. S., Angle, N., Tomono, C. K., Xavier, A. E.,
Freischlag, J. A., Collins, A. E., Law, R. E., & Gelabert, H. A. (2002b). Rat and
human aortic smooth muscle cells display differing migration and matrix
metalloproteinase activities in response to dexamethasone. J.Vasc.Surg. 35, 1253-
1259.
Pufe, T., Scholz-Ahrens, K. E., Franke, A. T. M,, Petersen, W., <entlein, R., Varoga,
D., Tillmann, B., Schrezenmeier, J., & Glijer, C. C. (2003). The role of vascular
endothelial growth fcator in glucocorticiod-induced bone loss: evaluation in a
minipig model. Bone 33, 869-876.
Pufe, T., Wildemann, B., Petersen, W., Mentlein, R., Raschke, M., & Schmidmaier,
G. (2002). Quantitative measurement of the splice variants 120 and 164 of the
angiogenic peptide vascular endothelial growth factor in the time flow of fracture
healing: a study in the rat. Cell Tissue Res. 309, 387-392.
Pugh, C. W. & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: role of
the HIF system. Nat.Med. 9, 677-684.
Qi, J. H. & Claesson-Welsh, L. (2001). VEGF-induced activation of
phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp.Cell Res. 263,
173-182.
Rafiee, P., Heidemann, J., Ogawa, H., Johnson, N. A., Fisher, P. J., Li, M. S.,
Otterson, M. F., Johnson, C. P., & Binion, D. G. (2004). Cyclosporin A differentially
inhibits multiple steps in VEGF induced angiogenesis in human microvascular
endothelial cells through altered intracellular signaling. Cell Commun.Signal. 2, 3.
269
Rajagopalan, S., Mohler, E. R., Ill, Lederman, R. J., Mendelsohn, F. O., Saucedo, J.
F., Goldman, C. K., Blebea, J., Macko, J., Kessler, P. D., Rasmussen, H. S., &
Annex, B. H. (2003). Regional angiogenesis with vascular endothelial growth factor
in peripheral arterial disease: a phase II randomized, double-blind, controlled study
of adenoviral delivery of vascular endothelial growth factor 121 in patients with
disabling intermittent claudication. Circulation 108,1933-1938.
Refojo, D., Liberman, A. C., Holsboer, F., & Arzt, E. (2001). Transcription factor-
mediated molecular mechanisms involved in the functional cross-talk between
cytokines and glucocorticoids. Immunol.CellBiol. 79, 385-394.
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R.,
Gass, P., Schmid, W., Herrlich, P., Angel, P., & Schutz, G. (1998). DNA binding of
the glucocorticoid receptor is not essential for survival. Cell 93, 531-541.
Reichardt, H. M., Tuckermann, J. P., Gottlicher, M., Vujic, M., Weih, F., Angel, P.,
Herrlich, P., & Schutz, G. (2001). Repression of inflammatory responses in the
absence of DNA binding by the glucocorticoid receptor. EMBO J. 20, 7168-7173.
Revest, J. M., Di, B. F., Kitchener, P., Rouge-Pont, F., Desmedt, A., Turiault, M.,
Tronche, F., & Piazza, P. V. (2005). The MAPK pathway and Egr-1 mediate stress-
related behavioral effects of glucocorticoids. Nat.Neurosci. 8, 664-672.
Ribatti, D., Crivellato, E., Candussio, L., Nico, B., Vacca, A., Roncali, L., &
Dammacco, F. (2001). Mast cells and their secretory granules are angiogenic in the
chick embryo chorioallantoic membrane. Clin.ExpAllergy 31, 602-608.
Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671-674.
Roberts, W. G. & Palade, G. E. (1995). Increased microvascular permeability and
endothelial fenestration induced by vascular endothelial growth factor. J.Cell Sci.
108 (Pt 6), 2369-2379.
Roca, C. & Adams, R. H. (2007). Regulation on vascular morphogenesis by Notch
signaling. Genes and Development 21, 2511-2524.
Roman-Bias, J. A. & Jimenez, S. A. (2006). NF-kappaB as a potential therapeutic
target in osteoarthritis and rheumatoid arthritis. Osteoarthritis.Cartilage. 14, 839-
848.
Rotschild, T., Nandgaonkar, B. N., Yu, K., & Higgins, R. D. (1999). Dexamethasone
reduces oxygen induced retinopathy in a mouse model. Pediatric Research 46, 94-
100.
Rousseau, S., Houle, F., & Huot, J. (2000). Integrating the VEGF signals leading to
actin-based motility in vascular endothelial cells. Trends Cardiovasc.Med. 10, 321-
327.
270
Rubenstein, N. M., Callahan, J. A., Lo, D. H., & Firestone, G. L. (2007). Selective
glucocorticoid control of Rho kinase isoforms regulate cell-cell interactions.
Biochemical andBiophysical Research Communications 354, 603-607.
Rupnick, M. A., Panigrahy, D., Zhang, C. Y., Dallabrida, S. M., Lowell, B. B.,
Langer, R., & Folkman, M. J. (2002). Adipose tissue mass can be regulated through
the vasculature. Proc.NatLAcad.Sci.U.SA 99,10730-10735.
Russell, K. S., Haynes, M. P., Sinha, D., Clerisme, E., & Bender, J. R. (2000).
Human vascular endothelial cells contain membrane binding sites for estradiol,
which mediate rapid intracellular signaling. Proc.NatlAcad.Sci.U.SA 97, 5930-
5935.
Ryu, J. S., Majeska, R. J., Ma, Y., LaChapelle, L., & Guller, S. (1999). Steroid
regulation of human placental integrins: suppression of alpha2 integrin expression in
cytotrophoblasts by glucocorticoids. Endocrinology 140, 3904-3908.
Sainson, R. C., Aoto, J., Nakatsu, M. N., Holderfield, M., Conn, E., Koller, E., &
Hughes, C. C. (2005). Cell-autonomous notch signaling regulates endothelial cell
branching and proliferation during vascular tubulogenesis. FASEB Journal 19, 1027-
1029.
Saito, K., Oku, T., Ata, N., Miyashiro, H., Hattori, M., & Saiki, I. (1997). A modified
and convenient method for assessing tumor cell invasion and migration and its
application to screening for inhibitors. Biol.Pharm.Bull. 20, 345-348.
Saito, M., Hamasaki, M., & Shibuya, M. (2003). Induction of tube formation by
angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous
VEGF. Cancer Sci. 94, 782-790.
Sales, K. J., List, T., Boddy, S. C., Williams, A. R., Anderson, R. A., Naor, Z., &
Jabbour, H. N. (2005). A novel angiogenic role for prostaglandin F2alpha-FP
receptor interaction in human endometrial adenocarcinomas. Cancer Research 65,
7707-7716.
Sales, K. J., Milne, S. A., Williams, A. R., Anderson, R. A., & Jabbour, H. N.
(2004). Expression, localization, and signaling of prostaglandin F2 alpha receptor in
human endometrial adenocarcinoma: regulation of proliferation by activation of the
epidermal growth factor receptor and mitogen-activated protein kinase signaling
pathways. J.Clin.Endocrinol.Metab 89, 986-993.
Sanz, L., Pascual, M., Munoz, A., Gonzalez, M. A., Salvador, C. H., & varez-
Vallina, L. (2002). Development of a computer-assisted high-throughput screening
platform for anti-angiogenic testing. Microvascular Research 63, 335-339.
Saruta, T. (1996). Mechanism of glucocorticoid-induced hypertension.
Hypertens.Res. 19,1-8.
271
Schafer, S. C., Wallerath, T., Closs, E. I., Schmidt, C., Schwarz, P. M., Forstermann,
U., & Lehr, H. A. (2005). Dexamethasone suppresses eNOS and CAT-1 and induces
oxidative stress in mouse resistance arterioles. Am,J.Physiol Heart Circ.Physiol 288,
H436-H444.
Schmid, D., Burmester, G. R., Tripmacher, R., Kuhnke, A., & Buttgereit, F. (2000).
Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent,
activated, and glucocorticoid-treated states. Biosci.Rep. 20, 289-302.
Schreiber, J. R., Hsueh, A. J., & Baulieu, E. E. (1983). Binding of the anti-progestin
RU-486 to rat ovary steroid receptors. Contraception 28, 77-85.
Schumacher, B., Pecher, P., von Specht, B. U., & Stegmann, T. (1998). Induction of
neoangiogenesis in ischemic myocardium by human growth factors: first clinical
results of a new treatment of coronary heart disease. Circulation 97, 645-650.
Scott, B. A., Lawrence, B., Nguyen, H. H., & Meyer, W. J. (1987). Aldosterone and
dexamethasone binding in human arterial smooth muscle cells. Journal of
Hypertension 5, 739-744.
Seckl, J. R. & Walker, B. R. (2001). 11 (1-Hydroxysteroid dehydrogenase type 1 - a
tissue-specific amplifier of glucocorticoid action. Endocrinology 142, 1371-1376.
Semenza, G. L. (2001). Hypoxia-inducible factor 1: control of oxygen homeostasis in
health and disease. Pediatr.Res. 49, 614-617.
Shen, T. L., Park, A. Y., Alcaraz, A., Peng, X., Jang, I., Koni, P., Flavell, R. A., Gu,
H., & Guan, J. L. (2005). Conditional knockout of focal adhesion kinase in
endothelial cells reveals its role in angiogenesis and vascular development in late
embryogenesis. J.Cell Biol. 169, 941-952.
Shen, W. G., Peng, W. X., Dai, G., Xu, J. F., Zhang, Y., & Li, C. J. (2007).
Calmodulin is essential for angiogenesis in response to hypoxic stress in endothelial
cells. Cell Biol.Int. 31,126-134.
Shi, Q., Aida, K., Vandeberg, J. L., & Wang, X. L. (2004). Passage-dependent
changes in baboon endothelial cells—relevance to in vitro aging. DNA Cell Biol. 23,
502-509.
Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., & Klagsbrun, M.
(1984). Heparin affinity: purification of a tumor-derived capillary endothelial cell
growth factor. Science 223,1296-1299.
Short, S. M., Derrien, A., Narsimhan, R. P., Lawler, J., Ingber, D. E., & Zetter, B. R.
(2005). Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats
is mediated by betal integrins. J.Cell Biol. 168, 643-653.
272
Shweiki, D., Itin, A., Neufeld, G., Gitay-Goren, H., & Keshet, E. (1993). Patterns of
expression of vascular endothelial growth factor (VEGF) and VEGF receptors in
mice suggest a role in hormonally regulated angiogenesis. J.Clin.Invest 91, 2235-
2243.
Siekmann, A. F. & Lawson, N. D. (2007). Notch signalling limits angiogenic cell
behaviour in developing zebrafish arteries. Nature 445, 781-784.
Simoncini, T., Mannella, P., Fornari, L., Caruso, A., Varone, G., & Genazzani, A. R.
(2004). Genomic and non-genomic effects of estrogens on endothelial cells. Steroids
69, 537-542.
Small, G. R., Hadoke, P. W., Sharif, I., Dover, A. R., Armour, D., Kenyon, C. J.,
Gray, G. A., & Walker, B. R. (2005). Preventing local regeneration of
glucocorticoids by llbeta-hydroxysteroid dehydrogenase type 1 enhances
angiogenesis. Proc.Natl.Acad.Sci.U.S.A 102,12165-12170.
Staton, C. A., Stribbling, S. M., Tazzyman, S., Hughes, R., Brown, N. J., & Lewis,
C. E. (2004). Current methods for assaying angiogenesis in vitro and in vivo.
IntJ.Exp.Pathol. 85, 233-248.
Stein, M. D., Stevens, J. M., & Herndon, D. N. (1983). Defective neutrophil
chemotaxis resulting from thermal injury: restoration of directed migration by
increasing Boyden chamber filter pore size. Clin.Immunol.Immunopathol. 27, 234-
239.
Stephanou, A., Meskaoui, G., Vailhe, B., & Tracqui, P. (2006). The rigidity in fibrin
gels as a contributing factor to the dynamics of in vitro vascular cord formation.
Microvascular Research.
Stewart, P. M. & Krozowski, Z. S. (1999). llBeta hydroxysteroid dehydrogenase.
Vitamins andHormones 57, 249-324.
Stewart, P. M., Valentino, R., Wallace, A. M., Burt, D., Shackleton, C. H. L., &
Edwards, C. R. W. (1987). Mineralocorticoid activity of liquorice: 11(3-
hydroxysteroid dehydrogenase deficiency comes of age. Lancet ii, 821-824.
Stoltz, R. A., Abraham, N. G., & Laniado-Schwartzman, M. (1996). The role of NF-
kappaB in the angiogenic response of coronary microvessel endothelial cells.
Proc.Natl.Acad.Sci. U.S.A 93, 2832-2837.
Strawhecker, J. M., Betz, N. A., Neades, R. Y., Houser, W., & Pelling, J. C. (1989).
Binding of the 97 kDa glucocorticoid receptor to the 5' upstream flanking region of
the mouse c-Ha-ras oncogene. Oncogene 4,1317-1322.
Streit, M., Velasco, P., Riccardi, L., Spencer, L., Brown, L. F., Janes, L., Lange-
Asschenfeldt, B., Yano, K., Hawighorst, T., Iruela-Arispe, L., & Detmar, M. (2000).
Thrombospondin-1 suppresses wound healing and granulation tissue formation in the
skin of transgenic mice. EMBO J. 19, 3272-3282.
273
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., & Cheresh, D. A.
(2001). Apoptosis of adherent cells by recruitment of caspase-8 to unligated
integrins. J.Cell Biol. 155, 459-470.
Sugiyama, T., Yoshimoto, T., Tsuchiya, K., Gochou, N., Hirono, Y., Tateno, T.,
Fukai, N., Shichiri, M., & Hirata, Y. (2005). Aldosterone induces angiotensin
converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial
cells. Endocrinology 146, 3900-3906.
Sunder-Plassmann, G., Hofbauer, R., Sengoelge, G., & Horl, W. H. (1996).
Quantification of leukocyte migration: improvement of a method. Immunol.Invest 25,
49-63.
Takahashi, K., Mulliken, J. B., Kozakewich, H. P., Rogers, R. A., Folkman, J., &
Ezekowitz, R. A. (1994). Cellular markers that distinguish the phases of hemangioma
during infancy and childhood. J.Clin.Invest 93, 2357-2364.
Talks, K. L. & Harris, A. L. (2000). Current status of antiangiogenic factors.
BrJ.Haematol. 109, 477-489.
Tamura, K., Sakurai, T., & Kogo, H. (2006). Relationship between prostaglandin E2
and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular
endothelial cells. Vascul.Pharmacol. 44, 411-416.
Tamura, M., Sebastian, S., Gurates, B., Yang, S., Fang, Z., & Bulun, S. E. (2002).
Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in
human endothelial cells. J.Clin.Endocrinol.Metab 87, 3504-3507.
Tan, W. F., Zhang, X. W., Li, M. H., Yue, J. M., Chen, Y., Lin, L. P., & Ding, J.
(2004). Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular
endothelial growth factor-mediated anti-apoptotic effect. European Journal of
Pharmacology 499, 219-228.
Taraboletti, G. & Giavazzi, R. (2004). Modelling approaches for angiogenesis.
Eur.J.Cancer 40, 881-889.
Tepper, O. M., Capla, J. M., Galiano, R. D., Ceradini, D. J., Callaghan, M. J.,
Kleinman, M. E., & Gurtner, G. C. (2004). Adult vasculogenesis occurs through the
in situ recruitment, proliferation and tubulization of circulating bone marrow-derived
cells. Blood.
Thellin, O., Zorzi, W., Lakaye, B., De, B. B., Coumans, B., Hennen, G., Grisar, T.,
Igout, A., & Heinen, E. (1999). Housekeeping genes as internal standards: use and
limits. J.Biotechnol. 75, 291-295.
Thieringer, R., Le Grand, C. B., Carbin, L., Cai, T. Q., Wong, B., Wright, S. D., &
Hermanowski-Vosatka, A. (2001). 11 Beta-hydroxysteroid dehydrogenase type 1 is
induced in human monocytes upon differentiation to macrophages. J.Immunol. 167,
30-35.
274
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007). The Delta paradox:
DLL4 blockade leads to more tumour vessels but less tumour growth.
Nat.Rev.Cancer 7, 327-331.
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N.,
Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000). Angiopoietin-1 protects
the adult vasculature against plasma leakage. Nat.Med. 6, 460-463.
Tokida, Y., Aratani, Y., Morita, A., & Kitagawa, Y. (1990). Production of two
variant laminin forms by endothelial cells and shift of their relative levels by
angiostatic steroids. Journal ofBiological Chemistry 265,18123-18129.
Tomanek, R. J. & Schatteman, G. C. (2000). Angiogenesis: new insights and
therapeutic potential. Anat.Rec. 261,126-135.
Tong, J. P., Lam, D. S., Chan, W. M., Choy, K. W., Chan, K. P., & Pang, C. P.
(2006). Effects of triamcinolone on the expression of VEGF and PEDF in human
retinal pigment epithelial and human umbilical vein endothelial cells. Mol.Vis. 12,
1490-1495.
Tsuda, T., Wang, H., Timpl, R., & Chu, M. L. (2001). Fibulin-2 expression marks
transformed mesenchymal cells in developing cardiac valves, aortic arch vessels, and
coronary vessels. Dev.Dyn. 222, 89-100.
Tuder, R. M., Chacon, M., Alger, L., Wang, J., Taraseviciene-Stewart, L., Kasahara,
Y., Cool, C. D., Bishop, A. E., Geraci, M., Semenza, G. L., Yacoub, M., Polak, J.
M., & Voelkel, N. F. (2001). Expression of angiogenesis-related molecules in
plexiform lesions in severe pulmonary hypertension: evidence for a process of
disordered angiogenesis. J.Pathol. 195, 367-374.
Ulick, S., Levine, L. S., Gunczler, P., Zanconato, G., Ramirez, L. C., Rauh, W.,
Rosier, A., Bradlow, H. L., & New, M. I. (1979). A syndrome of apparent
mineralocorticoid excess associated with defects in the peripheral metabolism of
Cortisol. Journal ofClinical Endocrinology andMetabolism 49, 757-764.
Ullian, M. E. (1999). The role of corticosteroids in the regulation of vascular tone.
Cardiovascular Research 41, 55-64.
Unger, E. F., Banai, S., Shou, M., Lazarous, D. F., Jaklitsch, M. T., Scheinowitz, M.,
Correa, R., Klingbeil, C., & Epstein, S. E. (1994). Basic fibroblast growth factor
enhances myocardial collateral flow in a canine model. Am.J.Physiol 266, H1588-
H1595.
Vailhe, B., Vittet, D., & Feige, J. J. (2001). In vitro models of vasculogenesis and
angiogenesis. Lab Invest 81, 439-452.
van den, D. S., Mummery, C. L., & Westermann, C. J. (2003). Hereditary
hemorrhagic telangiectasia: an update on transforming growth factor beta signaling
in vasculogenesis and angiogenesis. CardiovascularResearch 58, 20-31.
275
Vandesompele, J., De, P. K., Pattyn, F., Poppe, B., Van, R. N., De, P. A., &
Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR data
by geometric averaging of multiple internal control genes. Genome Biol. 3,
RESEARCH0034.
Versaci, F., Gaspardone, A., Tomai, F., Ribichini, F., Russo, P., Proietti, I., Ghini, A.
S., Ferrero, V., Chiariello, L., Gioffre, P. A., Romeo, F., & Crea, F. (2002).
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery
Stent Implantation (IMPRESS Study). Journal of the American College of
Cardiology 40,1935-1942.
Vinals, F. & Pouyssegur, J. (1999). Confluence of vascular endothelial cells induces
cell cycle exit by inhibiting p42/p44 mitogen-activated protein kinase activity.
MolCell Biol. 19,2763-2772.
Waage, A. & Bakke, O. (1988). Glucocorticoids suppress the production of tumour
necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 63,
299-302.
Wake, D. J., Rask, E., Livingstone, D. E., Soderberg, S., Olsson, T., & Walker, B. R.
(2003). Local and systemic impact of transcriptional up-regulation of llbeta-
hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
J.Clin.Endocrinol.Metab 88, 3983-3988.
Walker, B. R., Yau, J. L., Brett, L. P., Seckl, J. R., Monder, C., Williams, B. C., &
Edwards, C. R. W. (1991). lip-Hydroxysteroid dehydrogenase in vascular smooth
muscle and heart: implications for cardiovascular responses to glucocorticoids.
Endocrinology 129, 3305-3312.
Walz, G., Aruffo, A., Kolanus, W., Bevilacqua, M., & Seed, B. (1990). Recognition
by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 250,
1132-1135.
Wang, A., Nomura, M., Patan, S., & Ware, J. A. (2002a). Inhibition of protein kinase
Calpha prevents endothelial cell migration and vascular tube formation in vitro and
myocardial neovascularization in vivo. Circulation Research 90, 609-616.
Wang, H. U., Chen, Z. F., & Anderson, D. J. (1998). Molecular distinction and
angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2
and its receptor Eph-B4. Cell 93, 741-753.
Wang, S., Indrawati, L., Wooters, M., Caro-Aguilar, I., Field, J., Kaufhold, R.,
Payne, A., Caulfield, M. J., Smith, J. G., & Heinrichs, J. H. (2007). A novel
automated method for enumeration of Chlamydia trachomatis inclusion forming
units. J.Immunol.Methods 324, 84-91.
276
Wang, Y. S., Friedrichs, U., Eichler, W., Hoffmann, S., & Wiedemann, P. (2002b).
Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube
formation in choroidal microvascular endothelial cells. Graefes
Arch.Clin.Exp.Ophthalmol 240, 42-48.
Wary, K. K., Mariotti, A., Zurzolo, C., & Giancotti, F. G. (1998). A requirement for
caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent
cell growth. Cell 94, 625-634.
Waters, R. E., Rotevatn, S., Li, P., Annex, B. H., & Yan, Z. (2004). Voluntary
running induces fiber type-specific angiogenesis in mouse skeletal muscle.
Am.J.Physiol Cell Physiol 287, C1342-C1348.
Webster, J. C. & Cidlowski, J. A. (1999). Mechanisms of Glucocorticoid-receptor-
mediated Repression of Gene Expression. Trends Endocrinol.Metab 10, 396-402.
Wen, F. Q., Liu, X., Manda, W., Terasaki, Y., Kobayashi, T., Abe, S., Fang, Q., Ertl,
R., Manouilova, L., & Rennard, S. I. (2003). TH2 Cytokine-enhanced and TGF-beta-
enhanced vascular endothelial growth factor production by cultured human airway
smooth muscle cells is attenuated by IFN-gamma and corticosteroids. JAllergy
Clin.Immunol. Ill, 1307-1318.
Whitworth, J. A., Schyvens, C. G., Zhang, Y., Andrews, M. C., Mangos, G. J., &
Kelly, J. J. (2002). The nitric oxide system in glucocorticoid-induced hypertension.
Journal ofHypertension 20,1035-1043.
Wiedermann, C. J., Auer, B., Sitte, B., Reinisch, N., Schratzberger, P., & Kahler, C.
M. (1996). Induction of endothelial cell differentiation into capillary-like structures
by substance P. European Journal ofPharmacology 298, 335-338.
Wilasrusmee, C., Da, S. M., Singh, B., Siddiqui, J., Bruch, D., Kittur, S.,
Wilasrusmee, S., & Kittur, D. S. (2003). Morphological and biochemical effects of
immunosuppressive drugs in a capillary tube assay for endothelial dysfunction.
Clin.Transplant. 17 Suppl 9, 6-12.
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T.,
Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., Mino, M., Cohen, K. S.,
Scadden, D. T., Hartford, A. C., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A.
X., Blaszkowsky, L. S., Chen, H. X., Shellito, P. C., Lauwers, G. Y., & Jain, R. K.
(2004). Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat.Med. 10,145-147.
Williams, T. M. & Lisanti, M. P. (2004). The caveolin proteins. Genome Biol. 5, 214.
Wu, J. & Bresnick, E. H. (2007). Glucocorticoid and growth factor synergism
requirement for Notch4 chromatin domain activation. Mol.Cell Biol. 27, 2411-2422.
277
Wu, W. S., Wang, F. S., Yang, K. D., Huang, C. C., & Kuo, Y. R. (2006).
Dexamethasone induction of keloid regression through effective suppression of
VEGF expression and keloid fibroblast proliferation. J.Invest Dermatol. 126, 1264-
1271.
Xue, M., Le, N. T., & Jackson, C. J. (2006). Targeting matrix metalloproteases to
improve cutaneous wound healing. Expert.Opin.Ther.Targets. 10,143-155.
Yamada, K., Naito, M., Hayashi, T., Asai, K., Yoshimine, N., & Iguchi, A. (1993).
Effects of dexamethasone on migration of human monocytes in response to oxidized
beta-very low density lipoprotein. Artery 20, 253-267.
Yamagishi, S., Kawakami, T., Fujimori, H., Yonekura, H., Tanaka, N., Yamamoto,
Y., Urayama, H., Watanabe, Y., & Yamamoto, H. (1999). Insulin stimulates the
growth and tube formation of human microvascular endothelial cells through
autocrine vascular endothelial growth factor. Microvascular Research 57, 329-339.
Yamaguchi, M., Hirai, K., Nakajima, K., Ohtoshi, T., Takaishi, T., Ohta, K., Morita,
Y., & Ito, K. (1994). Dexamethasone inhibits basophil migration. Allergy 49, 371-
375.
Yamaji, T., Tsuboi, H., Murata, N., Uchida, M., Kohno, T., Sugino, E., Hibino, S.,
Shimamura, M., & Oikawa, T. (1999). Anti-angiogenic activity of a novel synthetic
agent, 9alpha-fluoromedroxyprogesterone acetate. Cancer Lett. 145,107-114.
Yamamoto, K. R. (1985). Steroid receptor regulated transcription of specific genes
and gene networks. Annu.Rev.Genet. 19, 209-252.
Yamamoto, T., Terada, N., Nishizawa, Y., & Petrow, V. (1994). Angiostatic
activities of medroxyprogesterone acetate and its analogues. Int.J.Cancer 56, 393-
399.
Yamamoto, Y., Ishizu, A., Ikeda, H., Otsuka, N., & Yoshiki, T. (2004).
Dexamethasone increased plasminogen activator inhibitor-1 expression on human
umbilical vein endothelial cells: an additive effect to tumor necrosis factor-alpha.
Pathobiology 71, 295-301.
Yan, Q., Li, Y., Hendrickson, A., & Sage, E. H. (2001). Regulation of retinal
capillary cells by basic fibroblast growth factor, vascular endothelial growth factor,
and hypoxia. In Vitro Cell Dev.BiolAnim 37, 45-49.
Yan, S., Li, M., Chai, H., Yang, H., Lin, P. H., Yao, Q., & Chen, C. (2005). TNF-
alpha decreases expression of somatostatin, somatostatin receptors, and cortistatin in
human coronary endothelial cells. J.Surg.Res. 123, 294-301.
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash,
J. (2000). Vascular-specific growth factors and blood vessel formation. Nature 407,
242-248.
278
Yang, C. H., Huang, C. C., & Hsu, K. S. (2004). Behavioral stress modifies
hippocampal synaptic plasticity through corticosterone-induced sustained
extracellular signal-regulated kinase/mitogen-activated protein kinase activation.
Journal ofNeuroscience 24,11029-11034.
Yang, S. & Zhang, L. (2004). Glucocorticoids and vascular reactivity.
Curr.Vase.Pharmacol. 2,1-12.
Yarrow, J. C., Perlman, Z. E., Westwood, N. J., & Mitchison, T. J. (2004). A high-
throughput cell migration assay using scratch wound healing, a comparison of
image-based readout methods. BMC.Biotechnol. 4, 21.
Yoon, J. S., Kim, H. H., Han, J. W., Lee, Y., & Lee, J. S. (2006). Effects of
intravenous immunoglobulin and methylprednisolone on human umbilical vein
endothelial cells in vitro. Immunobiology 211, 351-357.
Yoshida, A., Anand-Apte, B., & Zetter, B. R. (1996). Differential endothelial
migration and proliferation to basic fibroblast growth factor and vascular endothelial
growth factor. Growth Factors 13, 57-64.
Yossuck, P., Yan, Y., Tadesse, M., & Higgins, R. D. (2001). Dexamethasone alters
TNF-alpha expression in retinopathy. Mol.Genet.Metab 72,164-167.
Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996).
Time-dependent vascular regression and permeability changes in established human
tumor xenografts induced by an anti-vascular endothelial growth factor/vascular
permeability factor antibody. Proc.Natl.Acad.Sci.U.S.A 93,14765-14770.
Zahm, J. M., Kaplan, H., Herard, A. L., Doriot, F., Pierrot, D., Somelette, P., &
Puchelle, E. (1997). Cell migration and proliferation during the in vitro wound repair
of the respiratory epithelium. Cell Motil.Cytoskeleton 37, 33-43.
Zhang, N., Fang, Z., Contag, P. R., Purchio, A. F., & West, D. B. (2004). Tracking
angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-
luciferase transgenic mouse. Blood 103, 617-626.
Zhang, R., Min, W., & Sessa, W. C. (1995). Functional analysis of the human
endothelial nitric oxide synthase promoter. Spl and GATA factors are necessary for
basal transcription in endothelial cells. Journal ofBiological Chemistry 270, 15320-
15326.
Zhao, L., Xu, G., Zhou, J., Xing, H., Wang, S., Wu, M., Lu, Y. P., & Ma, D. (2006).
The effect of RhoA on human umbilical vein endothelial cell migration and
angiogenesis in vitro. Oncol.Rep. 15,1147-1152.
Zigmond, S. H. & Hirsch, J. G. (1973). Leukocyte locomotion and chemotaxis. New
methods for evaluation, and demonstration of a cell-derived chemotactic factor.
J.Exp.Med. 137, 387-410.
279
Zlot, C., Ingle, G., Hongo, J., Yang, S., Sheng, Z., Schwall, R., Paoni, N., Wang, F.,
Peale, F. V., Jr., & Gerritsen, M. E. (2003). Stanniocalcin 1 is an autocrine modulator
of endothelial angiogenic responses to hepatocyte growth factor. Journal of
Biological Chemistry 278, 47654-47659.
Zou, Y., Xu, X., & Chiou, G. C. (2006). Effect of interleukin-1 blockers, CK112, and
CK116 on rat experimental choroidal neovascularization in vivo and endothelial cell
cultures in vitro. J.Ocul.Pharmacol.Ther. 22,19-25.
Zuniga, J., Fuenzalida, M., Guerrero, A., Illanes, J., Dabancens, A., Diaz, E., &
Lemus, D. (2003). Effects of steroidal and non steroidal drugs on the
neovascularization response induced by tumoral TA3 supernatant on CAM from





Supplementary Figure 1 Dynamic nature of TLS formation identified by
time-lapse imaging
(Time-lapse movie-clip on enclosed CD)
HUVECs incubated on Matrigel in SlideFlasks in standard basal conditions for up to 24 hours
and images were captured at 3 separate positions per flask at 4 minute intervals using
time-lapse video microscopy. Movies were reconstructed using Windows Media Player
software and 1 second of clip is equivalent to 1 hour of real time. Two distinct phases of TLS
formation were identified in untreated control flasks using this method. Phase I consists of
network assembly; TLS number increased most rapidly during the first 4 hours after cell
seeding, and continued to increase reaching a maximum number of TLSs after 8 hours on
Matrigel in control flasks. Phase II involves the degradation of the TLS network whereby
cells detach from the substratum and lift off, resulting in a decrease in TLS number from 8
hours onwards. Most of the network was degraded after 24 hours under these conditions.
There was little evidence from these movie-clips of cell migration or proliferation and TLS
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Abstract. The ability of glucocorticoids to directly alter
arterial function, structure and the inflammatory re¬
sponse to vascular injury may contribute to their well-es¬
tablished link with the development ofcardiovascular dis¬
ease. Recent studies have emphasised the importance of
tissue-specific regulation of glucocorticoid availability
by the 11 /i-hydroxysteroid dehydrogenase (11HSD) iso¬
zymes, which inter-convert active glucocorticoids and
their inactive metabolites. The expression of both type 1
and type 2 1 lHSDs in the arterial wall suggests that pre-
receptormetabolism ofglucocorticoids may have a direct
impact on vascular physiology. Indeed there is evidence
that 11 HSDs influence glucocorticoid-mediated changes
in vascular contractility, vascular structure, the inflam¬
matory response to injury and the growth of new blood
vessels. Flence, inhibition of 11 HSD isozymes may pro¬
vide a novel therapeutic target in vascular disease.
Key words. 11 /TFIydroxysteroid dehydrogenase; inflammation; vascular contractility; angiogenesis; cardiovascular
disease.
Introduction
There is increasing evidence that direct interaction ofglu¬
cocorticoids with the vascular wall [1,2] contributes to
their association with increased risk of cardiovascular
disease [3,4], Certainly, glucocorticoids can interact both
with endothelial (EC) and with vascular smooth muscle
(VSMC) cells, and furthermore, glucocorticoid-mediated
enhancement of vascular contractility has been impli¬
cated in the development ofhypertension [5]. In addition,
glucocorticoids may directly modify new blood vessel
formation and vascular lesion development by inhibiting
inflammation, proliferation and angiogenic pathways in
the arterial wall [6, 7].
Interaction of glucocorticoids with the vasculature is un¬
likely to be regulated solely by circulating concentrations
of these steroids; pre-receptor metabolism within target
* Corresponding author.
tissues also has a profound influence on glucocorticoid
activity. Such tissue-specific modulation of glucocorti¬
coid activity, regulated by the isozymes of 11 /f-hydroxy-
steroid dehydrogenase (11HSD) [8], has a key role, for
example, in the development ofhypertension, obesity and
the metabolic syndrome [9-11], It is likely that pre-re-
ceptor metabolism of glucocorticoids influences steroid
action within the vessel wall since both isozymes of
11HSD are expressed in vascular cells [12], This article
reviews the current evidence that vascular 11 USD ex¬
pression influences glucocorticoid-mediated changes in
vascular growth, function, structure and the inflamma¬
tory response to vascular injury.
Glucocorticoid signalling in the vascular wall
Glucocorticoids (Cortisol in man, corticosterone in ro¬
dents) are predominantly synthesised in, and released
2 P. W. F. Hadoke et al. Intra-vascular glucocorticoid metabolism
from, the adrenal cortex. Circulating concentrations of
these steroids are under the control of the hypothalamic-
pituitary-adrenal (HPA) axis, whilst their bioavailability
is regulated by interaction with corticosteroid-binding
globulin (CBG) and albumin in the plasma. The small
proportion of unbound, circulating hormone is able to
cross the cell wall and interact with corticosteroid recep¬
tors. Classically, glucocorticoids interact with the cytoso-
lic glucocorticoid receptor (GR, or corticosteroid recep¬
tor type II). As described below, glucocorticoids may also
activate mineralocorticoid receptors (MR, or corticos¬
teroid receptor type I), but this occurs only in a few tis¬
sues. GR and MR are members of the nuclear hormone
receptor superfamily of ligand-activated transcription
factors [13]. Activation ofGR results in binding of recep¬
tor homodimers to glucocorticoid response elements in
target genes, leading to initiation or repression of tran¬
scription. There is also increasing evidence that gluco¬
corticoids exert specific, non-genomic actions. Examples
exist of rapid glucocorticoid-induced changes to phos-
pholipase A2 (PLA2) and phosphoinositide-3-kinase-me-
diated endothelial nitric-oxide synthase (eNOS) release
that are blocked by GR antagonism but not by inhibition
of transcription [14, 15]. These non-genomic effects are
thought to be mediated by membrane-bound GR [16]
(mGR; although the specific signalling pathways associ¬
ated with these receptors have not been established) or by
cytosolic GR (cGR) without requirement for either nu¬
clear translocation or effects on transcription. In the latter
case, chaperones or co-chaperones (such as Src) act as
signalling components and, therefore, mediators of glu¬
cocorticoid-induced effects [17],
Corticosteroid receptors are present in the cells of the
vascularwall, supporting the idea that glucocorticoids in¬
teract directly with the vasculature. Cytosolic MR and
GR have both been demonstrated in freshly isolated ves¬
sels [18, 19] and in cultured vascular cells (VSMCs [20,
21] and ECs [22-26]) from a variety of species. The dis¬
tribution of these receptors may vary with vascular terri¬
tory, as MR were detected in rabbit aortic and pulmonary
VSMCs but not in small arteries [27], Vascular GR are
known to be active as antagonism (with RU38486)
blocked dexamethasone-mediated induction of ACE ac¬
tivity in rat aortic ECs [28], Similarly, activity ofMR is
demonstrated by their contribution to angiotensin Il-in-
duced hypertrophy of VSMCs [29] and aldosterone-in-
duced swelling of ECs [22]. It has not been established
whether membrane binding sites for corticosteroids are
present, or have a role, in the vascular wall.
The downstream effects ofGR activation within the arte¬
rial wall, and their influence on cardiovascular risk fac¬
tors (such as hypertension), are imperfectly understood
[5], Glucocorticoids are essential for maintenance of
blood pressure in healthy individuals [1], whilst their
ability to increase peripheral vascular resistance in ani¬
mals devoid of renal mass indicates that a non-renal
mechanism contributes to glucocorticoid-induced hyper¬
tension [30], A considerable body of evidence suggests
that this non-renal mechanism may involve direct gluco-
corticoid-mediated alteration of EC and VSMC function
[1]. Consequently, regulation of glucocorticoid availabil¬
ity by 11 HSDs within the vascular wall may be an impor¬
tant influence on cardiovascular physiology and pathol¬
ogy-
Tissue-specific metabolism of glucocorticoids
by 11 /3-hydroxysteroid dehydrogenases
The 1 lHSDs, microsomal enzymes of the short-chain al¬
cohol dehydrogenase superfamily [8], interconvert active
glucocorticoids and their inert 11-keto forms [31]. Two
isozymes, 11HSD1 and 11IISD2, have been identified:
11HSD1 is a low-affinity NADP(H)-dependent, predom¬
inant reductase in vivo. Dehydrogenase activity of this
isozyme is generally not seen in intact cells or organs (in¬
cluding liver [32-34], adipose tissue [35], neurons [36]
and vascular smooth muscle [37]); early suggestions of
11HSD1 dehydrogenase activity in vascular smooth mus¬
cle [38] are probably attributable to 11HSD2 [37],
11HSD1 dehydrogenase activity observed in some prepa¬
rations in vitro [39] is probably attributable to release of
enzyme from damaged or dying cells, with dissociation
from hexose-6-phosphate dehydrogenase, which is
thought to maintain the high NADPH concentrations re¬
quired for reductase activity [40]. 11HSD1 has a Km in
the micromolar range for both Cortisol and corticosterone
[41] and is widely expressed in glucocorticoid-target tis¬
sues (including liver, lung, adipose tissue, brain, vascular
smooth muscle, skeletal muscle, anterior pituitary, go¬
nads and adrenal cortex [8]), where its role is to amplify
local glucocorticoid concentrations [42], Regulatory con¬
trol of 11HSD1 is complex, with its synthesis and activ¬
ity influenced by a variety of factors (such as glucocorti¬
coids [43^15], stress [46, 47], sex steroids [48], growth
hormone [49], cytokines [50] and peroxisome prolifera-
tor-activated receptor agonists [8]) and its activity driven
in the reductase direction through local generation of
NADPH by hexose-6-phosphate dehydrogenase [51],
Other factors that may drive 11HSD1 activity in the re¬
ductase direction include the cellular environment, co-
factor availability, redox potential and substrate concen¬
tration.
11HSD2, by contrast, is a high-affinity NAD-dependent,
exclusive dehydrogenase, which converts active gluco¬
corticoids into inactive 11 -ketosteroids and has a Km for
Cortisol and corticosterone in the nanomolar range. It is
found primarily in mineralocorticoid target tissues, such
as the kidney, sweat glands, salivary glands and colon 8],
where it is constitutively active and serves to protect MR
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from illicit occupation by glucocorticoids. Inhibition of
11IISD2 with liquorice or its derivatives results in gluco-
corticoid-dependent 'apparent' mineralocorticoid excess
and hypertension [52], Similarly, transgenic disruption of
11HSD2 [9] in mice, or congenital deficiency in man
[53], recapitulates the major features of the syndrome of
apparent mineralocorticoid excess (SAME). The impor¬
tance of 11HSD2 in SAME was demonstrated by the de¬
scription of a defect in Cortisol metabolism in children
with this syndrome [54]; this was later shown to be the re¬
sult ofmutations in the 11HSD2 gene [55, 56]. 11HSD2
is also expressed in tissues which are not classic MR tar¬
gets, including the lung, lymph nodes, heart, blood vessel
wall and placenta) [57-59]. In the placenta 11HSD2 acts
to protect the foetus from excessive exposure to maternal
glucocorticoids [60, 61], whereas cardiac 11HSD2 activ¬
ity may have a role in preventing fibrosis resulting from
stimulation ofMR by glucocorticoids [62],
The influence of 11HSD isozyme activity on cardiovas¬
cular physiology and pathophysiology is well recognised
(see Krozowski and Chai for review [63]), but details of
the role of 1 lHSDs within the vessel wall have emerged
only recently and remain somewhat uncertain.
Intra-vascular glucocorticoid metabolism
Both isozymes of 11HSD are expressed in the blood ves¬
sel wall, suggesting that they could influence vascular
function by regulating local availability of active gluco¬
corticoids [1, 64]. The cellular distribution of vascular
11HSD1 and 11HSD2 is not completely clear. Our stud¬
ies using mouse and rat aorta suggest that 11HSD2 is lo¬
calised to ECs, whereas 11HSD1 is predominantly in the
VSMC (fig. 1) [18, 65]. Others, in contrast, have reported
activity of both enzymes in the VSMC [37, 50] and also
in the EC [66], it should be noted that the latter investiga¬
tion [66] demonstrated only 11HSD1 in rat VSMC and
indicated that 11HSD1 was the predominant isozyme in
the endothelium. Direct comparison of studies is often
difficult, given the use of arteries from different species
and anatomical locations combined with a variety of
techniques for detecting 1 lHSDs. The balance of the lit¬
erature suggests that cellular distribution of 11 USD
isozymes differs in vessels from distinct anatomical loca¬
tions and that 11HSD activity increases as artery diame¬
ter diminishes; in the rat 11HSD, activity was greater in
resistance (mesenteric) arteries than in conduit vessels
(aorta) [65] and in the mouse 11 /^-reductase activity was
higher in iliofemoral arteries than in the aorta [A. R.
Dover et al., unpublished data]. These variations in cellu¬
lar distribution and activity suggest that the role of intra¬
vascular glucocorticoid metabolism is not the same in all
blood vessels.
There is increasing evidence that interconversion of ac¬
tive and inactive glucocorticoids by vascular cells may in¬
fluence glucocorticoid-mediated modulation of vascular
function, structure, growth and inflammation.
Glucocorticoids, llHSDs and vascular function
Although it is well established that glucocorticoids con¬
tribute to maintenance of vascular tone in vivo, the mech¬
anisms have been difficult to establish. A variety of inter¬
actions contribute to homeostasis, including glucocorti¬
coid-mediated regulation of cardiac output and fluid and
electrolyte balance, with salt and water handling modu¬
lated both directly [67] and indirectly by influences on the
production of angiotensinogen (liver), arginine vaso¬
pressin (AVP; hypothalamus) [68] and atrial natriuretic
peptide (ANP; cardiac myocytes) [69]. It is apparent,
however, that these cardiac and renal effects cannot ac¬
count totally for the glucocorticoid-mediated increase in
blood pressure, and there is evidence that a component of
hypertension arises from enhanced contractility of the
vascular wall [70-72], For example, reversal of adreno-
corticotophin-dependent hypertension by administration
ofl-arginine (the substrate for nitric oxide synthase) sug¬
gests that nitric oxide deficiency contributes to the eleva¬
tion of blood pressure [73, 74],
Glucocorticoid-dependent potentiation of noradrenaline-
and angiotensin II-mediated vasoconstriction has been at-
A<(> A<H)
Figure 1. Presence and distribution of 11 USD isozymes in the vas¬
cular wall. In situ hybridisation (Ai) and immunohistochemistry
(Aii) confirming both expression and activity of 11HSD1 within the
rat aortic wall; the enzyme was predominantly localised to medial
smooth muscle cells (left-hand panel, sense/control; right hand-
panel, antisense/antibody to 1111SD1). Immunohistochemistry de¬
monstrating (B) 11I1SD1 in rat mesenteric artery smooth muscle
and (Q 11HSD2 in human intra-renal artery endothelium [unpub¬
lished]. Reproduced from [65] with permission. © The Endocrine
Society, 1991.
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tributed to alterations within the VSMC and the EC (re¬
viewed in Walker and Williams [2] and Ullian [1]). Given
that glucocorticoids can act on both MR and GR, the in¬
creased contractility observed in many studies may be
secondary to increased stimulation of either receptor. Al¬
terations identified within the VSMC (including upregu-
lation of contractile receptors, altered intracellular sec¬
ond messenger activation and modulation of the activity
and synthesis of vasoactive substances) result in a direct
enhancement of contraction [1]. In contrast, changes in
the endothelium can increase contractility in two distinct
ways: by increased release of vasoconstrictor compounds
(e.g. angiotensin II, endothelin-1 [75, 76]) from the ECs
and by impaired endothelium-mediated relaxation. Loss
of endothelium-mediated relaxation [77], caused by im¬
paired activity of vasodilators (e.g. prostaglandins, nitric
oxide) [78-80], [reduces the ability of the endothelium to
modulate contraction.
An alternative mechanism through which glucocorticoids
may regulate vascular function is 'foetal programming' of
physiological responses [81], Exposure of the foetus to
excess maternal glucocorticoid (either by direct infusion
or by inhibition of placental 11HSD2) causes reduced
birth weight [82], an outcome associated with increased
risk of cardiovascular and metabolic disease in adulthood
[83], Two major causes of low birth weight, maternal di¬
etary restriction and maternal stress, may also be gluco-
corticoid-dependent [84, 85]. In the ovine foetus, gluco¬
corticoid infusion elevates blood pressure and alters vas¬
cular contractility in foetal sheep [86]; this may be
significant, as one outcome of foetal programming is el¬
evated blood pressure in adult offspring [87]. However,
although enhanced vascular contractility has been
demonstrated in rats with programmed hypertension, it is
not clear whether this contributes to the elevation of
blood pressure [88, 89], Furthermore, the mechanisms
through which pre-natal exposure to excess glucocorti¬
coid programme enhance contractility in adult offspring
have not been established.
Influence of llHSDs on vascular function
In SAME, 11HSD2 deficiency results in sodium reten¬
tion and severe hypertension, mediated in part by gluco-
corticoid-dependent activation of MR in the distal
nephron [90], There is, however, a considerable literature
to suggest that changes in 11HSD activity within the vas¬
cular wall also contribute to elevation of blood pressure.
A clear example of this is the demonstration that 11HSD
activity is impaired in arteries taken from rat models of
hypertension [91-93], A role for altered vascular function
is supported by reports that 11HSD inhibition (with gly-
cyrrhetinic acid) in rats produced an elevation of blood
pressure which, whilst mediated by MR activation, was
blocked by antagonists of the endothelin-1 system [94,
95]. Moreover, studies of dermal vasoconstriction in pa¬
tients exposed to liquorice, and in a single individual with
SAME [53, 96], demonstrated enhanced cortisol-medi-
ated constriction (fig. 2). The possibility that this is due
to changes in glucocorticoid metabolism within the vas¬
cular wall, rather than indirect systemic effects of sodium
retention, gained further credence with in vitro studies
which showed that bile acids (e.g. chenodeoxycholic
acid), which are endogenous inhibitors of 11 USD [97],
pharmacological inhibitors of 11 HSD (carbenoxolone,
glycyrrhetinic acid) [98, 99] and isozyme selective anti-
sense oligonucleotides [100] alter corticosterone-medi-
ated enhancement of vasoconstriction. Furthermore,
11HSD inhibition (with glycyrrhetinic acid) augmented
corticosterone-induced dysfunction in cultured human
ECs, indicating both a role for intra-cellular 11HSD and
independence from blood pressure elevation in vivo [95].
Care is required in interpreting these results, however,
as some 11HSD inhibitors can directly alter contractile
function by damaging the endothelium [101].
These pharmacological studies have been extended by the
use of arteries from 11HSD knockout mice. Aortic func¬
tion (and blood pressure) are unaltered in 11HSD1
mice suggesting that intravascular regeneration of active
glucocorticoids has no effect on vascular contractility
[102, 103]. This indicates that despite the ability of glu¬
cocorticoids to enhance vascular contraction, impaired




























Figure 2. The effect of congenital and acquired 11 HSD deficiency
on dermal vasoconstrictor sensitivity to Cortisol and beclometha¬
sone dipropionate. Inhibition of 11 HSD activity with liquorice-en¬
hanced dermal vasoconstriction (measured by skin blanching) in re¬
sponse to Cortisol but not to beclomethasonc diproprionate. A sim¬
ilar result was obtained in a patient (GB) with the syndrome of
apparent mineralocorticoid excess type 1 (11HSD2 deficiency).
These data indicate that local regulation of glucocorticoid activity
in the vascular wall contributes to contractile tone. Bars are s.e. NS,
not significant. Reproduced from [53] with permission. ©The Bio¬
chemical Society, 1992.
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data, however, suggest that the concept of protection of
ECs by 11HSD2 may be an oversimplification. In mouse
aortic rings, we could not induce EC dysfunction by in¬
cubating isolated rings with glucocorticoids (fig. 3b),
even in the absence of 11HSD2 [18]; whether dehydroge¬
nase activity of 11HSD1 [38] served to protect the en¬
dothelium is not clear, although our data suggest that
11HSD1 does not act as a dehydrogenase in intact arteries.
This raises the possibility that in vivo differences in vas¬
cular function in 11HSD2 knockout mice are dependent
on indirect mechanisms, e.g. related to hypertension or
sodium retention. Cell-specific manipulation of llHSDs
would be the most attractive means to dissect this biology
further, but has yet to be reported for vascular cells.
(b)
Noradrenaline (-log [M])
Figure 3. Effect of (a) transgenic deletion of 11HSD2 and (b) ex¬
posure to glucocorticoids on mouse aortic endothelial cell function.
In aortic rings isolated from control mice (squares), release of en-
dothelium-derived nitric oxide acts as a physiological antagonist of
noradrenaline-mediated contraction; thus, removal of the endothe¬
lium (open symbols) results in enhanced contraction. In aortae from
11HSD2"'" mice (a; triangles) this ability of the endothelium to
modulate contraction has been lost, suggesting glucocorticoid-me-
diated impairment of endothelial cell function. This is contested,
however, by the demonstration that (b) in vitro incubation (24 h, 37
°C; 10"7M corticosterone) ofaortic rings from control animals with
glucocorticoids (circles) did not produce a similar endothelial cell
dysfunction. Values are mean ± s.e. mean; n=8. Adapted with per¬
mission from [103] and [18]. © Lippincott, Williams and Wilkins.
duce contractile function. In contrast, enhanced contrac¬
tility was demonstrated in thoracic aortae from mice lack¬
ing 11HSD2 as a result of impaired endothelium-derived
NO activity [103], rather than changes in the VSMC
(fig. 3a). This suggests that 11HSD2 activity in the en¬
dothelium may serve to protect endothelium-dependent
relaxation from the detrimental effects of glucocorti¬
coids. This appears to be consistent with in vivo studies
which suggest that non-selective inhibitors of both iso¬
zymes of 1 H ISDs, such as liquorice derivatives, potenti¬
ate rather than impair the vascular actions of glucocorti¬
coids, suggesting inhibition of inactivation rather than re¬
activation of steroids within the vessel wall. More recent
Glucocorticoids, llHSDs and vascular inflammation
Whereas studies in transgenic mice have suggested that
11HSD2 activity may influence vascular function, whilst
11HSD1 does not, a much clearer role for 11 USD 1 has
been identified in regulation of vascular inflammation.
The anti-inflammatory and immunosuppressive effects of
glucocorticoids, which account for their most common
therapeutic applications, are due to GR-mediated interac¬
tions with blood vessels, inflammatory cells and media¬
tors of inflammatory responses [104]. For example, glu¬
cocorticoids decrease expression of adhesion factors, cy¬
tokines and chemokines, and so alter the recruitment of
immune cells such as neutrophils and macrophages to
sites of inflammation. This also results in a decrease in
leukocyte activation and proliferation. Furthermore, the
glucocorticoid receptor mediates lymphocyte apoptosis
[105] and suppresses the synthesis of inflammatory me¬
diators (e.g. prostanoids), and hydrocortisone stimulates
the synthesis of anti-inflammatory mediators (e.g. lipo-
cortins) [106]. Glucocorticoids, but not mineralocorti-
coids, can also promote the phagocytosis of apoptotic
leukocytes [107], and so contribute to the resolution of
inflammation. The expression of 11HSD1 inVSMCs [50]
and in activated macrophages [ 108] suggests that genera¬
tion ofglucocorticoid within these cells may contribute to
regulation of inflammation.
Influence of llHSDs on vascular inflammation
The demonstration that pro-inflammatory cytokines se¬
lectively upregulate 11HSD1 activity in human VSMCs
suggests that glucocorticoid generation within the vascu¬
lar wall provides a mechanism for local feedback regula¬
tion of inflammation [50], However, this has not been ex¬
amined in vivo. The ability of inflammatory mediators to
regulate 11HSD activity in VSMCs may be dependent
upon the phenotypic state of the cells (with enzyme ac-
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tivity upregulated in actively proliferating, but not in qui¬
escent, cells), the anatomical origin of a particular vessel,
the prevailing local glucocorticoid concentrations and the
modulation of the inflammatory response by neighbour¬
ing tissues [A. R. Dover et al., unpublished data]. Further
work is required to clarify the significance of cytokine-
mediated regulation of 11HSD1 in arterial cells, particu¬
larly given the importance of inflammation in the vascu¬
lar response to injury [109],
Alternatively, 11HSD1 may regulate inflammation by
controlling generation of glucocorticoids within the in¬
flammatory cells. Certainly, the ability of inflammatory
cytokines to upregulate 11IISD1 activity in activated hu¬
man macrophages [108] suggests, as in human VSMC
[50], a means of feedback regulation of inflammation
within these cells.
Glucocorticoids and vascular remodelling
The term 'vascular remodelling' has been used to cover a
range of structural changes in the arterial wall, and its
correct definition is the subject of debate (for review see
Bund and Lee [ 110]). In this review, the term 'vascular re¬
modelling' encompasses medial hypertrophy (thickening
of the vessel wall caused by increase in cell size) and hy¬
perplasia (thickening of the cell wall caused by an in¬
crease in cell number), as well as the intimal remodelling
seen in neointimal proliferation and the development of
atherosclerotic lesions. It has also been extended to in¬
clude angiogenic growth of new blood vessels.
The relationship between glucocorticoids and arterial re¬
modelling is well-established; for example, one year fol¬
lowing remission, patients with Cushing's syndrome
show reduced intimal/medial thickness and increased lu¬
men diameter in the carotid artery [111]. It should be
noted, however, that remodelling may be the indirect re¬
sult of systemic changes (e.g. increased blood pressure)
rather than direct interactions ofglucocorticoids with the
vessel wall. Glucocorticoids may induce vascular remod¬
elling by altering expression of genes for relevant growth
factors or by inhibiting processes that modulate growth
factor activity. For example, dexamethasone induces a
GR-dependent upregulation of endothelin-1 expression
[76], and Cortisol attenuates the activity of nitric oxide
[77] (itself a potent inhibitor of cell growth). Similarly,
dexamethasone- and hydrocortisone-mediated increases
in ACE activity in VSMCs [112] and ECs [75] may en¬
hance local generation of angiotensin II (a stimulant of
VSMC growth both in vitro [113] and in vivo [114]).
Hypertrophy
Vascular hypertrophy in rats exposed to mineralocorti-
coids, predominantly deoxycorticosterone acetate, and
salt [115] has been attributed to upregulation of the en¬
dothelin-1 gene [116], Similarly, glucocorticoids (dex¬
amethasone, hydrocortisone) have the ability to induce
vascular hypertrophy by augmenting the production of
[112, 117], and hypertrophic response to [118, 119], an¬
giotensin II. The significance of this hypertrophy is un¬
clear, however, as many investigations that demonstrate
enhanced vascular contractility in response to corticos-
terone involved a duration of exposure that would be in¬
sufficient for vascular hypertrophy to occur [120], Fur¬
thermore, glucocorticoid-mediated stimulation of growth
in the vascular wall is counterintuitive given that dexam¬
ethasone inhibits VSMC growth in culture [121-123] and
glucocorticoids prevent neointimal hyperplasia (see be¬
low). Thus, the direct influence ofglucocorticoids on vas¬
cular hypertrophy/hyperplasia is unclear, and any role of
local glucocorticoid metabolism by llHSDs in the pro¬
cess has yet to be investigated.
Neointimal proliferation
The development of neointimal lesions (e.g. in athero¬
sclerosis and in restenosis following revascularisation) is
a consequence of an excessive wound healing response in
the vessel wall [124,125]. Vascular injury results in infil¬
tration by inflammatory cells and subsequent migration
and proliferation ofVSMCs [109]. Consequently, inhibi¬
tion of either the inflammatory response [126] or VSMC
proliferation/migration [127] inhibits lesion development
in a variety of models. Since glucocorticoids (dexam¬
ethasone) can inhibit inflammation and VSMC prolifera¬
tion [121-123] and migration [128], it is not surprising
that their potential as anti-atherosclerotic [129] and anti-
restenotic agents [ 130] has been investigated [6], It is also
possible, however, that the action of glucocorticoids on
the vessel wall is deleterious in patients with vascular dis¬
ease. For example, given that ACE inhibition limits
neointima formation following balloon injury [131, 132],
stimulation ofACE activity by dexamethasone [75, 112]
could exacerbate lesion development. Also, inhibition of
endothelium-derived nitric oxide activity by glucocorti¬
coids could increase both VSMC proliferation and vascu¬
lar contraction. Further, the systemic effects of glucocor¬
ticoids on cardiovascular risk factors (glucose, insulin,
lipids and blood pressure) may offset beneficial effects
within the vessel wall.
Dexamethasone reduces cholesterol ester accumulation
in the aorta [133], and glucocorticoids (dexamethasone,
hydrocortisone) inhibit neointimal lesion formation in
rats [134, 135], rabbits [136-138] and dogs [139] (with a
few contradictory reports [140, 141]). Clinical trials in
humans, by contrast, have proved disappointing (with no¬
table exceptions [130]): methylprednisolone did not in¬
hibit restenosis after coronary angioplasty [142] or stent
implantation [143], whilst the combination ofa glucocor-
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ticoid with colchicine increased the risk of coronary
aneurysm following stent placement [144]. Discrepan¬
cies between clinical studies and animal models could be
attributed to species differences or, more probably, to
methodological variation (e.g. small sample size; inap¬
propriate patient selection, dose, duration of treatment,
route of administration). Exacerbation of lesion develop¬
ment by glucocorticoids could be explained by systemic
effects (e.g. weight gain with elevated blood pressure and
plasma lipids, which may be more prominent in humans
than in other species) or by a net stimulation of vascular
cell proliferation. Alternatively, changes in plasma lipids
could influence the ability of glucocorticoids to interact
with vascular cells. Lipoprotein(a) can downregulate GR
gene expression in human VSMCs, thus inhibiting any
protective actions of glucocorticoids and, possibly, repre¬
senting a novel atherogenic mechanism [145].
Angiogenesis
Angiogenesis, in which new blood vessels are formed
from an existing vascular network, is a complex process
regulated by a balance between counteracting endoge¬
nous activators and inhibitors [146], Physiological angio¬
genesis is an essential component of reproduction and
embryonic development. In postnatal and adult life, it is a
discrete process (e.g. in the reproductive tract, wound
healing and exercised skeletal muscle) of relatively short
duration [147]. In contrast, pathological angiogenesis is
usually persistent and unabated and often continues for
months or years [147]. Numerous disorders are charac¬
terised by excessive angiogenesis, including neoplasia,
rheumatoid arthritis and diabetic retinopathy [148]. Con¬
sequently, modulation of angiogenesis is regarded as an
attractive therapeutic goal in a variety of conditions.
A comprehensive review of the mechanisms of angiogen¬
esis is beyond the scope of this article (for recent reviews
see [146, 149]). For the present purposes it is useful to
consider angiogenesis to be a stepwise process compris¬
ing four distinct phases: (i) basement membrane disinte¬
gration, (ii) endothelial cell migration, (iii) channel for¬
mation and (iv) maturation. Of the numerous factors that
control this process, vascular endothelial cell growth fac¬
tor (VEGF) is widely considered to be of central impor¬
tance, since it is crucial for vascular development both in
the embryo and in adult tissues and it is EC specific.
Since its first demonstration by Folkman and colleagues,
over 20 years ago [150], the ability of glucocorticoids to
inhibit angiogenesis has been confirmed in vitro, in vivo
and in tumour-bearing animals [150], It was suggested
that inhibition of angiogenesis in the rabbit cornea
was independent of classical GR and MR activity [151].
For example, 17a-hydroxyprogesterone and tetrahydro-
S, which have no glucocorticoid or mineralocorticoid ac¬
tivity, retained an anti-angiogenic capability equivalent
to, or greater than, that ofhydrocortisone. Taken together,
these studies demonstrated a class of steroids for which
inhibition of angiogenesis appears to be the principal
function and hence were named 'angiostatic steroids.'
[151].
Despite considerable research, the mechanisms through
which glucocorticoids inhibit angiogenesis have not been
identified. Indeed, the role ofGR is still controversial, as
some of the 'angiostatic steroids' may actually have the
ability to stimulate these receptors. For example, we have
recently shown that inhibition ofangiogenesis by tetrahy-
drocorticosterone, one of the original angiostatic ster¬
oids, is dependent upon GR activation in mouse aortic
ring explants [G. R. Small et al., unpublished]. Some in¬
dication of mechanism was provided by early studies
which demonstrated, using nude mice or the non-antico¬
agulant hexasaccharide fragment of heparin, that the
combination of glucocorticoid and heparin was indepen¬
dent of an immune response and anti-coagulant function,
respectively [150]. At present, however, there are still sev¬
eral possible pathways through which glucocorticoids
may inhibit angiogenesis: (i) Degradation of extracellular
matrix, (ii) modification of cytokine production, (iii) in¬
hibition of protease activity, (iv) impairment of vessel
maturation and stabilisation, (v) inhibition of growth fac¬
tor activity, (vi) inhibition of the arachidonic acid cas¬
cade, (vii) inhibition of EC-leukocyte interactions and
(viii) non-transcriptional effects. The relative signifi¬
cance of these pathways has not been established.
llHSDs and vascular remodelling
Although the initial focus was on 11HSD2 and vascular
function, the most recent work in the field of intra-vascu¬
lar glucocorticoid metabolism has highlighted novel roles
for 11HSD1 in influencing vascular structure and remod¬
elling.
Neointimal remodelling and atherogenesis
The potential link between atherosclerosis and tissue-
specific generation of glucocorticoids by 11 USDs has
been underlined by recent demonstrations that selective
upregulation of 11 USD 1 in the adipose produces features
of the metabolic syndrome, including central obesity, hy¬
pertension and hypertriglyceridaemia [10,152], This sup¬
ports the concept that similarities between the metabolic
syndrome and Cushing's syndrome are explained by tis¬
sue-specific increases in 11HSD1 activity resulting in tis¬
sue-specific elevation ofglucocorticoid generation [153],
This link between 11 HSD 1 activity in glucocorticoid-tar-
get tissues and atherosclerotic risk factors is not limited
to the adipose, as hepatic overexpression of 11IISD1 also
results in elevated blood pressure and dyslipidaemia
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[154]. It has been proposed, therefore, that 111ISD1 inhi¬
bition may reduce atherogenesis. Very recently, systemic
administration of a selective 11HSD1 inhibitor was re¬
ported to virtually abolish lipid accumulation in the aorta
of atherosclerotic (apolipoprotein E' ) mice. However,
inhibition of 11HSD1 in ApoE ' mice produced only a
relatively modest reduction in serum triglycerides and
cholesterol [155], suggesting that mechanisms over and
above amelioration of systemic cardiovascular risk fac¬
tors may be responsible. It may be that inhibition of
11HSD1 within the vessel wall or within invading
macrophages [156] is crucial, but these mechanisms re¬
quire further clarification.
11 I ISD2-dependent protection ofMR from inappropriate
occupation by glucocorticoids may also influence athero¬
genesis. The role ofMR activation in the pathogenesis of
atherosclerosis [157] is demonstrated by aldosterone-in-
duced enhancement of lesion development in atheroscle¬
rotic (apolipoprotein E ') mice (probably by increasing
oxidative stress in macrophages and cells of the vascular
wall [157, 158]). This potentiation of lesion development
by aldosterone, which is largely independent of blood
pressure, is attenuated by MR antagonists [157], as is
constrictive remodelling following angioplasty [159].
The potential importance of 11HSD activity to the devel¬
opment of atherosclerotic lesions was recently extended
by the demonstration that, in addition to glucocorticoid
metabolism, llHSDs catalyse the conversion of the
atherogenic oxysterol 7-ketocholesterol to 7/?-hydroxy-
cholesterol [160]. 7-Ketocholesterol is present in micro-
molar concentrations in human atherosclerotic lesions


































Figure 4. The influence of 11HSD1 on glucocorticoid-mediated angiogenesis. (A) In mouse aortic rings cultured in Matrigel, corticosterone
and its inactive metabolite 11-dehydrocorticosterone attenuated new vessel growth. Glucocorticoid receptor antagonism (with RU38486,
filled columns) abolished the angiostatic response to both compounds (Ai), but 11 USD 1 deletion (hatched columns) selectively prevented
11-dehydrocorticosterone-mediated angiostasis (Aii). Similar results were obtained in vivo, using subcutaneous sponge implants (B), with
1111SD1 deletion (hatched columns) increasing angiogenesis under basal conditions and abolishing cortisone-, but not Cortisol-, mediated
inhibition of vessel growth. This mechanism contributed to regulation of myocardial angiogenesis following coronary artery ligation (C)
with increased vessel growth in 11HSD l-'" mice (coronary artery ligation, shaded bars; sham, open bars), "p < 0.05 compared with relevant
vehicle-treated control; **p<0.01 compared with wild-type mice; ***p<0.001 compared with relevant wild-type control or sham-oper¬
ated mouse. Reproduced with permission from [168]. © The National Academy of Sciences of the USA, 2005.
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association with atherosclerosis is demonstrated in the
condition cerebrotendinous xanthomatosis, in which pa¬
tients who have normal circulating cholesterol levels but
increased 7-ketocholesterol develop atherosclerosis pre¬
maturely [162]. Conversion of 7-ketocholesterol to 7/?-
hydroxycholesterol by 11 /J-IISD1 may represent the rate-
limiting step in a clearance pathway: in vivo inhibition of
11HSD1 in rats resulted in an accumulation of 7-ketoc¬
holesterol in the liver and increased concentrations in the
plasma [163], In addition to these hepatic effects, reduc¬
tion of 7-ketocholesterol by 11HSD1 within the vascular
wall may also be important. 7-Ketocholesterol and 7/1-hy-
droxycholetserol are both toxic to cells of the vascular
wall [164] and are potent inhibitors of endothelium-de-
pendent relaxation [165-167]. Consequently, reduction
of 7-ketocholesterol, and subsequent clearance of 7/J-hy-
drocholesterol, by protecting the vascular wall from dam¬
age may have a role in preventing lesion development.
The influence of 11-HSD activity on angiogenesis
Since inflammatory cytokines can promote angiogenesis,
we hypothesised that 11/1-HSD1 in the vessel wall may
regulate new vessel formation by controlling the local re¬
generation of active glucocorticoids. This possibly was
addressed using a combination of in vitro, in vivo and
pathological models of angiogenesis [168]. Using a
model oftube formation from mouse aortic rings cultured
in Matrigel [169], we demonstrated (fig. 4a) that angio¬
genesis was inhibited by physiological concentrations of
active glucocorticoid (corticosterone) but also by its in¬
active metabolite (11-dehydrocorticosterone). Both these
responses were blocked by RU38486, but not by spirono¬
lactone, indicating GR dependence. However, whereas
11HSD1-inhibition (with carbenoxolone) or deletion
(aortic rings from 1IIISDI' mice) had no effect on the
response to corticosterone, they abolished the ability of
11 -dehydrocorticosterone to inhibit angiogenesis (fig.
4b). This indicated that 111ISD1-dependent regeneration
ofactive glucocorticoid within the vascular wall regulates
new vessel growth. Application of a model of angiogene¬
sis in sub-cutaneous sponge implants, confirmed this role
for 11HSD1 in vivo, showing that 11HSD1 deletion pro¬
duced increased angiogenesis in un-treated sponges and
blocked the ability of cortisone (but not Cortisol) to in¬
hibit new vessel formation. The pathophysiological sig¬
nificance of these observations was emphasised in heal¬
ing cutaneous wounds and in the myocardial response to
coronary artery ligation (fig. 4C). In both cases, 11HSD1
deletion resulted in increased angiogenesis, demonstrat¬
ing that 1 IIISDI regulates the growth of new blood ves¬
sels in healing tissues.
Altered angiogenesis in 11HSD1' [168] mice could,
conceivably, be the result of changes in macrophage ac¬
tivity. Given that 11HSD1 is expressed in macrophages
[170], and regeneration of glucocorticoids enhances pha¬
gocytosis of apoptotic neutrophils [107], absence of
11HSD1 may confer a prolonged and enhanced acute in¬
flammatory response, thus stimulating angiogenesis. The
use of ex vivo models such as isolated aortic rings cul¬
tured in extracellular matrices [171] has made it possible
to differentiate between these two intimately related path¬
ways, angiogenesis and inflammation, and specifically
address the effects of glucocorticoids on angiogenesis in
the absence of a systemic response. This has produced ev¬
idence that glucocorticoids regulate angiogenesis by di¬
rect interaction with the vessel wall [168].
Conclusions
It is apparent that glucocorticoids have the ability to regu¬
late both the structure and the function of the artery wall,
with significant implications for vascular physiology and
pathophysiology. Emerging evidence suggests that pre-re-
ceptormetabolism of glucocorticoids within vascular ECs
and VSMCs provides a mechanism for regulating these in¬
teractions. Relatively few studies have addressed the role
of intravascular 11HSD activity, and most of those avail¬
able have focussed on vascular function. There is, how¬
ever, a growing body of evidence to suggest that 11HSD
isozymes within the arterial wall modulate vascular con¬
tractility, the angiogenic growth ofnew blood vessels, and
the atherosclerotic process. Whether these isozymes also
influence the inflammatory response to vascular injury
and the inter-conversion of atherogenic oxysterols in vas¬
cular smooth muscle has still to be determined. Further
clarification of the role of llHSDs in vascular cells is
likely to increase our understanding of the link between
glucocorticoids and a variety of vascular diseases, and to
demonstrate their potential as therapeutic targets for treat¬
ment of these conditions.
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